
<html lang="en"     class="pb-page"  data-request-id="542ed375-fef0-4fbe-ab30-b28d71e33c7a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;article:article:10.1021/acs.jmedchem.0c01265;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement" /></meta><meta name="dc.Creator" content="Yelena  Mostinski" /></meta><meta name="dc.Creator" content="Guus J. J. E.  Heynen" /></meta><meta name="dc.Creator" content="Maria Pascual  López-Alberca" /></meta><meta name="dc.Creator" content="Jerome  Paul" /></meta><meta name="dc.Creator" content="Sandra  Miksche" /></meta><meta name="dc.Creator" content="Silke  Radetzki" /></meta><meta name="dc.Creator" content="David  Schaller" /></meta><meta name="dc.Creator" content="Elena  Shanina" /></meta><meta name="dc.Creator" content="Carola  Seyffarth" /></meta><meta name="dc.Creator" content="Yuliya  Kolomeets" /></meta><meta name="dc.Creator" content="Nandor  Ziebart" /></meta><meta name="dc.Creator" content="Judith  de Schryver" /></meta><meta name="dc.Creator" content="Sylvia  Oestreich" /></meta><meta name="dc.Creator" content="Martin  Neuenschwander" /></meta><meta name="dc.Creator" content="Yvette  Roske" /></meta><meta name="dc.Creator" content="Udo  Heinemann" /></meta><meta name="dc.Creator" content="Christoph  Rademacher" /></meta><meta name="dc.Creator" content="Andrea  Volkamer" /></meta><meta name="dc.Creator" content="Jens Peter  von Kries" /></meta><meta name="dc.Creator" content="Walter  Birchmeier" /></meta><meta name="dc.Creator" content="Marc  Nazaré" /></meta><meta name="dc.Description" content="The tyrosine phosphatase SHP2 controls the activity of pivotal signaling pathways, including MAPK, JAK-STAT, and PI3K-Akt. Aberrant SHP2 activity leads to uncontrolled cell proliferation, tumorigen..." /></meta><meta name="Description" content="The tyrosine phosphatase SHP2 controls the activity of pivotal signaling pathways, including MAPK, JAK-STAT, and PI3K-Akt. Aberrant SHP2 activity leads to uncontrolled cell proliferation, tumorigen..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 19, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01265" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01265" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01265" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01265" /></link>
        
    
    

<title>From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01265" /></meta><meta property="og:title" content="From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0017.jpeg" /></meta><meta property="og:description" content="The tyrosine phosphatase SHP2 controls the activity of pivotal signaling pathways, including MAPK, JAK-STAT, and PI3K-Akt. Aberrant SHP2 activity leads to uncontrolled cell proliferation, tumorigenesis, and metastasis. SHP2 signaling was recently linked to drug resistance against cancer medications such as MEK and BRAF inhibitors. In this work, we present the development of a novel class of azaindole SHP2 inhibitors. We applied scaffold hopping and bioisosteric replacement concepts to eliminate unwanted structural motifs and to improve the inhibitor characteristics of the previously reported pyrazolone SHP2 inhibitors. The most potent azaindole 45 inhibits SHP2 with an IC50 = 0.031 μM in an enzymatic assay and with an IC50 = 2.6 μM in human pancreas cells (HPAF-II). Evaluation in a series of cellular assays for metastasis and drug resistance demonstrated efficient SHP2 blockade. Finally, 45 inhibited proliferation of two cancer cell lines that are resistant to cancer drugs and diminished ERK signaling." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01265"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01265">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01265&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01265&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01265&amp;href=/doi/10.1021/acs.jmedchem.0c01265" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 14780-14804</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01305" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01215" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yelena Mostinski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yelena Mostinski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yelena++Mostinski">Yelena Mostinski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guus J. J. E. Heynen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guus J. J. E. Heynen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guus+J.+J.+E.++Heynen">Guus J. J. E. Heynen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maria Pascual López-Alberca</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria Pascual López-Alberca</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria+Pascual++L%C3%B3pez-Alberca">Maria Pascual López-Alberca</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jerome Paul</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jerome Paul</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jerome++Paul">Jerome Paul</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sandra Miksche</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sandra Miksche</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sandra++Miksche">Sandra Miksche</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Silke Radetzki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Silke Radetzki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Silke++Radetzki">Silke Radetzki</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Schaller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Schaller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Charité−Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Schaller">David Schaller</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elena Shanina</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elena Shanina</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Max-Planck-Institut für Kolloid- und Grenzflächenforschung, Am Mühlenberg, 1, 14476 Potsdam, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elena++Shanina">Elena Shanina</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carola Seyffarth</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carola Seyffarth</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carola++Seyffarth">Carola Seyffarth</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuliya Kolomeets</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuliya Kolomeets</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuliya++Kolomeets">Yuliya Kolomeets</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nandor Ziebart</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nandor Ziebart</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nandor++Ziebart">Nandor Ziebart</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Judith de Schryver</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Judith de Schryver</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Judith++de+Schryver">Judith de Schryver</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sylvia Oestreich</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sylvia Oestreich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sylvia++Oestreich">Sylvia Oestreich</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin Neuenschwander</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin Neuenschwander</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Neuenschwander">Martin Neuenschwander</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yvette Roske</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yvette Roske</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yvette++Roske">Yvette Roske</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Udo Heinemann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Udo Heinemann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Udo++Heinemann">Udo Heinemann</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christoph Rademacher</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christoph Rademacher</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Max-Planck-Institut für Kolloid- und Grenzflächenforschung, Am Mühlenberg, 1, 14476 Potsdam, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christoph++Rademacher">Christoph Rademacher</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7082-7239" title="Orcid link">http://orcid.org/0000-0001-7082-7239</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrea Volkamer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrea Volkamer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Charité−Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Volkamer">Andrea Volkamer</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3760-580X" title="Orcid link">http://orcid.org/0000-0002-3760-580X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jens Peter von Kries</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jens Peter von Kries</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jens+Peter++von+Kries">Jens Peter von Kries</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Walter Birchmeier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Walter Birchmeier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Walter++Birchmeier">Walter Birchmeier</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Marc Nazaré</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marc Nazaré</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#620c031803100722040f124f0007100e0b0c4c0607"><span class="__cf_email__" data-cfemail="fa949b809b889fba9c978ad7989f88969394d49e9f">[email protected]</span></a>. Phone: +49 30 9406-3083.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marc++Nazar%C3%A9">Marc Nazaré</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1602-2330" title="Orcid link">http://orcid.org/0000-0002-1602-2330</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01265&amp;href=/doi/10.1021%2Facs.jmedchem.0c01265" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 14780–14804</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 19, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 July 2020</li><li><span class="item_label"><b>Published</b> online</span>19 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01265" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01265</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D14780%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYelena%2BMostinski%252C%2BGuus%2BJ.%2BJ.%2BE.%2BHeynen%252C%2BMaria%2BPascual%2BL%25C3%25B3pez-Alberca%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D23%26contentID%3Dacs.jmedchem.0c01265%26title%3DFrom%2BPyrazolones%2Bto%2BAzaindoles%253A%2BEvolution%2Bof%2BActive-Site%2BSHP2%2BInhibitors%2BBased%2Bon%2BScaffold%2BHopping%2Band%2BBioisosteric%2BReplacement%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14804%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01265"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1611</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01265" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yelena&quot;,&quot;last_name&quot;:&quot;Mostinski&quot;},{&quot;first_name&quot;:&quot;Guus&quot;,&quot;last_name&quot;:&quot;J. J. E. Heynen&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Pascual López-Alberca&quot;},{&quot;first_name&quot;:&quot;Jerome&quot;,&quot;last_name&quot;:&quot;Paul&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;Miksche&quot;},{&quot;first_name&quot;:&quot;Silke&quot;,&quot;last_name&quot;:&quot;Radetzki&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Schaller&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;Shanina&quot;},{&quot;first_name&quot;:&quot;Carola&quot;,&quot;last_name&quot;:&quot;Seyffarth&quot;},{&quot;first_name&quot;:&quot;Yuliya&quot;,&quot;last_name&quot;:&quot;Kolomeets&quot;},{&quot;first_name&quot;:&quot;Nandor&quot;,&quot;last_name&quot;:&quot;Ziebart&quot;},{&quot;first_name&quot;:&quot;Judith&quot;,&quot;last_name&quot;:&quot;de Schryver&quot;},{&quot;first_name&quot;:&quot;Sylvia&quot;,&quot;last_name&quot;:&quot;Oestreich&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Neuenschwander&quot;},{&quot;first_name&quot;:&quot;Yvette&quot;,&quot;last_name&quot;:&quot;Roske&quot;},{&quot;first_name&quot;:&quot;Udo&quot;,&quot;last_name&quot;:&quot;Heinemann&quot;},{&quot;first_name&quot;:&quot;Christoph&quot;,&quot;last_name&quot;:&quot;Rademacher&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Volkamer&quot;},{&quot;first_name&quot;:&quot;Jens&quot;,&quot;last_name&quot;:&quot;Peter von Kries&quot;},{&quot;first_name&quot;:&quot;Walter&quot;,&quot;last_name&quot;:&quot;Birchmeier&quot;},{&quot;first_name&quot;:&quot;Marc&quot;,&quot;last_name&quot;:&quot;Nazaré&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14780-14804&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01265&quot;},&quot;abstract&quot;:&quot;The tyrosine phosphatase SHP2 controls the activity of pivotal signaling pathways, including MAPK, JAK-STAT, and PI3K-Akt. Aberrant SHP2 activity leads to uncontrolled cell proliferation, tumorigenesis, and metastasis. SHP2 signaling was recently linked to drug resistance against cancer medications such as MEK and BRAF inhibitors. In this work, we present the development of a novel class of azaindole SHP2 inhibitors. We applied scaffold hopping and bioisosteric replacement concepts to eliminate unwanted structural motifs and to improve the inhibitor characteristics of the previously reported pyrazolone SHP2 inhibitors. The most potent azaindole 45 inhibits SHP2 with an IC50 = 0.031 μM in an enzymatic assay and with an IC50 = 2.6 μM in human pancreas cells (HPAF-II). Evaluation in a series of cellular assays for metastasis and drug resistance demonstrated efficient SHP2 blockade. Finally, 45 inhibited proliferation of two cancer cell lines that are resistant to cancer drugs and diminished ERK signaling.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01265&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01265" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01265&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01265" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01265&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01265" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01265&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01265&amp;href=/doi/10.1021/acs.jmedchem.0c01265" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01265" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01265" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01265%26sid%3Dliteratum%253Aachs%26pmid%3D33210922%26genre%3Darticle%26aulast%3DMostinski%26date%3D2020%26atitle%3DFrom%2BPyrazolones%2Bto%2BAzaindoles%253A%2BEvolution%2Bof%2BActive-Site%2BSHP2%2BInhibitors%2BBased%2Bon%2BScaffold%2BHopping%2Band%2BBioisosteric%2BReplacement%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D14780%26epage%3D14804%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The tyrosine phosphatase SHP2 controls the activity of pivotal signaling pathways, including MAPK, JAK-STAT, and PI3K-Akt. Aberrant SHP2 activity leads to uncontrolled cell proliferation, tumorigenesis, and metastasis. SHP2 signaling was recently linked to drug resistance against cancer medications such as MEK and BRAF inhibitors. In this work, we present the development of a novel class of azaindole SHP2 inhibitors. We applied scaffold hopping and bioisosteric replacement concepts to eliminate unwanted structural motifs and to improve the inhibitor characteristics of the previously reported pyrazolone SHP2 inhibitors. The most potent azaindole <b>45</b> inhibits SHP2 with an IC<sub>50</sub> = 0.031 μM in an enzymatic assay and with an IC<sub>50</sub> = 2.6 μM in human pancreas cells (HPAF-II). Evaluation in a series of cellular assays for metastasis and drug resistance demonstrated efficient SHP2 blockade. Finally, <b>45</b> inhibited proliferation of two cancer cell lines that are resistant to cancer drugs and diminished ERK signaling.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07518" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07518" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The protein tyrosine phosphatase SHP2 is a member of a human protein phosphatases family (PTPs) and encoded by the <i>PTPN11</i> proto-oncogene.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> This ubiquitously expressed enzyme controls the activation of several intracellular signaling pathways, including receptor tyrosine kinase (e.g., met-receptor), MAPK, JAK-STAT, and PI3K-Akt.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> It has been reported that mutations in <i>PTPN11</i> lead to the development of various diseases, such as Noonan syndrome, LEOPARD syndrome, juvenile myelomonocytic leukemia, and several types of solid tumors.<a onclick="showRef(event, 'ref2 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref2 ref5 ref6">(2,5,6)</a> The clear connection between activating mutations of <i>PTPN11</i> and these disorders qualify SHP2 as a highly relevant biological target for the development of anticancer therapeutics. Moreover, the regulatory function of SHP2 in intracellular signaling pathways provides an opportunity for controlling the activity of known oncogenes, such as <i>BRAF</i> and <i>RAS</i>. Identifying alternative ways to block these targets is of utmost importance, especially in view of the emerging clinical threat of drug resistance and relapsing tumors.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> Furthermore, recent reports on previously unrevealed key functions of SHP2 in various intracellular pathways are successively illustrating its key pathophysiological significance in several cancers and in development of drug resistance.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14">(10−14)</a> Therefore, several studies were devoted to the discovery of small-molecule inhibitors of SHP2 as a prime phosphatase target for anticancer therapy.<a onclick="showRef(event, 'ref3 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref3 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25">(3,15−25)</a></div><div class="NLM_p">Structurally, SHP2 consists of three domains—N-terminal and C-terminal SH2 recognition elements and a PTP catalytic domain. When the enzyme is in a basal auto-inhibited state, the SH2 domains are covering the catalytic cavity of the PTP site. After activation by binding of the phosphorylated tyrosine-bearing proteins and peptides to SH2 domains, SHP2 undergoes conformational changes disrupting the autoinhibitory interaction between the SH2 domain and the PTP site, thereby transforming into an open conformation and exposing the substrate-binding catalytic site.<a onclick="showRef(event, 'ref2 ref26'); return false;" href="javascript:void(0);" class="ref ref2 ref26">(2,26)</a> The development of a small molecule that will compete with the endogenous substrates and block the catalytic site is one of the main strategies of inhibition of SHP2 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, compounds <b>1–4</b>).<a onclick="showRef(event, 'ref2 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref2 ref19 ref20 ref21 ref22">(2,19−22)</a> Despite several promising reports, none of the described inhibitors proceeded to advanced clinical studies so far. One of the major reasons for the low success rate in the development of SHP2 inhibitors is the shallow, highly polar, lysine and arginine-rich active site, which is highly conserved among the PTPs.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> Therefore, the design and synthesis of potent but selective and cell-permeable small-molecule inhibitors is a complex and challenging endeavor. Recently, in an attempt to overcome these obstacles of active-site inhibition, allosteric modulation of SHP2 activity was investigated. The allosteric mechanism is based on stabilization of the auto-inhibited conformation of SHP2 by simultaneous binding to all three domains and shifting the equilibrium from the active state to the inactive state (the “inverse agonist principle”). Several small-molecule inhibitors, acting as a so-called “molecular glue”, that bind and inhibit SHP2 through an allosteric mechanism were reported (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, compounds <b>5–6</b>).<a onclick="showRef(event, 'ref17 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref17 ref29 ref30 ref31">(17,29−31)</a> These small molecules demonstrated remarkable phosphatase selectivity and potency, and several candidates entered clinical trials.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> However, some studies indicated that the allosteric modulators may exhibit limited hERG selectivity<a onclick="showRef(event, 'ref15 ref29'); return false;" href="javascript:void(0);" class="ref ref15 ref29">(15,29)</a> and exert a surprisingly low efficacy against distinct oncogenic SHP2 variants in advanced biological studies.<a onclick="showRef(event, 'ref32 ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35 ref36">(32−36)</a> This limitation is associated with the high vulnerability of the allosteric three-domain-binding mode to mutations and to the existing high degree of aberrant activation of SHP2 in several cancers.<a onclick="showRef(event, 'ref32 ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35 ref36">(32−36)</a> Therefore, although allosteric inhibition of SHP2 seems to be an excellent mode of suppression for some oncogenic SHP2 variants, these specific compounds might not be clinically useful to inhibit frequently encountered mutated SHP2 variants.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Consequently, the development of chemically different SHP2 inhibitors, which are less sensitive to oncogenic mutations and underlie a robust mode of action, which address the activated state of SHP2 is highly desirable.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Previously reported SHP2 inhibitors and their IC<sub>50</sub> values. Compounds <b>1–4</b> represent active-site inhibitors and <b>5–6</b> are allosteric binders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In our previous work, we described the development of pyrazolone-based inhibitors of SHP2. The hit candidate PHPS1 was identified through virtual high-throughput screening and optimized to GS493.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> These molecules are selective, active-site-directed competitive inhibitors with prominent activity in enzymatic and cellular assays. We demonstrated that these active-site inhibitors have a remarkable synergistic efficacy with the <i>MEK</i> and <i>BRAF</i> inhibitors and achieved sustained inhibition of tumor cell proliferation <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref7 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref9">(7,9)</a></div><div class="NLM_p last">Despite its potency, the identified compound class possesses several unfavorable functionalities and liabilities, which prevents it from being a suitable platform for further lead optimization. A major concern is related to a chemically unstable hydrazone fragment attached to the pyrazolone scaffold that potentially releases toxic metabolites <i>in vivo</i> and shares structural features belonging to promiscuous pan-assay interference compounds (PAINS).<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> The presence of a nitro group in PHPS1, and in GS493, which incorporates two nitro groups, may account for potential cytotoxicity <i>in vivo</i>,<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> and the sulfonic acid hampers the cell permeability of the inhibitors. However, both the nitro and sulfonic groups are thought to be engaged in key binding interactions with the SHP2 catalytic site, and therefore, their replacement is a challenging task.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> In the current work, we designed and synthesized highly potent, selective, and drug-like inhibitors of SHP2,<a onclick="showRef(event, 'ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45">(43−45)</a> based on the substitution of these detrimental structural features according to structure-activity relationship (SAR) studies, which included scaffold hopping and bioisosteric replacement approaches.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50547" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50547" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Scaffold Hopping of the Pyrazolone Core</h3><div class="NLM_p">Our optimization study started with the investigation of a rescaffolding of the pyrazolone core and elimination of the hydrazone moiety.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> Unfortunately, the cocrystal structure of SHP2 and the respective pyrazolone inhibitor is not available. Moreover, the determination of the endogenous substrates of SHP2 is still limited to date; thus, it is a daunting endeavor to successfully mimic their putative interactions. We therefore resorted to a ligand-based alignment approach preserving the vectorial information and structural features commonly known to be essential to address the phosphatase catalytic mechanism. For the initial attempts of scaffold hopping, we preserved the monocyclic framework by incorporation of the stable carboxamide-imidazole backbone. Unfortunately, the corresponding imidazole analogue <b>8</b> of PHPS1 was inactive (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Supported by comparative alignment studies with PHPS1, we concluded that a more rigid bicyclic core might be crucial for inhibitor binding, as the carboxamide-imidazole backbone is too flexible to provide optimal orientation of the substituents for favorable interactions with the catalytic site. Hence, we proceeded to a conformational lock/ring-closure strategy and synthesized a bicyclic pyrazolo-triazole PHPS1 analogue <b>9</b>, which gratifyingly exhibited inhibitory activity with an IC<sub>50</sub> = 12 μM (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_002.pdf" class="ext-link">Figure S1</a>). This supported our hypothesis that a ring-closure to a bicyclic aromatic system would be a viable strategy for further variations and would not impose significant detrimental effects on the molecular recognition of the peripheral substituents of the small-molecule ligand with the active site of SHP2.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Heterocyclic Candidates for Pyrazolone Scaffold Replacement</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0008.gif" alt="" id="GRAPHIC-d7e612-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0009.gif" alt="" id="gr7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">To evaluate the IC<sub>50</sub> of compounds <b>7–11</b>, a DiFMUP concentration of 20 μM was used. For full assay details see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Lit. value for IC<sub>50</sub> of PHPS1 = 2.1 μM. See ref <a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a>. Other reference compounds values: IC<sub>50</sub> PTP II-B08 = 30 μM; IC<sub>50</sub> NSC-87877 = 4.5 μM.</p></div></div><div></div></div><div class="NLM_p last">This finding led us to examine additional heterocycles, with lower apparent similarity to the pyrazolone hit, but with higher abundance among existing drugs or drug candidates. In addition, we hypothesized that a 5,6-fused system would provide optimal geometrical preorientation, preserving the original trajectory for the sulfonic group.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> We focused our efforts on the replacement of the pyrazolone core by azaindole and indazole analogues. These privileged heterocyclic cores attracted our attention because of their high stability, straightforward synthetic derivatization possibilities, and good drug-like properties.<a onclick="showRef(event, 'ref49 ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51 ref52 ref53">(49−53)</a> Satisfyingly, indazole <b>10</b> and azaindole <b>11</b> showed higher inhibitory activity than the parent triazolo-pyrazole analogue. Because of the highly privileged nature of the azaindole candidate, we considered this framework as the most promising starting point and focused therefore our further optimization efforts on this scaffold.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Chemistry</h3><div class="NLM_p">1,3,5-Trisubstituted 7-azaindoles were synthesized as outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The synthetic route commenced with the iodination of the 3-position of commercially available 5-bromo-7-azaindole <b>12</b> following a previously reported procedure.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The second step involved a Chan-Lam N-arylation to generate intermediate compound <b>14</b>. Unfortunately, the yield of the products was low, despite considerable excess of reagents used. To overcome these limitations, we varied the solvent, base, temperature, and copper source. Nonetheless, no significant improvements in yield were observed. This poor outcome is in line with other literature precedents, where only a scarce number of examples for N-arylation of substituted azaindoles with typically low yields are reported.<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a> The poor outcome of the reaction can be explained by the deactivating nature of the substituents and “trapping” effect of the neighboring nitrogen of the pyridine unit. Subsequent Suzuki couplings required K<sub>2</sub>CO<sub>3</sub>/Pd(dppf)Cl<sub>2</sub> or NaHCO<sub>3</sub>/Pd(PPh<sub>3</sub>)<sub>4</sub> catalytic systems depending on the nature of the employed boron species. In order to overcome the limitations of the Chan-Lam coupling step, we attempted first to carry out Suzuki coupling; however, this transformation failed—no conversion to the desired product was observed and the starting material slowly decomposed over time. Seeking an alternative route, we protected the <i>N1</i> of the azaindole with a Boc moiety, and sequentially substituted the 3- and 5-positions with corresponding aryl groups utilizing Suzuki coupling, followed by removal of the Boc group. The final N-substitution was performed using Ullman conditions (for the detailed scheme see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_002.pdf" class="ext-link">Scheme S1</a>). Overall, the synthesis of azaindoles <b>16</b> was successfully accomplished by both Ullman and Chan-Lam protocols. However, the Ullman protocol requires a protection–deprotection strategy, thus this synthetic path is longer and despite higher yields obtained in each step of this route, it has a similar overall yield. Therefore, we resorted to the Chan-Lam reaction-based approach as the main strategy for the synthesis of the azaindole products. In summary, all compounds could be obtained by the developed synthetic route, which is robust, efficient, and short, providing the final molecules in only four steps. For the preparation of the product with nonaromatic substituents on the pyrrole ring, we replaced the Chan-Lam arylation step by a classic NaH-assisted reaction (for details see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for the compounds <b>28</b> and <b>30–32</b>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Azaindoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions (a) NIS, acetone, rt; 2–4 h, 92% (b) Cu(OAc)<sub>2</sub>, DIPEA, rt, 48 h; 18–21% (c) NaHCO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 3:1 ACN/water, 100 °C, 12 h, 42–69% for the first coupling, 2–98% for the second coupling (d) K<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, dioxane/water, 80 °C, 3–6 h, 22–71% for the first coupling, 2.5–38% for the second coupling.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Bioisosteric Replacement of Nitro and Sulfonic Acid Functionalities and SAR Evaluation of Azaindoles</h3><div class="NLM_p">After rescaffolding of the pyrazolone core, the next step was to investigate the potential for a bioisosteric replacement of the highly charged permeability-hampering sulfonic acid group.<a onclick="showRef(event, 'ref46 ref47 ref57'); return false;" href="javascript:void(0);" class="ref ref46 ref47 ref57">(46,47,57)</a> In stark contrast to previous replacement attempts at the pyrazolone core,<a onclick="showRef(event, 'ref38 ref58'); return false;" href="javascript:void(0);" class="ref ref38 ref58">(38,58)</a> this structural fragment could be successfully exchanged by a simple carboxylic acid (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Compounds <b>17</b> and <b>18</b> bearing such a carboxylic acid in para- or meta-position showed superior inhibitory activity with IC<sub>50</sub> of 0.13 and 0.41 μM, respectively. We therefore concluded that the azaindoles incorporating a benzoic acid functionality would provide a promising basis for further SAR exploration. Moreover, besides the fact that the carboxylic group represents a physiologically much more benign functionality compared to the sulfonic acid, in particular for intracellular targets, it is a convenient synthetic platform for a potential pro-drug approach. Because meta- and para-substituted benzoic acids were similarly active, we continued the SAR exploration aiming for a replacement of the nitro group by testing both benzoic acid isomers and varying the R<sup>2</sup> substitution at the 3-position of the azaindole.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of R<sup>2</sup> and R<sup>3</sup><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0010.gif" alt="" id="GRAPHIC-d7e807-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0011.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Bioisosteric replacement of nitro and sulfonic acid moieties.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">To evaluate the IC<sub>50</sub> of compounds <b>17–27</b>, a DiFMUP concentration of 10 μM was used. For full assay details, see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Reference cmpd values: PHPS1 IC<sub>50</sub> = 0.06 μM; PTP II-B08 IC<sub>50</sub> = 12 μM; NSC-87877 IC<sub>50</sub> = 0.41 μM; PTP1B inhibitor IC<sub>50</sub> = 3.1 μM.</p></div></div><div></div></div><div class="NLM_p">Finding an appropriate replacement of the nitro moiety has proven to be challenging<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> because systematic studies of a general bioisosteric relationship of the nitro functionality with other chemical groups are lacking. Intuitively, strong electron-withdrawing groups, such as trifluoromethyl and −CN, are used for bioisosteric substitution of the nitro functionality.<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a> In addition, the incorporation of oxygen- and nitrogen-containing heterocycles such as oxazolines and oxadiazoles was found to be beneficial in several reports.<a onclick="showRef(event, 'ref63 ref64 ref65 ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref63 ref64 ref65 ref66 ref67">(63−67)</a> Guided by these observations, we prepared several analogues of <b>17</b> and <b>18</b>, replacing the nitro group (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) and tested their ability to inhibit SHP2. Several azaindoles demonstrated good activity with IC<sub>50</sub> values below 1 μM, among the analogues containing a trifluoromethyl group <b>21</b> and <b>22</b>, nitrile-bearing analogue <b>27</b>, and the benzoxadiazoles <b>19</b> and <b>20</b>, the latter being particularly promising, because of their lower lipophilicity. The good inhibitory effect of these derivatives aligns well with previous findings, showing the ability of the small molecules bearing nitro-benzoxadiazole to inhibit the closely related PTP1B enzyme.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Moreover, the benzoxadiazole moiety is highly fluorescent, and it provides an additional useful feature for the intended cellular permeability studies. Compounds <b>23–26</b>, however, demonstrated only moderate activity, compared to the nitro analogue <b>17</b>. A dioxolane-bearing derivative <b>26</b> supported the assumption that a strong electron-withdrawing group might be required for the successful replacement of the nitro moiety. Along these lines, pyridines <b>23–24</b> and the pyrimidine <b>25</b> analogue indicated that the presence of a protruding substituent is indispensable to establish these important interactions with the binding cavity. At this point by comparing the activity of several pairs of the meta–para benzoic acid isomers, we had sufficient evidence to conclude that the para-derivative outperforms the meta-analogue, and we therefore decided to utilize para-<b>19</b> as a platform for the next optimization step exploring the <i>N1</i>-azaindole substitution.</div><div class="NLM_p">Despite their good biological activity, the novel compounds showed only limited aqueous solubility because of the flat aromatic, hence highly lipophilic structure. Consequently, we introduced variations at R<sup>1</sup> aiming for a higher solubility while maintaining or improving the activity (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Our previous docking studies of the parent pyrazolone<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> indicated that this aromatic ring is not engaged in hydrogen bond interactions with the SHP2 enzyme, and thus, we assumed a higher degree of freedom for the modification of this moiety. For example, we synthesized isopropyl-bearing derivative <b>28</b>, a known bioisostere for aromatic rings. However, despite this assumption, analogue <b>28</b> was lacking any significant activity. We then attempted to outbalance affinity versus solubility by the introduction of a bulky but hydrophilic tosylate group, but the compound <b>29</b> showed considerably reduced inhibition of SHP2. Even small changes such as introducing a methylene spacer to enhance conformational flexibility in compounds <b>30</b> and <b>31</b> resulted in a decrease of activity, indicating detrimental interactions with the protein environment at the catalytic site. The same trend was observed with the meta-methoxy analogue <b>32</b>. Installation of a simple unsubstituted phenyl group (compound <b>33</b>) resulted in improved activity, but as expected, the solubility was further reduced. In an additional effort to circumvent the solubility limitations, we synthesized azaindazole congener <b>34</b> of the most promising compound <b>19</b>. We speculated that an azaindazole with an auxiliary nitrogen on the heterocyclic scaffold may enhance solubility and cellular permeability. Unfortunately, the solubility of azaindazole <b>34</b> was low, which was reflected in the absence of activity because of precipitation under assay conditions. We further tried to increase the solubility of the azaindazole by incorporating the tetrahydropyran (THP) ether instead of the R<sup>1</sup> aromatic ring, but the corresponding azaindazole <b>35</b> was only weakly active. Overall, the first iteration in this SAR study again confirmed compound <b>19</b> as the best template for the subsequent second optimization round.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Investigation of the Scope for a Broader R1 Variation toward Improved Solubility</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0012.gif" alt="" id="GRAPHIC-d7e971-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0013.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">To evaluate the IC<sub>50</sub> of compounds <b>28-33</b>, a DiFMUP concentration of 10 μM was used. For full assay details, see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Reference cmpd values: PHPS1 IC<sub>50</sub> = 0.06 μM; PTP II-B08 IC<sub>50</sub> = 12 μM; NSC-87877 IC<sub>50</sub> = 0.41 μM; PTP1B inhibitor IC<sub>50</sub> = 3.1 μM.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">To evaluate the IC<sub>50</sub> of compounds <b>34–35</b>, a DiFMUP concentration of 20 μM was used.</p></div></div><div></div></div><div class="NLM_p">Here, we focused our attention on the R<sup>3</sup> residue, bearing the carboxylic group (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). This functionality was found to be pivotal in previous and current studies.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Therefore, we hypothesized that finding the optimal position in the catalytic pocket addressing ARG465 by salt-bridge formation may be most beneficial for enhanced activity. More flexible and shorter nonaromatic moieties were therefore tethered to provide compounds <b>36–38</b>. Here, we observed the strong trend of the inhibitor activity improvement with the increase in length and rigidity of the R<sup>3</sup> substituent. Thus, the aromatic ring as a spacer was confirmed to have favorable properties for achieving the optimal position and interactions of the carboxylic acid. To validate the importance of a negatively charged carboxylic acid and the flexibility to a further bioisosteric replacement, we constructed ester <b>39</b> and sulfonamide <b>40</b>. As expected, deletion of the charged carboxylic acid by an ester moiety (<b>39</b>) decreased the inhibitor activity significantly. Intriguingly, the sulfonamide acid analogue <b>40</b> was highly active, which indicates that a sulfonamide moiety may serve as an appropriate bioisostere of the sulfonic and carboxylic acid in this context.<a onclick="showRef(event, 'ref25 ref69'); return false;" href="javascript:void(0);" class="ref ref25 ref69">(25,69)</a> Next, taking into consideration the pseudo symmetrical “propeller” nature of the decorated azaindoles, we anticipated that our small-molecule inhibitor may have various possible orientations for occupying the catalytic pocket. To test our hypothesis, we synthesized the analogue <b>41</b>, in which the critical affinity generating moieties, that is, the carboxylic acid and the benzoxadiazole at R<sup>2</sup> and R<sup>3</sup> were inverted. In line with our expectation, <b>41</b> was able to inhibit SHP2 with a remarkable IC<sub>50</sub> = 0.065 μM. This supported our assumption that the benzoxadiazole and carboxylic groups could be swapped. We speculated that the azaindole bearing two carboxylic acids may exhibit superior activity and may possess synthetic advantages such as one-pot functionalization of 3- and 5-positions. However, the corresponding analogue <b>42</b> exhibited surprisingly low inhibitory activity. Replacement of the carboxylic acid at R<sup>2</sup> by an aromatic lactone <b>43</b> restored the activity; however, the compound was highly unstable and underwent fast hydrolysis to its inactive open carboxylic acid analogue <b>44</b> under any storage and assay conditions. To overcome this stability issue and in search for an isomorphic noncharged hybrid moiety, resembling the benzoxadiazole and a hydrolysis-resistant lactone group, we replaced the benzo lactone at residue R<sup>2</sup> by a stable coumarine lactone. Gratifyingly, the corresponding compound <b>45</b> was found to have the highest inhibitory activity on SHP2 within the entire SAR study with an IC<sub>50</sub> = 0.031 μM. We therefore proceeded to investigate the most active azaindole of the series with regard to phosphatase and kinase selectivity and studies in advanced cellular models of metastasis and drug resistance. We also performed docking and molecular dynamic experiments to validate the SAR study findings.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Second Iteration of SAR Studies</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0014.gif" alt="" id="GRAPHIC-d7e1094-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0015.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">To evaluate the IC<sub>50</sub> of the compounds <b>36–42</b> and <b>45</b>, a DiFMUP concentration of 10 μM was used. Reference cmpd values: PHPS1 IC<sub>50</sub> = 0.062 μM; PTP II-B08 IC<sub>50</sub> = 12 μM; NSC-87877 IC<sub>50</sub> = 0.41 μM; PTP1B inhibitor IC<sub>50</sub> = 3.1 μM.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">To evaluate the IC<sub>50</sub> of the compounds <b>43-44</b>, a DiFMUP concentration of 20 μM was used.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">PTP1B inhibitor IC<sub>50</sub> reference value for <b>45</b> is 2.5 μM.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Structural Basis of Inhibition—Docking and Molecular Dynamics</h3><div class="NLM_p">To rationalize the SAR of the presented ligand series, compounds were docked into the SHP2 catalytic domain of PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X">3O5X</a><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> using the OpenEye Python Toolkit.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> The cocrystalized ligand of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X">3O5X</a> was employed in the hybrid docking method<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> implemented in OEDocking to guide the ligand placement because it contains a benzoic acid similar to the majority of compounds of the investigated ligand series (<b>17–45</b>).</div><div class="NLM_p">Similar to the cocrystalized inhibitor of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X">3O5X</a>, the most consistent binding mode of docked compounds involves a charge interaction with ARG465 and a π–cation interaction with LYS366 as identified with LigandScout 4.4<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> (see <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The hydrogen bonds with the backbone nitrogen of ARG465 and the thiol of CYS459 are only observed in case of the cocrystalized inhibitor of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X">3O5X</a>, which is consistent with the lack of a hydroxyl group at the benzoic acid moiety of the investigated compound series. Additionally, the identified binding mode involves a hydrophobic contact with TYR279, a further π–cation interaction with LYS364 and hydrogen bonds with ASN281 and GLN506. This binding mode could be observed for compounds <b>17–21</b>, <b>27</b>, <b>33</b>, <b>41</b>, and <b>45</b>, which all show an IC<sub>50</sub> below 1 μM (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_002.pdf" class="ext-link">Figure S2</a>). Interestingly, albeit the azaindole moiety of the two most active compounds <b>41</b> and <b>45</b> is placed in two different orientations, the docking poses allow almost identical interactions (see <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). This symmetric behavior can also be observed for compound <b>19</b>, in which R<sup>2</sup> and R<sup>3</sup> are inverted compared to compound <b>41</b>, but compound <b>19</b> still shows considerable inhibitory potency. The lower potency of compound <b>19</b> could thereby be explained by less favorable hydrogen bond interactions formed by the benzoxadiazole moiety, which is perfectly embedded between ASN281 and GLN506 in case of compound <b>41</b>. The importance of hydrogen bonds with these two residues is also supported by the decreased activity of compounds <b>23</b>, <b>24</b>, and <b>25</b>, which contain either a pyridine or a pyrimidine group at R<sup>2</sup> that are too limited in size to perform suitable hydrogen bonding interactions. In line with that, docking poses indicate an acceptor-like interaction formed by the fluorine atoms of the trifluoromethyl groups of active compounds <b>21</b> and <b>22</b> with ASN281 and GLN506. However, the lower activity of compound <b>26</b> cannot be easily explained with this binding mode because it contains a benzodioxolane that would allow for favorable hydrogen bond interactions similar to the benzoxadiazole moiety of compound <b>19</b>. Possibly, the more flexible nonplanar nature of the dioxolane ring prevents the formation of the optimal interactions.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding mode of cocrystalized ligand (II-B08) of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X">3O5X</a><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> (A) and of compounds <b>41</b> (B) and <b>45</b> (C) observed in docking studies targeting the catalytic domain of SHP2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X">3O5X</a><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>). Yellow sphere—hydrophobic interaction, red arrow—hydrogen bond acceptor, red asterisk—negative ionizable, blue ring—aromatic interaction. Figure produced using LigandScout 4.4.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Switching the carboxyl group of R<sup>3</sup> from para- (compounds <b>17</b>, <b>19</b>, <b>21</b>, and <b>23</b>) to meta-position (compounds <b>18</b>, <b>20</b>, <b>22</b>, and <b>24</b>) results in all pairs in a drop of inhibitory potency, which can be rationalized by a less favorable position of the aromatic ring not allowing π–cation interactions with LYS366 (see <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_002.pdf" class="ext-link">Figure S2</a>). The absence of suitable interactions with LYS366 and ARG465 could also explain the reduced activity of compounds <b>36</b>, <b>37</b>, <b>38</b>, and <b>39</b> that are either too limited in size, miss the aromatic character needed for π–cation interactions, or cannot participate in a charged interaction with ARG465. The high activity of compound <b>40</b> can be attributed to the relatively low p<i>K</i><sub>a</sub> of the aryl-sulfonamide moiety, making the sulfonamide proton sufficiently acidic for effective hydrogen bond interaction.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><div class="NLM_p">The activity results from compounds <b>28–33</b> clearly indicate a strong preference for rigid structures with an aromatic moiety at R<sup>3</sup>. Compound <b>28</b> lacks any aromatic character on the R<sup>1</sup> position and was inactive at a testing concentration of 10 μM. Compounds <b>29–31</b> introduce a rotatable bond that may result in an entropic penalty when binding to the catalytic domain of SHP2. Compound <b>32</b> was synthesized with the methoxy group in meta-position that may either clash with the protein or point into the solvent, which could explain its reduced activity compared to compound <b>19</b> with a methoxy group in para-position. Interestingly, compound <b>33</b> with an unsubstituted benzene moiety shows improved inhibitory potency compared to its para-methoxy-substituted counterpart <b>19</b>, which is supported by the observation that the methoxy group is not involved in any critical interactions.</div><div class="NLM_p">The docking poses of compounds <b>41</b> and <b>45</b> present the most favorable interaction pattern observed within the investigated ligand series, which is also reflected by their superior inhibitory potency. To evaluate the identified binding mode further, the docking pose of the most active compound <b>45</b> was subjected to unbiased MD Simulation using Desmond 6.1.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> An analysis of the root-mean-squared deviation (rmsd) of ligand and protein atoms in VMD 1.9.3<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> revealed a similar behavior for protein and ligand motions (see <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Although the ligand appears to leave the position after 4 ns, it returns to the initial binding mode quickly. In conclusion, the binding pose stayed stable over 20 ns of MD simulation, which underlines the validity of the identified binding mode.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Results from a 20 ns MD simulation of SHP2 in complex with the most active compound <b>45</b>. (A) Depiction of 10 snapshots taken every 2 ns. (B) rmsd plot for ligand and protein atoms. Figures produced using PyMOL 1.8.6<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> and Microsoft Excel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Phosphatase Selectivity</h3><div class="NLM_p">Selective active-site inhibition of PTPs, including SHP2, has proven to be an extremely challenging task, primarily because of the highly conserved and positively charged nature of the PTP active site. We therefore tested the most potent azaindole <b>45</b> against a panel of 10 representative PTPs. Selectivity was high and greater than 35-fold for PP1B, PP1A, PTPRC/CD45, DUSP22/MKPX, and PTPN2/TC-PTP and satisfyingly good for PTP1B (13-fold) but, however, only moderate with a 4-fold selectivity for the closely related phosphatase SHP1 (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Phosphatase Selectivity Evaluation for Compound <b>45</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">selectivity ratio</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SHP2</td><td class="colsep0 rowsep0" align="left">0.031</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PP1B</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PP1A</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PP2A alpha/PP2R1A complex</td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTPN6/SHP1</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left">4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTPRC/CD45</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DUSP22/MKPX</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTPN2/TC-PTP</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTPN7/LC-PTP</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left">4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTPN12/PTP-PEST</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left">4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTPN1/PTP1B-CD</td><td class="colsep0 rowsep0" align="left">0.41</td><td class="colsep0 rowsep0" align="left">13</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">For full experimental conditions, see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_002.pdf" class="ext-link">Table S1</a>.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Evaluation of Kinase Activity</h3><div class="NLM_p">As the rescaffolding studies of our SHP2 inhibitor yielded the azaindole core as a highly abundant and privileged kinase inhibitor motif in drug discovery,<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> we wanted to exclude any off-target kinase activity. The crucial feature for kinase inhibition, in particular when decorated with aromatic moieties at the 3- and 5-positions, is the hydrogen bond donor–acceptor pattern of the unsubstituted NH donor at <i>N1</i> and the pyrrolidine nitrogen at the 7-position of azaindoles with the hinge region of kinases.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Albeit, in principle, the installation of any functional group at this <i>N1</i> nitrogen should abolish off-target kinase activity, we wanted to examine and confirm this against a representative panel of kinases. For comparison, we used the benzofurazan-bearing molecule <b>46</b>, which is the truncated analogue of <b>19</b> without the crucial substituent at <i>N1</i> of the azaindole. Interestingly, several kinase inhibitors incorporate such a benzofurazan moiety.<a onclick="showRef(event, 'ref77 ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref77 ref78 ref79">(77−79)</a> Both compounds were tested against a general panel of ten house-keeping kinases at high concentration (100 μM) and low ATP concentration (10 μM). As expected, N-substituted azaindoles showed only negligible inhibition of the kinases (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). In contrast, the <i>N1</i>-truncated derivative <b>46</b> when tested against the same kinase panel was significantly more prone to kinase recognition and showed compelling kinase inhibition for CDK1, AKT1, KDR, RSK1, and TRKA. Moreover, <b>46</b> was tested against SHP2 and was 26-fold less active than parent <b>19</b> (IC<sub>50</sub> = 6.1 μM), highlighting again the significance of the <i>N1</i> aryl substitution. Thus, despite apparent structural similarity between inhibitors <b>46</b> and <b>19</b>, the <i>N1</i> aryl moiety turned out to be a prominent selectivity switch driving inhibition toward the desired enzyme class of either phosphatase or kinase. The most active compound <b>45</b> was tested against the same panel of kinases and showed low interference (for detailed results see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_002.pdf" class="ext-link">Table S3</a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Structural Differences and Similarities of Kinase and Phosphatase Inhibitors<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0016.gif" alt="" id="GRAPHIC-d7e1614-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">% enzyme inhibition</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center" char="."><b>19</b> (100 μM)</th><th class="colsep0 rowsep0" align="center" char="."><b>46</b> (100 μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AKT1</td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Src</td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK1/cyclin B</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="char" char=".">–35<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">–95<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KDR/VEGFR2</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char=".">92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRb</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKA</td><td class="colsep0 rowsep0" align="char" char=".">–43<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RIPK2</td><td class="colsep0 rowsep0" align="char" char=".">–3</td><td class="colsep0 rowsep0" align="char" char=".">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RSK2</td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TRKA</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">97</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">For full experimental conditions, see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_002.pdf" class="ext-link">Table S2</a>.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Negative values might indicate precipitation under assay conditions.</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Evaluation of Azaindole Inhibitor <b>45</b> in Cellular Models of Metastasis and Tumor Resistance</h3><div class="NLM_p">We next turned our attention to the evaluation of our most active inhibitor <b>45</b> in more advanced cellular models of metastasis and drug resistance. First, we investigated if <b>45</b> was able to block HGF-induced cell scattering and branching morphogenesis of the human pancreatic adenocarcinoma cell line HPAF-II. This cellular system recapitulates the metastatic process of cell spreading and outgrowth and has been shown to be strongly dependent on SHP2 activation.<a onclick="showRef(event, 'ref4 ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref4 ref80 ref81">(4,80,81)</a> Compound <b>45</b> was tested against HPAF-II pancreatic cancer cells in different concentrations and clearly showed a dose-dependent ability of the azaindole <b>45</b> to block the HGF-induced scattering phenotype (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A,B). Concentration-dependent quantification of the inhibitory effect by analysis of minimum neighbor distances of proximal Hoechst stained nuclei revealed an IC<sub>50</sub> = 2.6 μM, while the previous reference pyrazolone GS493 showed an IC<sub>50</sub> of 3.4 μM. Blocking of the cell scattering and reversal of this phenotype was further confirmed by impedance measurements as a second independent readout (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D,E). In addition, <b>45</b> showed good cell permeability and intracellular enrichment in the absence of any signs of cell toxicity over 24 h (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_002.pdf" class="ext-link">Figure S3</a>). To further confirm and preclude any interference of these results with a perturbation of the cellular viability or any other nonspecific effect, we proceeded to investigate cytotoxicity of <b>45</b> in HPAF-II and HepG2 cells in a long-term incubation of 72 h at high concentration of up to 40 μM. Again, no significant cytotoxic effects could be observed in the relevant concentration range in both cell lines, even under these prolonged incubation times (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Azaindoles inhibit HGF-induced cell separation in scatter and impedance assays in HPAF-II pancreatic cancer cells. (A) The HPAF-II cell colonies were dissociated because of stimulation with HGF in the control cells (−HGF/+HGF). Treatment with compound <b>45</b> causes inhibition of cell scattering. (B) Quantification of changes in cell scattering was done by analysis of minimum neighbor distances. The mean ± SD values are shown, representing the relative activity compared to control conditions (+HGF/1, −HGF/0). (C) HPAF-II and HepG2 cells were exposed with different concentrations of compounds for 72 h. Cytotoxicity was determined by fluorescence microscopy using TO-PRO-3 staining for dead cell quantification. Mean values ± SD of damaged cells are indicated. (D) Impedance assay displays the changes in cell attachment and spreading because of HGF stimulation during the first 4 h, where the maximum cell index value was reached for the positive control (+HGF). The normalized cell index curves show a clear dose-dependent inhibition by the compound <b>45</b>. (E) Impedance assay dose–response curve. The graph shows the result of the end-point analysis after 4 h HGF exposure and treatment with compound <b>45</b>, demonstrating the inhibitory effect. The relative activity of normalized cell index values compared to control conditions (+HGF/1, −HGF/0) are displayed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Compound <b>45</b> Blocks Proliferation in Two Drug-Resistant Cancer Cell Lines and Inhibits ERK Signaling</h3><div class="NLM_p">Previous investigations have shown that simultaneous inhibition of SHP2 and MEK have a synergistic effect and allow for superior tumor growth control in RAS-mutant tumors.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> In addition, cooperative inhibition of BRAF and SHP2 can overcome resistance to BRAF inhibitors mediated by EGFR activation in colon cancer cells.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> We therefore investigated if <b>45</b> in combination with BRAF inhibitor PLX4032 could also block proliferation of BRAF inhibitor-resistant VACO432 colon cancer cells in a colony formation assay. While both PLX4032 and <b>45</b> exhibited only a small effect when applied as single compounds, VACO432 cell proliferation was markedly inhibited by <b>45</b>/PLX4032 cotreatment (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). A similar result was obtained in HCC1806 breast cancer cells, which are resistant to PI3K inhibition by BYL719 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). In this model, <b>45</b> sensitized HCC1806 cells considerably to BYL719 treatment, while monotreatment with these compounds was not as effective.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Synergistic combination of <b>45</b> with BYL719 and PLX4032 in VACO432 and HCC1806 cell lines. (A) <i>In vitro</i> coinhibition by PLX4032 (vemurafenib) and SHP2 (<b>45</b>) in colony formation experiments with the VACO432 human colorectal cancer cell line. (B) <i>In vitro</i> coinhibition by BYL719 (alpelisib) and SHP2 (<b>45</b>) in colony formation experiments with the HCC1806 human breast cancer cell line. Three independently repeated experiments were performed with similar results. (C) Blocking of ERK phosphorylation by PLX4032 and <b>45</b> cotreatment. Inhibition of ERK feedback reactivation is sustained after 48 h compared to PLX4032 monotreatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To evaluate the biochemical effect on ERK signaling of <b>45</b> and PLX4032 treatment, we subjected treated VACO432 cell lysates to western blotting. Cells treated with PLX4032 alone retained considerable phosphorylated ERK levels after 24 and 48 h. This explains the BRAF inhibitor-resistant phenotype because ERK activity is essential for the proliferation of these cells. In contrast, cotreatment with <b>45</b> and PLX4032 led to a substantial decrease in ERK phosphorylation compared to PLX4032 monotreatment (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). Taken together, these results show that <b>45</b> is capable of preventing a BRAF inhibitor-resistant phenotype in a colon cancer cell line model and a PI3K inhibitor-resistant phenotype in a breast cancer cell line. In VACO432 cells, this is explained by the ability of <b>45</b> to effectively inhibit ERK signaling, when used in combination with PLX4032.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24365" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24365" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We identified a novel class of azaindole SHP2 inhibitors, based on scaffold hopping of a previously reported pyrazolone framework and subsequent refinement by SAR optimization. Successful replacement of all physiologically incompatible functionalities provided a much more drug-like lead platform, which incorporates a privileged azaindole core, as well as coumarine and benzofurazan moieties, present in numerous approved drugs. The novel azaindole inhibitors showed high activity against SHP2, with an IC<sub>50</sub> of 0.031 μM for <b>45</b>. Docking studies aligned well with the observed SAR trends and provided a structural rationalization for the inhibitor binding mode. This could be further supported by molecular dynamic studies for the most active azaindole <b>45</b> showing that the identified binding poses were stable.</div><div class="NLM_p last">SHP2 activity was further cross-validated in advanced cellular assays recapitulating metastatic tumor outgrowth and drug-resistant tumor cells. In impedance and scatter assay treatment of HPAF-II pancreatic cancer cells with <b>45</b> led to almost full reversion of an HGF-induced scattering phenotype. Compound <b>45</b> exhibited synergistic activity in combination with BYL719 and PLX4032 and was able to inhibit cell proliferation in drug-resistant VACO432 colorectal cancer and HCC1806 breast cancer cells. Remarkably, the azaindole-based inhibitor showed no signs of unspecific cytotoxicity and was not active against a panel of representative kinases, distinguishing it from the parent pyrazolone. In view of recently increased interest toward SHP2 and the urge of finding adequate therapeutic approaches for drug resistance and tumor relapse, we believe that our compounds can serve as a platform for further lead optimization and as a valuable chemical tool for unraveling the (patho-)physiological role of SHP2 in cancer.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11240" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11240" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Chemistry</h3><div class="NLM_p last">All chemicals were purchased from commercial suppliers: Fluorochem, Sigma-Aldrich, and Alfa Aesar and used as received unless otherwise specified. NMR spectra were recorded at either 295 K (300 MHz) or 300 K (600 MHz) at either Bruker AV 300 (300, 75 MHz) or Bruker AV 600 (600, 151 MHz) spectrometers. Chemical shifts are reported in ppm (δ) referenced to TMS (δ = 0.00 ppm), dimethylsulfoxide (DMSO) (2.50 ppm), and CHCl<sub>3</sub> (7.26 ppm). LC/MS analysis was performed on an Agilent LC/MS 1260 analytical HPLC with DAD coupled to an Agilent 6120 single quadrupole mass spectrometer (ESI-SQ) equipped with a Thermo Fisher Scientific Accucore C18 column, 2.1 × 30 mm, 2.6 μm. Method: ESI<sup>+</sup>, flux: 0.8 mL/min, 5–95% CH<sub>3</sub>CN in H<sub>2</sub>O + 0.1% FA, total runtime: 2.5 min. High-resolution mass spectra were recorded on an Agilent 6220A accurate-mass time-of-flight mass spectrometer (ESI-TOF) with Agilent 1200 HPLC/DAD front-end. The HPLC was equipped with an Agilent Poroshell 120, C18 column, 2.1 × 100 mm, 1.8 μm. Method: ESI<sup>+</sup>, flux: 0.6 mL/min, 5–99% CH<sub>3</sub>CN in H<sub>2</sub>O + 0.1% FA, total runtime: 4.5 min. Unless otherwise stated, all compounds were purified using an Isolera one Biotage flash chromatography system utilizing silica gel-packed columns RediSep Rf from Teledyne Isco. Purity and characterization of all final compounds was established by a combination of LC–MS, LC–HRMS, and NMR analytical techniques. All compounds were found to be >95% pure by LC–MS and LC–HRMS analysis unless otherwise stated.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Synthesis of Carboxamido-indazole <b>8</b></h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Methyl 3-(4-Nitrophenyl)-2,3-dioxopropanoate (<b>47</b>)</h4><div class="NLM_p last">Methyl 3-(4-nitrophenyl)-2,3-dioxopropanoate (<b>47</b>) was synthesized according to previously reported procedure.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Briefly, methyl 3-(4-nitrophenyl)-3-oxo-2-(triphenyl-l5-phosphaneylidene)propanoate (2.0 g, 4.14 mmol, 1.0 equiv) was dissolved in 10 mL dichloromethane (DCM) and added to a stirred solution of DMSO in acetone (0.1 M, 103 mL). The mixture was stirred for 1 h at room temperature after which the solvent was evaporated. The crude product was purified by column chromatography (SiO<sub>2</sub>, cyclohexane/ethylacetate 100:0 → 40:60) to obtain <b>47</b> in 83% yield (878 mg).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Methyl 4-(4-Nitrophenyl)-2-phenyl-1<i>H</i>-imidazole-5-carboxylate (<b>48</b>)</h4><div class="NLM_p last"><b>47</b> (878 mg, 3.44 mmol, 1 equiv) and benzaldehyde (0.702 mL, 6.88 mmol, 2 equiv) were added to a slurry of ammonium acetate (2.65 g) in acetic acid (10 mL). The mixture was stirred 2 h at 70 °C, then cooled to room temperature, and concentrated <i>in vacuo</i>. The crude mixture was redissolved in ethylacetate and washed with water, NaHCO<sub>3</sub>, and brine. The ethylacetate layer was dried with MgSO<sub>4</sub> and concentrated <i>in vacuo</i>. The crude was purified by flash chromatography using EtOAc in cyclohexane as the eluent to obtain <b>48</b> in 9% yield (110.2 mg, 0.340 mmol, yellow amorphous solid). LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>13</sub>N<sub>3</sub>O<sub>4</sub> 323.30 (M + H)<sup>+</sup>; found, 323.95 (M + H)<sup>+</sup>.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4-(4-Nitrophenyl)-2-phenyl-1<i>H</i>-imidazole-5-carboxylic Acid (<b>49</b>)</h4><div class="NLM_p last"><b>48</b> (110.2 mg, 0.34 mmol, 1 equiv) was dissolved in MeOH (4 mL), and LiOH (2 mL, 1 M) was added. The mixture was stirred for 3 h under microwave irradiation at 90 °C. The progress of the reaction was monitored by LCMS (3.3 min; M + H<sup>+</sup> = 309.95). After reaction completion, the mixture was diluted with water and acidified with HCl to a pH = 2–3. The precipitated product was collected by suction filtration. The filter cake was washed with sufficient water and dried in vacuum to yield <b>49</b> in 95% (102 mg, 0.329 mmol). The crude product was taken to the next step without further purification.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-(4-(4-Nitrophenyl)-2-phenyl-1<i>H</i>-imidazole-5-carboxamido)benzenesulfonic Acid (<b>8</b>)</h4><div class="NLM_p last"><b>49</b> (100.0 mg, 0.32 mmol, 1 equiv), <i>p</i>-sulfanilic acid (56.0 mg, 0.32 mmol, 1 equiv), EDCI (43.7 mg, 0.32 mmol, 1 equiv), HOBT (62.0 mg, 0.32 mmol, 1 equiv), and DMAP (4.0 mg, 0.032 mmol, 0.1 equiv) were stirred in dimethylformamide (DMF) (3 mL) at room temperature for 72 h. The solution was poured to 1 M HCl (5 mL) and extracted with EtOAc 2 × 10 mL. The product was precipitated, and the solids were collected by suction filtration. The filter cake was washed with little EtOAc and dried <i>in vacuo</i>, yielding <b>8</b> in 27% (40 mg, 0.08 mmol, yellow amorphous solid). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.23 (s, 1H), 8.35 (d, <i>J</i> = 8.8 Hz, 2H), 8.25–8.13 (m, 4H), 7.76 (d, <i>J</i> = 8.5 Hz, 2H), 7.65–7.38 (m, 5H).</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Synthesis of Pyrazolo-triazole <b>9</b></h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>tert</i>-Butyl 2-Cyano-3-(4-nitrophenyl)-3-oxopropanoate (<b>50</b>)</h4><div class="NLM_p last">To a stirred suspension of sodium hydride (60%, 400 mg, 10.0 mmol) in tetrahydrofuran (THF) <i>tert</i>-butyl-cyano acetate (0.77 mL, 5.39 mmol) was added dropwise at 0 °C, and the reaction mixture was stirred for 30 min. After addition of 4-nitro-benzoic acid chloride (1.00 g, 5.39 mmol), the reaction mixture was allowed to warm to room temperature over a period of 6 h and was brought to pH = 3 by treatment with concentrated HCl. After extraction with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL), the combined organic layers were dried (MgSO<sub>4</sub>) and filtered, and the solvent was removed under reduced pressure. <i>tert</i>-Butyl 2-cyano-3-(4-nitrophenyl)-3-oxopropanoate (1.56 g, 100%) was obtained as a yellow amorphous solid and used in the next step without further purification. The crude product <i>tert</i>-butyl 2-cyano-3-(4-nitrophenyl)-3-oxopropanoate (1.55 g, 5.34 mmol) was dissolved in AcCN (10 mL), treated with trifluoroacetic acid (TFA) (5 mL) and pyridine (3 mL), and heated under reflux for 22 h. The reaction solution was concentrated in vacuum, the residue was diluted with H<sub>2</sub>O and extracted with CH<sub>2</sub>Cl<sub>2</sub> (4 × 20 mL). The combined organic layers were dried (MgSO<sub>4</sub>) and filtered, and the solvent was removed under reduced pressure to give <b>50</b> (635 mg, 3.34 mmol, 62% over 2 steps) as a yellow amorphous solid. Compound <b>50</b> was used in the next step without further purification.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 3-(4-Nitrophenyl)-1-phenyl-1<i>H</i>-pyrazol-5-amine (<b>51</b>)</h4><div class="NLM_p last">A mixture of nitrile <b>50</b> (300 mg, 1.58 mmol) and phenylhydrazine hydrochloride (228 mg, 1.58 mmol) in MeOH (2 mL) was heated at 120 °C for 45 min in a microwave. Filtering of the resulting precipitate and washing with MeOH yield pyrazole <b>51</b> (484 mg, 1.53 mmol, 97%) as a colorless amorphous solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.27 (d, <i>J</i> = 8.6 Hz, 2H, Ar–H), 8.05 (d, <i>J</i> = 8.7 Hz, 2H, Ar–H), 7.69 (d, <i>J</i> = 7.9 Hz, 2H, Ar–H), 7.55 (t, <i>J</i> = 7.7 Hz, 2H, Ar–H), 7.41 (t, <i>J</i> = 7.3 Hz, 1H, Ar–H), 6.10 (s, 1H, Ar–H), 5.62 (s, 2H, −NH<sub>2</sub>) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 149.3, 148.4, 146.8, 140.5, 139.4, 129.7, 127.3, 126.3, 124.5, 123.7, 88.3. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>13</sub>N<sub>4</sub>O<sub>2</sub> 281.1033 (M + H)<sup>+</sup>; found, 281.1032 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>E</i>)-4-((5-Amino-3-(4-nitrophenyl)-1-phenyl-1<i>H</i>-pyrazol-4-yl)diazenyl)benzenesulfonic Acid (<b>52</b>)</h4><div class="NLM_p last">Phenylsulfonic acid (570 mg, 3.33 mmol) was dissolved in 2 M HCl (1 mL), and the solution was cooled to 0 °C, followed by addition of NaNO<sub>2</sub> (215 mg, 3.12 mmol) in H<sub>2</sub>O (2.5 mL). Amine <b>51</b> (583 mg, 2.0 mmol) and NaOAc (850 mg) were suspended in EtOH (11 mL) and added dropwise to the reaction mixture. After warming to room temperature, the precipitate was filtered off and washed with H<sub>2</sub>O. Drying in high vacuum gave <b>52</b> (366 mg, 0.75 mmol, 40%) as orange amorphous solid, which was used directly in the next step without further purification. LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>16</sub>N<sub>6</sub>O<sub>5</sub>S<sup>+</sup> 465.10 (M + H)<sup>+</sup>; found, 465.03 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-(6-(4-Nitrophenyl)-4-phenylpyrazolo[3,4-<i>d</i>][1,2,3]triazol-2(4<i>H</i>)-yl)benzenesulfonic Acid (<b>9</b>)</h4><div class="NLM_p last">Diazene <b>52</b> (200 mg, 0.39 mmol) was dissolved in anhydrous DMF (8 mL), and CuSO<sub>4</sub>·5H<sub>2</sub>O (96 mg, 0.39 mmol) as well as K<sub>2</sub>CO<sub>3</sub> (320 mg, 2.32 mmol) was added subsequently. After heating under reflux for 5 h, the solvent was removed, and the solid was washed with H<sub>2</sub>O and dried in high vacuum to give <b>9</b> (140 mg, 0.30 mmol, 78%) as a brown oily solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.51 (d, <i>J</i> = 8.9 Hz, 2H), 8.47 (d, <i>J</i> = 8.8 Hz, 2H), 8.30 (d, <i>J</i> = 8.6 Hz, 2H), 8.15 (d, <i>J</i> = 7.9 Hz, 2H), 7.91 (d, <i>J</i> = 8.7 Hz, 2H), 7.68 (t, <i>J</i> = 7.9 Hz, 2H), 7.39 (t, <i>J</i> = 7.4 Hz, 1H) ppm. HRMS (neg. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>13</sub>N<sub>6</sub>O<sub>5</sub>S<sup>–</sup> 461.0674 [M – H]<sup>−</sup>; found, 461.0682 [M – H]<sup>−</sup>.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Synthesis of Indazole <b>10</b></h3><div class="NLM_p"><i>tert</i>-Butyl 5-bromo-3-(4-nitrophenyl)-1<i>H</i>-indazole-1-carboxylate (<b>53</b>) was prepared utilizing <i>tert</i>-butyl 5-bromo-3-iodo-1<i>H</i>-indazole-1-carboxylate (29.1 mg, 0.305 mmol, 1 equiv), Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (29 mg, 0.04 equiv), 4-nitrophenylboronic acid pinacol ester (76.0 mg, 0.305 mmol, 1.0 equiv), and K<sub>2</sub>CO<sub>3</sub> (1.22 mmol, 0168.9 g, 4 equiv) in degassed dioxane/water (1:3, 0.06 M) at 80 °C for 1 h. The solution was allowed to cool to room temperature, diluted with EtOAc and H<sub>2</sub>O, and extracted with EtOAc. The combined organic layers were dried with MgSO<sub>4</sub> and concentrated <i>in vacuo</i>. The crude product was checked by LCMS and contained product <b>53</b> (LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 440.1/442.0 (M + Na)<sup>+</sup>, <i>R</i><sub><i>t</i></sub> = 1.44 min), and boc-deprotected product (318.1/320.1 (M + H)<sup>+</sup>, <i>R</i><sub><i>t</i></sub> = 1.23 min), and the mixture was taken to the next step without further purification.</div><div class="NLM_p">5-(4-((Neopentyltrioxidaneyl)thio)phenyl)-3-(4-nitrophenyl)-1<i>H</i>-indazole (<b>54</b>) was prepared utilizing <b>53</b> (ca. 0.305 mmol, 1 equiv, crude, mixture of boc-protected and deprotected azaindole), Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (30 mg, 0.038 mmol, 0.12 equiv), neopentyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonate (134 mg, 0.380 mmol, 1.24 equiv), and K<sub>2</sub>CO<sub>3</sub> (1.21 mmol, 210 mg, 5 equiv) in degassed dioxane/water (1:3, 0.06 M) at 80 °C for 1 h. The solution was allowed to cool to room temperature, diluted with EtOAc and H<sub>2</sub>O, and extracted with EtOAc. The combined organic layers were dried with MgSO<sub>4</sub> and concentrated <i>in vacuo</i>. The crude product was purified by column chromatography to provide title compound <b>54</b> (20 mg, 14% for 2 steps, yellow amorphous solid). LCMS: <i>m</i>/<i>z</i> 440.1/442.0 (M + Na)<sup>+</sup>, <i>R</i><sub><i>t</i></sub> = 1.38 min. Alternatively, collected <i>tert</i>-butyl 5-(4-((neopentyltrioxidaneyl)thio)phenyl)-3-(4-nitrophenyl)-1<i>H</i>-indazole-1-carboxylate may be submitted to a Boc deprotection with TFA in DCM for 2 h to provide <b>54</b> in quantitative yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.50–8.36 (m, 2H), 8.29–8.14 (m, 3H), 8.06–7.98 (m, 2H), 7.90–7.67 (m, 4H), 3.77 (s, 2H), 0.96 (s, 11H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 466.2 (M + H)<sup>+</sup>.</div><div class="NLM_p last">4-(1-(4-Methoxyphenyl)-3-(4-nitrophenyl)-1<i>H</i>-indazol-5-yl)benzenesulfonic acid (<b>10</b>) was prepared as follows: <b>54</b> (90 mg, 0.19 mmol, 1 equiv) was dissolved in dioxane (12 mL), and then <i>trans</i>-1,2-cyclohexanediamine (21.6 mg, 0.096 mmol, 0.5 equiv), CuI (3.6 mg, 0.0096 mmol, 0.05 equiv), K<sub>3</sub>PO<sub>4</sub> (84 mg, 0.38 mmol, 2 equiv), and 4-methoxy-1-iodobenzene (9 mg, 0.038 mmol, 1.2 equiv) were added sequentially. The reaction was heated to 100 °C and stirred for 24 h, then solution was allowed to cool to room temperature, diluted with EtOAc and H<sub>2</sub>O, and extracted with EtOAc. The crude product was dissolved in DMF (2 mL), TBAF (75 mg, 0.69 mmol, 4 equiv) was added, and the reaction stirred for 2 h. The mixture was concentrated <i>in vacuo</i> and purified by HPLC (30–100% ACN in water) to yield 4-(1-(4-methoxyphenyl)-3-(4-nitrophenyl)-1<i>H</i>-indazol-5-yl)benzenesulfonic acid <b>10</b> (17 mg, 0.034 mmol, 18% for 2 steps, light-orange amorphous solid). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.53–8.37 (m, 4 H), 7.94–7.85 (m, 2H), 7.85–7.68 (m, 6H), 3.92–3.84 (m, 2H), 3.88 (s, 3H). HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>19</sub>N<sub>3</sub>O<sub>6</sub>S, 502.1067 [M + H]<sup>+</sup>; found, 502.1054 [M + H]<sup>+</sup>.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Synthesis of the Compounds <b>11</b> and <b>17–46</b></h3><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> General Procedure A: Cham–Lam Coupling of Azaindoles</h4><div class="NLM_p">To a stirred suspension of 5-bromo-3-iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine, boronic acid (2.5–3.0 equiv) and Cu(OAc)<sub>2</sub> (2.5–3.0 equiv) in DCM (0.026 M), DIPEA (2.5–4.5 equiv) was added in one portion. After stirring for 48 h at room temperature, the mixture was filtered and concentrated <i>in vacuo</i>. The crude product was purified by column chromatography (SiO<sub>2</sub>, cyclohexane/DCM) to yield N-arylated 5-bromo-3-iodo azaindoles.</div><div id="sec4_5_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 5-Bromo-3-iodo-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>55</b>)</h5><div class="NLM_p last">General procedure A was applied using 5-bromo-3-iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (1.0 g, 3.1 mmol), (4-methoxyphenyl)boronic acid (1.18 g, 7.75 mmol), Cu(OAc)<sub>2</sub> (1.41 g, 7.75 mmol) and DIPEA (1.4 mL, 7.75 mmol). The crude product was purified by column chromatography (SiO<sub>2</sub>, cyclohexane/DCM, 26–50% DCM) to give <b>55</b> in 21% yield (270.0 mg, 0.63 mmol, white amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.39–8.32 (m, 1H), 7.94–7.88 (m, 1H), 7.56–7.47 (m, 3H), 7.08–7.00 (d, <i>J</i> = 8.9 Hz, 2H), 3.87 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 158.9, 145.8, 145.4, 133.7, 131.8, 130.3, 125.9 (2C), 125.4, 114.9 (2C), 113.3, 55.8, 54.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>11</sub>BrIN<sub>2</sub>O, 428.9094/430.9075 [M + H]<sup>+</sup>; found, 428.9072/430.9054 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 5-Bromo-3-iodo-1-isopropyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>56</b>)</h5><div class="NLM_p last">NaH (60% in oil, 84 mg, 1.36 mmol) was added to a stirred solution of 5-bromo-3-iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (400 mg, 1.24 mmol, 1 equiv) in DMF (50 mL) at 0 °C. After stirring of the reaction mixture for 5 min, 2-bromopropane (174 μL, 1.86 mmol, 1.5 equiv) was added. The mixture was stirred for 1 h at room temperature and then quenched with 50 mL water. The water layer was extracted three times with 50 mL of DCM, and the combined organic layers were dried over MgSO<sub>4</sub> and concentrated <i>in vacuo</i>. The crude product was extracted two times with 150 mL of hot Et<sub>2</sub>O. The organic layers were combined, filtered, and evaporated to dryness to give <b>56</b> in 88% yield (400 mg, 1.096 mmol). The compound was used directly for the next reaction step without further purification. LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>11</sub>BrIN<sub>2</sub>, 364.9/366.9 [M + H]<sup>+</sup>; found, 364.8/366.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 5-Bromo-3-iodo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>57</b>)</h5><div class="NLM_p last">To a stirred solution of 5-bromo-3-iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (4.00 g, 12.4 mmol) in DMF was added NaH (60%, 573 mg, 14.3 mmol) in small portions. Then, TosCl was added, and the solution was stirred at room temperature for 3 h. After addition of H<sub>2</sub>O, the precipitate was filtered off, the water layer was extracted three times with 50 mL of DCM, and the combined organic layers were dried over MgSO<sub>4</sub> and concentrated <i>in vacuo</i>. The crude product was purified by column chromatography (SiO<sub>2</sub>, cyclohexane/DCM, 26–50% DCM) to give <b>57</b> (3.23 g, 54%, white amorphous solid). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.55–8.45 (1H, m), 8.22 (s, 1H), 8.04–7.95 (m, 3H), 7.46–7.34 (m, 2H), 2.34 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 146.1, 146.0, 144.4, 133.9, 132.4, 131.9, 130.2 (2C), 127.7 (2C), 126.6, 115.7, 63.1, 21.1. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>11</sub>BrIN<sub>2</sub>O<sub>2</sub>S, 476.8764/478.8744 [M + H]<sup>+</sup>; found, 476.8743/478.8722 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 1-Benzyl-5-bromo-3-iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>58</b>)</h5><div class="NLM_p last">NaH (60% in oil, 180 mg, 4.5 mmol, 3 equiv) was added to a stirred solution of 5-bromo-3-iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (500 mg, 1.5 mmol, 1 equiv) in DMF (50 mL). After stirring of the reaction mixture for 30 min, benzyl bromide (267 μL, 2.25 mmol, 1.5 equiv) was added. The mixture was stirred for 12 h at room temperature and then quenched with water. The water layer was extracted three times with DCM, and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. The crude product <b>58</b> (650 mg) was pure enough as judged by NMR and used for the next reaction step without further purification.</div></div><div id="sec4_5_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 5-Bromo-3-iodo-1-(4-methoxybenzyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>59</b>)</h5><div class="NLM_p last">NaH (60% in oil, 84 mg, 1.36 mmol) was added to a stirred solution of 5-bromo-3-iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (400 mg, 1.24 mmol, 1 equiv) in DMF (50 mL) at 0 °C. After stirring of the reaction mixture for 5 min, 4-methoxylbenzyl bromide (267 μL, 1.86 mmol, 1.5 equiv) was added. The mixture was stirred for 1 h at room temperature and then quenched with 50 mL water. The water layer was extracted three times with 50 mL of DCM, and the combined organic layers were dried over MgSO<sub>4</sub> and concentrated <i>in vacuo</i>. The crude was extracted two times with 150 mL of Et<sub>2</sub>O under reflux. The hot solutions were combined, filtered, and evaporated to dryness. The residue was triturated with 8 mL of Et<sub>2</sub>O, sonicated for 5 min, filtered, and dried <i>in vacuo</i> to give <b>59</b> in 49% yield (292 mg, 0.659 mmol). The compound was used directly for the next step without further purification LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>13</sub>BrIN<sub>2</sub>O; 442.9/444.9 [M + H]<sup>+</sup>; found, 442.9/444.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 5-Bromo-3-iodo-1-(3-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>60</b>)</h5><div class="NLM_p last">General procedure A was applied using 5-bromo-3-iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (2.0 g, 6.2 mmol), (3-methoxyphenyl)boronic acid (2.36 g, 15.5 mmol), Cu(OAc)<sub>2</sub> (2.8 g, 15.5 mmol), and DIPEA (2.72 mL, 15.5 mmol). The crude product was purified by column chromatography (SiO<sub>2</sub>, cyclohexane/DCM, 26–50% DCM) to give 5-bromo-3-iodo-1-(3-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>60</b> in 21% yield (535 mg, 1.2 mmol, white amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.43–8.38 (m, 1H), 7.97–7.89 (m, 1H), 7.63 (s, 1H), 7.43 (d, <i>J</i> = 8.1 Hz, 1H), 7.28–7.16 (m, 2H), 6.94 (ddd, <i>J</i> = 8.4, 2.5, 0.9 Hz, 1H), 3.89 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 160.3, 145.5, 145.3, 138.3, 133.2, 131.7, 130.2, 125.6, 116.0, 113.5, 112.7, 110.0, 55.5, 55.3. HRMS (pos. ESI): <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>11</sub>BrIN<sub>2</sub>O, 428.9094/430.9075 [M + H]<sup>+</sup>; found, 428.9116/430.9098 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 5-Bromo-3-iodo-1-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>61</b>)</h5><div class="NLM_p last">General procedure A was adapted using 5-bromo-3-iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (1.5 g, 4.6 mmol), phenylboronic acid (1.7 g, 13.8 mmol, 3 equiv), Cu(OAc)<sub>2</sub> (2.5 g, 13.8 mmol, 3 equiv), and DIPEA (3.6 mL, 22.5 mmol, 4.5 equiv) that was added in one portion. After stirring for 48 h at room temperature, the mixture was filtered and concentrated <i>in vacuo</i>. The crude product was purified by column chromatography (SiO<sub>2</sub>, cyclohexane/DCM, 26–50% DCM) to give <b>61</b> in 18% yield (340 mg, 0.85 mmol, beige amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.42–8.32 (m, 1H), 7.95–7.89 (m, 1H), 7.74–7.62 (m, 2H), 7.62 (s, 1H), 7.57–7.45 (m, 2H), 7.46–7.34 (m, 1H). LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>9</sub>BrIN<sub>2</sub>, 398.9/400.9 [M + H]<sup>+</sup>; found, 398.8/400.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> Methyl 3-Iodo-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carboxylate (<b>62</b>)</h5><div class="NLM_p last">General procedure A was applied using methyl 3-iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carboxylate (2.22 g, 7.3 mmol), <i>p</i>-methoxyphenylboronic acid (2.8 g, 18.0 mmol), Cu(OAc)<sub>2</sub> (3.34 g, 18 mmol), and DIPEA (3.6 mL, 18 mmol) that was added in one portion. After stirring for 48 h at room temperature, the mixture was filtered and concentrated <i>in vacuo</i>. The crude product was purified by column chromatography (SiO<sub>2</sub>, cyclohexane/DCM, 26–50% DCM) to give methyl 3-iodo-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carboxylate <b>62</b> in 20% yield (588 mg, 1.44 mmol, white amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 9.02–8.95 (m, 1H), 8.45–8.37 (m, 1H), 7.59 (s, 1H), 7.58–7.50 (m, 2H), 7.13–7.69 (m, 2H), 3.97 (s, 3H), 3.85 (s, 3H). LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>14</sub>IN<sub>2</sub>O<sub>3</sub>, 409.0 [M + H]<sup>+</sup>; found, 408.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_1_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 5-Bromo-3-iodo-1-(4-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine (<b>63</b>)</h5><div class="NLM_p last">5-Bromo-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine (2.1 g, 6.5 mmol), (4-methoxyphenyl)boronic acid (1.10 g, 7.2 mmol, 1.2 equiv), and Cu(OAc)<sub>2</sub> (1.17 g, 6.5 mmol, 1 equiv) were mixed in MeOH (170 mL). After stirring for 48 h at room temperature, the mixture was filtered and concentrated <i>in vacuo</i>. The crude product was purified by column chromatography (SiO<sub>2</sub>, cyclohexane/DCM 74:26 → 50:50) to obtain <b>63</b> (590.0 mg, 0.13 mmol, 21%, yellowish amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.44–8.36 (m, 1H), 7.96–7.92 (m, 1H), 7.60–7.50 (m, 3H), 7.11–7.03 (d, <i>J</i> = 8.9 Hz, 2H), 3.88 (s, 3H). LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>10</sub>BrIN<sub>3</sub>O, 429.9/431.9 [M + H]<sup>+</sup>; found, 429.8/431.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_1_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 5-Bromo-3-iodo-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine (<b>64</b>)</h5><div class="NLM_p last">5-Bromo-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine (500.0 mg, 1.54 mmol, 1 equiv) was dissolved in EtOAc (9 mL), and then catalytic amounts of <i>p</i>-TSA and DHP (260.0 mg, 2.09 mmol, 2 equiv) were added sequentially at room temperature. The mixture was heated to 60 °C and stirred for 12 h. The solution was allowed to cool and concentrated <i>in vacuo</i>. The crude product was purified by column chromatography (SiO<sub>2</sub>, cyclohexane/DCM 74:26 → 50:50) to give 5-bromo-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine <b>64</b> in 80% yield (500 mg, 1.23 mmol, yellowish oily solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.62 (d, <i>J</i> = 2.1 Hz, 1H), 7.98 (d, <i>J</i> = 2.1 Hz, 1H), 6.05 (dd, <i>J</i> = 10.5, 2.5 Hz, 1H), 4.17–4.02 (m, 1H), 3.85–3.65 (m, 1H), 3.57–3.32 (m, 1H), 2.73–2.50 (m, 1H), 2.00 (ddd, <i>J</i> = 15.6, 5.0, 2.8 Hz, 1H), 1.67–1.56 (m, 3H). LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>10</sub>BrIN<sub>3</sub>O, 407.9/409.9 [M + H]<sup>+</sup>; found, 407.9/409.9 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> General Procedure B: Suzuki Coupling Using Pd(PPh<sub>3</sub>)<sub>4</sub></h4><div class="NLM_p last">Pd(PPh<sub>3</sub>)<sub>4</sub> (0.075 equiv) was added to a stirred solution of heterocyclic halide (1 equiv), boronic acid or boronate ester (1.2 equiv), and NaHCO<sub>3</sub> (3 equiv) in degassed H<sub>2</sub>O/MeCN (1:3, 0.02 M) at 100 °C. The resulting reaction mixture was stirred for 12–16 h under N<sub>2</sub>. The solution was allowed to cool to room temperature, diluted with DCM and H<sub>2</sub>O, and extracted with DCM. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub> or MgSO<sub>4</sub> and concentrated <i>in vacuo</i>. The crude product was purified by column chromatography to yield the substituted product or recrystallization and silica filtration to yield the substituted product or used directly as a crude for the further step.</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> General Procedure C: Suzuki Coupling Using Pd(dppf)Cl<sub>2</sub></h4><div class="NLM_p">Heterocyclic halide (1 equiv), Pd(dppf)Cl<sub>2</sub> (0.025 equiv), boronic acid or boronate ester (1.0–1.2 equiv), and K<sub>2</sub>CO<sub>3</sub> (3 equiv) were dissolved in degassed H<sub>2</sub>O/dioxane (1:3, 0.06 M), and the resulting reaction mixture was stirred for 3–12 h at 80 °C under N<sub>2</sub>. The solution was allowed to cool to room temperature, diluted with DCM and H<sub>2</sub>O, and extracted with DCM. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub> or MgSO<sub>4</sub> and concentrated <i>in vacuo</i>. The crude product was purified by column chromatography or recrystallization and silica filtration to yield the product. In some cases, the product was pure enough and used without further purification in the subsequent reaction step.</div><div id="sec4_5_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 5-Bromo-(1-(4-methoxyphenyl)-3-(4-nitrophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine) (<b>65</b>)</h5><div class="NLM_p last">General B was applied using halide <b>55</b> (770 mg, 1.795 mmol), 4,4,5,5-tetramethyl-2-(4-nitrophenyl)-1,3-dioxolane (541 mg, 2.153 mmol), NaHCO<sub>3</sub> (453.7 mg, 5.38 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (156 mg, 0.134 mmol) in 70 mL of 3:1 MeCN/H<sub>2</sub>O. The reaction mixture was diluted with DCM (25 mL) and water (25 mL). The aqueous phase was extracted three times with DCM (25 mL). The organic phases were combined, dried over MgSO<sub>4</sub>, and evaporated to dryness. The crude residue was boiled with 10 mL of MeOH, sonicated, and filtered to yield crude 5-bromo-1-(4-methoxyphenyl)-3-(4-nitrophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>65</b> (300 mg, 0.131 mmol, amorphous orange solid). The compound was directly used in the next reaction step without further purification. LCMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>15</sub>BrN<sub>3</sub>O<sub>3</sub>, 424.0/426.0[M + H]<sup>+</sup>; found, 423.9/425.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 5-(5-Bromo-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole (<b>66</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>55</b> (300 mg, 0.7 mmol), benzo[<i>c</i>][1,2,5]oxadiazole-5-boronic acid pinacol ester (206 mg, 0.84 mmol), NaHCO<sub>3</sub> (176 mg, 2.1 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (61 mg, 0.05 mmol), and 35 mL of 3:1 MeCN/H<sub>2</sub>O. Purification of the crude by flash column chromatography (SiO<sub>2</sub>, 0–30% ethyl acetate in cyclohexane) yielded 5-(5-bromo-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole <b>66</b> in 51% yield (150 mg, 0.36 mmol, yellow amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.49–8.43 (m, 2H), 8.02 (s, 1H), 7.94 (dd, <i>J</i> = 9.5 Hz, 1.0, 1H), 7.83 (s, 1H), 7.74 (dd, <i>J</i> = 9.4, 1.4 Hz, 1H), 7.66–7.54 (m, 2H), 7.15–7.06 (m, 2H), 3.92 (s, 3H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.2, 149.7, 148.1, 146.1, 144.3, 136.9, 133.7, 131.2, 129.9, 129.5, 125.6 (2C), 119.7, 116.4, 114.4, 113.4 (2C), 112.6, 109.3, 55.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>14</sub>BrN<sub>4</sub>O<sub>2</sub>, 421.0295/423.0277 [M + H]<sup>+</sup>; found, 421.0272/423.0252 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> 5-Bromo-1-(4-methoxyphenyl)-3-(4-(trifluoromethyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>67</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>55</b> (300 mg, 0.69 mmol), 4-trifluorohenylboronic acid (146 mg, 0.77 mmol), K<sub>2</sub>CO<sub>3</sub> (290 mg, 2.1 mmol), and Pd(dppf)Cl<sub>2</sub> (13 mg, 0.017 mmol) in 13 mL of 3:1 dioxane/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 0–40% ethyl acetate in cyclohexane, slow gradient) provided 5-bromo-1-(4-methoxyphenyl)-3-(4-(trifluoromethyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>67</b> in 39% yield (122 mg, 0.27 mmol, white amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.47–8.39 (m, 1H), 8.38–8.29 (m, 1H), 7.76–7.70 (m, 4H), 7.62 (s, 1H), 7.60 (d, <i>J</i> = 8.5 Hz, 2H), 7.07 (d, <i>J</i> = 8.3 Hz, 2H), 3.88 (s, 3H). LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>15</sub>BrF<sub>3</sub>N<sub>2</sub>O, 447.0/449.0 [M + H]<sup>+</sup>; 447.1/449.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> 5-Bromo-1-(4-methoxyphenyl)-3-(pyridin-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>68</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>55</b> (280 mg, 0.65 mmol), 3,4-pyridinylboronic acid (79 mg, 0.65 mmol), K<sub>2</sub>CO<sub>3</sub> (269 mg, 1.95 mmol), and Pd(dppf)Cl<sub>2</sub> (11 mg, 0.015 mmol) in 8 mL of 3:1 dioxane/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 0–100% EtOAc in cyclohexane) yielded 5-bromo-1-(4-methoxyphenyl)-3-(pyridin-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>68</b> in 34% yield (85 mg, 0.22 mmol, white amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.79–8.65 (m, 2H), 8.54–8.37 (m, 2H), 7.82 (s, 1H), 7.69–7.53 (m, 4H), 7.20–7.01 (m, 2H), 3.89 (s, 3H). LCMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>15</sub>BrN<sub>3</sub>O, 380.0/382.0 [M + H]<sup>+</sup>; found, 380.0/382.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 5-Bromo-1-(4-methoxyphenyl)-3-(pyrimidin-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>69</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>55</b> (200 mg, 0.46 mmol), 3-5,5-pyrimidinboronic acid (57 mg, 0.46 mmol), K<sub>2</sub>CO<sub>3</sub> (192 mg, 1.3 mmol), and Pd(dppf)Cl<sub>2</sub> (9 mg, 0.012 mmol) in 6 mL of 6:2 dioxane/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 0–100% EtOAc in cyclohexane) yielded 5-bromo-1-(4-methoxyphenyl)-3-(pyrimidin-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine in an inseparable mixture with triphenylphosphine oxide. The impure product <b>69</b> was used for the next reaction step without further purification.</div></div><div id="sec4_5_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> 3-(Benzo[<i>d</i>][1,3]dioxol-5-yl)-5-bromo-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>70</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>55</b> (300 mg, 0.69 mmol), benzo[<i>d</i>][1,3]dioxol-5-ylboronic acid (138 mg, 0.82 mmol), NaHCO<sub>3</sub> (174 mg, 2.0 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (60 mg, 0.05 mmol) in 40 mL of 3:1 MeCN/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 0–40% ethyl acetate in cyclohexane, slow gradient) yielded 3-(benzo[<i>d</i>][1,3]dioxol-5-yl)-5-bromo-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>70</b> in 42% yield (124 mg, 0.29 mmol, white amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.47–8.38 (m, 1H), 8.38–8.27 (m, 1H), 7.68–7.60 (m, 2H), 7.53 (s, 1H), 7.16–7.03 (m, 4H), 7.01–6.89 (m, 1H), 6.02 (s, 2H), 3.87 (s, 3H), <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 158.6, 148.4, 146.7, 146.3, 144.5, 130.9, 130.3, 127.8, 126.3, 125.7 (2C), 121.0, 120.7, 116.0, 114.8 (2C), 112.8, 109.1, 107.9, 101.3, 55.7. LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>16</sub>BrN<sub>2</sub>O<sub>3</sub>, 423.0/425.0 [M + H]<sup>+</sup>; found, 423.07425.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> 4-((5-(4-Bromophenyl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile) (<b>71</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>55</b> (300 mg, 0.69 mmol), 4-cyanophenylboronic acid (112 mg, 0.77 mmol), K<sub>2</sub>CO<sub>3</sub> (290 mg, 2.1 mmol), and Pd(dppf)Cl<sub>2</sub> (13 mg, 0.017 mmol) in 13 mL of 3:1 dioxane/H<sub>2</sub>O. After extraction of the water layer with DCM and drying with Na<sub>2</sub>SO<sub>4</sub>, the solution was concentrated under vacuum until the formation of a precipitate. The precipitate was collected by filtration and dried under vacuum to give 4-(5-(4-bromophenyl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>71</b> in 28% yield (78 mg, 0.19 mmol, white amorphous solid). This solid was taken to the next reaction step without further purification as NMR and LCMS analysis revealed that the compound was pure enough.</div></div><div id="sec4_5_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 5-(5-Bromo-1-isopropyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole (<b>72</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>56</b> (250 mg, 0.564 mmol), benzo[<i>c</i>][1,2,5]oxadiazole-5-boronic acid (167 mg, 0.677 mmol), K<sub>2</sub>CO<sub>3</sub> (233 mg, 1.692 mmol), and Pd(dppf)Cl<sub>2</sub> (10.3 mg, 0.014 mmol) in 10 mL of 3:1 dioxane/H<sub>2</sub>O, and the reaction was stirred at 55 °C. The mixture was diluted with DCM (30 mL) and extracted two times with 10% K<sub>2</sub>CO<sub>3</sub> solution, followed by brine. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was stirred with 10 mL of Et<sub>2</sub>O under sonication for 5 min. The supernatant was removed (repeated twice), and the remaining solid was dried <i>in vacuo</i>. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 0% to 40% ethyl acetate in cyclohexane, slow gradient) provided 5-(5-bromo-1-isopropyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole <b>72</b> in 71% yield (280 mg, 0.784 mmol, yellow amorphous solid). LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>14</sub>BrN<sub>4</sub>O, 357.03/359.03 [M + H]<sup>+</sup>; found, 357.0/359.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 5-(5-Bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole (<b>73</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>57</b> (1.00 g, 2.10 mmol), benzo[<i>c</i>][1,2,5]oxadiazole-5-boronic acid pinacol ester (619 mg, 2.520 mmol), NaHCO<sub>3</sub> (528 mg, 6.29 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (174 mg, 0.151 mmol) in 100 mL of MeCN, and 33.3 mL of H<sub>2</sub>O. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 0–100% ethyl acetate in cyclohexane) yielded 5-(5-bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole <b>73</b> in 69% yield (630 mg, 0.13 mmol, yellow amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.57–8.52 (m, 1H), 8.34–8.27 (m, 1H), 8.18–8.05 (m, 3H), 7.98 (d, <i>J</i> = 9.6 Hz, 2H), 7.72–7.61 (m, 1H), 7.34 (d, <i>J</i> = 8.2 Hz, 2H), 2.41 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 149.5, 148.5, 146.7, 146.3, 145.8, 135.5, 134.6, 132.2, 131.1, 129.9 (2C), 128.6 (2C), 126.0, 122.2, 117.8, 117.3, 116.1, 112.8, 21.8. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>14</sub>BrN<sub>4</sub>O<sub>3</sub>S, 468.9965 [M + H]<sup>+</sup>; found, 468.9936 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> 5-(1-Benzyl-5-bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole (<b>74</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>58</b> (334 mg, 0.809 mmol), benzo[<i>c</i>][1,2,5]oxadiazole-5-boronic acid (238 mg, 0.970 mmol), K<sub>2</sub>CO<sub>3</sub> (336 mg, 2.43 mmol), and Pd(dppf)Cl<sub>2</sub> (15 mg, 0.020 mmol) in 13 mL of 3:1 dioxane/H<sub>2</sub>O. The mixture was diluted with DCM and extracted two times with water, followed by brine. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was stirred with Et<sub>2</sub>O under sonication for 5 min. The supernatant was removed, and the remaining solid was dried <i>in vacuo</i> to give 5-(1-benzyl-5-bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole <b>74</b> in 57% yield (188 mg, 0.464 mmol, brown oily solid). The product was used in the next reaction step without further purification. LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>14</sub>BrN<sub>4</sub>O, 405.03/407.03 [M + H]<sup>+</sup>; found, 404.9/406.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 5-(5-Bromo-1-(4-methoxybenzyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole (<b>75</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>59</b> (250 mg, 0.564 mmol), benzo[<i>c</i>][1,2,5]oxadiazole-5-boronic acid (167 mg, 0.677 mmol), K<sub>2</sub>CO<sub>3</sub> (233 mg, 1.692 mmol), and Pd(dppf)Cl<sub>2</sub> (10.3 mg, 0.014 mmol) in 10 mL of 3:1 dioxane/H<sub>2</sub>O. The mixture was diluted with DCM (30 mL) and extracted two times with 10% K<sub>2</sub>CO<sub>3</sub> solution, followed by brine. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was stirred with 10 mL of Et<sub>2</sub>O under sonication for 5 min. The supernatant was removed (repeated twice), and the remaining solid was dried <i>in vacuo</i> to give 5-(5-bromo-1-(4-methoxybenzyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole <b>75</b> in quantitative yield (272 mg, 0.625 mmol, brown amorphous solid). The product was taken for the next step without further purification. LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>16</sub>BrN<sub>4</sub>O<sub>2</sub>, 435.04/437.04 [M + H]<sup>+</sup>; found, 434.9/437.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> 5-(5-Bromo-1-(3-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole (<b>76</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>60</b> (535 mg, 1.24 mmol), benzo[<i>c</i>][1,2,5]oxadiazole-5-boronic acid pinacol ester (307 mg, 1.24 mmol), K<sub>2</sub>CO<sub>3</sub> (513 mg, 2.1 mmol), and Pd(dppf)Cl<sub>2</sub> (18 mg, 0.05 mmol) in 24 mL of 3:1 dioxane/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 0–40% ethyl acetate in hexane) yielded 5-(5-bromo-1-(3-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole <b>76</b> in 43% yield (210 mg, 0.53 mmol, yellow amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.49 (s, 1H), 8.45 (s, 1H), 8.02 (s, 1H), 7.95 (d, <i>J</i> = 9.3 Hz, 1H), 7.87 (s, 1H), 7.75 (d, <i>J</i> = 9.3 Hz, 1H), 7.53–7.42 (m, 1H), 7.38–7.27 (m, 2H), 6.97 (d, <i>J</i> = 8.3 Hz, 1H), 3.90 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 160.6, 149.9, 148.5, 146.6, 145.5, 138.4, 136.9, 132.7, 130.6, 130.5, 128.3, 120.7, 117.4, 116.5, 114.4, 114.0, 113.1, 111.0, 110.7, 55.7. LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>14</sub>BrN<sub>4</sub>O<sub>2</sub>, 421.0/423.0 [M + H]<sup>+</sup>; found, 420.9/423.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> 5-(5-Bromo-1-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole (<b>77</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>61</b> (200 mg, 0.5 mmol), benzo[<i>c</i>][1,2,5]oxadiazole-5-boronic acid pinacol ester (123 mg, 0.5 mmol), K<sub>2</sub>CO<sub>3</sub> (207 mg, 1.5 mmol), and Pd(dppf)Cl<sub>2</sub> (9.2 mg, 0.0125 mmol) in 10 mL of 3:1 dioxane/H<sub>2</sub>O. The obtained crude product (117 mg) was analyzed by LCMS and NMR and was pure enough for the next reaction step without further purification.</div></div><div id="sec4_5_3_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> 5-(5-Bromo-1-(4-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole (<b>78</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>63</b> (300 mg, 0.70 mmol), benzo[<i>c</i>][1,2,5]oxadiazole-5-boronic acid pinacol ester (205 mg, 0.84 mmol), NaHCO<sub>3</sub> (180 mg, 2.14 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (59 mg, 0.052 mmol) in 40 mL of 3:1 MeCN/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (0–50% ethyl acetate in cyclohexane) gave 5-(5-bromo-1-(4-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole <b>78</b> in 38% yield (110 mg, 0.26 mmol, yellow amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.74–8.68 (m, 1H), 8.70–8.57 (m, 1H), 8.41–8.27 (m, 2H), 8.19–8.09 (m, 2H), 8.07–7.94 (m, 1H), 7.16–7.07 (m, 2H), 3.90 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 158.8, 150.6, 149.6, 149.5, 149.0, 140.2, 135.8, 132.1, 131.9, 131.8, 123.6 (2C), 117.4, 116.2, 114.7, 114.6 (2C), 112.9, 77.2, 55.8.</div></div><div id="sec4_5_3_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> 5-(5-Bromo-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole (<b>79</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>64</b> (385 mg, 0.94 mmol), benzo[<i>c</i>][1,2,5]oxadiazole-5-boronic acid pinacol ester (280 mg, 1.1 mmol), NaHCO<sub>3</sub> (235 mg, 2.8 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (81 mg, 0.07 mmol) in 55 mL of 3:1 MeCN/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (0–40% ethylacetate in cyclohexane) gave 5-5-(5-bromo-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole <b>79</b> in 54% yield (200 mg, 0.5 mmol, yellow amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.67 (d, <i>J</i> = 2.1 Hz, 1H), 8.57 (d, <i>J</i> = 2.1 Hz, 1H), 8.37–8.20 (m, 2H), 7.96 (dd, <i>J</i> = 9.7, 0.8 Hz, 1H), 6.20 (dd, <i>J</i> = 10.4, 2.6 Hz, 1H), 4.28–4.09 (m, 1H), 4.00–3.78 (m, 1H), 2.85–2.62 (m, 1H), 2.30–2.14 (m, 1H), 2.11–1.98 (m, 1H), 1.93–1.57 (m, 3H).</div></div><div id="sec4_5_3_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> Methyl 4-(5-Bromo-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzoate (<b>80</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>55</b> (304 mg, 0.71 mmol), 4-methoxycarbonylphenylboronic acid (127 mg, 0.71 mmol), K<sub>2</sub>CO<sub>3</sub> (293 mg, 2.11 mmol), and 13 mg (0.017 mmol) of Pd(dppf)Cl<sub>2</sub>, 13 mL of 3:1 dioxane/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 0–50% EtOAc in cyclohexane) yielded methyl 4-(5-bromo-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzoate <b>80</b> in 22% yield (65 mg, 0.15 mmol, white amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.45–8.34 (m, 2H), 8.15 (d, <i>J</i> = 8.2 Hz, 2H), 7.77–7.66 (m, 3H), 7.61 (d, <i>J</i> = 8.4 Hz, 2H), 7.07 (d, <i>J</i> = 8.2 Hz, 2H), 3.96 (s, 3H), 3.88 (s, 3H). LCMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>18</sub>BrN<sub>2</sub>O<sub>3</sub>, 437.1/439.1 [M + H]<sup>+</sup>; found, 436.9/438.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> 6-(5-Bromo-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)isobenzofuran-1(3<i>H</i>)-one (<b>81</b>)</h5><div class="NLM_p last">General procedure B coupling was applied using <b>55</b> (200 mg, 0.47 mmol), 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isobenzofuran-1(3<i>H</i>)-one (145 mg,0.56 mmol), NaHCO<sub>3</sub> (117 mg, 1.4 mmol) Pd(PPh<sub>3</sub>)<sub>4</sub> (38 mg, 0.034 mmol), and 35 mL of 3:1 MeCN/H<sub>2</sub>O. The crude mixture was cooled to room temperature and filtrated. The resulted filtrate was dissolved in DCM and extracted with water. The organic phase was concentrated <i>in vacuo</i> to provide crude 6-(5-bromo-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)isobenzofuran-1(3<i>H</i>)-one <b>81</b> in 25% yield. Because of a rapid hydrolysis of the lactone, the crude product was taken to the next step without further purification.</div></div><div id="sec4_5_3_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> 7-(5-Bromo-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-2<i>H</i>-chromen-2-one (<b>82</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>55</b> (159.6 mg, 0.373 mmol), 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2<i>H</i>-chromen-2-one (121.8 mg, 0.447 mmol), K<sub>2</sub>CO<sub>3</sub> (154.6 mg, 1.119 mmol), and Pd(dppf)Cl<sub>2</sub> (6.8 mg, 0.009 mmol) in 7.5 mL of 3:1 dioxane/H<sub>2</sub>O, and the reaction was stirred at 55 °C. The mixture was diluted with DCM (30 mL) and extracted two times with 5% K<sub>2</sub>CO<sub>3</sub> solution, followed by brine. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and evaporated. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 0–50%) THF in DCM provided 7-(5-bromo-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-2<i>H</i>-chromen-2-one <b>82</b> in 30% yield (50 mg, 0.111 mmol, yellow amorphous solid). LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>16</sub>BrN<sub>2</sub>O<sub>3</sub>, 447.03/449.02 [M + H]<sup>+</sup>; found, 446.9/449.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> 4-(1-(4-Methoxyphenyl)-3-(4-nitrophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzenesulfonic Acid (<b>11</b>)</h5><div class="NLM_p last">Compound <b>11</b> was synthesized according to general procedure B using halide <b>65</b> (100 mg, 0.236 mmol), (4-((neopentyloxy)sulfonyl)phenyl)boronic acid (354.3 mg, 0.377 mmol), NaHCO<sub>3</sub> (79.3 mg, 0.944 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (20.5 mg, 0.018 mmol) in 10 mL of 3:1 MeCN/H<sub>2</sub>O. The reaction mixture was diluted with DCM (30 mL), more water (25 mL) was added, and the solution was extracted four times with 30 mL of 4:1 DCM/THF. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude residue was sonicated with 10 mL of 9:1 Et<sub>2</sub>O/DCM for 5 min, and centrifuged. The supernatant was removed, and the remaining was solid dried <i>in vacuo</i>. The compound was dissolved in 2.5 mL of DMF, 130 mg (1.186 mmol) of tetramethylammonium chloride was added, and the solution was refluxed overnight. After cooling to room temperature, a yellow precipitate was formed, isolated by filtration, and refluxed in 1 mL of DMF. After cooling to room temperature, the yellow suspension was filtered through a Buchner funnel. The solid was washed with 5 mL of EtOH, 10 mL of EtOAc, and 10 mL of Et<sub>2</sub>O and dried <i>in vacuo</i> to give 4-(1-(4-methoxyphenyl)-3-(4-nitrophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzenesulfonic acid <b>11</b> in 10% yield (12 mg, 0.024 mmol, amorphous yellow solid). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.90–8.76 (m, 2H), 8.73–8.64 (m, 1H), 8.46–8.28 (m, 4H), 8.24 (d, <i>J</i> = 8.8 Hz, 2H), 8.18 (d, <i>J</i> = 8.7 Hz, 2H), 7.87 (d, <i>J</i> = 8.8 Hz, 2H), 7.18 (d, <i>J</i> = 8.9 Hz, 2H), 3.86 (s, 3H). HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>20</sub>N<sub>3</sub>O<sub>6</sub>S, 502.1067 [M + H]<sup>+</sup>; found, 502.1054 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 4-(1-(4-Methoxyphenyl)-3-(4-nitrophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>17</b>)</h5><div class="NLM_p last">Compound <b>17</b> was synthesized according to general procedure B using 75 mg (0.177 mmol) of halide <b>65</b> (75 mg, 0.177 mmol), 4-carboxyphenylboronic acid (35.2 mg, 0.212 mmol), NaHCO<sub>3</sub> (44.6 mg, 0.531 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (25.3 mg, 0.013 mmol) in 7.5 mL of 3:1 MeCN/H<sub>2</sub>O. The reaction mixture was diluted with DCM (30 mL), more water (25 mL) was added, and the solution was extracted once with dichlormethane. Then, the water layer was acidified until the formation of an orange precipitate and extracted four times with 30 mL of 4:1 DCM/THF. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude product was purified by column chromatography (SiO<sub>2</sub>, THF in DCM, 0–50% + 0.01% AcOH). The combined fractions were evaporated, and the residue was sonicated with 1 mL of DCM for 5 min and centrifuged. The supernatant was removed, and the remaining solid was dried <i>in vacuo</i> to give 4-(1-(4-methoxyphenyl)-3-(4-nitrophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>17</b> in 36% yield (30 mg, 0.064 mmol, orange amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.81–8.76 (m, 2H), 8.64 (s, 1H), 8.32 (d, <i>J</i> = 8.9 Hz, 2H), 8.23 (d, <i>J</i> = 8.9 Hz, 2H), 8.07 (d, <i>J</i> = 8.4 Hz, 2H), 7.99 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 (d, <i>J</i> = 8.9 Hz, 2H), 7.17 (d, <i>J</i> = 8.9 Hz, 2H), 3.86 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.2, 158.2, 147.5, 145.2, 143.1, 142.5, 141.2, 130.4, 130.0, 130.0 (2C), 129.5, 127.4 (2C), 127.2 (2C), 126.9, 125.5 (2C), 124.3 (2C), 118.3, 114.4 (2C), 113.6, 55.6. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>20</sub>N<sub>3</sub>O<sub>5</sub>, 465.1325 [M+]<sup>+</sup>; found, 465.1296 [M+]<sup>+</sup>.</div></div><div id="sec4_5_3_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> 3-(1-(4-Methoxyphenyl)-3-(4-nitrophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>18</b>)</h5><div class="NLM_p last">Compound <b>18</b> was synthesized according to general procedure B using halide <b>65</b> (75 mg, 0.177 mmol), 4-carboxyphenylboronic acid (35.2 mg, 0.212 mmol), NaHCO<sub>3</sub> (44.6 mg, 0.531 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (25.3 mg, 0.013 mmol) in 7.5 mL of 3:1 MeCN/H<sub>2</sub>O. The reaction mixture was diluted with DCM (30 mL), more water (25 mL) was added, and the solution was extracted with DCM. The water layer was acidified until the formation of an orange precipitate and extracted four times with 30 mL of 4:1 DCM/THF. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude residue was purified by column chromatography (THF in DCM, 0–50% + 0.01% AcOH). The combined fractions were evaporated, and the residue was sonicated with 1 mL of DCM for 5 min and centrifuged. The supernatant was removed, and the remaining solid was dried <i>in vacuo</i> to give 3-(1-(4-methoxyphenyl)-3-(4-nitrophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>18</b> in 34% yield (28 mg, 0.060 mmol, amorphous orange solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.75–8.67 (m, 2H), 8.62 (s, 1H), 8.37–8.27 (m, 3H), 8.24–8.19 (m, 2H), 8.12–8.04 (m, 1H), 8.01–7.96 (m, 1H), 7.90–7.81 (m, 2H), 7.66 (t, <i>J</i> = 7.7 Hz, 1H), 7.17 (d, <i>J</i> = 9.0 Hz, 2H), 3.86 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.2, 158.0, 147.3, 145.1, 142.9, 141.2, 138.8, 132.0, 131.6, 130.3, 129.9, 129.8, 129.4, 128.2, 128.0, 127.1 (2C), 126.7, 125.5 (2C), 124.3 (2C), 118.2, 114.4 (2C), 113.5, 55.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>20</sub>N<sub>3</sub>O<sub>5</sub>, 466.1397 [M + H]<sup>+</sup>; found, 466.1376 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> 4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>19</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>66</b> (100 mg, 0.24 mmol), 4-carboxyphenylboronic acid (47 mg, 0.28 mmol), NaHCO<sub>3</sub> (60 mg, 0.72 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (21 mg, 0.018 mmol) in 10 mL of 3:1 MeCN/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 0–10% methanol in DCM) yielded 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>19</b> in 30% yield (33 mg, 0.07 mmol, orange amorphous solid). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.90–8.80 (m, 1H), 8.78–8.66 (m, 2H), 8.52 (s, 1H), 8.30 (d, <i>J</i> = 9.0 Hz, 1H), 8.16 (m, 5H), 8.16–7.92 (m, 2H), 7.24–7.07 (m, 2H), 3.87 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.3, 158.1, 149.8, 148.1, 147.5, 143.2, 142.4, 137.4, 133.9, 130.5, 130.3, 129.9 (2C), 129.5, 128.0, 127.5 (2C), 127.3, 125.5 (2C), 118.2, 116.3, 114.4 (2C), 113.5, 109.2, 55.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>19</sub>N<sub>4</sub>O<sub>4</sub>, 463.1401 [M + H]<sup>+</sup>; found, 463.1421 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 3-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>20</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>66</b> (50 mg, 0.12 mmol), 3-carboxyphenylboronic acid (24 mg, 0.14 mmol), NaHCO<sub>3</sub> (30 mg, 0.36 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (11 mg, 0.009 mmol) in 5 mL of 3:1 MeCN/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 30–100% ethyl acetate in cyclohexane) yielded 3-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>20</b> in 30% yield (14 mg, 0.035 mmol, orange amorphous solid). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.87–8.83 (m, 1H), 8.74–8.68 (m, 2H), 8.52 (s, 1H), 8.34 (s, 1H), 8.29–8.25 (m, 1H), 8.16–8.11 (m, 2H), 8.02–7.97 (m, 1H), 7.90–7.86 (m, 2H), 7.67 (t, <i>J</i> = 7.7 Hz, 1H), 7.22–7.13 (m, 2H), 3.86 (s, 3H) ppm. <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.3, 158.1, 149.8, 148.1, 147.3, 143.1, 138.7, 137.4, 134.0, 132.0, 131.6, 130.4, 130.3, 129.9, 129.3, 128.2, 128.1, 127.3, 125.5 (2C), 118.2, 116.3, 114.4 (2C), 113.5, 109.2, 55.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>19</sub>N<sub>4</sub>O<sub>4</sub>, 463.1401 [M + H]<sup>+</sup>; found, 463.1378 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> 4-(1-(4-Methoxyphenyl)-3-(4-(trifluoromethyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>21</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>67</b> (70 mg, 0.156 mmol), 4-carboxyphenylboronic acid (31.6 mg, 0.190 mmol), NaHCO<sub>3</sub> (39.5 mg, 0.470 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (13.5 mg, 0.012 mmol) in 10 mL of 3:1 MeCN/H<sub>2</sub>O. The reaction mixture was diluted with DCM (50 mL), more water (25 mL) was added, and the solution was extracted one time with DCM. Then, the water layer was acidified until the formation of a precipitate and then extracted four times with 30 mL of a mixture of DCM/THF 4:1. The combined organic layer was dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude residue was absorbed on isolute and purified by column chromatography (SiO<sub>2</sub>, THF in DCM, 0–50%) to obtain 4-(1-(4-methoxyphenyl)-3-(4-(trifluoromethyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>21</b> in 84% yield (64.3 mg, 0.131 mmol, pale pink amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.80–8.74 (m, 1H), 8.74–8.68 (m, 1H), 8.49 (s, 1H), 8.15 (d, <i>J</i> = 8.1 Hz, 2H), 8.06 (d, <i>J</i> = 8.4 Hz, 2H), 7.97 (d, <i>J</i> = 8.4 Hz, 2H), 7.87 (d, <i>J</i> = 8.9 Hz, 2H), 7.83 (d, <i>J</i> = 8.2 Hz, 2H), 7.17 (d, <i>J</i> = 9.0 Hz, 2H), 3.85 (s, 3H). <sup>19</sup>F NMR (564 MHz, DMSO-<i>d</i><sub>6</sub>): δ −60.7. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>20</sub>F<sub>3</sub>N<sub>2</sub>O, 489.1421 [M + H]<sup>+</sup>; found, 489.1441[M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> 3-(1-(4-Methoxyphenyl)-3-(4-(trifluoromethyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>22</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>67</b> (43 mg, 0.096 mmol), 3-carboxyphenylboronic acid (19.4 mg, 0.117 mmol), NaHCO<sub>3</sub> (24.2 mg, 0.288 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (9.6 mg, 0.008 mmol) in 6 mL of 3:1 MeCN/H<sub>2</sub>O. The reaction mixture was diluted with DCM (50 mL), more water (25 mL) was added, and the solution was extracted one time with DCM. Then, the water layer was acidified until the formation of a pale yellow precipitate and extracted four times with 30 mL of a mixture of DCM/THF 4:1. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude residue was purified by column chromatography (SiO<sub>2</sub>, THF in DCM, 0–50%) to give 3-(1-(4-methoxyphenyl)-3-(4-(trifluoromethyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>22</b> in 98% yield (46.0 mg 0.094 mmol, pale yellow amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.74–8.69 (m, 1H), 8.66–8.63 (m, 1H), 8.50 (s, 1H), 8.37–8.27 (m, 1H), 8.14 (d, <i>J</i> = 8.0 Hz, 2H), 8.10–8.04 (m, 1H), 8.02.-7.98 (m, 1H), 7.92–7.87 (m, 2H), 7.83 (d, <i>J</i> = 8.1 Hz, 2H), 7.64 (t, <i>J</i> = 7.7 Hz, 1H), 7.17 (d, <i>J</i> = 8.9 Hz, 2H), 3.86 (s, 3H). <sup>19</sup>F NMR (564 MHz, DMSO-<i>d</i><sub>6</sub>): δ −60.7. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>20</sub>F<sub>3</sub>N<sub>2</sub>O, 489.1421 [M + H]<sup>+</sup>; found, 489.1438 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> 4-(1-(4-Methoxyphenyl)-3-(pyridin-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>23</b>)</h5><div class="NLM_p last">Compound <b>23</b> was synthesized according to general procedure B using halide <b>68</b> (122 mg, 0.321 mmol), 4-carboxyphenylboronic acid (63.9 mg, 0.385 mmol), NaHCO<sub>3</sub> (80.9 mg, 0.963 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (27.8 mg, 0.024 mmol) in 7.5 mL of 3:1 MeCN/H<sub>2</sub>O. The reaction mixture was diluted with DCM (30 mL), more water (25 mL) was added, and the solution was extracted once with DCM. The organic layer was discarded, and the water layer was acidified and extracted four times with 30 mL of 4:1 DCM/THF. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude residue was purified by column chromatography (SiO<sub>2</sub>, THF in DCM, 0–50%). The combined fractions were evaporated, and the residue was sonicated with 5 mL of Et<sub>2</sub>O for 5 min, and then centrifuged. The supernatant was removed, and the remaining was solid dried <i>in vacuo</i> to give 4-(1-(4-methoxyphenyl)-3-(pyridin-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>23</b> in 23% yield (31 mg, 0.074 mmol, yellow amorphous solid). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.80–8.71 (m, 2H), 8.71–8.55 (m, 3H), 8.10–8.03 (m, 2H), 8.03–7.95 (m, 4H), 7.91–7.80 (m, 2H), 7.23–7.10 (m, 2H), 3.85 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.1, 158.1, 149.6, 147.5, 143.0, 142.5, 141.8, 130.3, 129.9, 129.9 (3C), 129.5, 129.3, 127.4 (2C), 126.8, 125.5 (2C), 121.0 (2C), 118.2, 114.4 (2C), 112.6, 55.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>, 421.1426 [M]<sup>+</sup>; found, 421.1459 [M]<sup>+</sup>.</div></div><div id="sec4_5_3_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> 3-(1-(4-Methoxyphenyl)-3-(pyridin-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>24</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>68</b> (85 mg, 0.22 mmol), 3-carboxyphenylboronic acid (44 mg, 0.26 mmol), K<sub>2</sub>CO<sub>3</sub> (91 mg, 0.66 mmol), and Pd(dppf)Cl<sub>2</sub> (4 mg, 0.006 mmol) in 4 mL of 3:1 dioxane/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 0–25% MeOH in DCM) yielded 4-(1-(4-methoxyphenyl)-3-(pyridin-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>24</b> in 10% yield (9.5 mg, 0.022 mmol, white amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.81–8.68 (m, 2H), 8.67–8.62 (m, 3H), 8.32 (s, 1H), 8.10 (d, <i>J</i> = 7.7 Hz, 1H), 8.01 (d, <i>J</i> = 7.7 Hz, 1H), 7.96 (d, <i>J</i> = 5.2 Hz, 2H), 7.87 (d, <i>J</i> = 8.6 Hz, 2H), 7.68 (t, <i>J</i> = 7.7 Hz, 1H), 7.19 (d, <i>J</i> = 8.6 Hz, 2H), 3.88 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.4, 158.1, 150.1 (2C), 142.9, 142.9, 141.4, 138.7, 131.9, 130.4, 129.8, 129.5, 129.4, 128.2, 127.9, 126.8, 125.5 (2C), 120.9 (2C), 118.2, 114.5 (2C), 112.6, 55.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub>, 422.1499 [M + H]<sup>+</sup>; found, 422.1489 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> 4-(1-(4-Methoxyphenyl)-3-(pyrimidin-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>25</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>69</b> (30 mg, 0.08 mmol), 4-carboxyphenylboronic acid (17 mg, 0.09 mmol), NaHCO<sub>3</sub> (21 mg, 0.24 mmol), and Pd(PPh3)<sub>4</sub> (6 mg, 0.005 mmol) in 7 mL of 3:1 MeCN/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 0–25% MeOH in DCM) yielded 4-(1-(4-methoxyphenyl)-3-(pyrimidin-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>25</b> in 25% yield (8.4 mg, 0.019 mmol, white amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.43–9.34 (m, 2H), 9.17 (s, 1H), 8.81–8.73 (m, 2H), 8.63 (s, 1H), 8.12–7.99 (m, 4H), 7.88 (d, <i>J</i> = 8.9 Hz, 2H), 7.20 (d, <i>J</i> = 8.9 Hz, 2H), 3.88 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.2, 158.0, 156.1, 154.3 (2C), 147.2, 143.0, 142.4, 130.4, 129.9 (2C), 129.6, 129.2, 128.8, 128.3, 127.4 (2C), 126.9, 125.4 (2C), 118.2, 114.5 (2C), 108.9, 55.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>19</sub>N<sub>4</sub>O<sub>3</sub>, [M + H]<sup>+</sup> 423.1463; found, [M + H]<sup>+</sup> 423.1452.</div></div><div id="sec4_5_3_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> 4-(3-(Benzo[<i>d</i>][1,3]dioxol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>26</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>70</b> (50 mg, 0.12 mmol), 4-carboxyphenylboronic acid (23 mg, 0.14 mmol), NaHCO<sub>3</sub> (30 mg, 0.30 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (10 mg, 0.009 mmol) in 5 mL of 3:1 MeCN/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (30–100% ethyl acetate in cyclohexane) yielded 4-(3-(benzo[<i>d</i>][1,3]dioxol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>26</b> in 22% yield (12 mg, 0.026 mmol, white amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.74–8.67 (m, 1H), 8.57–8.52 (m, 1H), 8.24 (s, 1H), 8.06 (d, <i>J</i> = 8.3 Hz, 2H), 7.96 (d, <i>J</i> = 8.3 Hz, 2H), 7.89–7.83 (m, 2H), 7.49–7.44 (m, 1H), 7.41–7.33 (m, 1H), 7.19–7.13 (m, 2H), 7.05 (d, <i>J</i> = 8.0 Hz, 1H), 6.09 (s, 2H), 3.86 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.2, 157.6, 147.8, 147.0, 146.0, 142.8, 142.4, 130.8, 130.0 (2C), 129.4, 128.5, 127.8, 127.2 (2C), 126.7, 126.4, 125.0 (2C), 120.3, 118.6, 115.7, 114.3 (2C), 108.8, 107.5, 100.9, 55.4. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>21</sub>N<sub>2</sub>O<sub>5</sub>, 465.1445 [M + H]<sup>+</sup>; found, 465.1449 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> 4-(3-(4-Cyanophenyl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>27</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>71</b> (73 mg, 0.18 mmol), 4-carboxyphenylboronic acid (33 mg, 0.2 mmol), NaHCO<sub>3</sub> (45 mg, 0.54 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (16 mg, 0.014 mmol) in 8 mL of 3:1 MeCN/H<sub>2</sub>O. Purification of the crude product by recrystallization from cold DCM, redissolving in EtOAc, and filtration on short plug of silica yielded 4-(3-(4-cyanophenyl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>27</b> in 34% yield (27 mg, 0.035 mmol, white amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.76–8.73 (m, 1H), 8.72–8.69 (m, 1H), 8.57 (s, 1H), 8.16 (d, <i>J</i> = 8.3 Hz, 2H), 8.09 (d, <i>J</i> = 8.3 Hz, 2H), 7.99 (d, <i>J</i> = 8.0 Hz, 2H), 7.94 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 (d, <i>J</i> = 8.9 Hz, 2H), 7.18 (d, <i>J</i> = 8.9 Hz, 2H), 3.86 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.1, 158.0, 147.3, 142.9, 142.5, 138.9, 132.8 (2C), 130.4, 129.9 (2C), 129.5, 129.2, 128.9, 127.3 (2C), 127.1 (2C), 126.7, 125.4 (2C), 119.2, 118.2, 114.4 (2C), 113.9, 108.2, 55.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub>, 446.1499 [M + H]<sup>+</sup>; found, 446.1480 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> 4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-isopropyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>28</b>)</h5><div class="NLM_p last">Compound <b>28</b> was synthesized according to general procedure B using halide <b>72</b> (114 mg, 0.319 mmol), 4-carboxyphenylboronic acid (80.0 mg, 0.383 mmol), NaHCO<sub>3</sub> (80 mg, 0.957 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (27.6 mg, 0.020 mmol) in 10 mL of 3:1 MeCN/H<sub>2</sub>O. The reaction mixture was diluted with DCM (30 mL), more water (25 mL) was added, and the solution was extracted with DCM. The organic layer was discarded, and the water layer was acidified and extracted four times with 30 mL of 4:1 DCM/THF. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude residue was purified by column chromatography (SiO<sub>2</sub>, THF in DCM, 0–15%). The combined fractions were evaporated, and the residue was sonicated with 5 mL of <i>n</i>-pentane for 5 min and centrifuged. The supernatant was removed, and the remaining solid was dried <i>in vacuo</i> to give 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-isopropyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>28</b> in 28% yield (36 mg, 0.090 mmol, amorphous yellow solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.84–8.77 (m, 1H), 8.74–8.72 (m, 1H), 8.61 (s, 1H), 8.45–8.40 (m, 1H), 8.22 (dd, <i>J</i> = 9.4, 1.5 Hz, 1H), 8.11 (dd, <i>J</i> = 9.4, 0.9 Hz, 1H), 8.08–8.04 (m, 2H), 8.04–7.99 (m, 2H), 5.22 (p, <i>J</i> = 6.8 Hz, 1H), 1.59 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.3, 149.9, 148.1, 147.1, 142.4, 139.1, 138.0, 133.9, 132.0, 131.5, 129.3, 129.2, 128.2, 128.1, 128.0, 127.0, 117.5, 116.1, 112.2, 107.9, 45.9, 22.4 (2C). HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>19</sub>N<sub>4</sub>O<sub>3</sub>, 399.1480 [M + H]<sup>+</sup>; found, 399.1452 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> 4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>29</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>73</b> (58 mg, 0.12 mmol), 4-carboxyphenylboronic acid (24 mg, 0.15 mmol), NaHCO<sub>3</sub> (30 mg, 0.36 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (10 mg, 0.008 mmol) in 7 mL of 3:1 MeCN/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 30–100% ethyl acetate in cyclohexane, with 5% MeOH for complete elution of the product) yielded 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>29</b> in 11% yield (7 mg, 0.014 mmol, white amorphous solid). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.88–8.81 (m, 1H), 8.81–8.74 (m, 1H), 8.74–8.65 (m, 1H), 8.65–8.57 (m, 1H), 8.28–8.16 (m, 2H), 8.16–8.10 (m, 2H), 8.08–8.02 (m, 2H), 8.03–7.93 (m, 2H), 7.51–7.42 (m, 2H), 2.36 (s, 3H). HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>19</sub>N<sub>4</sub>O<sub>5</sub>S, 511.1071 [M + H]<sup>+</sup>; found, 511.1070 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> 4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-benzyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>30</b>)</h5><div class="NLM_p last">Compound <b>30</b> was synthesized according to general procedure B using halide <b>74</b> (80 mg, 0.197 mmol), 4-carboxyphenylboronic acid (40.0 mg, 0.236 mmol), NaHCO<sub>3</sub> (50.0 mg, 0.591 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (16.5 mg, 0.014 mmol) in 10 mL of 3:1 MeCN/H<sub>2</sub>O. The reaction mixture was diluted with DCM (30 mL), more water (25 mL) was added, and the solution was extracted once with DCM. Then, the water layer was acidified and extracted four times with 30 mL of 4:1 DCM/THF. The organic layer was dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude residue was purified by column chromatography (SiO<sub>2</sub>, THF in DCM, 0–50%). The combined fractions were evaporated, and the residue was sonicated with 5 mL of Et<sub>2</sub>O for 5 min, and then centrifuged. The supernatant was removed, and the remaining solid was dried <i>in vacuo</i> to give 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-benzyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>30</b> in 65% yield (57 mg, 0.127 mmol yellow amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.85 (d, <i>J</i> = 2.0 Hz, 1H), 8.76 (d, <i>J</i> = 2.0 Hz, 1H), 8.60 (s, 1H), 8.45 (t, <i>J</i> = 1.2 Hz, 1H), 8.16–8.08 (m, 2H), 8.07 (d, <i>J</i> = 8.4 Hz, 2H), 8.02 (d, <i>J</i> = 8.4 Hz, 2H), 7.39–7.32 (m, 4H), 7.31–7.25 (m, 1H), 5.61 (s, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.4, 153.0, 151.3, 150.9, 146.2, 145.9, 140.8, 140.8, 136.9, 134.4, 133.1 (2C), 132.6, 132.2, 131.9 (2C), 130.8, 130.7 (2C), 130.6 (2C), 130.5, 120.6, 119.5, 115.7, 111.7, 70.2. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>19</sub>N<sub>4</sub>O<sub>3</sub>, 447.1452 [M + H]<sup>+</sup>; found, 447.1481 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> 4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxybenzyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>31</b>)</h5><div class="NLM_p last">Compound <b>31</b> was synthesized according to general procedure B using halide <b>75</b> (117 mg, 0.245 mmol), 4-carboxyphenylboronic acid (50.0 mg, 0.295 mmol), NaHCO<sub>3</sub> (61.7 mg, 0.735 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (21.0 mg, 0.018 mmol) in 10 mL of 3:1 MeCN/H<sub>2</sub>O. The reaction mixture was diluted with DCM (30 mL), more water (25 mL) was added, and the solution was extracted with DCM. The organic layer was discarded, and the water layer was acidified and extracted four times with 30 mL of 4:1 DCM/THF. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude residue was purified by column chromatography (SiO<sub>2</sub>, THF in DCM, 0–50%). The combined fractions were evaporated, and the residue was sonicated with 5 mL of Et<sub>2</sub>O for 5 min and then centrifuged. The supernatant was removed, and the remaining solid was dried <i>in vacuo</i> to give 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxybenzyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>31</b> in 2% yield (3 mg, 0.006 mmol, yellow amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.84–8.81 (m, 1H), 8.78–8.75 (m, 1H), 8.57 (s, 1H), 8.46–8.42 (m, 1H), 8.13–8.09 (m, 2H), 8.07 (d, <i>J</i> = 8.3 Hz, 2H), 8.02 (d, <i>J</i> = 8.4 Hz, 2H), 7.36 (d, <i>J</i> = 8.7 Hz, 2H), 6.90 (d, <i>J</i> = 8.7 Hz, 2H), 5.52 (s, 2H), 3.71 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.2, 158.8, 149.8, 148.1, 147.6, 142.9, 142.7, 137.6, 133.7, 131.1, 129.9 (2C), 129.6, 129.4, 129.1, 129.0 (2C), 127.5 (2C), 127.2, 117.4, 116.3, 114.0 (2C), 112.4, 108.4, 55.1, 47.3. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>21</sub>N<sub>4</sub>O<sub>4</sub>, 477.1564 [M + H]<sup>+</sup>; found, 477.1557 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> 4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(3-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>32</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>76</b> (210 mg, 0.50 mmol), 4-carboxyphenylboronic acid (90 mg, 0.55 mmol), K<sub>2</sub>CO<sub>3</sub> (206 mg, 0.54 mmol), and Pd(dppf)Cl<sub>2</sub> (9 mg, 0.014 mmol) in 8 mL of 3:1 dioxane/H<sub>2</sub>O. The reaction was stirred for 5 h and then allowed to cool down to room temperature. The mixture was acidified until the formation of a yellow precipitate (pH = 4.5) and extracted three times with DCM. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. The crude product was purified by column chromatography to 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(3-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>32</b> in 2.5% yield (6 mg, 0.015 mmol, yellow solid). The solid residue in the aqueous layer was boiled with addition of acetic acid, filtrated, and lyophilized. The NMR of the solid showed that the product coprecipitated with acetic acid. The yield of 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(3-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid acetate is 48% yield (125 mg, 0.24 mmol, yellow amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.91–8.88 (m, 1H), 8.85–8.76 (m, 2H), 8.57 (s, 1H), 8.30 (dd, <i>J</i> = 9.4, 1.5 Hz, 1H), 8.17 (d, <i>J</i> = 9.4, 1H), 8.11–8.06 (m, 2H), 8.04–7.98 (m, 2H), 7.68–7.63 (m, 2H), 7.54 (t, <i>J</i> = 8.1 Hz, 1H), 7.05–7.02 (m, 1H), 3.91 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.1, 159.9, 149.7, 148.1, 147.4, 143.2, 142.3, 138.3, 137.2, 134.0, 130.2 (2C), 130.0, 129.9, 129.7, 127.5 (2C), 127.4, 118.6, 116.3, 115.9, 114.1, 112.2, 109.7, 109.6, 55.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>19</sub>N<sub>4</sub>O<sub>4</sub>, 463.1401 [M + H]<sup>+</sup>; found, 463.1404 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> 4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>33</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>77</b> (32 mg, 0.08 mmol), 4-carboxyphenylboronic acid (16 mg, 0.1 mmol), NaHCO<sub>3</sub> (20 mg, 0.24 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (7 mg, 0.006 mmol) in 10 mL of 3:1 MeCN/H<sub>2</sub>O. The crude product was concentrated <i>in vacuo</i>, more water was added, and the solution was extracted with DCM. Then, the water layer was acidified until the formation of a yellow precipitate and extracted one more time with DCM. The organic layer was discarded (albeit containing traces of product), and the major portion of the water was decanted. The crude precipitate was lyophilized, and the dry product was dissolved in ACN/MeOH, absorbed on isolute, and purified by column chromatography (SiO<sub>2</sub>, MeOH in DCM, 0–25%) to give 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>33</b> in 14% yield (5.3 mg, 0.011 mmol, yellow amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.91–8.85 (m, 1H), 8.84–8.80 (m, 1H), 8.81–8.77 (m, 1H), 8.57 (s, 1H), 8.30 (d, <i>J</i> = 9.4 Hz, 1H), 8.17 (d, <i>J</i> = 9.4 Hz, 1H), 8.12–8.06 (m, 2H), 8.06–8.01 (m, 2H), 8.01–7.94 (m, 2H), 7.70–7.60 (m, 2H), 7.46 (t, <i>J</i> = 7.5 Hz, 1H). HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>17</sub>N<sub>4</sub>O<sub>3</sub>, 434.1326 [M + H]<sup>+</sup>; found, 434.1341 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> Methyl 4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)benzoate (<b>83</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>78</b> (66 mg, 0.16 mmol), 4-methoxycarbonylphenylboronic acid (36 mg, 0.20 mmol), NaHCO<sub>3</sub> (41 mg, 0.48 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (14 mg, 0.012 mmol) in 10 mL of 3:1 MeCN/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (0–100% DCM in cyclohexane) yielded 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)benzoate <b>83</b> in 37% (28 mg, 0.058 mmol, yellow amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 9.08–8.87 (m, 1H), 8.74–8.61 (m, 1H), 8.50–8.35 (m, 2H), 8.30–8.15 (m, 4H), 8.11–7.94 (m, 1H), 7.89–7.73 (m, 2H), 7.23–7.07 (m, 2H), 3.99 (s, 3H), 3.91 (s, 3H). HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>20</sub>N<sub>5</sub>O<sub>4</sub>, [M + H]<sup>+</sup>, 478.1510; found, 478.1522.</div></div><div id="sec4_5_3_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> 4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>34</b>)</h5><div class="NLM_p last">Corresponding indazol ester <b>83</b> (26 mg, 0.06 mmol, 1 equiv) was dissolved in dioxane (1.5 mL), and an aqueous solution of NaOH (5 equiv, 2 M) was added. The mixture was stirred at 60 °C for 12 h. The crude product was concentrated <i>in vacuo</i>, more water was added, and the solution was extracted one time with DCM. Then, the water layer was acidified until the formation of a yellow precipitate and extracted one more time with DCM. The organic layer was discarded, and the major portion of the water was decanted. A yellow solid was washed with DCM and acetone and lyophilized to give 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)benzoic acid <b>34</b> in 68% yield (18 mg, 0.04 mmol, yellow amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.22–9.11 (m, 1H), 9.10–8.97 (m, 1H), 8.94 (m, 1H), 8.54–8.37 (m, 1H), 8.29–8.14 (m, 3H), 8.14–7.87 (m, 4H), 7.23–7.07 (m, 2H), 3.87 (s, 3H). HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>18</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 464.1353; found, 464.1379. IC<sub>50</sub> > 100 μM (DiFMUP assay, DiFMUP concentration = 20 μM).</div></div><div id="sec4_5_3_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> Methyl 4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)benzoate (<b>84</b>)</h5><div class="NLM_p last">General procedure B coupling was applied using halide <b>79</b> (100 mg, 0.25 mmol), 4-methoxycarbonylphenylboronic acid (54 mg, 0.30 mmol), NaHCO<sub>3</sub> (63 mg, 0.75 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (21 mg, 0.012 mmol) in 10 mL of 3:1 MeCN/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (0–50% ethylacetate in cyclohexane) gave methyl 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)benzoate <b>84</b> in 40% yield (45 mg, 0.10 mmol, white amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.94–8.79 (m, 1H), 8.61–8.48 (m, 1H), 8.42–8.26 (m, 2H), 8.24–8.10 (m, 2H), 8.01–7.86 (m, 1H), 7.78–7.67 (m, 2H), 6.33–6.18 (m, 1H), 4.28–4.07 (m, 1H), 4.05–3.78 (m, 4H), 2.88–2.65 (m, 1H), 2.29–2.14 (m, 1H), 2.14–1.99 (m, 1H), 1.98–1.78 (m, 2H), 1.78–1.59 (m, 1H). HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>22</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 456.2; found, 456.0.</div></div><div id="sec4_5_3_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> 4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>35</b>)</h5><div class="NLM_p last">The corresponding azaindazole ester <b>84</b> (45 mg, 0.01 mmol, 1 equiv) was dissolved in dioxane (1.5 mL) and an aqueous solution of NaOH (5 equiv, 2 M) was added. The mixture was stirred at 60 °C for 12 h. The crude was concentrated <i>in vacuo</i>, more water was added, and the solution was extracted one time with DCM. Then, the water layer was acidified until the formation of a white precipitate and extracted one more time with DCM. The organic layer was discarded, and the major portion of the water was decanted. White solid was washed with DCM and acetone and lyophilized to give 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)benzoic acid <b>35</b> in 54% yield (24 mg, 0.054 mmol, white amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 9.22–9.08 (m, 1H), 9.07–8.99 (m, 1H), 8.90 (s, 1H), 8.45–8.30 (m, 1H), 8.23–8.14 (m, 1H), 8.14–7.97 (m, 4H), 6.27–6.03 (m, 1H), 4.08–3.88 (m, 1H), 3.85–3.64 (m, 1H), 2.70–2.53 (m, 1H), 2.18–1.95 (m, 2H), 1.95–1.74 (m, 1H), 1.74–1.55 (m, 2H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.2, 150.7, 149.5, 149.0, 148.6, 141.5, 140.7, 135.4, 132.1, 130.6, 130.1, 129.9 (2C), 129.3, 127.8 (2C), 116.7, 113.3, 113.2, 82.1, 67.3, 39.5, 28.8, 24.7, 22.3. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>20</sub>N<sub>5</sub>O<sub>4</sub>, [M + H]<sup>+</sup>, 443.1540; found, 443.1542. IC<sub>50</sub> > 100 μM (DiFMUP assay, DiFMUP concentration = 20 μM).</div></div><div id="sec4_5_3_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> Methyl 3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carboxylate (<b>85</b>)</h5><div class="NLM_p last">General procedure B was adapted using halide <b>62</b> (200 mg, 0.49 mmol), benzo[<i>c</i>][1,2,5]oxadiazole-5-boronic acid pinacol ester (258 mg, 0.10 mmol), K<sub>2</sub>CO<sub>3</sub> (430 mg, 3.14 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (14 mg, 0.012 mmol) in 9 mL of 3:1 MeCN/H<sub>2</sub>O. Purification of the crude product by flash column chromatography (SiO<sub>2</sub>, 30–100% ethyl acetate in cyclohexane) yielded methyl 3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carboxylate <b>60</b> in 18% yield (33 mg, 0.08 mmol, yellow amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 9.17–9.03 (m, 1H), 9.03–8.94 (m, 1H), 816–8.09 (m, 1H), 8.01–7.92 (m, 1H), 7.90 (s, 1H), 7.86–7.72 (m, 1H), 7.73–7.57 (m, 2H), 7.22–7.14 (m, 2H), 4.00 (s, 3H),3.89 (s, 3H). LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>17</sub>N<sub>4</sub>O<sub>4</sub>, 401.1 [M + H]<sup>+</sup>; found, 401.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> 3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carboxylic Acid (<b>36</b>)</h5><div class="NLM_p last">Ester <b>85</b> (30 mg, 0.075 mmol, 1 equiv) was dissolved in dioxane (3 mL) and aqueous NaOH (5 equiv, 2 M) was added. The mixture was stirred at 60 °C for 12 h. The crude product was concentrated <i>in vacuo</i>, more water was added, and the solution was extracted one time with DCM. Then, the water layer was acidified until the formation of a yellow precipitate (pH = 4.0–4.5). The solid was collected by vacuum filtration, washed with DCM and ether, and lyophilized to give 3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carboxylic acid <b>36</b> in 77% yield (24 mg, 0.057 mmol, yellow amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 9.02–8.98 (m, 1H), 8.98–8.89 (m, 1H), 8.76 (s, 1H), 8.39–8.35 (m, 1H), 8.23–8.15 (m, 2H), 7.88–7.80 (m, 2H), 7.22–7.14 (m, 2H), 3.87 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.9, 158.3, 149.6, 149.2, 148.2, 145.6, 137.2, 133.8, 131.2, 130.3, 129.9, 125.8 (2C), 117.5, 117.0, 116.7, 114.5 (2C), 114.0, 109.5, 55.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>15</sub>N<sub>4</sub>O<sub>4</sub>, 388.1118 [M + H]<sup>+</sup>; found, [M + H]<sup>+</sup> 388.1121.</div></div><div id="sec4_5_3_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> Ethyl (<i>E</i>)-3-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)acrylate (<b>86</b>)</h5><div class="NLM_p last"><b>66</b> (117 mg, 0.28 mmol, 1 equiv), ethyl acrylate (83 mg, 0.83 mmol, 3.0 equiv), Pd(OAc)<sub>2</sub> (6.24 mg, 0.03 mmol, 0.1 equiv), and tris(2-methylphenyl)phosphine (16.9 mg, 0.06 mmol, 0.2 equiv) were dissolved in a mixture of TEA/DMF 2:5 (7 mL), and purged with N<sub>2</sub> prior to use. The mixture was heated to 120 °C and stirred for 12 h under N<sub>2</sub>. The mixture was cooled to room temperature and water was added. The water layer was extracted three times with DCM, dried with Na<sub>2</sub>SO<sub>4</sub>, and evaporated under vacuum. The crude product was purified by silica gel chromatography (SiO<sub>2</sub>, DCM in cyclohexane, 0–50%) to give ethyl (<i>E</i>)-3-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)acrylate <b>86</b> in 17% yield (21 mg, 0.05 mmol, yellow amorphous solid). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.66–8.60 (m, 1H), 8.57–8.44 (m, 1H), 8.11–8.03 (m, 1H), 7.99–7.84 (m, 3H), 7.84–7.74 (m, 1H), 7.70–7.60 (m, 2H), 7.17–7.05 (m, 2H), 6.60 (d, <i>J</i> = 16.0 Hz, 1H), 4.32 (q, <i>J</i> = 7.1 Hz, 2H), 3.89 (s, 3H), 1.39 (t, <i>J</i> = 7.1 Hz, 3H) ppm. LCMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>21</sub>N<sub>4</sub>O<sub>4</sub>, 441.2 [M + H]<sup>+</sup>; found, 441.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> 3-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)acrylic Acid (<b>37</b>)</h5><div class="NLM_p last">Ester <b>86</b> (20 mg, 0.045 mmol, 1 equiv) was dissolved in THF (1.5 mL), and an aqueous solution of LiOH (5 equiv, 2 M) was added. The mixture was stirred at room temperature for 24 h, then an additional portion of LiOH (5 equiv, 2 M) was added. The reaction was stirred for additional 24 h, then the crude product was concentrated <i>in vacuo</i>, more water was added, and the solution was extracted one time with DCM. The water layer was acidified until the formation of a yellow precipitate (pH = 4.0–4.5). The solid was collected by vacuum filtration, washed with DCM and ether, and lyophilized to give 3-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)acrylic acid <b>37</b> in 44% yield (8 mg, 0.02 mmol, yellow amorphous solid). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.06–8.96 (m, 1H), 8.80–8.68 (m, 2H), 8.52 (s, 1H), 8.34–8.19 (m, 1H), 8.19–8.06 (m, 1H), 7.92–7.78 (m, 3H), 7.24–7.10 (m, 2H), 6.90 (d, <i>J</i> = 16.1 Hz, 1H), 3.87 (s, 3H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.8, 158.1, 149.8, 148.1, 144.9, 141.9, 137.1, 133.8, 130.9, 130.1, 128.5, 125.5 (3C), 124.8, 119.0, 118.2, 116.2, 114.4 (2C), 113.6, 109.2, 55.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>17</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 414.1275; found, [M + H]<sup>+</sup> 414.1286.</div></div><div id="sec4_5_3_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> 4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)cyclohex-3-ene-1-carboxylic Acid (<b>38</b>)</h5><div class="NLM_p last">Compound <b>38</b> was synthesized according to general procedure B using halide <b>66</b> (43 mg, 0.102 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-ene-1-carboxylic acid (30.9 mg, 0.122 mmol), NaHCO<sub>3</sub> (25.7 mg, 0.306 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (8.8 mg, 0.008 mmol) in 5 mL of 3:1 MeCN/H<sub>2</sub>O. The reaction mixture was diluted with DCM (30 mL), more water (25 mL) was added, and the solution was extracted one time with DCM. The organic layer was discarded, and the water layer was acidified and extracted four times with 30 mL of 4:1 DCM/THF. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude residue was purified by column chromatography (SiO<sub>2</sub>, THF in DCM, 0–25%). The combined fractions were evaporated, and the residue was sonicated with 5 mL of 1:1 <i>n</i>-pentane/Et<sub>2</sub>O for 5 min and then centrifuged. The supernatant was removed, and the remaining solid was dried <i>in vacuo</i> to give 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)cyclohex-3-ene-1-carboxylic acid <b>38</b> in 38% yield (18 mg, 0.036 mmol, amorphous yellow solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.65 (s, 1H), 8.58–8.56 (m, 1H), 8.56–8.53 (m, 1H), 8.47–8.44 (m, 1H), 8.22 (dd, <i>J</i> = 9.4, 1.5 Hz, 1H), 8.13 (dd, <i>J</i> = 9.4, 0.9 Hz, 1H), 7.85 (d, <i>J</i> = 8.9 Hz, 2H), 7.16 (d, <i>J</i> = 8.9 Hz, 2H), 6.39–6.34 (m, 1H), 3.85 (s, 3H), 2.80–2.59 (m, 4H), 2.54–2.47 (m, 1H), 2.25–2.15 (m, 1H), 1.93–1.75 (m, 1H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 176.4, 157.9, 149.7, 148.1, 146.9, 142.1, 141.7, 137.6, 133.9, 131.7, 130.4, 129.9, 125.3 (2C), 124.7, 123.4, 117.7, 116.3, 114.3 (2C), 113.2, 108.7, 55.5, 38.0, 27.9, 26.5, 25.3. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>23</sub>N<sub>4</sub>O<sub>4</sub>, 467.1750 [M + H]<sup>+</sup>; found, 467.1714 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> Ethyl-4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoate (<b>39</b>)</h5><div class="NLM_p last">Compound <b>39</b> was synthesized according to general procedure B using halide <b>66</b> (100 mg, 0.237 mmol), 4-(ethoxycarbonyl)phenyl)boronic acid (55.3 mg, 0.284 mmol), NaHCO<sub>3</sub> (59.8 mg, 0.712 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (20.6 mg, 0.018 mmol) in 10 mL of 3:1 MeCN/H<sub>2</sub>O. The reaction mixture was diluted with DCM (30 mL), more water (25 mL) was added, and the solution was extracted four times with 30 mL of 4:1 DCM/THF. The organic layer was dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude residue was dissolved in 5 mL of EtOH abs and cooled to 0 °C, and 18 μL of thionyl chloride was added. The mixture was refluxed for 4 h, concentrated <i>in vacuo</i>, and afterward submitted for flash column chromatography without further workup. The product was eluted with THF in DCM (SiO<sub>2</sub>, 0–25%) to give impure ethyl-4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoate <b>39</b> in 43% yield over two steps (50 mg, 0.102 mmol, yellow amorphous solid, 70% purity, the byproduct is 5,5′-(1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-3,5-diyl)bis(benzo[<i>c</i>][1,2,5]oxadiazole). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.88 (dd, <i>J</i> = 5.1, 2.2 Hz, 1H), 8.78–8.74 (m, 1H), 8.72 (s, 1H), 8.54–8.50 (m, 1H), 8.30–8.22 (m, 1H), 8.13 (dd, <i>J</i> = 9.4, 1.0 Hz, 1H), 8.08 (d, <i>J</i> = 8.4 Hz, 2H), 8.06–8.03 (m, 2H), 7.90–7.83 (m, 2H), 7.17 (dd, <i>J</i> = 9.1, 2.3 Hz, 2H), 4.36 (q, <i>J</i> = 7.1 Hz, 2H), 3.86 (s, 3H), 1.36 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>, representative peaks): δ 165.6, 158.1, 149.8, 148.1, 147.5, 143.2, 142.8, 137.4, 134.0, 130.6, 130.2, 129.7 (2C), 129.3, 127.6 (2C), 127.3, 125.5 (2C), 118.2, 116.3, 114.4 (2C), 113.6, 109.2, 60.8, 55.5, 14.2. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>23</sub>N<sub>5</sub>O<sub>4</sub>S, [M + H]<sup>+</sup> 491.1714; found, 491.1743.</div></div><div id="sec4_5_3_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> <i>N</i>-(4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)phenyl)methanesulfonamide (<b>40</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>66</b> (150 mg, 0.35 mmol), 4-aminophenylboronic pinacol ester (93 mg, 0.42 mmol), NaHCO<sub>3</sub> (87 mg, 1.05 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (27 mg, 0.026 mmol) in 20 mL of 3:1 MeCN/H<sub>2</sub>O. After stirring the reaction overnight, the mixture was cooled to room temperature, and water was added. The water layer was extracted three times with DCM, and the combined organic layers were concentrated <i>in vacuo</i> to give 180 mg of crude amine intermediate. After analysis of the <sup>1</sup>H NMR, the isolated product was taken to the next reaction step without further purification. Crude 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)aniline (60 mg) was dissolved in 4 mL of DCM, and 28 μL of pyridine (2.5 equiv, 0.34 mmol) and 26 μL of methanesulfonyl chloride (2.5 equiv, 0.34 mmol) were added at room temperature. The mixture was stirred for 16 h, concentrated <i>in vacuo</i>, and then submitted to flash column chromatography without further workup. The product was eluted with ethyl acetate in cyclohexane (SiO<sub>2</sub>, 0–100%) to give pure <i>N</i>-(4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)phenyl)methanesulfonamide <b>40</b> in 40% yield over two steps (24 mg, 0.046 mmol, yellow amorphous solid). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.97–9.81 (bs, 1H), 8.80–8.75 (m, 1H), 8.75–8.70 (m, 1H), 8.70–8.66 (m, 1H), 8.50 (s, 1H), 8.30–8.23 (m, 1H), 8.18–8.10 (m, 1H), 7.93–7.81 (m, 4H), 7.40–7.31 (m, 2H), 7.24–7.10 (m, 2H), 3.88 (s, 3H), 3.06 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.0, 149.8, 148.1, 147.1, 142.9, 137.5, 134.0, 133.6, 130.4, 130.3, 130.1, 128.3 (2C), 126.5, 125.4 (2C), 120.2 (3C), 118.2, 116.3, 114.4 (2C), 113.3, 109.0, 55.5, 40.1. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>22</sub>N<sub>5</sub>O<sub>4</sub>S, [M + H]<sup>+</sup> 513.1416; found, [M + H]<sup>+</sup> 513.1419.</div></div><div id="sec4_5_3_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> Methyl 4-(5-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzoate (<b>87</b>)</h5><div class="NLM_p last">General procedure B was applied using halide <b>80</b> (62 mg, 0.14 mmol), benzo[<i>c</i>][1,2,5]oxadiazole-5-boronic acid pinacol ester (41 mg, 0.17 mmol), NaHCO<sub>3</sub> (35 mg, 0.42 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (12 mg, 0.011 mmol) in 10 mL of 3:1 MeCN/H<sub>2</sub>O. After the standard workup procedure, 65 mg of the crude mixture was obtained. NMR of the crude mixture showed clean product, 52 mg was taken for the next step without further purification, and the remaining 13 mg was subjected to further purification. Recrystallization from cold DCM, redissolving in EtOAc, and filtration over short plug of silica yielded methyl 4-(5-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzoate <b>87</b> in 60% yield (8 mg, 0.017 mmol, yellow-orange amorphous solid). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.76–8.71 (m, 1H), 8.56–8.50 (m, 1H), 8.24–8.17 (m, 2H), 8.07–7.96 (m, 2H), 7.86–7.76 (m, 4H), 7.75–7.66 (m, 2H), 7.16–7.09 (m, 2H), 3.96 (s, 3H), 3.91 (s, 3H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.0, 158.9, 149.8, 148.6, 148.4, 143.4, 142.5, 138.8, 133.2 (2C), 130.6, 130.6 (2C), 128.8, 128.4, 127.8, 127.1, 126.9 (2C), 126.0 (2C), 119.3, 117.3, 116.1, 114.9, 113.0, 55.8, 52.3. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>21</sub>N<sub>4</sub>O<sub>4</sub> 477.1557 [M + H]<sup>+</sup>; found, 477.1556 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> 4-(5-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzoic Acid (<b>41</b>)</h5><div class="NLM_p last">Methylester <b>87</b> (52 mg, 0.11 mmol, 1 equiv) was dissolved in dioxane (2.6 mL) and MeOH (2.6 mL), and an aqueous solution of NaOH (0.35 mL, 12 equiv, 4 M) was added. The mixture was stirred at 60 °C for 1 h. The crude product was concentrated <i>in vacuo</i>, and more water was added. Then, the water layer was acidified until the formation of a yellow precipitate (pH = 4.5) and extracted three times with DCM. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. The crude product was purified by column chromatography (SiO<sub>2</sub>, 50–100% EtOAc in cyclohexane) to give 4-(5-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzoic acid <b>41</b> in 4% yield (2.6 mg, 0.056 mmol, yellow amorphous solid) for two steps. The remaining solid in the aqueous layer was refluxed upon addition of acetic acid, filtrated, and lyophilized. The NMR of the solid showed a pure compound identical to the product obtained by column chromatography. The yield of combined products was 37% (24 mg, 0.051 mmol) over 2 steps. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.92–8.81 (m, 2H), 8.57–8.40 (m, 2H), 8.25–8.15 (m, 2H), 8.14–7.98 (m, 4H), 7.91–7.83 (m, 2H), 7.21–7.11 (m, 2H), 3.87 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.2, 157.9, 149.6, 148.3, 147.6, 143.0, 142.1, 138.2, 134.0, 130.4, 130.0 (2C), 128.8, 128.3, 127.8, 127.4, 126.6 (2C), 125.4 (2C), 118.3, 116.5, 114.8, 114.4 (2C), 112.3, 55.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>19</sub>N<sub>4</sub>O<sub>4</sub>, 463.1401 [M + H]<sup>+</sup>; found, 463.1401 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> 4,4′-(1-(4-Methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-3,5-diyl)dibenzoic Acid (<b>42</b>)</h5><div class="NLM_p last">General procedure C was applied using halide <b>55</b> (100 mg, 0.233 mmol), 4-methoxycarbonyl-phenylboronic acid (125 mg, 0.694 mmol), K<sub>2</sub>CO<sub>3</sub> (300 mg, 2.170 mmol), and Pd(dppf)Cl<sub>2</sub> (6 mg, 0.008 mmol) in 10 mL of 3:1 dioxane/H<sub>2</sub>O. The reaction mixture was diluted with DCM (50 mL), more water (25 mL) was added, and the solution was extracted four times with 30 mL of DCM and THF 4:1. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude residue was purified by column chromatography (SiO<sub>2</sub>, THF in DCM, 0–10%) to yield dimethyl 4,4′-(1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-3,5-diyl)dibenzoate contaminated with 4-methoxycarbonyl-phenylboronic acid. The residue was dissolved in DCM (100 mL) and extracted three times with 10% K<sub>2</sub>CO<sub>3</sub> solution (15 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i> to yield monosubstituted intermediate in 38% yield (44.5 mg, 0.090 mmol, white solid), which was used directly for the next reaction step. Dimethyl 4,4′-(1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo [2,3-<i>b</i>] pyridine-3,5-diyl)dibenzoate (44.5 mg, 0.090 mmol) was dissolved in 6 mL of THF and 2 mL of MeOH after which a solution of 73 mg (1.8 mmol, 2 mL, 0.9 M) of NaOH in water was added, and the solution was stirred at room temperature for 8 h. The organic solvents were removed <i>in vacuo</i>. The remaining aqueous solution was diluted with DCM (10 mL), more water (15 mL) was added, and the solution was extracted one time with DCM. Then, the water layer was acidified until the formation of a white precipitate and extracted four times with 25 mL of DCM and THF 4:1. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The residue was boiled with DCM (3 mL) and after that sonicated. The supernatant was removed (repeated twice), and the solid was dried <i>in vacuo</i> to obtain 4,4′-(1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-3,5-diyl)dibenzoic acid <b>42</b> in 10% yield (11 mg, 0.023 mmol) as a white amorphous solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.75 (d, <i>J</i> = 2.1 Hz, 1H), 8.70 (d, <i>J</i> = 2.1 Hz, 1H), 8.49 (s, 1H), 8.09–8.03 (m, 6H), 7.98 (d, <i>J</i> = 8.4 Hz, 2H), 7.87 (d, <i>J</i> = 8.9 Hz, 2H), 7.17 (d, <i>J</i> = 8.9 Hz, 2H), 3.86 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.2, 167.1, 157.9, 147.3, 142.8, 142.6, 138.4, 130.5, 130.1 (2C), 130.0 (2C), 129.4, 129.1, 128.6, 128.2, 127.3 (2C), 126.7, 126.6 (2C), 125.4 (2C), 118.4, 114.7, 114.4 (2C), 55.5. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>21</sub>N<sub>2</sub>O<sub>5</sub>, 465.1478 [M + H]<sup>+</sup>; found, 465.1445 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> 4-(1-(4-Methoxyphenyl)-3-(3-oxo-1,3-dihydroisobenzofuran-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>43</b>)</h5><div class="NLM_p last">Compound <b>43</b> was synthesized according to general procedure B using halide <b>81</b> (45 mg, 0.103 mmol), 4-cabroxyphenyl boronic acid (20.59 mg, 0.124 mmol), NaHCO<sub>3</sub> (26.06 mg, 0.310 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (8.60 mg, 0.0074 mmol) in 6 mL of 3:1 MeCN/H<sub>2</sub>O. The crude mixture was cooled to room temperature and filtrated. The resulted filtrate was dissolved in ethyl acetate and extracted with water. The organic phase was concentrated <i>in vacuo</i> and purified by flash column chromatography (0–100% DCM in cyclohexane) to yield <b>43</b> in 6% (3 mg, 0.003 mmol, yellow amorphous solid). The product contained 10% of open form <b>44</b> and undergoes spontaneous further hydrolysis over time. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.75 (q, <i>J</i> = 2.2 Hz, 2H), 8.58 (s, 1H), 8.25 (s, 1H), 8.15 (d, <i>J</i> = 9.0 Hz, 1H), 8.08 (d, <i>J</i> = 12.0 Hz, 2H), 7.98 (d, <i>J</i> = 6.0 Hz, 2H), 7.93 (d, <i>J</i> = 6.0 Hz, 1H), 7.89–7.86 (m, 2H), 7.18 (d, <i>J</i> = 6.0 Hz, 2H), 5.50 (s, 2H), 3.86 (s, 3H<sub>3</sub>). HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>20</sub>N<sub>2</sub>O<sub>5</sub>, 477.1445 [M + H]<sup>+</sup>; found, 477.1417 [M + H]<sup>+</sup>. IC<sub>50</sub> = 0.58 μM (DiFMUP assay, DiFMUP concentration = 20 μM).</div></div><div id="sec4_5_3_52" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> 5-(5-(4-Carboxyphenyl)-1-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-2-(hydroxymethyl)benzoic Acid (<b>44</b>)</h5><div class="NLM_p last">Compound <b>44</b> was synthesized according to general procedure B using halide <b>81</b> (45 mg, 0.103 mmol), 4-cabroxyphenyl boronic acid (20.59 mg, 0.124 mmol), NaHCO<sub>3</sub> (26.06 mg, 0.310 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (8.60 mg, 0.0074 mmol) in 6 mL of 3:1 MeCN/H<sub>2</sub>O. The crude mixture was cooled to room temperature and filtrated. The resulted filtrate was dissolved in ethylacetate and extracted with water. The organic phase was concentrated <i>in vacuo</i> and purified by flash column chromatography (0–100% DCM in cyclohexane) to give <b>44</b> in 20% yield (10 mg, 0.01 mmol, yellow amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.74 (s, 1H), 8.67 (s, 1H), 8.42 (s, 1H), 8.19 (s, 1H), 8.06 (d, <i>J</i> = 6.0 Hz, 2H), 8.01–7.98 (m, 1H), 7.93 (d, <i>J</i> = 6.0 Hz, 2H), 7.91–7.84 (m, 3H), 7.17 (d, <i>J</i> = 6.0 Hz, 2H), 4.94 (s, 2H), 3.85 (s, 3H) ppm. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>23</sub>N<sub>2</sub>O<sub>6</sub>, 495.1551 [M + H]<sup>+</sup>; found, 495.1525 [M + H]<sup>+</sup>. IC<sub>50</sub> = 17.0 μM (DiFMUP assay, DiFMUP concentration = 20 μM).</div></div><div id="sec4_5_3_53" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> 4-(1-(4-Methoxyphenyl)-3-(2-oxo-2<i>H</i>-chromen-7-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>45</b>)</h5><div class="NLM_p last">Compound <b>45</b> was synthesized according to general procedure B using halide <b>82</b> (50 mg, 0.112 mmol), 4-carboxyphenylboronic acid (22 mg, 0.134 mmol), NaHCO<sub>3</sub> (28.2, 0.336 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (3 mg, 0.003 mmol) in 8 mL of 3:1 MeCN/H<sub>2</sub>O. The reaction mixture was diluted with DCM (30 mL), and more water (25 mL) was added, and the solution was extracted with DCM. Then, the water layer was acidified and extracted four times with 30 mL of 4:1 DCM/THF. The combined organic layer was dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude residue was purified by column chromatography (SiO<sub>2</sub>, THF in DCM, 0–35%). The combined fractions were evaporated, and the residue was sonicated with 5 mL of Et<sub>2</sub>O for 5 min, centrifuged, and the supernatant was removed. This procedure was repeated with <i>n</i>-pentane. The remaining solid was dried <i>in vacuo</i> to obtain 4-(1-(4-methoxyphenyl)-3-(2-oxo-2<i>H</i>-chromen-7-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic acid <b>45</b> in 11% yield (6 mg, 0.012 mmol, yellow amorphous solid). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.76–8.70 (m, 2H), 8.56 (s, 1H), 8.11 (d, <i>J</i> = 9.3 Hz, 1H), 8.07 (d, <i>J</i> = 8.3 Hz, 2H), 8.00–7.97 (m, 2H), 7.97–7.93 (m, 2H), 7.87 (d, <i>J</i> = 7.9, 1.0 Hz, 2H), 7.83–7.80 (m, 1H), 7.21–7.14 (m, 2H), 6.47 (d, <i>J</i> = 9.6, 0.9 Hz, 1H), 3.86 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.2, 160.2, 157.9, 154.3, 147.3, 144.1, 142.9, 142.5, 137.9, 130.4, 129.9 (2C), 129.2, 129.1, 129.0, 127.4, 126.8, 125.3 (2C), 123.0 (2C), 118.3, 116.9, 115.0, 114.4 (2C), 114.2, 113.4, 55.5 ppm. HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>20</sub>N<sub>2</sub>O<sub>5</sub>, [M + H]<sup>+</sup> 489.1445; found, 489.1459.</div></div><div id="sec4_5_3_54" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> 4-(3-(Benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoic Acid (<b>46</b>)</h5><div class="NLM_p">Compound <b>46</b> was obtained as a byproduct in the preparation of <b>29</b> in 13% yield. Alternatively, <b>46</b> can be prepared from methyl 4-(3-(benzo[<i>c</i>][1,2,5]oxadiazol-5-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzoate by hydrolysis with 2 M NaOH. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.55–12.42 (bs, 1H), 8.84–8.76 (m, 1H), 8.76–8.66 (m, 1H), 8.46–8.35 (m, 2H), 8.24–8.15 (m, 1H), 8.11–8.03 (m, 3H), 8.01–7.94 (m, 2H). HRMS (pos. ESI-TOF): <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>13</sub>N<sub>4</sub>O, 357.0987 [M + H]<sup>+</sup>; found, 357.0992 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Reference compounds PHPS1, GS493, II-B08, and NSC87877 were purchased from commercial suppliers Merck (Merck Millipore) and Merck (Sigma-Aldrich).</div></div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> Biochemical SHP2 Assay</h3><div class="NLM_p">Biochemical assay for the determination of IC<sub>50</sub> values for compounds <b>1–5</b> and <b>43–44</b> was carried out according to the following DiFMUP protocol. Recombinant SHP2 (amino acids 262–532, produced in house) was utilized. Test compounds were dissolved in (DMSO) at a concentration of 10 or 100 mM, and the assay was carried out at a final concentration of below 1% DMSO. DiFMUP assay buffer contains a final concentration of 25 mM MOPSO (pH 7.0), 50 mM NaCl, 0.05% Tween 20, 0.1% bovine serum albumin (BSA), 1 mM dithiothreitol (DTT), freshly added prior to each measurement, and between 0.12 and 0.8 ng/μL SHP2 (final concentration, applied concentration adjusted to the activity of the enzyme batch used). The final assay volume was 30 μL. Enzyme and the test compound in buffer solution were incubated for 1 h at RT. The reaction was started by adding 20 μM DiFMUP. Measurements were performed on a plate reader (SAFIRE II, Tecan) with the following settings: fluorescence reading from top; excitation wavelength: 360 nm (bandwidth 20 nm); emission wavelength 460 nm (bandwidth 20 nm); and five readings with a time interval of 135 s. Measurements were performed in triplicate. IC<sub>50</sub> values were calculated with Prism 5 (for Windows, Version 5.01, Graph Pad Software, Inc.).</div><div class="NLM_p last">Biochemical assay for the determination of IC<sub>50</sub> values for compounds <b>17–42</b> and <b>45–46</b> was carried out by Reaction Biology Corp utilizing the DiFMUP assay protocol. Recombinant SHP2 (amino acids 246–593) was utilized. Briefly, test compounds were dissolved in DMSO at a concentration of 10 mM, and the assay was carried out at a final DMSO concentration <1%. The DiFMUP assay buffer contained a final concentration of 25 mM HEPES (pH 7.5), 5 mM MgCl<sub>2</sub>, 0.01% Brij-35, 1 mM DTT, and 1% DMSO. Enzyme and the test compound were incubated in buffer solution for 20 min at room temperature. The reaction was started by adding DiFMUP with a final concentration of 10 μM. Measurements were performed in duplicate using a 10-dose response protocol (concentration 100 to 0.005 μM). The following compounds were used as a reference—PHPS1, NSC87877, PTP II-B08, PTP1B inhibitor. The enzyme activities were monitored (Ex/Em 355/460) as a time-course measurement of the increase in the fluorescence signal from the fluorescence substrate for 120 min at room temperature. Shown data represent the average of duplicate measurement.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> Docking and Binding Mode Investigations</h3><div class="NLM_p last">The catalytic domain of SHP2 from the protein data bank (PDB) entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X">3O5X</a> was employed for docking studies with the OpenEye Python toolkit [OpenEye Toolkits 2019.Oct.2; OpenEye Scientific Software: Santa Fe, NM, 2019].<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> The OEChem and OESpruce modules were used to add hydrogens and to prepare protein and cocrystalized ligand for docking. Docking of the investigated ligand series was performed with the hybrid method, which uses the goodness of shape and interaction overlap between the docked molecule and the cocrystalized ligand to bias the exhaustive search of the docking algorithm. Reasonable tautomeric states were generated for each ligand at pH 7.4 using the OEQuacpac module. Conformations were generated with OEOmega, and 20 docking poses were produced with high search resolution using the OEDocking module. Chemgauss4 was used as a scoring function. Finally, docking poses were analyzed in terms of pharmacophoric interaction patterns using LigandScout 4.4 [LigandScout 4.4, Inteligand: Vienna, Austria, 2019].<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> Molecular Dynamic Simulation</h3><div class="NLM_p last">The previously prepared catalytic domain of SHP2 in complex with the identified docking pose of the most active compound (<b>45</b>) was solvated in a cubic box with 10 Å padding with the SPC water model and 0.15 NaCl using Maestro 12.3 [Maestro 12.3, Schrödinger Release 2020-1; Schrödinger, LLC: New York, NY, 2020]. The solvated system was subjected to 20 ns of unbiased MD simulation with Desmond 6.1<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> [Desmond 6.1, Schrödinger Release 2020-1; Schrödinger, LLC: New York, NY, 2020] using the default equilibration and simulation settings. Coordinates were saved every 100 ps and analyzed using the molecular visualization program VMD 1.9.3 [VMD 1.9.3; University of Illinois at Urbana–Champaign: Urbana, IL, 2016].<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> Phosphatase Profiling</h3><div class="NLM_p last">Biochemical assay for the determination of IC<sub>50</sub> values was carried out by Reaction Biology Corp utilizing the DiFMUP assay protocol. Briefly, test compounds were dissolved in DMSO at a concentration of 10 mM, and the assay was carried out at a final DMSO concentration <1%. The DiFMUP assay buffer contained a final concentration of 25 mM HEPES (pH 7.5), 5 mM MgCl<sub>2</sub>, 0.01% Brij-35, 1 mM DTT, and 1% DMSO. For PP2A alpha/PPP2R1A complex, PP1A, and PP1B, 1 mM MnCl<sub>2</sub> was added to reaction buffer. Enzymes and test compound were incubated in buffer solution for 20 min at room temperature. The reaction was started by adding DiFMUP with a final concentration of 2 μM for PTPN1/PTP1B-CD, 30 μM for PP1B, and 10 μM for all other PTPs. Measurements were performed in duplicate using a 10-dose response protocol (concentration 100 to 0.005 μM). Following compounds were used as a reference—PTP1B inhibitor and canthardic acid. The enzyme activities were monitored (Ex/Em 355/460) as a time-course measurement of the increase in the fluorescence signal from the fluorescence substrate for 120 min at room temperature. Shown data represent the average of duplicate measurement.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> Kinase Profiling</h3><div class="NLM_p last">Kinase activity assay was carried out by Reaction Biology Corp. Briefly, test compounds were dissolved in DMSO at a concentration of 10 mM, and the assay was carried out at a final DMSO concentration <1%. The reaction assay buffer contained a final concentration of 20 mM Hepes (pH 7.5), 10 mM MgCl<sub>2</sub>, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM DTT, and 1% DMSO. Required cofactors were added individually to each kinase reaction. Enzyme and the test compound (final concentration 100 μM) were incubated in buffer solution for 20 min at room temperature. The reaction was started by adding <sup>33</sup>P-γ-ATP with a final concentration of 10 μM. Kinase reaction was incubated for 2 h at room temperature, and reactions were spotted onto P81 ion-exchange paper. Kinase activity was detected by the filter-binding method. Measurements were performed in duplicate using a single dose response protocol, and percentage of kinase activity was calculated. Shown data represent the average of duplicate measurement. Staurosporine was used as a reference.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> Cell Culture</h3><div class="NLM_p">The human pancreatic adenocarcinoma cell line HPAF-II (ATCC CRL-1997) obtained from ATCC (American Type Culture Collection) was cultured in Dulbecco’s modified Eagle’s medium (Gibco BRL, Gaithersburg, MD, USA) containing 4.5 g/L glucose, supplemented with 10% (v/v) fetal bovine serum (FBS, Gibco BRL), and 100 U/mL penicillin–streptomycin (Gibco BRL).</div><div class="NLM_p last">The human hepatocellular carcinoma cell line HepG2, purchased from ATCC (HB-8065) was maintained in RPMI-1640 medium (Gibco BRL), supplemented with 10% (v/v) FBS (Gibco BRL), and 100 U/mL penicillin–streptomycin (Gibco BRL).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> Scatter Assay</h3><div class="NLM_p">HPAF-II cells were plated at a density of 1000 cells per well in medium supplemented with 5% FBS into 384-well cell-bind microplates (Corning Life Sciences, Acton, MA, USA) and incubated for 24 h prior to treatment. The test compounds were dissolved and stored in DMSO at a concentration of 10 mM, and a 2-fold serial predilution was prepared yielding a final DMSO concentration of 0.4% (v/v). Compound medium solutions were added to the assay plates and incubated for 1 h. Subsequently, recombinant human hepatocyte growth factor (HGF, provided by W. Birchmeier) was added to a final concentration of 300 pM. The cells were further incubated for 20 h, fixed with 4% formaldehyde/phosphate-buffered saline, and the nuclei were stained with Hoechst 33342 (10 μM, Sigma-Aldrich).</div><div class="NLM_p last">An Array-Scan XTI Reader (Thermo Fisher Scientific Inc.) was used to acquire images in the Hoechst 33342-associated filter channel (BGRFR 386_23) with a 10× objective. For each well, four image fields were acquired, ensuring that typically 1000 cells or more could be analyzed using the morphology analysis bioapplication of the HCS Studio software. The cell scattering was quantified based on the analysis of nuclei minimum distances. Valid nuclei were identified applying thresholds for size, shape, and intensity. The percentage of nuclei showing a minimum neighbor distance above a defined threshold value was calculated.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> Impedance</h3><div class="NLM_p">The scatterassay was additionally applied to label-free kinetic impedance measurements using the xCeLLigence RTCA SP System (ACEA Biosciences Inc., San Diego, CA, USA). This live-cell assay was performed with HPAF-II cells in a 96-well E-plate format. The electrical impedance was measured by the RTCA-integrated software as a dimensionless parameter termed CI.</div><div class="NLM_p last">After doing the background measurement of 50 μL medium per well, 12,000 cells were added in 40 μL of medium to each well of the E-plate 96. The attachment and growth of the cells was recorded by the xCELLigence system every 30 min for 20 h. Then, the cells were preincubated with the compounds for 1 h by transferring 5 μL of 20-fold concentrated compound medium solutions, followed by stimulation with recombinant human HGF by adding a predilution of 5 μL per well to achieve a final concentration of 300 pM. Controls received medium plus DMSO with a final concentration of 0.2%. The impedance was monitored every 5 min for 4 h.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> Cell Growth and Cytotoxicity</h3><div class="NLM_p last">The cells (HPAF-II and HepG2) were seeded in 384-well microplates at 750 cells in 40 μL medium per well (CellCarrier-384 ultra, PerkinElmer) and incubated for 20 h. Then, 10 μL per well of 5-fold concentrated serial compound dilutions were added into the plates (final concentration 40 −0.6 μM, 0.4% DMSO). Following further incubation for 72 h, a live-cell staining of nuclei was performed using Hoechst 33342 (1 μM, Sigma-Aldrich) and TO-PRO-3 (1 μM, Invitrogen) as the dead cell indicator. The Array-Scan XTI Reader (Thermo Fisher Scientific Inc.) was used to acquire images with a 10× objective in the Hoechst 33342-associated filter channel (BGRFR 386_23) and the TO-PRO-3-associated far-red filter channel (BGRFR 650_13). Cell proliferation was determined by counting of valid Hoechst 33342 fluorescent cell nuclei, whereas the number of TO-PRO-3 fluorescent nuclei was used for the cytotoxicity analysis.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> Colony Formation Assay</h3><div class="NLM_p last">VACO432 and HCC1806 cells were seeded at 5000 cells/well in 12-well plates (Sarstedt) and allowed to adhere overnight. The next day, compounds were added as indicated and treatments were refreshed every 3–4 days. When vehicle (DMSO)-treated cells (indicated as “UT” in all figures) reached confluence, all wells were fixed in 3.7% formaldehyde, stained with 0.1% crystal violet and subsequently scanned.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> Western Blotting</h3><div class="NLM_p last">Cell samples were lysed in RIPA buffer [50 mM Tris pH 7.4, 150 mM NaCl, 1% NP40, 0.1% sodium dodecyl sulfate (SDS) and 0.5% sodium deoxycholate] supplemented with protease inhibitor (Roche, #11836153001) and phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich, #P57261 and #P0044). Protein concentrations were determined by Pierce BCA protein assay kit (Thermo Scientific, #23225). Proteins were separated by SDS-PAGE in Laemmli buffer (0.25 M Tris, 1.92 M glycine, 1% SDS), transferred to polyvinylidene difluoride membranes (Carl Roth, pore size 0.45 μM) in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol), and subsequently incubated overnight at 4 °C with indicated antibodies in 5% BSA in PBST. ECL (PerkinElmer, NEL104001EA) was used to detect antibodies in a Vilber Fusion FX. Antibodies against HSP90 (sc-13119) and p-ERK Y204 (sc-7383) were purchased from Santa Cruz Biotechnology..</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i112"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01265" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02011" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02011" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01265?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01265</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Docking complexes in PDB format (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_001.zip" class="ext-link">ZIP</a>)</p></li><li><p class="inline">Ligand alignment studies, alternative synthetic pathway for the preparation of the azaindoles, docking poses of the representative compounds, full-detailed phosphatase and kinase profiling, cell permeability experiments, and HRMS data of the key compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds <b>8</b>–<b>46</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_001.zip">jm0c01265_si_001.zip (465.35 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_002.pdf">jm0c01265_si_002.pdf (994.9 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_003.csv">jm0c01265_si_003.csv (3.27 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01265" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73302" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73302" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marc Nazaré</span> - <span class="hlFld-Affiliation affiliation">Leibniz-Forschungsinstitut
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1602-2330" title="Orcid link">http://orcid.org/0000-0002-1602-2330</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ec828d968d9e89ac8a819cc18e899e808582c28889"><span class="__cf_email__" data-cfemail="9ef0ffe4ffecfbdef8f3eeb3fcfbecf2f7f0b0fafb">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yelena Mostinski</span> - <span class="hlFld-Affiliation affiliation">Leibniz-Forschungsinstitut
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guus J. J. E. Heynen</span> - <span class="hlFld-Affiliation affiliation">Max
Delbrück Center for Molecular Medicine in the Helmholtz Association
(MDC), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Pascual López-Alberca</span> - <span class="hlFld-Affiliation affiliation">Leibniz-Forschungsinstitut
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jerome Paul</span> - <span class="hlFld-Affiliation affiliation">Leibniz-Forschungsinstitut
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra Miksche</span> - <span class="hlFld-Affiliation affiliation">Leibniz-Forschungsinstitut
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silke Radetzki</span> - <span class="hlFld-Affiliation affiliation">Leibniz-Forschungsinstitut
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Schaller</span> - <span class="hlFld-Affiliation affiliation">Charité−Universitätsmedizin
Berlin, Charitéplatz
1, 10117 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena Shanina</span> - <span class="hlFld-Affiliation affiliation">Max-Planck-Institut
für Kolloid- und Grenzflächenforschung, Am Mühlenberg, 1, 14476 Potsdam, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carola Seyffarth</span> - <span class="hlFld-Affiliation affiliation">Leibniz-Forschungsinstitut
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuliya Kolomeets</span> - <span class="hlFld-Affiliation affiliation">Leibniz-Forschungsinstitut
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nandor Ziebart</span> - <span class="hlFld-Affiliation affiliation">Leibniz-Forschungsinstitut
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Judith de Schryver</span> - <span class="hlFld-Affiliation affiliation">Leibniz-Forschungsinstitut
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sylvia Oestreich</span> - <span class="hlFld-Affiliation affiliation">Leibniz-Forschungsinstitut
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span>; 
    <span>Present Address:
                        Vaxxilon Deutschland GmbH, Magnusstraße 11, 12489 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Neuenschwander</span> - <span class="hlFld-Affiliation affiliation">Leibniz-Forschungsinstitut
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yvette Roske</span> - <span class="hlFld-Affiliation affiliation">Max
Delbrück Center for Molecular Medicine in the Helmholtz Association
(MDC), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Udo Heinemann</span> - <span class="hlFld-Affiliation affiliation">Max
Delbrück Center for Molecular Medicine in the Helmholtz Association
(MDC), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christoph Rademacher</span> - <span class="hlFld-Affiliation affiliation">Max-Planck-Institut
für Kolloid- und Grenzflächenforschung, Am Mühlenberg, 1, 14476 Potsdam, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7082-7239" title="Orcid link">http://orcid.org/0000-0001-7082-7239</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Volkamer</span> - <span class="hlFld-Affiliation affiliation">Charité−Universitätsmedizin
Berlin, Charitéplatz
1, 10117 Berlin, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3760-580X" title="Orcid link">http://orcid.org/0000-0002-3760-580X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jens Peter von Kries</span> - <span class="hlFld-Affiliation affiliation">Leibniz-Forschungsinstitut
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Walter Birchmeier</span> - <span class="hlFld-Affiliation affiliation">Max
Delbrück Center for Molecular Medicine in the Helmholtz Association
(MDC), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i115">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57385" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57385" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">M.N., Y.M., M.P.L.-A., J.d.S., S.M., and J.P. would like to thank Dr. Edgar Specker (FMP) and the NMR core facility of the FMP for their excellent support on compound characterization. Y.M. thanks the Minerva-Stiftung of the Max Planck Society for a postdoctoral fellowship. A.V. and D.S. thank Prof. Dr. Gerhard Wolber (Freie Universität Berlin) for providing a license for LigandScout 4.4.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">SHP2</td><td class="NLM_def"><p class="first last">Src homology-2 domain containing protein tyrosine phosphatase-2</p></td></tr><tr><td class="NLM_term">PTP</td><td class="NLM_def"><p class="first last">protein tyrosine phosphatase</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">JAK-STAT</td><td class="NLM_def"><p class="first last">Janus kinase/signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">PI3K-akt</td><td class="NLM_def"><p class="first last">phosphatidylinositol-3-kinase-Akt</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">MAPK/ERK kinase</p></td></tr><tr><td class="NLM_term">BRAF</td><td class="NLM_def"><p class="first last">v-raf murine sarcoma viral oncogene homolog B1</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">PAINS</td><td class="NLM_def"><p class="first last">pan-assay interference compounds</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyloxycarbonyl</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DiFMUP</td><td class="NLM_def"><p class="first last">difluoromethylumbelliferyl phosphate</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyran</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated protein kinase</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethylsulfoxide</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term">SDS</td><td class="NLM_def"><p class="first last">sodium dodecyl sulfate</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i117">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82705" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82705" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 82 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaitzidis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">The Tyrosine Phosphatase Shp2 (PTPN11) in Cancer</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1007/s10555-008-9126-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1007%2Fs10555-008-9126-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=18286234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=179-192&author=G.+Chanauthor=D.+Kalaitzidisauthor=B.+G.+Neel&title=The+Tyrosine+Phosphatase+Shp2+%28PTPN11%29+in+Cancer&doi=10.1007%2Fs10555-008-9126-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase Shp2 (PTPN11) in cancer</span></div><div class="casAuthors">Chan, Gordon; Kalaitzidis, Demetrios; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-192</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Diverse cellular processes are regulated by tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs).  De-regulated tyrosyl phosphorylation, evoked by gain-of-function mutations and/or over-expression of PTKs, contributes to the pathogenesis of many cancers and other human diseases.  PTPs, because they oppose the action of PTKs, had been considered to be prime suspects for potential tumor suppressor genes.  Surprisingly, few, if any, tumor suppressor PTPs have been identified.  However, the Src homol.-2 domain-contg. phosphatase Shp2 (encoded by PTPN11) is a bona fide proto-oncogene.  Germline mutations in PTPN11 cause Noonan and LEOPARD syndromes, whereas somatic PTPN11 mutations occur in several types of hematol. malignancies, most notably juvenile myelomonocytic leukemia and, more rarely, in solid tumors.  Shp2 also is an essential component in several other oncogene signaling pathways.  Elucidation of the events underlying Shp2-evoked transformation may provide new insights into oncogenic mechanisms and novel targets for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbJ8OYsBzvg7Vg90H21EOLACvtfcHk0lh_ENc-RYPUwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D&md5=fb514f60b97f8ff0dcc0dbd57cab2c9a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs10555-008-9126-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-008-9126-y%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%26aulast%3DKalaitzidis%26aufirst%3DD.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DThe%2520Tyrosine%2520Phosphatase%2520Shp2%2520%2528PTPN11%2529%2520in%2520Cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2008%26volume%3D27%26spage%3D179%26epage%3D192%26doi%3D10.1007%2Fs10555-008-9126-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosário, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span> <span> </span><span class="NLM_article-title">The Tyrosine Phosphatase Shp2 In Development And Cancer</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/s0065-230x(10)06002-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2FS0065-230X%2810%2906002-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=20399956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovVGjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2010&pages=53-89&author=K.+S.+Grossmannauthor=M.+Ros%C3%A1rioauthor=C.+Birchmeierauthor=W.+Birchmeier&title=The+Tyrosine+Phosphatase+Shp2+In+Development+And+Cancer&doi=10.1016%2Fs0065-230x%2810%2906002-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase Shp2 in development and cancer</span></div><div class="casAuthors">Grossmann, Katja S.; Rosario, Marta; Birchmeier, Carmen; Birchmeier, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-89</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Deregulation of signaling pathways, through mutation or other mol. changes, can ultimately result in disease.  The tyrosine phosphatase Shp2 has emerged as a major regulator of receptor tyrosine kinase (RTK) and cytokine receptor signaling.  In the last decade, germline mutations in the human PTPN11 gene, encoding Shp2, were linked to Noonan (NS) and LEOPARD syndromes, two multisymptomatic developmental disorders that are characterized by short stature, craniofacial defects, cardiac defects, and mental retardation.  Somatic Shp2 mutations are also assocd. with several types of human malignancies, such as the most common juvenile leukemia, juvenile myelomonocytic leukemia (JMML).  Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be assocd. with LEOPARD syndrome.  Animal models that carry conditional LOF and GOF mutations have allowed a better understanding of the mechanism of Shp2 function in disease, and shed light on the role of Shp2 in signaling pathways that control decisive events during embryonic development or during cellular transformation/tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgraxAD7u8HbVg90H21EOLACvtfcHk0lh_ENc-RYPUwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovVGjtr4%253D&md5=45bc842913f2ac8e0fec7c6e1ed8576a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0065-230X%2810%2906002-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-230X%252810%252906002-1%26sid%3Dliteratum%253Aachs%26aulast%3DGrossmann%26aufirst%3DK.%2BS.%26aulast%3DRos%25C3%25A1rio%26aufirst%3DM.%26aulast%3DBirchmeier%26aufirst%3DC.%26aulast%3DBirchmeier%26aufirst%3DW.%26atitle%3DThe%2520Tyrosine%2520Phosphatase%2520Shp2%2520In%2520Development%2520And%2520Cancer%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2010%26volume%3D106%26spage%3D53%26epage%3D89%26doi%3D10.1016%2Fs0065-230x%2810%2906002-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11368</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00249</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00249" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVaqsrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11368&author=X.+Yuanauthor=H.+Buauthor=J.+Zhouauthor=C.-Y.+Yangauthor=H.+Zhang&title=Recent+Advances+of+SHP2+Inhibitors+in+Cancer+Therapy%3A+Current+Development+and+Clinical+Application&doi=10.1021%2Facs.jmedchem.0c00249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application</span></div><div class="casAuthors">Yuan, Xinrui; Bu, Hong; Zhou, Jinpei; Yang, Chao-Yie; Zhang, Huibin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11368-11396</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  SHP2 (Src homol.-2 domain-contg. protein tyrosine phosphatase-2) is a non-receptor protein tyrosine phosphatase that removes tyrosine phosphorylation.  Functionally, SHP2 serves as an important hub to connect several intracellular oncogenic signaling pathways, such as Jak/STAT, PI3K/AKT, RAS/Raf/MAPK, and PD-1/PD-L1 pathways.  Mutations and/or overexpression of SHP2 has been assocd. with genetic developmental diseases and cancers.  Because of the role of SHP2 plays in many diseases, the development of inhibitors targeting the catalytic site in SHP2 has been pursued for more than a decade, but none has advanced to clin. development.  Recent discovery of allosteric inhibitors has inspired a novel approach to selectively target SHP2 via the noncatalytic site.  To date, four SHP2 allosteric inhibitors have entered clin. trials for the treatment of solid tumors.  This review will provide a summary of the physiol. and biol. functions of SHP2 and discuss the development of nonallosteric/allosteric SHP2 inhibitors in recent years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBJjQ8BLJRdLVg90H21EOLACvtfcHk0ljg5YJ_CZ97lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVaqsrbK&md5=d7c4a8a93ab73aa4f0e9df0577c38444</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00249%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DBu%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DRecent%2520Advances%2520of%2520SHP2%2520Inhibitors%2520in%2520Cancer%2520Therapy%253A%2520Current%2520Development%2520and%2520Clinical%2520Application%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11368%26doi%3D10.1021%2Facs.jmedchem.0c00249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaeper, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehring, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempkes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span> <span> </span><span class="NLM_article-title">Coupling of Gab1 to c-Met, Grb2, and Shp2 Mediates Biological Responses</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">1419</span>– <span class="NLM_lpage">1432</span>, <span class="refDoi"> DOI: 10.1083/jcb.149.7.1419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1083%2Fjcb.149.7.1419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10871282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVKnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2000&pages=1419-1432&author=U.+Schaeperauthor=N.+H.+Gehringauthor=K.+P.+Fuchsauthor=M.+Sachsauthor=B.+Kempkesauthor=W.+Birchmeier&title=Coupling+of+Gab1+to+c-Met%2C+Grb2%2C+and+Shp2+Mediates+Biological+Responses&doi=10.1083%2Fjcb.149.7.1419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses</span></div><div class="casAuthors">Schaeper, Ute; Gehring, Niels H.; Fuchs, Klaus P.; Sachs, Martin; Kempkes, Bettina; Birchmeier, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1419-1432</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Gab1 is a substrate of the receptor tyrosine kinase c-Met and involved in c-Met-specific branching morphogenesis.  It assocs. directly with c-Met via the c-Met-binding domain, which is not related to known phosphotyrosine-binding domains.  In addn., Gab1 is engaged in a constitutive complex with the adaptor protein Grb2.  We have now mapped the c-Met and Grb2 interaction sites using reverse yeast two-hybrid technol.  The c-Met-binding site is localized to a 13-amino acid region unique to Gab1.  Insertion of this site into the Gab1-related protein p97/Gab2 was sufficient to confer c-Met-binding activity.  Assocn. with Grb2 was mapped to two sites: a classical SH3-binding site (PXXP) and a novel Grb2 SH3 consensus-binding motif (PX(V/I)(D/N)RXXKP).  To detect phosphorylation-dependent interactions of Gab1 with downstream substrates, we developed a modified yeast two-hybrid assay and identified PI(3)K, Shc, Shp2, and CRKL as interaction partners of Gab1.  In a trk-met-Gab1-specific branching morphogenesis assay, assocn. of Gab1 with Shp2, but not PI(3)K, CRKL, or Shc was essential to induce a biol. response in MDCK cells.  Overexpression of a Gab1 mutant deficient in Shp2 interaction could also block HGF/SF-induced activation of the MAPK pathway, suggesting that Shp2 is crit. for c-Met/Gab1-specific signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprKVabpaeh0bVg90H21EOLACvtfcHk0ljg5YJ_CZ97lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVKnsr0%253D&md5=34fc6f8db814c2e60eaebf2af07dec26</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1083%2Fjcb.149.7.1419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.149.7.1419%26sid%3Dliteratum%253Aachs%26aulast%3DSchaeper%26aufirst%3DU.%26aulast%3DGehring%26aufirst%3DN.%2BH.%26aulast%3DFuchs%26aufirst%3DK.%2BP.%26aulast%3DSachs%26aufirst%3DM.%26aulast%3DKempkes%26aufirst%3DB.%26aulast%3DBirchmeier%26aufirst%3DW.%26atitle%3DCoupling%2520of%2520Gab1%2520to%2520c-Met%252C%2520Grb2%252C%2520and%2520Shp2%2520Mediates%2520Biological%2520Responses%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2000%26volume%3D149%26spage%3D1419%26epage%3D1432%26doi%3D10.1083%2Fjcb.149.7.1419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">The Role of Shp2 (PTPN11) in Cancer</span>. <i>Curr. Opin. Genet. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.gde.2006.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.gde.2006.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=17227708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslOgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=23-30&author=M.+G.+Mohiauthor=B.+G.+Neel&title=The+Role+of+Shp2+%28PTPN11%29+in+Cancer&doi=10.1016%2Fj.gde.2006.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Shp2 (PTPN11) in cancer</span></div><div class="casAuthors">Mohi, M. Golam; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-30</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs), regulates numerous cellular processes.  Altered expression and/or mutations in PTKs are linked to many forms of cancer, yet until recently little was known about the roles of PTPs in normal cells or in cancer.  Earlier work established that a member of the PTP superfamily, PTEN, is an important tumor suppressor gene.  We now know that at least one other PTP, the SH2 domain-contg. phosphatase Shp2, is a bona fide oncogene that is mutated in several types of leukemia and hyperactivated by other mechanisms in some solid tumors.  Understanding how Shp2 and other PTPs contribute to oncogenesis should provide new insights into pathogenesis and might suggest new targets for anti-neoplastic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ0V_cNPfFwLVg90H21EOLACvtfcHk0ljg5YJ_CZ97lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslOgtQ%253D%253D&md5=a571192d3fffdff69ddfc264bb9108ce</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2006.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2006.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DMohi%26aufirst%3DM.%2BG.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DThe%2520Role%2520of%2520Shp2%2520%2528PTPN11%2529%2520in%2520Cancer%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2007%26volume%3D17%26spage%3D23%26epage%3D30%26doi%3D10.1016%2Fj.gde.2006.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jopling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Geemen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Hertog, J.</span></span> <span> </span><span class="NLM_article-title">Shp2 Knockdown and Noonan/LEOPARD Mutant Shp2-Induced Gastrulation Defects</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e225</span> <span class="refDoi"> DOI: 10.1371/journal.pgen.0030225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1371%2Fjournal.pgen.0030225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=18159945" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&author=C.+Joplingauthor=D.+van+Geemenauthor=J.+den+Hertog&title=Shp2+Knockdown+and+Noonan%2FLEOPARD+Mutant+Shp2-Induced+Gastrulation+Defects&doi=10.1371%2Fjournal.pgen.0030225"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.0030225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.0030225%26sid%3Dliteratum%253Aachs%26aulast%3DJopling%26aufirst%3DC.%26aulast%3Dvan%2BGeemen%26aufirst%3DD.%26aulast%3Dden%2BHertog%26aufirst%3DJ.%26atitle%3DShp2%2520Knockdown%2520and%2520Noonan%252FLEOPARD%2520Mutant%2520Shp2-Induced%2520Gastrulation%2520Defects%26jtitle%3DPLoS%2520Genet.%26date%3D2007%26volume%3D3%26doi%3D10.1371%2Fjournal.pgen.0030225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G. J. J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vecchione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1985</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2015.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.celrep.2015.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=26365186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1978-1985&author=A.+Prahalladauthor=G.+J.+J.+E.+Heynenauthor=G.+Germanoauthor=S.+M.+Willemsauthor=B.+Eversauthor=L.+Vecchioneauthor=V.+Gambinoauthor=C.+Lieftinkauthor=R.+L.+Beijersbergenauthor=F.+Di+Nicolantonioauthor=A.+Bardelliauthor=R.+Bernards&title=PTPN11+Is+a+Central+Node+in+Intrinsic+and+Acquired+Resistance+to+Targeted+Cancer+Drugs&doi=10.1016%2Fj.celrep.2015.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs</span></div><div class="casAuthors">Prahallad, Anirudh; Heynen, Guus J. J. E.; Germano, Giovanni; Willems, Stefan M.; Evers, Bastiaan; Vecchione, Loredana; Gambino, Valentina; Lieftink, Cor; Beijersbergen, Roderick L.; Di Nicolantonio, Federica; Bardelli, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1978-1985</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon cancers are intrinsically resistant to these drugs because of feedback activation of EGFR.  We performed an RNA-interference-based genetic screen in BRAF mutant colon cancer cells to search for phosphatases whose knockdown induces sensitivity to BRAF inhibition.  We found that suppression of protein tyrosine phosphatase non-receptor type 11 (PTPN11) confers sensitivity to BRAF inhibitors in colon cancer.  Mechanistically, we found that inhibition of PTPN11 blocks signaling from receptor tyrosine kinases (RTKs) to the RAS-MEK-ERK pathway.  PTPN11 suppression is lethal to cells that are driven by activated RTKs and prevents acquired resistance to targeted cancer drugs that results from RTK activation.  Our findings identify PTPN11 as a drug target to combat both intrinsic and acquired resistance to several targeted cancer drugs.  Moreover, activated PTPN11 can serve as a biomarker of drug resistance resulting from RTK activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr2cE8g_Ejr7Vg90H21EOLACvtfcHk0lg_yp7_7DT3Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7fN&md5=521d9847bba4c7c6529ad355da097787</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DHeynen%26aufirst%3DG.%2BJ.%2BJ.%2BE.%26aulast%3DGermano%26aufirst%3DG.%26aulast%3DWillems%26aufirst%3DS.%2BM.%26aulast%3DEvers%26aufirst%3DB.%26aulast%3DVecchione%26aufirst%3DL.%26aulast%3DGambino%26aufirst%3DV.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DPTPN11%2520Is%2520a%2520Central%2520Node%2520in%2520Intrinsic%2520and%2520Acquired%2520Resistance%2520to%2520Targeted%2520Cancer%2520Drugs%26jtitle%3DCell%2520Rep.%26date%3D2015%26volume%3D12%26spage%3D1978%26epage%3D1985%26doi%3D10.1016%2Fj.celrep.2015.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mainardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulero-Sánchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krimpenfort, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves-Ribeiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">SHP2 is Required for Growth of KRAS-Mutant Non-Small-Cell Lung Cancer In Vivo</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0023-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fs41591-018-0023-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=29808006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=961-967&author=S.+Mainardiauthor=A.+Mulero-S%C3%A1nchezauthor=A.+Prahalladauthor=G.+Germanoauthor=A.+Bosmaauthor=P.+Krimpenfortauthor=C.+Lieftinkauthor=J.+D.+Steinbergauthor=N.+de+Witauthor=S.+Gon%C3%A7alves-Ribeiroauthor=E.+Nadalauthor=A.+Bardelliauthor=A.+Villanuevaauthor=R.+Bernards&title=SHP2+is+Required+for+Growth+of+KRAS-Mutant+Non-Small-Cell+Lung+Cancer+In+Vivo&doi=10.1038%2Fs41591-018-0023-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo</span></div><div class="casAuthors">Mainardi, Sara; Mulero-Sanchez, Antonio; Prahallad, Anirudh; Germano, Giovanni; Bosma, Astrid; Krimpenfort, Paul; Lieftink, Cor; Steinberg, Jeffrey D.; de Wit, Niels; Goncalves-Ribeiro, Samuel; Nadal, Ernest; Bardelli, Alberto; Villanueva, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">961-967</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">RAS mutations are frequent in human cancer, esp. in pancreatic, colorectal and non-small-cell lung cancers (NSCLCs).  Inhibition of the RAS oncoproteins has proven difficult, and attempts to target downstream effectors have been hampered by the activation of compensatory resistance mechanisms.  It is also well established that KRAS-mutant tumors are insensitive to inhibition of upstream growth factor receptor signaling.  Thus, epidermal growth factor receptor antibody therapy is only effective in KRAS wild-type colon cancers.  Consistently, inhibition of SHP2 (also known as PTPN11), which links receptor tyrosine kinase signaling to the RAS-RAF-MEK-ERK pathway11,12, was shown to be ineffective in KRAS-mutant or BRAF-mutant cancer cell lines.  Tha data also indicate that SHP2 inhibition in KRAS-mutant NSCLC cells under normal cell culture conditions has little effect.  By contrast, SHP2 inhibition under growth factor-limiting conditions in vitro results in a senescence response.  In vivo, inhibition of SHP2 in KRAS-mutant NSCLC also provokes a senescence response, which is exacerbated by MEK inhibition.  Tha data identify SHP2 inhibition as an unexpected vulnerability of KRAS-mutant NSCLC cells that remains undetected in cell culture and can be exploited therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLHUMCtBqtZrVg90H21EOLACvtfcHk0ljUER8kDxXuWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvL&md5=8e1ce1eb5d30d3985aafdec9d07f205d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0023-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0023-9%26sid%3Dliteratum%253Aachs%26aulast%3DMainardi%26aufirst%3DS.%26aulast%3DMulero-S%25C3%25A1nchez%26aufirst%3DA.%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DGermano%26aufirst%3DG.%26aulast%3DBosma%26aufirst%3DA.%26aulast%3DKrimpenfort%26aufirst%3DP.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DSteinberg%26aufirst%3DJ.%2BD.%26aulast%3Dde%2BWit%26aufirst%3DN.%26aulast%3DGon%25C3%25A7alves-Ribeiro%26aufirst%3DS.%26aulast%3DNadal%26aufirst%3DE.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DSHP2%2520is%2520Required%2520for%2520Growth%2520of%2520KRAS-Mutant%2520Non-Small-Cell%2520Lung%2520Cancer%2520In%2520Vivo%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D961%26epage%3D967%26doi%3D10.1038%2Fs41591-018-0023-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruess, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciecielski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berninger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabacaoglu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Görgülü, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wörmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diakopoulos, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpathaki, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya-Aksoy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Laan, E. A. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Alberca, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazaré, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erkan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopt, U. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainz, B.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algül, H.</span></span> <span> </span><span class="NLM_article-title">Mutant KRAS-driven Cancers Depend on PTPN11/SHP2 Phosphatase</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0024-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fs41591-018-0024-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=29808009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=954-960&author=D.+A.+Ruessauthor=G.+J.+Heynenauthor=K.+J.+Ciecielskiauthor=J.+Aiauthor=A.+Berningerauthor=D.+Kabacaogluauthor=K.+G%C3%B6rg%C3%BCl%C3%BCauthor=Z.+Dantesauthor=S.+M.+W%C3%B6rmannauthor=K.+N.+Diakopoulosauthor=A.+F.+Karpathakiauthor=M.+Kowalskaauthor=E.+Kaya-Aksoyauthor=L.+Songauthor=E.+A.+Z.+van+der+Laanauthor=M.+P.+L%C3%B3pez-Albercaauthor=M.+Nazar%C3%A9author=M.+Reichertauthor=D.+Saurauthor=M.+M.+Erkanauthor=U.+T.+Hoptauthor=B.+Sainzauthor=W.+Birchmeierauthor=R.+M.+Schmidauthor=M.+Lesinaauthor=H.+Alg%C3%BCl&title=Mutant+KRAS-driven+Cancers+Depend+on+PTPN11%2FSHP2+Phosphatase&doi=10.1038%2Fs41591-018-0024-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase</span></div><div class="casAuthors">Ruess, Dietrich A.; Heynen, Guus J.; Ciecielski, Katrin J.; Ai, Jiaoyu; Berninger, Alexandra; Kabacaoglu, Derya; Goerguelue, Kivanc; Dantes, Zahra; Woermann, Sonja M.; Diakopoulos, Kalliope N.; Karpathaki, Angeliki F.; Kowalska, Marlena; Kaya-Aksoy, Ezgi; Song, Liang; van der Laan, Eveline A. Zeeuw; Lopez-Alberca, Maria P.; Nazare, Marc; Reichert, Maximilian; Saur, Dieter; Erkan, Mert M.; Hopt, Ulrich T.; Sainz, Jr, Bruno; Birchmeier, Walter; Schmid, Roland M.; Lesina, Marina; Alguel, Hana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">954-960</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine and integrin receptors1.  Its requirement for complete RAS-MAPK activation and its role as a neg. regulator of JAK-STAT signaling have established SHP2 as an essential player in oncogenic signaling pathways1-7.  Recently, a novel potent allosteric SHP2 inhibitor was presented as a viable therapeutic option for receptor tyrosine kinase-driven cancers, but was shown to be ineffective in KRAS-mutant tumor cell lines in vitro8.  Here, we report a central and indispensable role for SHP2 in oncogenic KRAS-driven tumors.  Genetic deletion of Ptpn11 profoundly inhibited tumor development in mutant KRAS-driven murine models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer.  We provide evidence for a crit. dependence of mutant KRAS on SHP2 during carcinogenesis.  Deletion or inhibition of SHP2 in established tumors delayed tumor progression but was not sufficient to achieve tumor regression.  However, SHP2 was necessary for resistance mechanisms upon blockade of MEK.  Synergy was obsd. when both SHP2 and MEK were targeted, resulting in sustained tumor growth control in murine and human patient-derived organoids and xenograft models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer.  Our data indicate the clin. utility of dual SHP2/MEK inhibition as a targeted therapy approach for KRAS-mutant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoepq09hU77abVg90H21EOLACvtfcHk0ljUER8kDxXuWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvF&md5=cc09897c2c4b8e32b035b991e5032f32</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0024-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0024-8%26sid%3Dliteratum%253Aachs%26aulast%3DRuess%26aufirst%3DD.%2BA.%26aulast%3DHeynen%26aufirst%3DG.%2BJ.%26aulast%3DCiecielski%26aufirst%3DK.%2BJ.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DBerninger%26aufirst%3DA.%26aulast%3DKabacaoglu%26aufirst%3DD.%26aulast%3DG%25C3%25B6rg%25C3%25BCl%25C3%25BC%26aufirst%3DK.%26aulast%3DDantes%26aufirst%3DZ.%26aulast%3DW%25C3%25B6rmann%26aufirst%3DS.%2BM.%26aulast%3DDiakopoulos%26aufirst%3DK.%2BN.%26aulast%3DKarpathaki%26aufirst%3DA.%2BF.%26aulast%3DKowalska%26aufirst%3DM.%26aulast%3DKaya-Aksoy%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DL.%26aulast%3Dvan%2Bder%2BLaan%26aufirst%3DE.%2BA.%2BZ.%26aulast%3DL%25C3%25B3pez-Alberca%26aufirst%3DM.%2BP.%26aulast%3DNazar%25C3%25A9%26aufirst%3DM.%26aulast%3DReichert%26aufirst%3DM.%26aulast%3DSaur%26aufirst%3DD.%26aulast%3DErkan%26aufirst%3DM.%2BM.%26aulast%3DHopt%26aufirst%3DU.%2BT.%26aulast%3DSainz%26aufirst%3DB.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DSchmid%26aufirst%3DR.%2BM.%26aulast%3DLesina%26aufirst%3DM.%26aulast%3DAlg%25C3%25BCl%26aufirst%3DH.%26atitle%3DMutant%2520KRAS-driven%2520Cancers%2520Depend%2520on%2520PTPN11%252FSHP2%2520Phosphatase%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D954%26epage%3D960%26doi%3D10.1038%2Fs41591-018-0024-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chitranshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dheer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salekdeh, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbasi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Wall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span> <span> </span><span class="NLM_article-title">Loss of Shp2 Rescues BDNF/TrkB Signaling and Contributes to Improved Retinal Ganglion Cell Neuroprotection</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2018.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.ymthe.2018.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=30341011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXis1WqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=424-441&author=N.+Chitranshiauthor=Y.+Dheerauthor=M.+Mirzaeiauthor=Y.+Wuauthor=G.+H.+Salekdehauthor=M.+Abbasiauthor=V.+Guptaauthor=R.+Vander+Wallauthor=Y.+Youauthor=S.+L.+Grahamauthor=V.+Gupta&title=Loss+of+Shp2+Rescues+BDNF%2FTrkB+Signaling+and+Contributes+to+Improved+Retinal+Ganglion+Cell+Neuroprotection&doi=10.1016%2Fj.ymthe.2018.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of Shp2 Rescues BDNF/TrkB Signaling and Contributes to Improved Retinal Ganglion Cell Neuroprotection</span></div><div class="casAuthors">Chitranshi, Nitin; Dheer, Yogita; Mirzaei, Mehdi; Wu, Yunqi; Salekdeh, Ghasem H.; Abbasi, Mojdeh; Gupta, Veer; Vander Wall, Roshana; You, Yuyi; Graham, Stuart L.; Gupta, Vivek</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">424-441</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Glaucoma is characterized by the loss of retinal ganglion cells (RGC), and accordingly the preservation of RGCs and their axons has recently attracted significant attention to improve therapeutic outcomes in the disease.  Here, we report that Src homol. region 2-contg. protein tyrosine phosphatase 2 (Shp2) undergoes activation in the RGCs, in animal model of glaucoma as well as in the human glaucoma tissues and that Shp2 dephosphorylates tropomyosin receptor kinase B (TrkB) receptor, leading to reduced BDNF/TrkB neuroprotective survival signaling.  This was elucidated by specifically modulating Shp2 expression in the RGCs in vivo, using adeno-assocd. virus serotype 2 (AAV2) constructs.  Shp2 upregulation promoted endoplasmic reticulum (ER) stress and apoptosis, along with functional and structural deficits in the inner retina.  In contrast, loss of Shp2 decelerated the loss of RGCs, preserved their function, and suppressed ER stress and apoptosis in glaucoma.  This report constitutes the first identification of Shp2-mediated TrkB regulatory mechanisms in the RGCs that can become a potential therapeutic target in both glaucoma and other neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPxvPqp9eo-LVg90H21EOLACvtfcHk0ljUER8kDxXuWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXis1WqurY%253D&md5=3416eacabb611e5ad0540a8b6ec3c13a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2018.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2018.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DChitranshi%26aufirst%3DN.%26aulast%3DDheer%26aufirst%3DY.%26aulast%3DMirzaei%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DSalekdeh%26aufirst%3DG.%2BH.%26aulast%3DAbbasi%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DVander%2BWall%26aufirst%3DR.%26aulast%3DYou%26aufirst%3DY.%26aulast%3DGraham%26aufirst%3DS.%2BL.%26aulast%3DGupta%26aufirst%3DV.%26atitle%3DLoss%2520of%2520Shp2%2520Rescues%2520BDNF%252FTrkB%2520Signaling%2520and%2520Contributes%2520to%2520Improved%2520Retinal%2520Ganglion%2520Cell%2520Neuroprotection%26jtitle%3DMol.%2520Ther.%26date%3D2019%26volume%3D27%26spage%3D424%26epage%3D441%26doi%3D10.1016%2Fj.ymthe.2018.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrlich, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span> <span> </span><span class="NLM_article-title">SHP2 Regulates Intramembranous Ossification by Modifying the TGFbeta and BMP2 Signaling Pathway</span>. <i>Bone</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1016/j.bone.2018.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bone.2018.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=30471432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGgu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=327-335&author=L.+Wangauthor=J.+Huangauthor=D.+C.+Mooreauthor=Y.+Songauthor=M.+G.+Ehrlichauthor=W.+Yang&title=SHP2+Regulates+Intramembranous+Ossification+by+Modifying+the+TGFbeta+and+BMP2+Signaling+Pathway&doi=10.1016%2Fj.bone.2018.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 regulates intramembranous ossification by modifying the TGFβ and BMP2 signaling pathway</span></div><div class="casAuthors">Wang, Lijun; Huang, Jiahui; Moore, Douglas C.; Song, Yueming; Ehrlich, Michael G.; Yang, Wentian</div><div class="citationInfo"><span class="NLM_cas:title">Bone (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">327-335</span>CODEN:
                <span class="NLM_cas:coden">BONEDL</span>;
        ISSN:<span class="NLM_cas:issn">1873-2763</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">SHP2 is a ubiquitously expressed protein tyrosine phosphatase, which is involved in many signaling pathways to regulate the skeletal development.  In endochondral ossification, SHP2 is known to modify the osteogenic fate of osteochondroprogenitors and to impair the osteoblastic transdifferentiation of hypertrophic chondrocytes.  However, how SHP2 regulates osteoblast differentiation in intramembranous ossification remains incompletely understood.  To address this question, we generated a mouse model to ablate SHP2 in the Prrx1-expressing mesenchymal progenitors by using "Cre-loxP"-mediated gene excision and examd. the development of calvarial bone, in which the main process of bone formation is intramembranous ossification.  Phenotypic characterization showed that SHP2 mutants have severe defects in calvarial bone formation.  Cell lineage tracing and in situ hybridization data showed less osteoblast differentiation of mesenchymal cells and reduced osteogenic genes expression, resp.  Further mechanistic studies revealed enhanced TGFβ and suppressed BMP2 signaling in SHP2 ablated mesenchymal progenitors and their derivs.  Our study uncovered the crit. role of SHP2 in osteoblast differentiation through intramembranous ossification and might provide a potential target to treat craniofacial skeleton disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj6PRZSjPQ87Vg90H21EOLACvtfcHk0lgSP9Emerbd_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGgu73M&md5=4aa0958c7548a2f9819e05f97d64620e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bone.2018.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bone.2018.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DD.%2BC.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DEhrlich%26aufirst%3DM.%2BG.%26aulast%3DYang%26aufirst%3DW.%26atitle%3DSHP2%2520Regulates%2520Intramembranous%2520Ossification%2520by%2520Modifying%2520the%2520TGFbeta%2520and%2520BMP2%2520Signaling%2520Pathway%26jtitle%3DBone%26date%3D2019%26volume%3D120%26spage%3D327%26epage%3D335%26doi%3D10.1016%2Fj.bone.2018.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leugers, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hefti, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span> <span> </span><span class="NLM_article-title">Tau Interacts With SHP2 in Neuronal Systems And in Alzheimer’s Disease Brains</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">jcs229054</span>, <span class="refDoi"> DOI: 10.1242/jcs.229054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1242%2Fjcs.229054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=31201283" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2019&pages=jcs229054&author=Y.+Kimauthor=G.+Liuauthor=C.+J.+Leugersauthor=J.+D.+Muellerauthor=M.+B.+Francisauthor=M.+M.+Heftiauthor=J.+A.+Schneiderauthor=G.+Lee&title=Tau+Interacts+With+SHP2+in+Neuronal+Systems+And+in+Alzheimer%E2%80%99s+Disease+Brains&doi=10.1242%2Fjcs.229054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1242%2Fjcs.229054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.229054%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLeugers%26aufirst%3DC.%2BJ.%26aulast%3DMueller%26aufirst%3DJ.%2BD.%26aulast%3DFrancis%26aufirst%3DM.%2BB.%26aulast%3DHefti%26aufirst%3DM.%2BM.%26aulast%3DSchneider%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DG.%26atitle%3DTau%2520Interacts%2520With%2520SHP2%2520in%2520Neuronal%2520Systems%2520And%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Brains%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2019%26volume%3D132%26spage%3Djcs229054%26doi%3D10.1242%2Fjcs.229054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of Targeting SHP2 in Human Developmental Disorders and Cancers</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">112117</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.ejmech.2020.112117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=32061959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFWgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=112117&author=D.+Shenauthor=W.+Chenauthor=J.+Zhuauthor=G.+Wuauthor=R.+Shenauthor=M.+Xiauthor=H.+Sun&title=Therapeutic+Potential+of+Targeting+SHP2+in+Human+Developmental+Disorders+and+Cancers&doi=10.1016%2Fj.ejmech.2020.112117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of targeting SHP2 in human developmental disorders and cancers</span></div><div class="casAuthors">Shen, Dadong; Chen, Wenxia; Zhu, Jinlin; Wu, Guofeng; Shen, Runpu; Xi, Meiyang; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112117</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Src homol. 2 (SH2)-contg. protein tyrosine phosphatase 2 (SHP2), encoded by PTPN11, regulates cell proliferation, differentiation, apoptosis and survival via releasing intramol. autoinhibition and modulating various signaling pathways, such as mitogen-activated protein kinase (MAPK) pathway.  Mutations and aberrant expression of SHP2 are implicated in human developmental disorders, leukemias and several solid tumors.  As an oncoprotein in some cancers, SHP2 represents a rational target for inhibitors to interfere.  Nevertheless, its tumor suppressive effect has also been uncovered, indicating the context-specificity.  Even so, two types of SHP2 inhibitors including targeting catalytic pocket and allosteric sites have been developed assocd. with resolved cocrystal complexes.  Herein, we describe its structure, biol. function, deregulation in human diseases and summarize recent advance in development of SHP2 inhibitors, trying to give an insight into the therapeutic potential in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkb-7jOXJ8DLVg90H21EOLACvtfcHk0lgSP9Emerbd_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFWgsrk%253D&md5=9f40f6d2a560deac59c2b24616ac9f94</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112117%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DXi%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DTherapeutic%2520Potential%2520of%2520Targeting%2520SHP2%2520in%2520Human%2520Developmental%2520Disorders%2520and%2520Cancers%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D190%26spage%3D112117%26doi%3D10.1016%2Fj.ejmech.2020.112117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting SHP2 as a Promising Strategy for Cancer Immunotherapy</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">104595</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2019.104595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.phrs.2019.104595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=31838080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGgsrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&pages=104595&author=Q.+Liuauthor=J.+Quauthor=M.+Zhaoauthor=Q.+Xuauthor=Y.+Sun&title=Targeting+SHP2+as+a+Promising+Strategy+for+Cancer+Immunotherapy&doi=10.1016%2Fj.phrs.2019.104595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting SHP2 as a promising strategy for cancer immunotherapy</span></div><div class="casAuthors">Liu, Qianqian; Qu, Jiao; Zhao, Mingxia; Xu, Qiang; Sun, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104595</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Src homol.-2-contg. protein tyrosine phosphatase 2 (SHP2) is a major phosphatase involved in several cellular processes.  In recent years, SHP2 has been the focus of significant attention in human diseases, particular in cancer.  Several studies have shown that SHP2 plays an important role in regulating immune cell functions in tumor microenvironment.  A few clin. trials conducted using SHP2 allosteric inhibitors have shown remarkable anti-tumor benefits and good safety profiles.  This review focuses on the current understanding of the regulation of SHP2 and highlights the vital roles of SHP2 in T lymphocytes, macrophages and cancer cells.  It also summarizes the current development of SHP2 inhibitors as a promising strategy for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZzWn2YQmawLVg90H21EOLACvtfcHk0lgSP9Emerbd_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGgsrnN&md5=5335503a2397f7c09f87e589a8f037ec</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2019.104595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2019.104595%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DTargeting%2520SHP2%2520as%2520a%2520Promising%2520Strategy%2520for%2520Cancer%2520Immunotherapy%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D152%26spage%3D104595%26doi%3D10.1016%2Fj.phrs.2019.104595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1793-1802&author=P.+Sarverauthor=M.+Ackerauthor=J.+T.+Bagdanoffauthor=Z.+Chenauthor=Y.-N.+Chenauthor=H.+Chanauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=H.+Haoauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=G.+Liuauthor=S.+Liuauthor=C.+Liuauthor=E.+McNeillauthor=M.+Mohseniauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=V.+Tamezauthor=R.+Tichkuleauthor=C.+Towlerauthor=H.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=B.+Yuauthor=M.+J.+LaMarche&title=6-Amino-3-methylpyrimidinones+as+Potent%2C+Selective%2C+and+Orally+Efficacious+SHP2+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span></div><div class="casAuthors">Sarver, Patrick; Acker, Michael; Bagdanoff, Jeffrey T.; Chen, Zhouliang; Chen, Ying-Nan; Chan, Homan; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hao, Huaixiang; Hentemann, Murphy; Koenig, Robert; Kato, Mitsunori; LaBonte, Laura R.; Liu, Gang; Liu, Shumei; Liu, Chen; McNeill, Eric; Mohseni, Morvarid; Sendzik, Martin; Stams, Travis; Spence, Stan; Tamez, Victoriano; Tichkule, Ritesh; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; Yu, Bing; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1793-1802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase SHP2 is an oncoprotein assocd. with cancer as well as a potential immune modulator because of its role in the programmed cell death PD-L1/PD-1 pathway.  In the preceding manuscript, we described the optimization of a fused, bicyclic screening hit for potency, selectivity, and physicochem. properties in order to further expand the chem. diversity of allosteric SHP2 inhibitors.  In this manuscript, we describe the further expansion of our approach, morphing the fused, bicyclic system into a novel monocyclic pyrimidinone scaffold through our understanding of SAR and use of structure-based design.  These studies led to the identification of SHP394 (1), an orally efficacious inhibitor of SHP2, with high lipophilic efficiency, improved potency, and enhanced pharmacokinetic properties.  We also report other pyrimidinone analogs with favorable pharmacokinetic and potency profiles.  Overall, this work improves upon our previously described allosteric inhibitors and exemplifies and extends the range of permissible chem. templates that inhibit SHP2 via the allosteric mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaRey6_uE0ULVg90H21EOLACvtfcHk0lhBgXuOY2aZyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D&md5=29c357236b7ff51596385e3e256320a5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01726%26sid%3Dliteratum%253Aachs%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.-N.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DH.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMcNeill%26aufirst%3DE.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DTichkule%26aufirst%3DR.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3D6-Amino-3-methylpyrimidinones%2520as%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Efficacious%2520SHP2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1793%26epage%3D1802%26doi%3D10.1021%2Facs.jmedchem.8b01726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarafianos, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C.-K.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1125</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00513</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00513" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A280%3ADC%252BB3crivFClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1125-1137&author=X.+Wuauthor=G.+Xuauthor=X.+Liauthor=W.+Xuauthor=Q.+Liauthor=W.+Liuauthor=K.+A.+Kirbyauthor=M.+L.+Lohauthor=J.+Liauthor=S.+G.+Sarafianosauthor=C.-K.+Qu&title=Small+Molecule+Inhibitor+that+Stabilizes+the+Autoinhibited+Conformation+of+the+Oncogenic+Tyrosine+Phosphatase+SHP2&doi=10.1021%2Facs.jmedchem.8b00513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2</span></div><div class="casAuthors">Wu Xiaoqin; Li Xiaobo; Li Qianjin; Qu Cheng-Kui; Xu Gang; Li Xiaobo; Xu Weiren; Liu Wei; Qu Cheng-Kui; Kirby Karen A; Sarafianos Stefan G; Loh Mignon L; Li Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1125-1137</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Genetic mutations in the phosphatase PTPN11 (SHP2) are associated with childhood leukemias.  These mutations cause hyperactivation of SHP2 due to the disruption of the autoinhibitory conformation.  By targeting the activation-associated protein conformational change, we have identified an SHP2 inhibitor ( E)-1-(1-(5-(3-(2,4-dichlorophenyl)acryloyl)-2-ethoxy-4-hydroxybenzyl)-1,2,5,6-tetrahydropyridin-3-yl)-1 H-benzo[ d]imidazol-2(3 H)-one (LY6, 1) using computer-aided drug design database screening combined with cell-based assays.  This compound inhibited SHP2 with an IC50 value of 9.8 μM, 7-fold more selective for SHP2 than the highly related SHP1.  Fluorescence titration, thermal shift, and microscale thermophoresis quantitative binding assays confirmed its direct binding to SHP2.  This compound was further verified to effectively inhibit SHP2-mediated cell signaling and proliferation.  Furthermore, mouse and patient leukemia cells with PTPN11 activating mutations were more sensitive to this inhibitor than wild-type cells.  This small molecule SHP2 inhibitor has a potential to serve as a lead compound for further optimization studies to develop novel anti-SHP2 therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0hz4mjYe4HMSzjBFCN0BJfW6udTcc2easRwx_sji0U7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crivFClsQ%253D%253D&md5=e05fd7589519ad6928eb769225b9a607</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00513%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DKirby%26aufirst%3DK.%2BA.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26aulast%3DQu%26aufirst%3DC.-K.%26atitle%3DSmall%2520Molecule%2520Inhibitor%2520that%2520Stabilizes%2520the%2520Autoinhibited%2520Conformation%2520of%2520the%2520Oncogenic%2520Tyrosine%2520Phosphatase%2520SHP2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1125%26epage%3D1137%26doi%3D10.1021%2Facs.jmedchem.8b00513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonakos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunenfelder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slisz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span> <span> </span><span class="NLM_article-title">Allosteric Inhibition of SHP2 Phosphatase Inhibits Cancers Driven by Receptor Tyrosine Kinases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1038/nature18621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fnature18621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=27362227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVOns7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=148-152&author=Y.-N.+P.+Chenauthor=M.+J.+LaMarcheauthor=H.+M.+Chanauthor=P.+Fekkesauthor=J.+Garcia-Fortanetauthor=M.+G.+Ackerauthor=B.+Antonakosauthor=C.+H.-T.+Chenauthor=Z.+Chenauthor=V.+G.+Cookeauthor=J.+R.+Dobsonauthor=Z.+Dengauthor=F.+Feiauthor=B.+Firestoneauthor=M.+Fodorauthor=C.+Fridrichauthor=H.+Gaoauthor=D.+Grunenfelderauthor=H.-X.+Haoauthor=J.+Jacobauthor=S.+Hoauthor=K.+Hsiaoauthor=Z.+B.+Kangauthor=R.+Karkiauthor=M.+Katoauthor=J.+Larrowauthor=L.+R.+La+Bonteauthor=F.+Lenoirauthor=G.+Liuauthor=S.+Liuauthor=D.+Majumdarauthor=M.+J.+Meyerauthor=M.+Palermoauthor=L.+Perezauthor=M.+Puauthor=E.+Priceauthor=C.+Quinnauthor=S.+Shakyaauthor=M.+D.+Shultzauthor=J.+Sliszauthor=K.+Venkatesanauthor=P.+Wangauthor=M.+Warmuthauthor=S.+Williamsauthor=G.+Yangauthor=J.+Yuanauthor=J.-H.+Zhangauthor=P.+Zhuauthor=T.+Ramseyauthor=N.+J.+Keenauthor=W.+R.+Sellersauthor=T.+Stamsauthor=P.+D.+Fortin&title=Allosteric+Inhibition+of+SHP2+Phosphatase+Inhibits+Cancers+Driven+by+Receptor+Tyrosine+Kinases&doi=10.1038%2Fnature18621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases</span></div><div class="casAuthors">Chen, Ying-Nan P.; LaMarche, Matthew J.; Chan, Ho Man; Fekkes, Peter; Garcia-Fortanet, Jorge; Acker, Michael G.; Antonakos, Brandon; Chen, Christine Hiu-Tung; Chen, Zhouliang; Cooke, Vesselina G.; Dobson, Jason R.; Deng, Zhan; Fei, Feng; Firestone, Brant; Fodor, Michelle; Fridrich, Cary; Gao, Hui; Grunenfelder, Denise; Hao, Huai-Xiang; Jacob, Jaison; Ho, Samuel; Hsiao, Kathy; Kang, Zhao B.; Karki, Rajesh; Kato, Mitsunori; Larrow, Jay; La Bonte, Laura R.; Lenoir, Francois; Liu, Gang; Liu, Shumei; Majumdar, Dyuti; Meyer, Matthew J.; Palermo, Mark; Perez, Lawrence; Pu, Minying; Price, Edmund; Quinn, Christopher; Shakya, Subarna; Shultz, Michael D.; Slisz, Joanna; Venkatesan, Kavitha; Wang, Ping; Warmuth, Markus; Williams, Sarah; Yang, Guizhi; Yuan, Jing; Zhang, Ji-Hu; Zhu, Ping; Ramsey, Timothy; Keen, Nicholas J.; Sellers, William R.; Stams, Travis; Fortin, Pascal D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7610</span>),
    <span class="NLM_cas:pages">148-152</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an important role in signal transduction downstream of growth factor receptor signalling and was the first reported oncogenic tyrosine phosphatase.  Activating mutations of SHP2 have been assocd. with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukemia, lung and breast cancer and neuroblastoma.  SHP2 is ubiquitously expressed and regulates cell survival and proliferation primarily through activation of the RAS-ERK signalling pathway2,3.  It is also a key mediator of the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) immune checkpoint pathways.  Redn. of SHP2 activity suppresses tumor cell growth and is a potential target of cancer therapy.  Here we report the discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-mol. SHP2 inhibitor, SHP099, that stabilizes SHP2 in an auto-inhibited conformation.  SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism.  SHP099 suppresses RAS-ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumor xenograft models.  Together, these data demonstrate that pharmacol. inhibition of SHP2 is a valid therapeutic approach for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBs_e02S0Sp7Vg90H21EOLACvtfcHk0lhm45rMb7gO0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVOns7bI&md5=ec8a4b612d5008a2519bd846d45ce019</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature18621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18621%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.-N.%2BP.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DFekkes%26aufirst%3DP.%26aulast%3DGarcia-Fortanet%26aufirst%3DJ.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DAntonakos%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%2BH.-T.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DDobson%26aufirst%3DJ.%2BR.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DFei%26aufirst%3DF.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGrunenfelder%26aufirst%3DD.%26aulast%3DHao%26aufirst%3DH.-X.%26aulast%3DJacob%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DHsiao%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DLarrow%26aufirst%3DJ.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPalermo%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DC.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DSlisz%26aufirst%3DJ.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DZhu%26aufirst%3DP.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DKeen%26aufirst%3DN.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26atitle%3DAllosteric%2520Inhibition%2520of%2520SHP2%2520Phosphatase%2520Inhibits%2520Cancers%2520Driven%2520by%2520Receptor%2520Tyrosine%2520Kinases%26jtitle%3DNature%26date%3D2016%26volume%3D535%26spage%3D148%26epage%3D152%26doi%3D10.1038%2Fnature18621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia
Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunenfelder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7773</span>– <span class="NLM_lpage">7782</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00680</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00680" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKju7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7773-7782&author=J.+Garcia%0AFortanetauthor=C.+H.-T.+Chenauthor=Y.-N.+P.+Chenauthor=Z.+Chenauthor=Z.+Dengauthor=B.+Firestoneauthor=P.+Fekkesauthor=M.+Fodorauthor=P.+D.+Fortinauthor=C.+Fridrichauthor=D.+Grunenfelderauthor=S.+Hoauthor=Z.+B.+Kangauthor=R.+Karkiauthor=M.+Katoauthor=N.+Keenauthor=L.+R.+LaBonteauthor=J.+Larrowauthor=F.+Lenoirauthor=G.+Liuauthor=S.+Liuauthor=F.+Lombardoauthor=D.+Majumdarauthor=M.+J.+Meyerauthor=M.+Palermoauthor=L.+Perezauthor=M.+Puauthor=T.+Ramseyauthor=W.+R.+Sellersauthor=M.+D.+Shultzauthor=T.+Stamsauthor=C.+Towlerauthor=P.+Wangauthor=S.+L.+Williamsauthor=J.-H.+Zhangauthor=M.+J.+LaMarche&title=Allosteric+Inhibition+of+SHP2%3A+Identification+of+a+Potent%2C+Selective%2C+and+Orally+Efficacious+Phosphatase+Inhibitor&doi=10.1021%2Facs.jmedchem.6b00680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor</span></div><div class="casAuthors">Garcia Fortanet, Jorge; Chen, Christine Hiu-Tung; Chen, Ying-Nan P.; Chen, Zhouliang; Deng, Zhan; Firestone, Brant; Fekkes, Peter; Fodor, Michelle; Fortin, Pascal D.; Fridrich, Cary; Grunenfelder, Denise; Ho, Samuel; Kang, Zhao B.; Karki, Rajesh; Kato, Mitsunori; Keen, Nick; LaBonte, Laura R.; Larrow, Jay; Lenoir, Francois; Liu, Gang; Liu, Shumei; Lombardo, Franco; Majumdar, Dyuti; Meyer, Matthew J.; Palermo, Mark; Perez, Lawrence; Pu, Minying; Ramsey, Timothy; Sellers, William R.; Shultz, Michael D.; Stams, Travis; Towler, Christopher; Wang, Ping; Williams, Sarah L.; Zhang, Ji-Hu; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7773-7782</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell growth and differentiation via the MAPK signaling pathway.  SHP2 also purportedly plays an important role in the programmed cell death pathway (PD-1/PD-L1).  Because it is an oncoprotein assocd. with multiple cancer-related diseases, as well as a potential immunomodulator, controlling SHP2 activity is of significant therapeutic interest.  Recently in our labs., a small mol. inhibitor of SHP2 was identified as an allosteric modulator that stabilizes the autoinhibited conformation of SHP2.  A high throughput screen was performed to identify progressable chem. matter, and X-ray crystallog. revealed the location of binding in a previously undisclosed allosteric binding pocket.  Structure-based drug design was employed to optimize for SHP2 inhibition, and several new protein-ligand interactions were characterized.  These studies culminated in the discovery of 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine (SHP099, 1), a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6RT7zfZnvfLVg90H21EOLACvtfcHk0lhm45rMb7gO0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKju7fP&md5=dfe43b5253e172576386f86797087f7b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00680%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%2BFortanet%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%2BH.-T.%26aulast%3DChen%26aufirst%3DY.-N.%2BP.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFekkes%26aufirst%3DP.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DGrunenfelder%26aufirst%3DD.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLarrow%26aufirst%3DJ.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPalermo%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DAllosteric%2520Inhibition%2520of%2520SHP2%253A%2520Identification%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Efficacious%2520Phosphatase%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7773%26epage%3D7782%26doi%3D10.1021%2Facs.jmedchem.6b00680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">17626</span>, <span class="refDoi"> DOI: 10.1038/srep17626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fsrep17626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=26626996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGms7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=17626&author=C.+Chenauthor=M.+Caoauthor=S.+Zhuauthor=C.+Wangauthor=F.+Liangauthor=L.+Yanauthor=D.+Luo&title=Discovery+of+a+Novel+Inhibitor+of+the+Protein+Tyrosine+Phosphatase+Shp2&doi=10.1038%2Fsrep17626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2</span></div><div class="casAuthors">Chen, Chuan; Cao, Mengmeng; Zhu, Siyu; Wang, Cuicui; Liang, Fan; Yan, Leilei; Luo, Duqiang</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17626</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Shp2 is a ubiquitously expressed protein tyrosine phosphatase (PTP) related to adult acute myelogenous leukemia and human solid tumors.  In this report, we describe identification of a potent Shp2 inhibitor, Fumosorinone (Fumos) from entomogenous fungi, which shows selective inhibition of Shp2 over other tested PTPs.  Using a surface plasmon resonance anal., we further confirmed the phys. interaction between Shp2 and Fumos.  Fumos inhibits Shp2-dependent activation of the Ras/ERK signal pathway downstream of EGFR, and interrupts EGF-induced Gab1-Shp2 assocn.  As expected, Fumos shows little effects on the Shp2-independent ERK1/2 activation induced by PMA or oncogenic Ras.  Furthermore, Fumos down-regulates Src activation, inhibits phosphorylation of Paxillin and prevents tumor cell invasion.  These results suggest that Fumos can inhibit Shp2-dependent cell signaling in human cells and has a potential for treatment of Shp2-assocd. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoswqt5Y98UCrVg90H21EOLACvtfcHk0ljCBvBGi1QS1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGms7bN&md5=ae7d1a3adf914820e57a2862ade65cf7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fsrep17626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep17626%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Inhibitor%2520of%2520the%2520Protein%2520Tyrosine%2520Phosphatase%2520Shp2%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D17626%26doi%3D10.1038%2Fsrep17626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, W.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.-m.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.-r.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Open-Chain Analogs of Cyclic Peptides as Inhibitors of Cellular Shp2 Activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2562</span>– <span class="NLM_lpage">2567</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmc.2015.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=25865131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1ajsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2562-2567&author=X.-l.+Zhenauthor=W.-h.+Yinauthor=X.+Tianauthor=Z.-j.+Maauthor=S.-m.+Fanauthor=J.-r.+Hanauthor=S.+Liu&title=Synthesis+and+Biological+Evaluation+of+Open-Chain+Analogs+of+Cyclic+Peptides+as+Inhibitors+of+Cellular+Shp2+Activity&doi=10.1016%2Fj.bmc.2015.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of open-chain analogs of cyclic peptides as inhibitors of cellular Shp2 activity</span></div><div class="casAuthors">Zhen, Xiao-li; Yin, Wen-hui; Tian, Xia; Ma, Zhen-jie; Fan, Shi-ming; Han, Jian-rong; Liu, Shouxin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2562-2567</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of open-chain analogs of cyclic peptides was designed and synthesized using sansalvamide A as a model compd.  All compds. exhibited low antitumor activity.  Furthermore, the evaluation of their inhibitory potency toward IMPDH, SHP2, ACHE, proteasome, MAGL, and cathepsin B showed that all of the compds. were potent against protein tyrosine phosphatase Shp2.  Specifically, compds. (I) (Ar = Ph, 4-F-C6H4) and (II) (Ar1 = 4-Br-C6H4, 2-naphthol) were found to inhibit SHP2 with IC50 values in the low micromolar range and good selectivity.  Based on the mol. docking results, the binding modes of the chain cyclic peptides in the active center of SHP2 were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFj9G0DtykVbVg90H21EOLACvtfcHk0ljCBvBGi1QS1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1ajsbw%253D&md5=7d975b012b3e9afd6f2d670c47081709</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhen%26aufirst%3DX.-l.%26aulast%3DYin%26aufirst%3DW.-h.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DZ.-j.%26aulast%3DFan%26aufirst%3DS.-m.%26aulast%3DHan%26aufirst%3DJ.-r.%26aulast%3DLiu%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Open-Chain%2520Analogs%2520of%2520Cyclic%2520Peptides%2520as%2520Inhibitors%2520of%2520Cellular%2520Shp2%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D2562%26epage%3D2567%26doi%3D10.1016%2Fj.bmc.2015.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mali, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6594</span>– <span class="NLM_lpage">6609</span>, <span class="refDoi"> DOI: 10.1021/jm5006176</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006176" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFajtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6594-6609&author=L.-F.+Zengauthor=R.-Y.+Zhangauthor=Z.-H.+Yuauthor=S.+Liauthor=L.+Wuauthor=A.+M.+Gunawanauthor=B.+S.+Laneauthor=R.+S.+Maliauthor=X.+Liauthor=R.+J.+Chanauthor=R.+Kapurauthor=C.+D.+Wellsauthor=Z.-Y.+Zhang&title=Therapeutic+Potential+of+Targeting+the+Oncogenic+SHP2+Phosphatase&doi=10.1021%2Fjm5006176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase</span></div><div class="casAuthors">Zeng, Li-Fan; Zhang, Ruo-Yu; Yu, Zhi-Hong; Li, Sijiu; Wu, Li; Gunawan, Andrea M.; Lane, Brandon S.; Mali, Raghuveer S.; Li, Xingjun; Chan, Rebecca J.; Kapur, Reuben; Wells, Clark D.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6594-6609</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Src homol. 2 domain contg. protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase assocd. with various kinds of leukemia and solid tumors.  Thus, there is substantial interest in developing SHP2 inhibitors as potential anticancer and antileukemia agents.  Using a structure-guided and fragment-based library approach, we identified a novel hydroxyindole carboxylic acid-based SHP2 inhibitor (I), with an IC50 value of 200 nM and greater than 5-fold selectivity against 20 mammalian PTPs.  Structural and modeling studies reveal that the hydroxyindole carboxylic acid anchors the inhibitor to the SHP2 active site, while interactions of the oxalamide linker and the phenylthiophene tail with residues in the β5-β6 loop contribute to I's binding potency and selectivity.  Evidence suggests that I specifically attenuates the SHP2-dependent signaling inside the cell.  Moreover, I blocks growth factor mediated Erk1/2 and Akt activation and exhibits excellent antiproliferative activity in lung cancer and breast cancer as well as leukemia cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ko-q4-PSXbVg90H21EOLACvtfcHk0ljCBvBGi1QS1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFajtrvO&md5=ac8e5359387e614782c95c02f32fd97d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm5006176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006176%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DL.-F.%26aulast%3DZhang%26aufirst%3DR.-Y.%26aulast%3DYu%26aufirst%3DZ.-H.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DLane%26aufirst%3DB.%2BS.%26aulast%3DMali%26aufirst%3DR.%2BS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26atitle%3DTherapeutic%2520Potential%2520of%2520Targeting%2520the%2520Oncogenic%2520SHP2%2520Phosphatase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6594%26epage%3D6609%26doi%3D10.1021%2Fjm5006176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of SHP2 Tyrosine Phosphatase Discovered by Virtual Screening</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4238</span>– <span class="NLM_lpage">4242</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.05.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmcl.2011.05.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=21669525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFWku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4238-4242&author=Z.-H.+Yuauthor=L.+Chenauthor=L.+Wuauthor=S.+Liuauthor=L.+Wangauthor=Z.-Y.+Zhang&title=Small+Molecule+Inhibitors+of+SHP2+Tyrosine+Phosphatase+Discovered+by+Virtual+Screening&doi=10.1016%2Fj.bmcl.2011.05.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening</span></div><div class="casAuthors">Yu, Zhi-Hong; Chen, Lan; Wu, Li; Liu, Sijiu; Wang, Lina; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4238-4242</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SHP2, encoded by PTPN11, is a non-receptor protein tyrosine phosphatase (PTP) contg. two tandem Src homol.-2 (SH2) domains.  It is expressed ubiquitously and plays crit. roles in growth factor mediated processes, primarily by promoting the activation of the RAS/ERK signaling pathway.  Genetic and biochem. studies have identified SHP2 as the first bona fide oncoprotein in the PTP superfamily, and a promising target for anti-cancer and anti-leukemia therapy.  Here, we report a structure-based approach to identify SHP2 inhibitors with a novel scaffold.  Through sequential virtual screenings and in vitro inhibition assays, a reversible competitive SHP2 inhibitor (C21, I) was identified.  C21 is structurally distinct from all known SHP2 inhibitors.  Combining mol. dynamics simulation and binding free energy calcn., a most likely binding mode of C21 with SHP2 is proposed, and further validated by site-directed mutagenesis and structure-activity relationship studies.  This binding mode is consistent with the obsd. potency and specificity of C21, and reveals the mol. determinants for further optimization based on the new scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7ByUkOMeL57Vg90H21EOLACvtfcHk0lidNHkb3rT5_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFWku7o%253D&md5=9ff6409bd28a309bbdc8258da774fe66</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.05.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.05.078%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DZ.-H.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520SHP2%2520Tyrosine%2520Phosphatase%2520Discovered%2520by%2520Virtual%2520Screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4238%26epage%3D4242%26doi%3D10.1016%2Fj.bmcl.2011.05.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, M. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1124/mol.106.025536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1124%2Fmol.106.025536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=16717135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnslyjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=562-570&author=L.+Chenauthor=S.-S.+Sungauthor=M.+L.+R.+Yipauthor=H.+R.+Lawrenceauthor=Y.+Renauthor=W.+C.+Guidaauthor=S.+M.+Sebtiauthor=N.+J.+Lawrenceauthor=J.+Wu&title=Discovery+of+a+Novel+Shp2+Protein+Tyrosine+Phosphatase+Inhibitor&doi=10.1124%2Fmol.106.025536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel Shp2 protein tyrosine phosphatase inhibitor</span></div><div class="casAuthors">Chen, Liwei; Sung, Shen-Shu; Yip, M. L. Richard; Lawrence, Harshani R.; Ren, Yuan; Guida, Wayne C.; Sebti, Said M.; Lawrence, Nicholas J.; Wu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">562-570</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Shp2 is a non-receptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene.  It is involved in growth factor-induced activation of mitogen-activated protein (MAP) kinases Erk1 and Erk2 (Erk1/2) and has been implicated in the pathogenicity of the oncogenic bacterium Helicobacter pylori.  Moreover, gain-of-function Shp2 mutations have been found in childhood leukemias and Noonan syndrome.  Thus, small mol. Shp2 PTP inhibitors are much needed reagents for evaluation of Shp2 as a therapeutic target and for chem. biol. studies of Shp2 function.  By screening the National Cancer Institute (NCI) Diversity Set chem. library, we identified 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877) as a potent Shp2 PTP inhibitor.  Mol. modeling and site-directed mutagenesis studies suggested that NSC-87877 binds to the catalytic cleft of Shp2 PTP.  NSC-87877 cross-inhibited Shp1 in vitro, but it was selective for Shp2 over other PTPs (PTP1B, HePTP, DEP1, CD45, and LAR).  It is noteworthy that NSC-87877 inhibited epidermal growth factor (EGF)-induced activation of Shp2 PTP, Ras, and Erk1/2 in cell cultures but did not block EGF-induced Gab1 tyrosine phosphorylation or Gab1-Shp2 assocn.  Furthermore, NSC-87877 inhibited Erk1/2 activation by a Gab1-Shp2 chimera but did not affect the Shp2-independent Erk1/2 activation by phorbol 12-myristate 13-acetate.  These results identified NSC-87877 as the first PTP inhibitor capable of inhibiting Shp2 PTP in cell cultures without a detectable off-target effect.  Our study also provides the first pharmacol. evidence that Shp2 mediates EGF-induced Erk1/2 MAP kinase activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA4XVGUjw3W7Vg90H21EOLACvtfcHk0lidNHkb3rT5_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnslyjsrk%253D&md5=a2ce03150ecbe6937876bb292ced30dc</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.025536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.025536%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSung%26aufirst%3DS.-S.%26aulast%3DYip%26aufirst%3DM.%2BL.%2BR.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Shp2%2520Protein%2520Tyrosine%2520Phosphatase%2520Inhibitor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D70%26spage%3D562%26epage%3D570%26doi%3D10.1124%2Fmol.106.025536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabinger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span> <span> </span><span class="NLM_article-title">Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2482</span>– <span class="NLM_lpage">2493</span>, <span class="refDoi"> DOI: 10.1021/jm901645u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901645u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFyhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2482-2493&author=X.+Zhangauthor=Y.+Heauthor=S.+Liuauthor=Z.+Yuauthor=Z.-X.+Jiangauthor=Z.+Yangauthor=Y.+Dongauthor=S.+C.+Nabingerauthor=L.+Wuauthor=A.+M.+Gunawanauthor=L.+Wangauthor=R.+J.+Chanauthor=Z.-Y.+Zhang&title=Salicylic+Acid+Based+Small+Molecule+Inhibitor+for+the+Oncogenic+Src+homology-2+Domain+Containing+Protein+Tyrosine+Phosphatase-2+%28SHP2%29&doi=10.1021%2Fjm901645u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)</span></div><div class="casAuthors">Zhang, Xian; He, Yantao; Liu, Sijiu; Yu, Zhihong; Jiang, Zhong-Xing; Yang, Zhenyun; Dong, Yuanshu; Nabinger, Sarah C.; Wu, Li; Gunawan, Andrea M.; Wang, Lina; Chan, Rebecca J.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2482-2493</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Src homol.-2 domain contg. protein tyrosine phosphatase-2 (SHP2) plays a pivotal role in growth factor and cytokine signaling.  Gain-of-function SHP2 mutations are assocd. with Noonan syndrome, various kinds of leukemias, and solid tumors.  Thus, there is considerable interest in SHP2 as a potential target for anticancer and antileukemia therapy.  We report a salicylic acid based combinatorial library approach aimed at binding both active site and unique nearby subpockets for enhanced affinity and selectivity.  Screening of the library led to the identification of a SHP2 inhibitor II-B08 (compd. 9) with highly efficacious cellular activity.  Compd. 9 blocks growth factor stimulated ERK1/2 activation and hematopoietic progenitor proliferation, providing supporting evidence that chem. inhibition of SHP2 may be therapeutically useful for anticancer and antileukemia treatment.  X-ray crystallog. anal. of the structure of SHP2 in complex with 9 reveals mol. determinants that can be exploited for the acquisition of more potent and selective SHP2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC82T5JpCRArVg90H21EOLACvtfcHk0lidNHkb3rT5_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFyhs7k%253D&md5=6f87897eda38ea485dc08e189f1b5ca8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm901645u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901645u%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DZ.-X.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DNabinger%26aufirst%3DS.%2BC.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26atitle%3DSalicylic%2520Acid%2520Based%2520Small%2520Molecule%2520Inhibitor%2520for%2520the%2520Oncogenic%2520Src%2520homology-2%2520Domain%2520Containing%2520Protein%2520Tyrosine%2520Phosphatase-2%2520%2528SHP2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2482%26epage%3D2493%26doi%3D10.1021%2Fjm901645u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pireddu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanski, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, M. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Src homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (Shp2) Based on Oxindole Scaffolds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4956</span>, <span class="refDoi"> DOI: 10.1021/jm8002526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8002526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptl2hu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4948-4956&author=H.+R.+Lawrenceauthor=R.+Piredduauthor=L.+Chenauthor=Y.+Luoauthor=S.-S.+Sungauthor=A.+M.+Szymanskiauthor=M.+L.+R.+Yipauthor=W.+C.+Guidaauthor=S.+M.+Sebtiauthor=J.+Wuauthor=N.+J.+Lawrence&title=Inhibitors+of+Src+homology-2+Domain+Containing+Protein+Tyrosine+Phosphatase-2+%28Shp2%29+Based+on+Oxindole+Scaffolds&doi=10.1021%2Fjm8002526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (Shp2) Based on Oxindole Scaffolds</span></div><div class="casAuthors">Lawrence, Harshani R.; Pireddu, Roberta; Chen, Liwei; Luo, Yunting; Sung, Shen-Shu; Szymanski, Ann Marie; Yip, M. L. Richard; Guida, Wayne C.; Sebti, Said M.; Wu, Jie; Lawrence, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4948-4956</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Screening of the NCI diversity set of compds. has led to the identification of NSC-117199, which inhibits the protein tyrosine phosphatase (PTP) Shp2 with an IC50 of 47 μM.  A focused library incorporating an isatin scaffold was designed and evaluated for inhibition of Shp2 and Shp1 PTP activities.  Several compds. were identified that selectively inhibit Shp2 over Shp1 and PTP1B with low to submicromolar activity.  A model for the binding of the active compds. is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRqLAauyGNBbVg90H21EOLACvtfcHk0lhX4kZgY0N3vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptl2hu7o%253D&md5=572227c5a8cfffb108388616bd36fdfe</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm8002526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8002526%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DPireddu%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSung%26aufirst%3DS.-S.%26aulast%3DSzymanski%26aufirst%3DA.%2BM.%26aulast%3DYip%26aufirst%3DM.%2BL.%2BR.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26atitle%3DInhibitors%2520of%2520Src%2520homology-2%2520Domain%2520Containing%2520Protein%2520Tyrosine%2520Phosphatase-2%2520%2528Shp2%2529%2520Based%2520on%2520Oxindole%2520Scaffolds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4948%26epage%3D4956%26doi%3D10.1021%2Fjm8002526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marasco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berteotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyershaeuser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorausch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikorska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krausze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamel, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, T.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanism of SHP2 Activation by PD-1 Stimulation</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">eaay4458</span> <span class="refDoi"> DOI: 10.1126/sciadv.aay4458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1126%2Fsciadv.aay4458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=32064351" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&author=M.+Marascoauthor=A.+Berteottiauthor=J.+Weyershaeuserauthor=N.+Thorauschauthor=J.+Sikorskaauthor=J.+Krauszeauthor=H.+J.+Brandtauthor=J.+Kirkpatrickauthor=P.+Riosauthor=W.+W.+Schamelauthor=M.+Kohnauthor=T.+Carlomagno&title=Molecular+Mechanism+of+SHP2+Activation+by+PD-1+Stimulation&doi=10.1126%2Fsciadv.aay4458"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aay4458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aay4458%26sid%3Dliteratum%253Aachs%26aulast%3DMarasco%26aufirst%3DM.%26aulast%3DBerteotti%26aufirst%3DA.%26aulast%3DWeyershaeuser%26aufirst%3DJ.%26aulast%3DThorausch%26aufirst%3DN.%26aulast%3DSikorska%26aufirst%3DJ.%26aulast%3DKrausze%26aufirst%3DJ.%26aulast%3DBrandt%26aufirst%3DH.%2BJ.%26aulast%3DKirkpatrick%26aufirst%3DJ.%26aulast%3DRios%26aufirst%3DP.%26aulast%3DSchamel%26aufirst%3DW.%2BW.%26aulast%3DKohn%26aufirst%3DM.%26aulast%3DCarlomagno%26aufirst%3DT.%26atitle%3DMolecular%2520Mechanism%2520of%2520SHP2%2520Activation%2520by%2520PD-1%2520Stimulation%26jtitle%3DSci.%2520Adv.%26date%3D2020%26volume%3D6%26doi%3D10.1126%2Fsciadv.aay4458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span> <span> </span><span class="NLM_article-title">Protein Tyrosine Phosphatases: Prospects for Therapeutics</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1016/s1367-5931(00)00223-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2FS1367-5931%2800%2900223-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=11470605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltlyqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2001&pages=416-423&author=Z.-Y.+Zhang&title=Protein+Tyrosine+Phosphatases%3A+Prospects+for+Therapeutics&doi=10.1016%2Fs1367-5931%2800%2900223-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine phosphatases: prospects for therapeutics</span></div><div class="casAuthors">Zhang, Z.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">416-423</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with refs.  Protein tyrosine phosphatases (PTPs) form a large family of enzymes that serve as key regulatory components in signal transduction pathways.  Recent gene knockout studies in mice identify PTP1B as a promising target for anti-diabetes/obesity drug discovery.  PTPs are also implicated in a wide variety of other disorders, including cancer.  Significant progress has been made in identifying small mols. that simultaneously bind both the active site and a unique adjacent site that enables specific inhibition of individual PTP isoenzymes.  As a consequence, there are compelling reasons to believe that PTP inhibitors may ultimately serve as powerful therapeutic weapons in the authors' arsenal for battling human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgujWWYVWfjbVg90H21EOLACvtfcHk0lhX4kZgY0N3vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltlyqsLs%253D&md5=eee42d18a57b314321cffca4e3892ac1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS1367-5931%2800%2900223-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1367-5931%252800%252900223-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.-Y.%26atitle%3DProtein%2520Tyrosine%2520Phosphatases%253A%2520Prospects%2520for%2520Therapeutics%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2001%26volume%3D5%26spage%3D416%26epage%3D423%26doi%3D10.1016%2Fs1367-5931%2800%2900223-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of PTP1B Complexed With a Potent and Selective Bidentate Inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">12406</span>– <span class="NLM_lpage">12414</span>, <span class="refDoi"> DOI: 10.1074/jbc.m212491200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1074%2Fjbc.M212491200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=12547827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVOntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=12406-12414&author=J.-P.+Sunauthor=A.+A.+Fedorovauthor=S.-Y.+Leeauthor=X.-L.+Guoauthor=K.+Shenauthor=D.+S.+Lawrenceauthor=S.+C.+Almoauthor=Z.-Y.+Zhang&title=Crystal+Structure+of+PTP1B+Complexed+With+a+Potent+and+Selective+Bidentate+Inhibitor&doi=10.1074%2Fjbc.m212491200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of PTP1B Complexed with a Potent and Selective Bidentate Inhibitor</span></div><div class="casAuthors">Sun, Jin-Peng; Fedorov, Alexander A.; Lee, Seung-Yub; Guo, Xiao-Ling; Shen, Kui; Lawrence, David S.; Almo, Steven C.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">12406-12414</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase 1B (PTP1B) has been implicated as an important regulator in several signaling pathways including those initiated by insulin and leptin.  Potent and specific PTP1B inhibitors could serve as useful tools in elucidating the physiol. functions of PTP1B and may constitute valuable therapeutics in the treatment of several human diseases.  We have detd. the crystal structure of PTP1B in complex with compd. 2, the most potent and selective PTP1B inhibitor reported to date.  The structure at 2.15-Å resoln. reveals that compd. 2 simultaneously binds to the active site and a unique proximal noncatalytic site formed by Lys-41, Arg-47, and Asp-48.  The structural data are further corroborated by results from kinetic analyses of the interactions of PTP1B and its site-directed mutants with compd. 2 and several of its variants.  Although many of the residues important for interactions between PTP1B and compd. 2 are not unique to PTP1B, the combinations of all contact residues differ between PTP isoenzymes, which provide a structural basis for potent and selective PTP1B inhibition.  Our data further suggest that potent, yet highly selective, PTP1B inhibitory agents can be acquired by targeting the area defined by residues Lys-41, Arg-47, and Asp-48, in addn. to the previously identified second aryl phosphate-binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfSAHANv6sqbVg90H21EOLACvtfcHk0ljF00mOjoKncg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVOntLs%253D&md5=bf71f97839eb174ae4f644f72fb5289a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M212491200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M212491200%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.-P.%26aulast%3DFedorov%26aufirst%3DA.%2BA.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DGuo%26aufirst%3DX.-L.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DLawrence%26aufirst%3DD.%2BS.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26atitle%3DCrystal%2520Structure%2520of%2520PTP1B%2520Complexed%2520With%2520a%2520Potent%2520and%2520Selective%2520Bidentate%2520Inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D12406%26epage%3D12414%26doi%3D10.1074%2Fjbc.m212491200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntaganda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1781</span>– <span class="NLM_lpage">1792</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01725</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01725" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1781-1792&author=J.+T.+Bagdanoffauthor=Z.+Chenauthor=M.+Ackerauthor=Y.-N.+Chenauthor=H.+Chanauthor=M.+Doreauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=S.+Liuauthor=M.+Mohseniauthor=R.+Ntagandaauthor=P.+Sarverauthor=T.+Smithauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=C.+Towlerauthor=H.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=M.+J.+LaMarche&title=Optimization+of+Fused+Bicyclic+Allosteric+SHP2+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span></div><div class="casAuthors">Bagdanoff, Jeffrey T.; Chen, Zhouliang; Acker, Michael; Chen, Ying-Nan; Chan, Homan; Dore, Michael; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hentemann, Murphy; Kato, Mitsunori; Koenig, Robert; La Bonte, Laura R.; Liu, Shumei; Mohseni, Movarid; Ntaganda, Rukundo; Sarver, Patrick; Smith, Troy; Sendzik, Martin; Stams, Travis; Spence, Stan; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; La Marche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1781-1792</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a nonreceptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controlling cell growth, differentiation, and oncogenic transformation.  SHP2 also participates in the programed cell death pathway (PD-1/PD-L1) governing immune surveillance.  Small-mol. inhibition of SHP2 has been widely investigated, including in our previous reports describing SHP099 (2), which binds to a tunnel-like allosteric binding site.  To broaden our approach to allosteric inhibition of SHP2, we conducted addnl. hit finding, evaluation, and structure-based scaffold morphing.  These studies, reported here in the first of two papers, led to the identification of multiple 5,6-fused bicyclic scaffolds that bind to the same allosteric tunnel as 2.  We demonstrate the structural diversity permitted by the tunnel pharmacophore and culminated in the identification of pyrazolopyrimidinones (e.g., SHP389, 1) that modulate MAPK signaling in vivo.  These studies also served as the basis for further scaffold morphing and optimization, detailed in the following manuscript.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra2OF_vrNnP7Vg90H21EOLACvtfcHk0ljF00mOjoKncg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D&md5=e810a8a6bd1d1fb7bfadc5bc1448ff22</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01725%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.-N.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DDore%26aufirst%3DM.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DNtaganda%26aufirst%3DR.%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DOptimization%2520of%2520Fused%2520Bicyclic%2520Allosteric%2520SHP2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1781%26epage%3D1792%26doi%3D10.1021%2Facs.jmedchem.8b01725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.-L.</span></span> <span> </span><span class="NLM_article-title">Scaffold-based Novel SHP2 Allosteric Inhibitors Design Using Receptor-Ligand Pharmacophore Model, Virtual Screening and Molecular Dynamics</span>. <i>Comput. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1016/j.compbiolchem.2018.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.compbiolchem.2018.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=29494926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsF2kurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=179-188&author=W.-Y.+Jinauthor=Y.+Maauthor=W.-Y.+Liauthor=H.-L.+Liauthor=R.-L.+Wang&title=Scaffold-based+Novel+SHP2+Allosteric+Inhibitors+Design+Using+Receptor-Ligand+Pharmacophore+Model%2C+Virtual+Screening+and+Molecular+Dynamics&doi=10.1016%2Fj.compbiolchem.2018.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics</span></div><div class="casAuthors">Jin, Wen-Yan; Ma, Ying; Li, Wei-Ya; Li, Hong-Lian; Wang, Run-Ling</div><div class="citationInfo"><span class="NLM_cas:title">Computational Biology and Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">179-188</span>CODEN:
                <span class="NLM_cas:coden">CBCOCH</span>;
        ISSN:<span class="NLM_cas:issn">1476-9271</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SHP2 is a potential target for the development of novel therapies for SHP2-dependent cancers.  In our research, with the aid of the 'Receptor-Ligand Pharmacophore' technique, a 3D-QSAR method was carried out to explore structure activity relationship of SHP2 allosteric inhibitors.  Structure-based drug design was employed to optimize SHP099, an efficacious, potent, and selective SHP2 allosteric inhibitor.  A novel class of selective SHP2 allosteric inhibitors was discovered by using the powerful 'SBP', 'ADMET' and 'CDOCKER' techniques.  By means of mol. dynamics simulations, it was obsd. that these novel inhibitors not only had the same function as SHP099 did in inhibiting SHP2, but also had more favorable conformation for binding to the receptor.  Thus, this report may provide a new method in discovering novel and selective SHP2 allosteric inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzg1OlgVdJ5bVg90H21EOLACvtfcHk0ljF00mOjoKncg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsF2kurc%253D&md5=327433bbc88dbce0bdbda3369648e797</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.compbiolchem.2018.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.compbiolchem.2018.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DW.-Y.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.-Y.%26aulast%3DLi%26aufirst%3DH.-L.%26aulast%3DWang%26aufirst%3DR.-L.%26atitle%3DScaffold-based%2520Novel%2520SHP2%2520Allosteric%2520Inhibitors%2520Design%2520Using%2520Receptor-Ligand%2520Pharmacophore%2520Model%252C%2520Virtual%2520Screening%2520and%2520Molecular%2520Dynamics%26jtitle%3DComput.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D73%26spage%3D179%26epage%3D188%26doi%3D10.1016%2Fj.compbiolchem.2018.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellegast, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemulapalli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span> <span> </span><span class="NLM_article-title">Identification of an Allosteric Benzothiazolopyrimidone Inhibitor of the Oncogenic Protein Tyrosine Phosphatase SHP2</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6479</span>– <span class="NLM_lpage">6485</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmc.2017.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=29089257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A280%3ADC%252BC1M7mtlOksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=6479-6485&author=J.+R.+LaRochelleauthor=M.+Fodorauthor=J.+M.+Ellegastauthor=X.+Liuauthor=V.+Vemulapalliauthor=M.+Mohseniauthor=T.+Stamsauthor=S.+J.+Buhrlageauthor=K.+Stegmaierauthor=M.+J.+LaMarcheauthor=M.+G.+Ackerauthor=S.+C.+Blacklow&title=Identification+of+an+Allosteric+Benzothiazolopyrimidone+Inhibitor+of+the+Oncogenic+Protein+Tyrosine+Phosphatase+SHP2&doi=10.1016%2Fj.bmc.2017.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2</span></div><div class="casAuthors">LaRochelle Jonathan R; Liu Xiaoxi; Vemulapalli Vidyasiri; Buhrlage Sara J; Fodor Michelle; Stams Travis; Ellegast Jana M; Mohseni Morvarid; Acker Michael G; Stegmaier Kimberly; LaMarche Matthew J; Blacklow Stephen C</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6479-6485</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The PTPN11 oncogene encodes the cytoplasmic protein tyrosine phosphatase SHP2, which, through its role in multiple signaling pathways, promotes the progression of hematological malignancies and other cancers.  Here, we employ high-throughput screening to discover a lead chemical scaffold, the benzothiazolopyrimidones, that allosterically inhibits this oncogenic phosphatase by simultaneously engaging the C-SH2 and PTP domains.  We improved our lead to generate an analogue that better suppresses SHP2 activity in vitro.  Suppression of Erk phopsphorylation by the lead compound is also consistent with SHP2 inhibition in AML cells.  Our findings provide an alternative starting point for therapeutic intervention and will catalyze investigations into the relationship between SHP2 conformational regulation, activity, and disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQovWlxLHSQ4MRAV4D_Ins_fW6udTcc2ebjiwGz4JA_fLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7mtlOksA%253D%253D&md5=4425bb1a20f079aa02986fb0b8a082e7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DLaRochelle%26aufirst%3DJ.%2BR.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DEllegast%26aufirst%3DJ.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DVemulapalli%26aufirst%3DV.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26atitle%3DIdentification%2520of%2520an%2520Allosteric%2520Benzothiazolopyrimidone%2520Inhibitor%2520of%2520the%2520Oncogenic%2520Protein%2520Tyrosine%2520Phosphatase%2520SHP2%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D6479%26epage%3D6485%26doi%3D10.1016%2Fj.bmc.2017.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemulapalli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span> <span> </span><span class="NLM_article-title">Structural Reorganization of SHP2 by Oncogenic Mutations and Implications for Oncoprotein Resistance to Allosteric Inhibition</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4508</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-06823-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fs41467-018-06823-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=30375388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A280%3ADC%252BB3cvkslelsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4508&author=J.+R.+LaRochelleauthor=M.+Fodorauthor=V.+Vemulapalliauthor=M.+Mohseniauthor=P.+Wangauthor=T.+Stamsauthor=M.+J.+LaMarcheauthor=R.+Chopraauthor=M.+G.+Ackerauthor=S.+C.+Blacklow&title=Structural+Reorganization+of+SHP2+by+Oncogenic+Mutations+and+Implications+for+Oncoprotein+Resistance+to+Allosteric+Inhibition&doi=10.1038%2Fs41467-018-06823-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition</span></div><div class="casAuthors">LaRochelle Jonathan R; Vemulapalli Vidyasiri; Blacklow Stephen C; LaRochelle Jonathan R; Vemulapalli Vidyasiri; Blacklow Stephen C; Fodor Michelle; Mohseni Morvarid; Wang Ping; Stams Travis; LaMarche Matthew J; Chopra Rajiv; Acker Michael G</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4508</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Activating mutations in PTPN11, encoding the cytosolic protein tyrosine phosphatase SHP2, result in developmental disorders and act as oncogenic drivers in patients with hematologic cancers.  The allosteric inhibitor SHP099 stabilizes the wild-type SHP2 enzyme in an autoinhibited conformation that is itself destabilized by oncogenic mutations.  Here, we report the impact of the highly activated and most frequently observed mutation, E76K, on the structure of SHP2, and investigate the effect of E76K and other oncogenic mutations on allosteric inhibition by SHP099.  SHP2(E76K) adopts an open conformation but can be restored to the closed, autoinhibited conformation, near-identical to the unoccupied wild-type enzyme, when complexed with SHP099.  SHP099 inhibitory activity against oncogenic SHP2 variants in vitro and in cells scales inversely with the activating strength of the mutation, indicating that either oncoselective or vastly more potent inhibitors will be necessary to suppress oncogenic signaling by the most strongly activating SHP2 mutations in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRglXfZMl481dts4TFFB11gfW6udTcc2ebjiwGz4JA_fLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvkslelsA%253D%253D&md5=ceac9384173a0439b945b51f7bc65ea1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-06823-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-06823-9%26sid%3Dliteratum%253Aachs%26aulast%3DLaRochelle%26aufirst%3DJ.%2BR.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DVemulapalli%26aufirst%3DV.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26atitle%3DStructural%2520Reorganization%2520of%2520SHP2%2520by%2520Oncogenic%2520Mutations%2520and%2520Implications%2520for%2520Oncoprotein%2520Resistance%2520to%2520Allosteric%2520Inhibition%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D4508%26doi%3D10.1038%2Fs41467-018-06823-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, T. B. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.-X.</span></span> <span> </span><span class="NLM_article-title">Resistance to Allosteric SHP2 Inhibition in FGFR-Driven Cancers Through Rapid Feedback Activation of FGFR</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.27435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.18632%2Foncotarget.27435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=32076487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A280%3ADC%252BB387jvFCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=265-281&author=H.+Luauthor=C.+Liuauthor=H.+Huynhauthor=T.+B.+U.+Leauthor=M.+J.+LaMarcheauthor=M.+Mohseniauthor=J.+A.+Engelmanauthor=P.+S.+Hammermanauthor=G.+Caponigroauthor=H.-X.+Hao&title=Resistance+to+Allosteric+SHP2+Inhibition+in+FGFR-Driven+Cancers+Through+Rapid+Feedback+Activation+of+FGFR&doi=10.18632%2Foncotarget.27435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR</span></div><div class="casAuthors">Lu Hengyu; Liu Chen; Mohseni Morvarid; Engelman Jeffrey A; Hammerman Peter S; Caponigro Giordano; Hao Huai-Xiang; Huynh Hung; Le Thi Bich Uyen; LaMarche Matthew J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">265-281</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">SHP2 mediates RAS activation downstream of multiple receptor tyrosine kinases (RTKs) and cancer cell lines dependent on RTKs are in general dependent on SHP2.  Profiling of the allosteric SHP2 inhibitor SHP099 across cancer cell lines harboring various RTK dependencies reveals that FGFR-dependent cells are often insensitive to SHP099 when compared to EGFR-dependent cells.  We find that FGFR-driven cells depend on SHP2 but exhibit resistance to SHP2 inhibitors in vitro and in vivo.  Treatment of such models with SHP2 inhibitors results in an initial decrease in phosphorylated ERK1/2 (p-ERK) levels, however p-ERK levels rapidly rebound within two hours.  This p-ERK rebound is blocked by FGFR inhibitors or high doses of SHP2 inhibitors.  Mechanistically, compared with EGFR-driven cells, FGFR-driven cells tend to express high levels of RTK negative regulators such as the SPRY family proteins, which are rapidly downregulated upon ERK inhibition.  Moreover, over-expression of SPRY4 in FGFR-driven cells prevents MAPK pathway reactivation and sensitizes them to SHP2 inhibitors.  We also identified two novel combination approaches to enhance the efficacy of SHP2 inhibitors, either with a distinct site 2 allosteric SHP2 inhibitor or with a RAS-SOS1 interaction inhibitor.  Our findings suggest the rapid FGFR feedback activation following initial pathway inhibition by SHP2 inhibitors may promote the open conformation of SHP2 and lead to resistance to SHP2 inhibitors.  These findings may assist to refine patient selection and predict resistance mechanisms in the clinical development of SHP2 inhibitors and to suggest strategies for discovering SHP2 inhibitors that are more effective against upstream feedback activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4IpjIyuuylN-cVm4E2RlLfW6udTcc2ebjiwGz4JA_fLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387jvFCrug%253D%253D&md5=13f0863f77d980842bd0ba3981a65456</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.27435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.27435%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DHuynh%26aufirst%3DH.%26aulast%3DLe%26aufirst%3DT.%2BB.%2BU.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DHao%26aufirst%3DH.-X.%26atitle%3DResistance%2520to%2520Allosteric%2520SHP2%2520Inhibition%2520in%2520FGFR-Driven%2520Cancers%2520Through%2520Rapid%2520Feedback%2520Activation%2520of%2520FGFR%26jtitle%3DOncotarget%26date%3D2020%26volume%3D11%26spage%3D265%26epage%3D281%26doi%3D10.18632%2Foncotarget.27435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Emergence of Allosteric Drug-Resistance Mutations: New Challenges for Allosteric Drug Discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2019.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.drudis.2019.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=31634592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVaqtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=177-184&author=S.+Luauthor=Y.+Qiuauthor=D.+Niauthor=X.+Heauthor=J.+Puauthor=J.+Zhang&title=Emergence+of+Allosteric+Drug-Resistance+Mutations%3A+New+Challenges+for+Allosteric+Drug+Discovery&doi=10.1016%2Fj.drudis.2019.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of allosteric drug-resistance mutations: new challenges for allosteric drug discovery</span></div><div class="casAuthors">Lu, Shaoyong; Qiu, Yuran; Ni, Duan; He, Xinheng; Pu, Jun; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">177-184</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Allosteric drugs have several significant advantages over traditional orthosteric drugs, encompassing higher selectivity and lower toxicity.  Although allosteric drugs have potential advantages as therapeutic agents to treat human diseases, allosteric drug-resistance mutations still occur, rendering these drugs ineffective.  Here, we review the emergence of allosteric drug-resistance mutations with an emphasis on examples covering clin. important therapeutic targets, including Breakpoint cluster region-Abelson tyrosine kinase (Bcr-Abl), Akt kinase [also called Protein Kinase B (PKB)], isocitrate dehydrogenase (IDH), MAPK/ERK kinase (MEK), and SRC homol. 2 domain-contg. phosphatase 2 (SHP2).  We also discuss challenges assocd. with tackling allosteric drug resistance and the possible strategies to overcome this issue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4a4rK610lLLVg90H21EOLACvtfcHk0lihc4Nf0TH8kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVaqtr3I&md5=052d6b87051bd173ab692aa963bdd3ea</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2019.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2019.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DPu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DEmergence%2520of%2520Allosteric%2520Drug-Resistance%2520Mutations%253A%2520New%2520Challenges%2520for%2520Allosteric%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D177%26epage%3D184%26doi%3D10.1016%2Fj.drudis.2019.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Leukemia-Associated SHP2(E69K) Mutant by the Allosteric SHP2 Inhibitor SHP099</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1246</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0020-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fs41375-018-0020-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=29568093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOmsrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1246-1249&author=X.+Sunauthor=Y.+Renauthor=S.+Gunawanauthor=P.+Tengauthor=Z.+Chenauthor=H.+Lawrenceauthor=J.+Caiauthor=N.+Lawrenceauthor=J.+Wu&title=Selective+Inhibition+of+Leukemia-Associated+SHP2%28E69K%29+Mutant+by+the+Allosteric+SHP2+Inhibitor+SHP099&doi=10.1038%2Fs41375-018-0020-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099</span></div><div class="casAuthors">Sun, X.; Ren, Y.; Gunawan, S.; Teng, P.; Chen, Z.; Lawrence, H. R.; Cai, J.; Lawrence, N. J.; Wu, J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1246-1249</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The article studies selective inhibition of leukemia-assocd. SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099.  Our findings here identify SHP2E69K as a SHP099-sensitive mutation, wherein three of four most common oncogenic SHP2 mutants studied here are resistant to SHP099.  Moreover, whether Noonan syndrome-assocd. SHP2 mutants are sensitive to SHP099 remained to be tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBQzBW1E1YhLVg90H21EOLACvtfcHk0lihc4Nf0TH8kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOmsrrK&md5=2cb9342a2e06eac4b9d9043163e4095c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0020-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0020-5%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DGunawan%26aufirst%3DS.%26aulast%3DTeng%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLawrence%26aufirst%3DH.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DSelective%2520Inhibition%2520of%2520Leukemia-Associated%2520SHP2%2528E69K%2529%2520Mutant%2520by%2520the%2520Allosteric%2520SHP2%2520Inhibitor%2520SHP099%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D1246%26epage%3D1249%26doi%3D10.1038%2Fs41375-018-0020-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Backer, L. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raveendra-Panickar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celeridad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotegut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodiles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holleran, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergienko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosford, N. D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tautz, L.</span></span> <span> </span><span class="NLM_article-title">A Cellular Target Engagement Assay for the Characterization of SHP2 (PTPN11) Phosphatase Inhibitors</span>. <i>J. Bio. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>295</i></span>,  <span class="NLM_fpage">2601</span>– <span class="NLM_lpage">2613</span>, <span class="refDoi"> DOI: 10.1074/jbc.ra119.010838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1074%2Fjbc.RA119.010838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=31953320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFOiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2020&pages=2601-2613&author=C.+Romeroauthor=L.+J.+Lambertauthor=D.+J.+Shefflerauthor=L.+J.+S.+De+Backerauthor=D.+Raveendra-Panickarauthor=M.+Celeridadauthor=S.+Grotegutauthor=S.+Rodilesauthor=J.+Holleranauthor=E.+Sergienkoauthor=E.+B.+Pasqualeauthor=N.+D.+P.+Cosfordauthor=L.+Tautz&title=A+Cellular+Target+Engagement+Assay+for+the+Characterization+of+SHP2+%28PTPN11%29+Phosphatase+Inhibitors&doi=10.1074%2Fjbc.ra119.010838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors</span></div><div class="casAuthors">Romero, Celeste; Lambert, Lester J.; Sheffler, Douglas J.; De Backer, Laurent J. S.; Raveendra-Panickar, Dhanya; Celeridad, Maria; Grotegut, Stefan; Rodiles, Socorro; Holleran, John; Sergienko, Eduard; Pasquale, Elena B.; Cosford, Nicholas D. P.; Tautz, Lutz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2601-2613</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">1083-351X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The nonreceptor protein-tyrosine phosphatase (PTP) SHP2 is encoded by the proto-oncogene PTPN11 and is a ubiquitously expressed key regulator of cell signaling, acting on a no. of cellular processes and components, including the Ras/Raf/Erk, PI3K/Akt, and JAK/STAT pathways and immune checkpoint receptors.  Aberrant SHP2 activity has been implicated in all phases of tumor initiation, progression, and metastasis.  Gain-of-function PTPN11 mutations drive oncogenesis in several leukemias and cause developmental disorders with increased risk of malignancy such as Noonan syndrome.  Until recently, small mol.-based targeting of SHP2 was hampered by the failure of orthosteric active-site inhibitors to achieve selectivity and potency within a useful therapeutic window.  However, new SHP2 allosteric inhibitors with excellent potency and selectivity have sparked renewed interest in the selective targeting of SHP2 and other PTP family members.  Crucially, drug discovery campaigns focusing on SHP2 would greatly benefit from the ability to validate the cellular target engagement of candidate inhibitors.  Here, we report a cellular thermal shift assay that reliably detects target engagement of SHP2 inhibitors.  Using this assay, based on the DiscoverX InCell Pulse enzyme complementation technol., we characterized the binding of several SHP2 allosteric inhibitors in intact cells.  Moreover, we demonstrate the robustness and reliability of a 384-well miniaturized version of the assay for the screening of SHP2 inhibitors targeting either WT SHP2 or its oncogenic E76K variant.  Finally, we provide an example of the assay's ability to identify and characterize novel compds. with specific cellular potency for either WT or mutant SHP2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp919MGtTF9nrVg90H21EOLACvtfcHk0lihc4Nf0TH8kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFOiu7k%253D&md5=e744bad7159435d110927ffad19cba00</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.010838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.010838%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DC.%26aulast%3DLambert%26aufirst%3DL.%2BJ.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DDe%2BBacker%26aufirst%3DL.%2BJ.%2BS.%26aulast%3DRaveendra-Panickar%26aufirst%3DD.%26aulast%3DCeleridad%26aufirst%3DM.%26aulast%3DGrotegut%26aufirst%3DS.%26aulast%3DRodiles%26aufirst%3DS.%26aulast%3DHolleran%26aufirst%3DJ.%26aulast%3DSergienko%26aufirst%3DE.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DCosford%26aufirst%3DN.%2BD.%2BP.%26aulast%3DTautz%26aufirst%3DL.%26atitle%3DA%2520Cellular%2520Target%2520Engagement%2520Assay%2520for%2520the%2520Characterization%2520of%2520SHP2%2520%2528PTPN11%2529%2520Phosphatase%2520Inhibitors%26jtitle%3DJ.%2520Bio.%2520Chem.%26date%3D2020%26volume%3D295%26spage%3D2601%26epage%3D2613%26doi%3D10.1074%2Fjbc.ra119.010838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hellmuth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosskopf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurtele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roder, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kries, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span> <span> </span><span class="NLM_article-title">Specific Inhibitors of the Protein Tyrosine Phosphatase Shp2 Identified by High-Throughput Docking</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">7275</span>– <span class="NLM_lpage">7280</span>, <span class="refDoi"> DOI: 10.1073/pnas.0710468105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1073%2Fpnas.0710468105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=18480264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFCqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=7275-7280&author=K.+Hellmuthauthor=S.+Grosskopfauthor=C.+T.+Lumauthor=M.+Wurteleauthor=N.+Roderauthor=J.+P.+von+Kriesauthor=M.+Rosarioauthor=J.+Rademannauthor=W.+Birchmeier&title=Specific+Inhibitors+of+the+Protein+Tyrosine+Phosphatase+Shp2+Identified+by+High-Throughput+Docking&doi=10.1073%2Fpnas.0710468105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking</span></div><div class="casAuthors">Hellmuth, Klaus; Grosskopf, Stefanie; Lum, Ching Tung; Wuertele, Martin; Roeder, Nadine; von Kries, Jens Peter; Rosario, Marta; Rademann, Jorg; Birchmeier, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7275-7280</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The protein tyrosine phosphatase Shp2 is a pos. regulator of growth factor signaling.  Gain-of-function mutations in several types of leukemia define Shp2 as a bona fide oncogene.  We performed a high-throughput in silico screen for small-mol.-wt. compds. that bind the catalytic site of Shp2.  We have identified the phenylhydrazonopyrazolone sulfonate PHPS1 as a potent and cell-permeable inhibitor, which is specific for Shp2 over the closely related tyrosine phosphatases Shp1 and PTP1 B.  PHPS1 inhibits Shp2-dependent cellular events such as hepatocyte growth factor/scatter factor (HGF/SF)-induced epithelial cell scattering and branching morphogenesis.  PHPS1 also blocks Shp2-dependent downstream signaling, namely HGF/SF-induced sustained phosphorylation of the Erk1/2 MAP kinases and dephosphorylation of paxillin.  Furthermore, PHPS1 efficiently inhibits activation of Erk1/2 by the leukemia-assocd. Shp2 mutant, Shp2-E76K, and blocks the anchorage-independent growth of a variety of human tumor cell lines.  The PHPS compd. class is therefore suitable for further development of therapeutics for the treatment of Shp2-dependent diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGponh1kw_h7jrVg90H21EOLACvtfcHk0lijt1R4tsNa1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFCqsLs%253D&md5=39c7dda94e32134c305e135e4c48b9d1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0710468105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0710468105%26sid%3Dliteratum%253Aachs%26aulast%3DHellmuth%26aufirst%3DK.%26aulast%3DGrosskopf%26aufirst%3DS.%26aulast%3DLum%26aufirst%3DC.%2BT.%26aulast%3DWurtele%26aufirst%3DM.%26aulast%3DRoder%26aufirst%3DN.%26aulast%3Dvon%2BKries%26aufirst%3DJ.%2BP.%26aulast%3DRosario%26aufirst%3DM.%26aulast%3DRademann%26aufirst%3DJ.%26aulast%3DBirchmeier%26aufirst%3DW.%26atitle%3DSpecific%2520Inhibitors%2520of%2520the%2520Protein%2520Tyrosine%2520Phosphatase%2520Shp2%2520Identified%2520by%2520High-Throughput%2520Docking%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D7275%26epage%3D7280%26doi%3D10.1073%2Fpnas.0710468105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grosskopf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radetzki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kries, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibitors of the Protein Tyrosine Phosphatase SHP2 Block Cellular Motility and Growth of Cancer Cells In Vitro and In Vivo</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2Fcmdc.201500015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=25877780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFers7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=815-826&author=S.+Grosskopfauthor=C.+Eckertauthor=C.+Arkonaauthor=S.+Radetzkiauthor=K.+B%C3%B6hmauthor=U.+Heinemannauthor=G.+Wolberauthor=J.-P.+von+Kriesauthor=W.+Birchmeierauthor=J.+Rademann&title=Selective+Inhibitors+of+the+Protein+Tyrosine+Phosphatase+SHP2+Block+Cellular+Motility+and+Growth+of+Cancer+Cells+In+Vitro+and+In+Vivo&doi=10.1002%2Fcmdc.201500015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibitors of the Protein Tyrosine Phosphatase SHP2 Block Cellular Motility and Growth of Cancer Cells in vitro and in vivo</span></div><div class="casAuthors">Grosskopf, Stefanie; Eckert, Chris; Arkona, Christoph; Radetzki, Silke; Boehm, Kerstin; Heinemann, Udo; Wolber, Gerhard; von Kries, Jens-Peter; Birchmeier, Walter; Rademann, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">815-826</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective inhibitors of the protein tyrosine phosphatase SHP2 (src homol. region 2 domain phosphatase; PTPN11), an enzyme that is deregulated in numerous human tumors, were generated through a combination of chem. synthesis and structure-based rational design.  Seventy pyridazolon-4-ylidenehydrazinyl benzenesulfonates were prepd. and evaluated in enzyme assays.  The binding modes of active inhibitors were simulated in silico using a newly generated crystal structure of SHP2.  The most powerful compd. I inhibited SHP2 with an IC50 value of 71±15 nM in the enzyme assay and was 29- and 45-fold more active toward SHP2 than against related SHP1 and PTP1B.  In cell culture expts. compd. I was found to block hepatocyte growth factor (HGF)-stimulated epithelial-mesenchymal transition of human pancreatic adenocarcinoma (HPAF) cells, as indicated by a decrease in the min. neighbor distances of cells.  Moreover, I inhibited cell colony formation in the nonsmall-cell lung cancer cell line LXFA 526 L in soft agar.  Finally, I was obsd. to inhibit tumor growth in a murine xenograft model.  Therefore, the novel specific compd. I strengthens the hypothesis that SHP2 is a relevant protein target for the inhibition of mobility and invasiveness of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovDT-98edFurVg90H21EOLACvtfcHk0lijt1R4tsNa1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFers7g%253D&md5=72fa2915b67c514076144b3005441b17</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500015%26sid%3Dliteratum%253Aachs%26aulast%3DGrosskopf%26aufirst%3DS.%26aulast%3DEckert%26aufirst%3DC.%26aulast%3DArkona%26aufirst%3DC.%26aulast%3DRadetzki%26aufirst%3DS.%26aulast%3DB%25C3%25B6hm%26aufirst%3DK.%26aulast%3DHeinemann%26aufirst%3DU.%26aulast%3DWolber%26aufirst%3DG.%26aulast%3Dvon%2BKries%26aufirst%3DJ.-P.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DRademann%26aufirst%3DJ.%26atitle%3DSelective%2520Inhibitors%2520of%2520the%2520Protein%2520Tyrosine%2520Phosphatase%2520SHP2%2520Block%2520Cellular%2520Motility%2520and%2520Growth%2520of%2520Cancer%2520Cells%2520In%2520Vitro%2520and%2520In%2520Vivo%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D815%26epage%3D826%26doi%3D10.1002%2Fcmdc.201500015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gannett, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, B.</span></span> <span> </span><span class="NLM_article-title">Aryl Radical Formation During the Metabolism of Arylhydrazines by Microsomes</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1372</span>– <span class="NLM_lpage">1377</span>, <span class="refDoi"> DOI: 10.1021/tx970084y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx970084y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK2sXnsFOls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1997&pages=1372-1377&author=P.+M.+Gannettauthor=X.+Shiauthor=T.+Lawsonauthor=C.+Kolarauthor=B.+Toth&title=Aryl+Radical+Formation+During+the+Metabolism+of+Arylhydrazines+by+Microsomes&doi=10.1021%2Ftx970084y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Aryl Radical Formation during the Metabolism of Arylhydrazines by Microsomes</span></div><div class="casAuthors">Gannett, Peter M.; Shi, Xiangling; Lawson, Terence; Kolar, Carol; Toth, Bela</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1372-1377</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here we have looked for the formation of aryl radicals from arylhydrazines and microsomes by ESR spin trapping.  Only hydroxyl radicals are trapped upon incubation of p-methylphenylhydrazine with rat liver microsomes and 5,5-dimethyl-1-pyrroline N-oxide (DMPO).  However, hydroxyl and aryl radicals were trapped upon incubation of p-(methoxymethyl)phenylhydrazine with rat liver microsomes.  Evidence for hydroperoxyl radical formation was also obtained.  In contrast, when either of these substrates was incubated with microsomes from C5O cells, aryl and hydroxyl radicals were trapped.  The ESR signal intensity of the spin-trapped aryl radicals parallels the extent of C8-arylguanine formation in DNA, and therefore, the aryl radical is likely the intermediate responsible for C8-arylguanine adduct formation.  Aryl radicals and C8-arylguanine adducts may be related to the genotoxicity of arylhydrazines and related compds. that are oxidatively metabolized to arenediazonium ions, the precursor to aryl radicals, including arylalkyl nitrosamines, arylazo compds., and triazenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP1mMMJeouprVg90H21EOLACvtfcHk0lhj-ug1Lsb4dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsFOls7o%253D&md5=b5aea2acb5f1d4ed20721b35244fdf53</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Ftx970084y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx970084y%26sid%3Dliteratum%253Aachs%26aulast%3DGannett%26aufirst%3DP.%2BM.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DLawson%26aufirst%3DT.%26aulast%3DKolar%26aufirst%3DC.%26aulast%3DToth%26aufirst%3DB.%26atitle%3DAryl%2520Radical%2520Formation%2520During%2520the%2520Metabolism%2520of%2520Arylhydrazines%2520by%2520Microsomes%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1997%26volume%3D10%26spage%3D1372%26epage%3D1377%26doi%3D10.1021%2Ftx970084y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span> <span> </span><span class="NLM_article-title">Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00903</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00903" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=36-44&author=J.+B.+Baellauthor=J.+W.+M.+Nissink&title=Seven+Year+Itch%3A+Pan-Assay+Interference+Compounds+%28PAINS%29+in+2017-Utility+and+Limitations&doi=10.1021%2Facschembio.7b00903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations</span></div><div class="casAuthors">Baell, Jonathan B.; Nissink, J. Willem M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on all necessary considerations for the appropriate use of PAINs filters formulated to process hundreds and thousands of compds. in seconds, and identify PAINS in order to exclude them from further anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocZ7E_j7zxfbVg90H21EOLACvtfcHk0lhj-ug1Lsb4dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bK&md5=051115704137d6a91b8271702c619682</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00903%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26atitle%3DSeven%2520Year%2520Itch%253A%2520Pan-Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520in%25202017-Utility%2520and%2520Limitations%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D36%26epage%3D44%26doi%3D10.1021%2Facschembio.7b00903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murdock, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, S. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, M.-W.</span></span> <span> </span><span class="NLM_article-title">Effects of the Nitro-Group on the Mutagenicity and Toxicity of Some Benzamines</span>. <i>Environ. Mol. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1002/(sici)1098-2280(1996)27:1<67::aid-em9>3.0.co;2-b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2F%28SICI%291098-2280%281996%2927%3A1%3C67%3A%3AAID-EM9%3E3.0.CO%3B2-B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=8625950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK28XhsVOnt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1996&pages=67-74&author=K.-T.+Chungauthor=C.+A.+Murdockauthor=Y.+Zhouauthor=S.+E.+Stevensauthor=Y.-S.+Liauthor=C.-I.+Weiauthor=S.+Y.+Fernandoauthor=M.-W.+Chou&title=Effects+of+the+Nitro-Group+on+the+Mutagenicity+and+Toxicity+of+Some+Benzamines&doi=10.1002%2F%28sici%291098-2280%281996%2927%3A1%3C67%3A%3Aaid-em9%3E3.0.co%3B2-b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the nitro-group on the mutagenicity and toxicity of some benzamines</span></div><div class="casAuthors">Chung, King-Thom; Murdock, Chris A.; Zhou, Yonggui; Stevens, S. Edward, Jr.; Li, Ying-Sing; Wei, Cheng-I.; Fernando, S. Y.; Chou, Ming-W.</div><div class="citationInfo"><span class="NLM_cas:title">Environmental and Molecular Mutagenesis</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-74</span>CODEN:
                <span class="NLM_cas:coden">EMMUEG</span>;
        ISSN:<span class="NLM_cas:issn">0893-6692</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss</span>)
        </div><div class="casAbstract">The Ames Salmonella/microsomal assay was employed to test the mutagenicity of some benzamines (aniline, and o- and p-phenylenediamine) and their nitro-derivs. (p-nitroaniline, 2-nitro-p-phenylenediamine, 3- and 4-nitro-o-phenylenediamine), using strains TA98 and TA100 and their nitroreductase-deficient mutants, TA98NR and TA100NR, in the presence and absence of rat S9 mix.  The addn. of the nitro-group to benzamine mols. converted them into direct mutagens.  Furthermore, the position of the nitro-group affected their mutagenic activities.  Cytotoxicity testing with Chinese hamster ovary cells (CHO-K1) showed that the presence of the nitro-group in these compds. had no specific effect on toxicity.  The test compds. all showed a dose-related increase in inducing chromosomal aberration in CHO cells.  However, the presence of the nitro-group did not affect potency in inducing chromosomal aberrations.  Compds. contg. the nitro-group had higher initial oxidn. potentials and dipole moments (μ) than their nonnitro-contg. counterparts.  The mutagenicity and toxicity of these compds. were not related to physico-chem. properties, including oxidn. potential, energy difference (ΔE) between the LUMO and the HOMO, ionization potential (I.P.), and μ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFWlQRb-YEIrVg90H21EOLACvtfcHk0lg8bw00peljWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsVOnt78%253D&md5=baa95de9846ca0b18287f02e5dbff02f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291098-2280%281996%2927%3A1%3C67%3A%3AAID-EM9%3E3.0.CO%3B2-B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291098-2280%25281996%252927%253A1%253C67%253A%253AAID-EM9%253E3.0.CO%253B2-B%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DK.-T.%26aulast%3DMurdock%26aufirst%3DC.%2BA.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DStevens%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DY.-S.%26aulast%3DWei%26aufirst%3DC.-I.%26aulast%3DFernando%26aufirst%3DS.%2BY.%26aulast%3DChou%26aufirst%3DM.-W.%26atitle%3DEffects%2520of%2520the%2520Nitro-Group%2520on%2520the%2520Mutagenicity%2520and%2520Toxicity%2520of%2520Some%2520Benzamines%26jtitle%3DEnviron.%2520Mol.%2520Mutagen.%26date%3D1996%26volume%3D27%26spage%3D67%26epage%3D74%26doi%3D10.1002%2F%28sici%291098-2280%281996%2927%3A1%3C67%3A%3Aaid-em9%3E3.0.co%3B2-b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macherey, A. C.</span>; <span class="NLM_string-name">Dansette, P. M.</span></span> <span> </span><span class="NLM_article-title">Biotransformations Leading to Toxic Metabolites</span>. In  <i>The Practice of Medicinal Chemistry</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wermuth, C.</span>, <span class="NLM_string-name">Aldous, D.</span>, <span class="NLM_string-name">Raboisson, P.</span>, <span class="NLM_string-name">Rognan, D.</span></span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2015</span>; pp  <span class="NLM_fpage">675</span>– <span class="NLM_lpage">696</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2FB978-0-12-417205-0.00025-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=675-696&author=A.+C.+Macherey&author=P.+M.+Dansetteauthor=C.+Wermuth&author=D.+Aldous&author=P.+Raboisson&author=D.+Rognan&title=The+Practice+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-417205-0.00025-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-417205-0.00025-0%26sid%3Dliteratum%253Aachs%26aulast%3DMacherey%26aufirst%3DA.%2BC.%26atitle%3DBiotransformations%2520Leading%2520to%2520Toxic%2520Metabolites%26btitle%3DThe%2520Practice%2520of%2520Medicinal%2520Chemistry%26aulast%3DWermuth%26aufirst%3DC.%26pub%3DAcademic%2520Press%26date%3D2015%26spage%3D675%26epage%3D696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslait73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1701-1714&author=M.+D.+Shultz&title=Two+Decades+under+the+Influence+of+the+Rule+of+Five+and+the+Changing+Properties+of+Approved+Oral+Drugs&doi=10.1021%2Facs.jmedchem.8b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1701-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two decades have passed since the rule of five ushered in the concept of "drug-like" properties.  Attempts to quantify, correlate, and categorize mols. based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines.  Examn. of oral drug parameters approved before and after the original Ro5 anal. demonstrates that some parameters such as clogP and HBD remained const. while the cutoffs for parameters such as mol. wt. and HBA have increased substantially over the past 20 years.  The time dependent increase in the mol. wt. of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that mol. wt. is a "drug-like" property.  This anal. does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAnoxpQsv2kbVg90H21EOLACvtfcHk0lg8bw00peljWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslait73K&md5=d3c8b1107133dc0b7b277d22fa029597</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00686%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DTwo%2520Decades%2520under%2520the%2520Influence%2520of%2520the%2520Rule%2520of%2520Five%2520and%2520the%2520Changing%2520Properties%2520of%2520Approved%2520Oral%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1701%26epage%3D1714%26doi%3D10.1021%2Facs.jmedchem.8b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldblum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span> <span> </span><span class="NLM_article-title">Understanding Drug-Likeness</span>. <i>Wiley Interdiscip. Rev.: Comput. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1002/wcms.52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2Fwcms.52" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWrtrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=760-781&author=O.+Ursuauthor=A.+Rayanauthor=A.+Goldblumauthor=T.+I.+Oprea&title=Understanding+Drug-Likeness&doi=10.1002%2Fwcms.52"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding drug-likeness</span></div><div class="casAuthors">Ursu, Oleg; Rayan, Anwar; Goldblum, Amiram; Oprea, Tudor I.</div><div class="citationInfo"><span class="NLM_cas:title">Wiley Interdisciplinary Reviews: Computational Molecular Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">760-781</span>CODEN:
                <span class="NLM_cas:coden">WIRCAH</span>;
        ISSN:<span class="NLM_cas:issn">1759-0884</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  "Drug-likeness", a qual. property of chems. assigned by experts committee vote, is wedely integrated into the early stages of lead and drug discovery.  Its conceptual evolution paralleled work related to Pfizer's "rule of five" and lead-likeness, and is placed within this framework.  The discrimination between "drugs" (represented by a collection of pharmaceutically relevant small mols., some of which are marketed drugs) and "nondrugs" (typically, chem. reagents) is possible using a wide variety of statistical tools and chem. descriptor systems.  Here we summarize 18 papers focused on drug-likeness, and provide a comprehensive overview of progress in the field.  Tools that est. drug-likeness are valuable in the early stages of lead discovery, and can be used to filter out compds. with undersirable properties from screening libraries and to prioritize hits from primary screens.  As the goal is, most often, to develop orally available drugs, it is also useful to optimize drug-like pharmacokinetic properties.  We examine tools that evaluate drug-likeness and some of their shortcomings, challenges facing these tools, and address the following issues: What is the definition of drug-likeness and how can it be utilized to reduce attrition rate in drug discovery.  How difficult is it to distinguish drugs from nondrugs.  Are nondrug datasets reliable.  Can we est. oral drug-likeness.  We discuss a drug-like filter and recent advances in the prediction of oral drug-likeness.  The heuristic aspect of drug-likeness is also addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeTi02F5W647Vg90H21EOLACvtfcHk0lhAfzda56IVYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWrtrbO&md5=3cd46a7a7a082d6d3730e6bbf16712d2</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fwcms.52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwcms.52%26sid%3Dliteratum%253Aachs%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DRayan%26aufirst%3DA.%26aulast%3DGoldblum%26aufirst%3DA.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26atitle%3DUnderstanding%2520Drug-Likeness%26jtitle%3DWiley%2520Interdiscip.%2520Rev.%253A%2520Comput.%2520Mol.%2520Sci.%26date%3D2011%26volume%3D1%26spage%3D760%26epage%3D781%26doi%3D10.1002%2Fwcms.52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosey, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span> <span> </span><span class="NLM_article-title">BDDCS, the Rule of 5 and Drugability</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2016.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.addr.2016.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=27182629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFOisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2016&pages=89-98&author=L.+Z.+Benetauthor=C.+M.+Hoseyauthor=O.+Ursuauthor=T.+I.+Oprea&title=BDDCS%2C+the+Rule+of+5+and+Drugability&doi=10.1016%2Fj.addr.2016.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">BDDCS, the Rule of 5 and drugability</span></div><div class="casAuthors">Benet, Leslie Z.; Hosey, Chelsea M.; Ursu, Oleg; Oprea, Tudor I.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The Rule of 5 methodol. appears to be as useful today in defining drugability as when it was proposed, but recognizing that the database that we used includes only drugs that successfully reached the market.  We do not view addnl. criteria necessary nor did we find significant deficiencies in the four Rule of 5 criteria originally proposed by Lipinski and coworkers.  BDDCS builds upon the Rule of 5 and can quite successfully predict drug disposition characteristics for drugs both meeting and not meeting Rule of 5 criteria.  More recent expansions of classification systems have been proposed and do provide useful qual. and quant. predictions for clearance relationships.  However, the broad range of applicability of BDDCS beyond just clearance predictions gives a great deal of further usefulness for the combined Rule of 5/BDDCS system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF2rl3biM_77Vg90H21EOLACvtfcHk0lhAfzda56IVYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFOisLk%253D&md5=4512bd3c8f7eb921f91fbb9487f9cbb3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DHosey%26aufirst%3DC.%2BM.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26atitle%3DBDDCS%252C%2520the%2520Rule%2520of%25205%2520and%2520Drugability%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D101%26spage%3D89%26epage%3D98%26doi%3D10.1016%2Fj.addr.2016.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span> <span> </span><span class="NLM_article-title">Bioisosteres and Scaffold Hopping in Medicinal Chemistry</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1002/minf.201400037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2Fminf.201400037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=27485983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovFCmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=458-462&author=N.+Brown&title=Bioisosteres+and+Scaffold+Hopping+in+Medicinal+Chemistry&doi=10.1002%2Fminf.201400037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteres and Scaffold Hopping in Medicinal Chemistry</span></div><div class="casAuthors">Brown, Nathan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">458-462</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The twin concepts of bioisosteric replacement and scaffold hopping are increasingly becoming important in modern drug design.  The concepts of isosterism stretch back over a century, but only recently have systematic and data-intensive methods been used to explore appropriate replacements.  Here, a summary of the history of bioisosterism is presented to provide context to the methods applied.  Mol. similarity and data mining methods are introduced as approaches to introduce these replacements to rationalise the space of synthetic targets to consider in a medicinal chem. project.  Lastly, an outlook of the field is given of potential future improvements and areas of focus that should be considered to anyone interested in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjI1uBH0tL3rVg90H21EOLACvtfcHk0lhAfzda56IVYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovFCmtbc%253D&md5=01b5cfa1427ae7e038cf4478bf07be5a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fminf.201400037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201400037%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%26atitle%3DBioisosteres%2520and%2520Scaffold%2520Hopping%2520in%2520Medicinal%2520Chemistry%26jtitle%3DMol.%2520Inf.%26date%3D2014%26volume%3D33%26spage%3D458%26epage%3D462%26doi%3D10.1002%2Fminf.201400037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langdon, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span> <span> </span><span class="NLM_article-title">Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1002/minf.201000019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2Fminf.201000019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=27463193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsVSgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=366-385&author=S.+R.+Langdonauthor=P.+Ertlauthor=N.+Brown&title=Bioisosteric+Replacement+and+Scaffold+Hopping+in+Lead+Generation+and+Optimization&doi=10.1002%2Fminf.201000019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization</span></div><div class="casAuthors">Langdon, Sarah R.; Ertl, Peter; Brown, Nathan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">366-385</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Bioisosteric replacement and scaffold hopping are twin methods used in drug design to improve the synthetic accessibility, potency and drug like properties of a compd. and to move into novel chem. space.  Bioisosteric replacement involves swapping functional groups of a mol. with other functional groups that have similar biol. properties.  Scaffold hopping is the replacement of the core framework of a mol. with another scaffold that will improve the properties of the mol. or to find similar potent compds. that exist in novel chem. space.  This review outlines the key concepts, importance and challenges of both methods using examples and comparisons of techniques available for finding bioisosteric replacements and scaffold hops.  There are many methods available for bioisosteric replacement and scaffold hopping, all with their own advantages and disadvantages.  Drug design projects would benefit from a combination of these methods to retrieve diverse and complimentary results.  Continuing progress in these fields will allow further validation of both methods as well as the accumulation of knowledge on bioisosteres and possible scaffold replacements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJsbL69-PF-7Vg90H21EOLACvtfcHk0li5x_o3w5Xt2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsVSgur4%253D&md5=372b9094a34108fb978f5d9fa95831cd</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fminf.201000019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201000019%26sid%3Dliteratum%253Aachs%26aulast%3DLangdon%26aufirst%3DS.%2BR.%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DN.%26atitle%3DBioisosteric%2520Replacement%2520and%2520Scaffold%2520Hopping%2520in%2520Lead%2520Generation%2520and%2520Optimization%26jtitle%3DMol.%2520Inf.%26date%3D2010%26volume%3D29%26spage%3D366%26epage%3D385%26doi%3D10.1002%2Fminf.201000019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span> <span> </span><span class="NLM_article-title">Intramolecular Hydrogen Bonding in Medicinal Chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2601</span>– <span class="NLM_lpage">2611</span>, <span class="refDoi"> DOI: 10.1021/jm100087s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100087s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Clur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2601-2611&author=B.+Kuhnauthor=P.+Mohrauthor=M.+Stahl&title=Intramolecular+Hydrogen+Bonding+in+Medicinal+Chemistry&doi=10.1021%2Fjm100087s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Intramolecular Hydrogen Bonding in Medicinal Chemistry</span></div><div class="casAuthors">Kuhn, Bernd; Mohr, Peter; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2601-2611</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The formation of intramol. hydrogen bonds has a very pronounced effect on mol. structure and properties.  We study both aspects in detail with the aim of enabling a more rational use of this class of interactions in medicinal chem.  On the basis of exhaustive searches in crystal structure databases, we derive propensities for intramol. hydrogen bond formation of five- to eight-membered ring systems of relevance in drug discovery.  A no. of motifs, several of which are clearly underutilized in drug discovery, are analyzed in more detail by comparing small mol. and protein-ligand X-ray structures.  To investigate effects on physicochem. properties, sets of closely related structures with and without the ability to form intramol. hydrogen bonds were designed, synthesized, and characterized with respect to membrane permeability, water soly., and lipophilicity.  We find that changes in these properties depend on a subtle balance between the strength of the hydrogen bond interaction, geometry of the newly formed ring system, and the relative energies of the open and closed conformations in polar and unpolar environments.  A no. of general guidelines for medicinal chemists emerge from this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdaV7tFRU4k7Vg90H21EOLACvtfcHk0li5x_o3w5Xt2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Clur8%253D&md5=b9b6865dfcc9bdf7796d15218f6e8ff2</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm100087s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100087s%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DIntramolecular%2520Hydrogen%2520Bonding%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2601%26epage%3D2611%26doi%3D10.1021%2Fjm100087s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uang, B.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H.-P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Inhibitors of Aurora Kinases with Indazole Scaffold: In Silico Fragment-Based and Knowledge-Based Drug Design</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.08.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.ejmech.2016.08.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=27573544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVaktbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=186-199&author=C.-F.+Changauthor=W.-H.+Linauthor=Y.-Y.+Keauthor=Y.-S.+Linauthor=W.-C.+Wangauthor=C.-H.+Chenauthor=P.-C.+Kuoauthor=J.+T.+A.+Hsuauthor=B.-J.+Uangauthor=H.-P.+Hsieh&title=Discovery+of+Novel+Inhibitors+of+Aurora+Kinases+with+Indazole+Scaffold%3A+In+Silico+Fragment-Based+and+Knowledge-Based+Drug+Design&doi=10.1016%2Fj.ejmech.2016.08.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design</span></div><div class="casAuthors">Chang, Chun-Feng; Lin, Wen-Hsing; Ke, Yi-Yu; Lin, Yih-Shyan; Wang, Wen-Chieh; Chen, Chun-Hwa; Kuo, Po-Chu; Hsu, John T. A.; Uang, Biing-Jiun; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">186-199</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Aurora kinases have emerged as important anticancer targets so that there are several inhibitors have advanced into clin. study.  Herein, the authors identified novel indazole derivs. as potent Aurora kinases inhibitors by utilizing in silico fragment-based approach and knowledge-based drug design.  After intensive hit-to-lead optimization, compds. I (dual Aurora A and B), II (Aurora B selective) and III (Aurora A selective) possessed indazole privileged scaffold with different substituents, which provide sub-type kinase selectivity.  Computational modeling helps in understanding that the isoform selectivity could be targeted specific residue in the Aurora kinase binding pocket in particular targeting residues Arg220, Thr217 or Glu177.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6E3wCvY_TIrVg90H21EOLACvtfcHk0li5x_o3w5Xt2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVaktbfL&md5=0d049378be04d320ab2212fdc2aa1e6f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.08.026%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DC.-F.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DKe%26aufirst%3DY.-Y.%26aulast%3DLin%26aufirst%3DY.-S.%26aulast%3DWang%26aufirst%3DW.-C.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DKuo%26aufirst%3DP.-C.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%2BA.%26aulast%3DUang%26aufirst%3DB.-J.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DDiscovery%2520of%2520Novel%2520Inhibitors%2520of%2520Aurora%2520Kinases%2520with%2520Indazole%2520Scaffold%253A%2520In%2520Silico%2520Fragment-Based%2520and%2520Knowledge-Based%2520Drug%2520Design%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D186%26epage%3D199%26doi%3D10.1016%2Fj.ejmech.2016.08.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, A. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sale, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.-Q.</span></span> <span> </span><span class="NLM_article-title">A Robust Protocol for Pd(II)-catalyzed C-3 Arylation of (1H) Indazoles and Pyrazoles: Total Synthesis of Nigellidine Hydrobromide</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2374</span>– <span class="NLM_lpage">2379</span>, <span class="refDoi"> DOI: 10.1039/c3sc50184a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1039%2Fc3sc50184a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=23691269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntV2jsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=2374-2379&author=M.+Yeauthor=A.+J.+F.+Edmundsauthor=J.+A.+Morrisauthor=D.+Saleauthor=Y.+Zhangauthor=J.-Q.+Yu&title=A+Robust+Protocol+for+Pd%28II%29-catalyzed+C-3+Arylation+of+%281H%29+Indazoles+and+Pyrazoles%3A+Total+Synthesis+of+Nigellidine+Hydrobromide&doi=10.1039%2Fc3sc50184a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A robust protocol for Pd(ii)-catalyzed C-3 arylation of (1H) indazoles and pyrazoles: total synthesis of nigellidine hydrobromide</span></div><div class="casAuthors">Ye, Mengchun; Edmunds, Andrew J. F.; Morris, James A.; Sale, David; Zhang, Yejia; Yu, Jin-Quan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2374-2379</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">C3-arylated indazole and pyrazoles are privileged structural motifs in agrochems. and pharmaceuticals.  C-3 C-H arylation of (1H) indazole and pyrazole was a significant challenge due to the poor reactivity of the C-3 position.  Herein, the authors report a practical Pd(ii)/Phen catalyst and conditions for the direct C-3 arylation of indazole and pyrazole with ArI or ArBr without using Ag additives as halide scavengers.  The use of toluene, chlorobenzene, trifluoromethylbenzene and mesitylene as the solvent is crucial for the selectivity and reactivity.  The authors further demonstrate the robustness of this protocol through the first total synthesis of nigellidine hydrobromide as well as the expedient prepn. of heterocycles structurally related to pesticides and drug mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnosPRY5pAt7Vg90H21EOLACvtfcHk0lgNObHXH16nMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntV2jsrk%253D&md5=9918215eeff186e3ddae5b7ec89e4dfb</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1039%2Fc3sc50184a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3sc50184a%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DM.%26aulast%3DEdmunds%26aufirst%3DA.%2BJ.%2BF.%26aulast%3DMorris%26aufirst%3DJ.%2BA.%26aulast%3DSale%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DJ.-Q.%26atitle%3DA%2520Robust%2520Protocol%2520for%2520Pd%2528II%2529-catalyzed%2520C-3%2520Arylation%2520of%2520%25281H%2529%2520Indazoles%2520and%2520Pyrazoles%253A%2520Total%2520Synthesis%2520of%2520Nigellidine%2520Hydrobromide%26jtitle%3DChem.%2520Sci.%26date%3D2013%26volume%3D4%26spage%3D2374%26epage%3D2379%26doi%3D10.1039%2Fc3sc50184a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, N. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqui, M.</span></span> <span> </span><span class="NLM_article-title">Chemistry and Biology of Indoles and Indazoles: a Mini-Review</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1792</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.2174/1389557511313120009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.2174%2F1389557511313120009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=22625410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A280%3ADC%252BC38nlvFGjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1792-1800&author=N.+A.+S.+Aliauthor=B.+A.+Darauthor=V.+Pradhanauthor=M.+Farooqui&title=Chemistry+and+Biology+of+Indoles+and+Indazoles%3A+a+Mini-Review&doi=10.2174%2F1389557511313120009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry and biology of indoles and indazoles: a mini-review</span></div><div class="casAuthors">Ali Nasir Ali Shafakat; Dar Bashir Ahmad; Pradhan Vidya; Farooqui Mazahar</div><div class="citationInfo"><span class="NLM_cas:title">Mini reviews in medicinal chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1792-800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The present review article is related with the method of preparation, importance and medicinal application of indole and indazoles.  The studies of heterocycles is an evergreen field in the branch of organic chemistry and always attract the attention of chemists working not only in the area of natural products but also in the synthetic chemistry.  Moreover many useful drugs have emerged from the successful investigation carried out in this branch.  The derivatives of indoles and indazoles exhibits antibacterial, anticancer, antionidants, anti-inflammatory, antidiabetic, antiviral, atniproliferative, antituberculosis, antispermetogenic activity, antipsychotic drugs etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBPMO4d6esv-_Q9URG6Dx8fW6udTcc2ebDBjDgv9YAOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38nlvFGjsA%253D%253D&md5=1cc47f0a22c5e81f9cfff7e8382b3ffd</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2174%2F1389557511313120009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557511313120009%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DN.%2BA.%2BS.%26aulast%3DDar%26aufirst%3DB.%2BA.%26aulast%3DPradhan%26aufirst%3DV.%26aulast%3DFarooqui%26aufirst%3DM.%26atitle%3DChemistry%2520and%2520Biology%2520of%2520Indoles%2520and%2520Indazoles%253A%2520a%2520Mini-Review%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D1792%26epage%3D1800%26doi%3D10.2174%2F1389557511313120009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Irie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span> <span> </span><span class="NLM_article-title">7-Azaindole: A Versatile Scaffold for Developing Kinase Inhibitors</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1248/cpb.c17-00380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1248%2Fcpb.c17-00380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=29311509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOntr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2018&pages=29-36&author=T.+Irieauthor=M.+Sawa&title=7-Azaindole%3A+A+Versatile+Scaffold+for+Developing+Kinase+Inhibitors&doi=10.1248%2Fcpb.c17-00380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">7-Azaindole: a versatile scaffold for developing kinase inhibitors</span></div><div class="casAuthors">Irie, Takayuki; Sawa, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-36</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A review.  This review summarized recent examples of 7-azaindole-based kinase inhibitors and discusses their binding interactions with the kinase hinge regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9QuvBOqQ8GrVg90H21EOLACvtfcHk0lgNObHXH16nMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOntr%252FK&md5=69a5097cb54f2598d2e02414e74b3e6b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c17-00380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c17-00380%26sid%3Dliteratum%253Aachs%26aulast%3DIrie%26aufirst%3DT.%26aulast%3DSawa%26aufirst%3DM.%26atitle%3D7-Azaindole%253A%2520A%2520Versatile%2520Scaffold%2520for%2520Developing%2520Kinase%2520Inhibitors%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2018%26volume%3D66%26spage%3D29%26epage%3D36%26doi%3D10.1248%2Fcpb.c17-00380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mérour, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plé, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, S.</span></span> <span> </span><span class="NLM_article-title">The Azaindole Framework in the Design of Kinase Inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">19935</span>– <span class="NLM_lpage">19979</span>, <span class="refDoi"> DOI: 10.3390/molecules191219935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.3390%2Fmolecules191219935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=25460315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVymtLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=19935-19979&author=J.-Y.+M%C3%A9rourauthor=F.+Buronauthor=K.+Pl%C3%A9author=P.+Bonnetauthor=S.+Routier&title=The+Azaindole+Framework+in+the+Design+of+Kinase+Inhibitors&doi=10.3390%2Fmolecules191219935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The azaindole framework in the design of kinase inhibitors</span></div><div class="casAuthors">Merour, Jean-Yves; Buron, Frederic; Ple, Karen; Bonnet, Pascal; Routier, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">19935-19979, 45 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">This review article illustrates the growing use of azaindole derivs. as kinase inhibitors and their contribution to drug discovery and innovation.  The different protein kinases which have served as targets and the known mols. which have emerged from medicinal chem. and Fragment-Based Drug Discovery (FBDD) programs are presented.  The various synthetic routes used to access these compds. and the chem. pathways leading to their synthesis are also discussed.  An anal. of their mode of binding based on X-ray crystallog. data gives structural insights for the design of more potent and selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLLtZrGItBQbVg90H21EOLACvtfcHk0lg6Z1weW7gjfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVymtLbO&md5=7797450a99abb4a4c8e2492eb8a43dd7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.3390%2Fmolecules191219935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules191219935%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9rour%26aufirst%3DJ.-Y.%26aulast%3DBuron%26aufirst%3DF.%26aulast%3DPl%25C3%25A9%26aufirst%3DK.%26aulast%3DBonnet%26aufirst%3DP.%26aulast%3DRoutier%26aufirst%3DS.%26atitle%3DThe%2520Azaindole%2520Framework%2520in%2520the%2520Design%2520of%2520Kinase%2520Inhibitors%26jtitle%3DMolecules%26date%3D2014%26volume%3D19%26spage%3D19935%26epage%3D19979%26doi%3D10.3390%2Fmolecules191219935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loweth, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravula, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polesskaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marker, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewhurst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbard, H. A.</span></span> <span> </span><span class="NLM_article-title">Discovery, Synthesis, and Characterization of an Orally Bioavailable, Brain Penetrant Inhibitor of Mixed Lineage Kinase 3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8032</span>– <span class="NLM_lpage">8048</span>, <span class="refDoi"> DOI: 10.1021/jm401094t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401094t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVGjtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8032-8048&author=V.+S.+Goodfellowauthor=C.+J.+Lowethauthor=S.+B.+Ravulaauthor=T.+Wiemannauthor=T.+Nguyenauthor=Y.+Xuauthor=D.+E.+Toddauthor=D.+Sheppardauthor=S.+Pollackauthor=O.+Polesskayaauthor=D.+F.+Markerauthor=S.+Dewhurstauthor=H.+A.+Gelbard&title=Discovery%2C+Synthesis%2C+and+Characterization+of+an+Orally+Bioavailable%2C+Brain+Penetrant+Inhibitor+of+Mixed+Lineage+Kinase+3&doi=10.1021%2Fjm401094t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, Synthesis, and Characterization of an Orally Bioavailable, Brain Penetrant Inhibitor of Mixed Lineage Kinase 3</span></div><div class="casAuthors">Goodfellow, Val S.; Loweth, Colin J.; Ravula, Satheesh B.; Wiemann, Torsten; Nguyen, Thong; Xu, Yang; Todd, Daniel E.; Sheppard, David; Pollack, Scott; Polesskaya, Oksana; Marker, Daniel F.; Dewhurst, Stephen; Gelbard, Harris A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8032-8048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of mixed lineage kinase 3 (MLK3) is a potential strategy for treatment of Parkinson's disease and HIV-1 assocd. neurocognitive disorders (HAND), requiring an inhibitor that can achieve significant brain concn. levels.  We report here URMC-099 (1) an orally bioavailable (F = 41%), potent (IC50 = 14 nM) MLK3 inhibitor with excellent brain exposure in mouse PK models and minimal interference with key human CYP450 enzymes or hERG channels.  The compd. inhibits LPS-induced TNFα release in microglial cells, HIV-1 Tat-induced release of cytokines in human monocytes and up-regulation of phospho-JNK in Tat-injected brains of mice.  Compd. 1 likely functions in HAND preclin. models by inhibiting multiple kinase pathways, including MLK3 and LRRK2 (IC50 = 11 nM).  We compare the kinase specificity and BBB penetration of 1 with CEP-1347 (2).  Compd. 1 is well tolerated, with excellent in vivo activity in HAND models, and is under investigation for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosmrog4axXu7Vg90H21EOLACvtfcHk0lgV9LUyeT5B7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVGjtrfK&md5=53cb667f098b4de13a3a96b92cd546bf</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm401094t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401094t%26sid%3Dliteratum%253Aachs%26aulast%3DGoodfellow%26aufirst%3DV.%2BS.%26aulast%3DLoweth%26aufirst%3DC.%2BJ.%26aulast%3DRavula%26aufirst%3DS.%2BB.%26aulast%3DWiemann%26aufirst%3DT.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DTodd%26aufirst%3DD.%2BE.%26aulast%3DSheppard%26aufirst%3DD.%26aulast%3DPollack%26aufirst%3DS.%26aulast%3DPolesskaya%26aufirst%3DO.%26aulast%3DMarker%26aufirst%3DD.%2BF.%26aulast%3DDewhurst%26aufirst%3DS.%26aulast%3DGelbard%26aufirst%3DH.%2BA.%26atitle%3DDiscovery%252C%2520Synthesis%252C%2520and%2520Characterization%2520of%2520an%2520Orally%2520Bioavailable%252C%2520Brain%2520Penetrant%2520Inhibitor%2520of%2520Mixed%2520Lineage%2520Kinase%25203%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8032%26epage%3D8048%26doi%3D10.1021%2Fjm401094t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Billedeau, R. J.</span>; <span class="NLM_string-name">Kondru, R. K.</span>; <span class="NLM_string-name">Lopez-Tapia, F. J.</span>; <span class="NLM_string-name">Lou, Y.</span>; <span class="NLM_string-name">Owens, T. D.</span>; <span class="NLM_string-name">Qian, Y.</span>; <span class="NLM_string-name">So, S.-S.</span>; <span class="NLM_string-name">Thakkar, K. C.</span>; <span class="NLM_string-name">Wanner, J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Bruton’s Tyrosine Kinase</span>. U.S. Patent <span class="NLM_patent">20,120,295,885A1</span>, Nov 22, <span class="NLM_year">2012</span>, CA157:734758.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+J.+Billedeau&author=R.+K.+Kondru&author=F.+J.+Lopez-Tapia&author=Y.+Lou&author=T.+D.+Owens&author=Y.+Qian&author=S.-S.+So&author=K.+C.+Thakkar&author=J.+Wanner&title=Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBilledeau%26aufirst%3DR.%2BJ.%26atitle%3DInhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axford, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kecman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis-Symynkywicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papillon, J. P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dales, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regard, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinkeviciene, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marro, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Indole Pharmacophore for the Irreversible Inhibition of Myeloperoxidase (MPO)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115548</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2020.115548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmc.2020.115548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=32503688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVWis7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115548&author=A.+Patnaikauthor=L.+Axfordauthor=L.+Dengauthor=E.+Cohickauthor=X.+Renauthor=S.+Loiauthor=S.+Kecmanauthor=M.+Hollis-Symynkywiczauthor=T.+J.+Harrisonauthor=J.+P.+N.+Papillonauthor=N.+Dalesauthor=L.+G.+Hamannauthor=L.+Leeauthor=J.+B.+Regardauthor=J.+Marcinkevicieneauthor=M.+L.+Marroauthor=A.+W.+Patterson&title=Discovery+of+a+Novel+Indole+Pharmacophore+for+the+Irreversible+Inhibition+of+Myeloperoxidase+%28MPO%29&doi=10.1016%2Fj.bmc.2020.115548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel indole pharmacophore for the irreversible inhibition of myeloperoxidase (MPO)</span></div><div class="casAuthors">Patnaik, Anup; Axford, Laura; Deng, Lin; Cohick, Evan; Ren, Xianglin; Loi, Sally; Kecman, Sam; Hollis-Symynkywicz, Micah; Harrison, Tyler J.; Papillon, Julien P. N.; Dales, Natalie; Hamann, Lawrence G.; Lee, Lac; Regard, Jean B.; Marcinkeviciene, Jovita; Marro, Martin L.; Patterson, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">115548</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Myeloperoxidase (MPO) activity and subsequent generation of hypochlorous acid has been assocd. with the killing of host-invading microorganisms (e.g. bacteria, viruses, and fungi).  However, during oxidative stress, high MPO activity can damage host tissue and is linked to several chronic inflammatory conditions.  Herein, we describe the development of a novel biaryl, indole-pyrazole series of irreversible mechanism-based inhibitors of MPO.  Derived from an indole-contg. high-throughput screen hit, optimization efforts resulted in potent and selective 6-substituted indoles with good oral bioavailability and in vivo activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo70Gf5KXoebbVg90H21EOLACvtfcHk0lgV9LUyeT5B7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVWis7bJ&md5=f4dd960e658fb912bec1f0d9a1256ecb</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2020.115548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2020.115548%26sid%3Dliteratum%253Aachs%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DAxford%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DCohick%26aufirst%3DE.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DKecman%26aufirst%3DS.%26aulast%3DHollis-Symynkywicz%26aufirst%3DM.%26aulast%3DHarrison%26aufirst%3DT.%2BJ.%26aulast%3DPapillon%26aufirst%3DJ.%2BP.%2BN.%26aulast%3DDales%26aufirst%3DN.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DRegard%26aufirst%3DJ.%2BB.%26aulast%3DMarcinkeviciene%26aufirst%3DJ.%26aulast%3DMarro%26aufirst%3DM.%2BL.%26aulast%3DPatterson%26aufirst%3DA.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Indole%2520Pharmacophore%2520for%2520the%2520Irreversible%2520Inhibition%2520of%2520Myeloperoxidase%2520%2528MPO%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115548%26doi%3D10.1016%2Fj.bmc.2020.115548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span> <span> </span><span class="NLM_article-title">Exploring the Other Side of Biologically Relevant Chemical Space: Insights into Carboxylic, Sulfonic and Phosphonic Acid Bioisosteric Relationships</span>. <i>J. Mol. Graphics Modell.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1016/j.jmgm.2007.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.jmgm.2007.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=17544772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ams7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=728-739&author=A.+Macchiaruloauthor=R.+Pellicciari&title=Exploring+the+Other+Side+of+Biologically+Relevant+Chemical+Space%3A+Insights+into+Carboxylic%2C+Sulfonic+and+Phosphonic+Acid+Bioisosteric+Relationships&doi=10.1016%2Fj.jmgm.2007.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the other side of biologically relevant chemical space: Insights into carboxylic, sulfonic and phosphonic acid bioisosteric relationships</span></div><div class="casAuthors">Macchiarulo, Antonio; Pellicciari, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">728-739</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bioisosteric replacements were widely and successfully applied to develop bioisosteric series of biol. active compds. in medicinal chem.  In this work, the concept of bioisosterism is revisited using a novel approach based on charting the "other side" of biol. relevant chem. space.  This space is composed by the ensemble of binding sites of protein structures.  Explorations into the "other side" of biol. relevant chem. space are exploited to gain insight into the principles that rules mol. recognition and bioisosteric relationships of mol. fragments.  We focused, in particular, on the construction of the "other side" of chem. space covered by binding sites of small mols. contg. carboxylic, sulfonic, and phosphonic acidic groups.  The anal. of differences in the occupation of that space by distinct types of binding sites unveils how evolution has worked in assessing principles that rule the selectivity of mol. recognition, and improves our knowledge on the mol. basis of bioisosteric relationships among carboxylic, sulfonic, and phosphonic acidic groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmUvbx3H_KfrVg90H21EOLACvtfcHk0lj7TS32RDKm7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ams7jE&md5=880e56f011b29d3aeef2ad624369e3e4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.jmgm.2007.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmgm.2007.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DPellicciari%26aufirst%3DR.%26atitle%3DExploring%2520the%2520Other%2520Side%2520of%2520Biologically%2520Relevant%2520Chemical%2520Space%253A%2520Insights%2520into%2520Carboxylic%252C%2520Sulfonic%2520and%2520Phosphonic%2520Acid%2520Bioisosteric%2520Relationships%26jtitle%3DJ.%2520Mol.%2520Graphics%2520Modell.%26date%3D2007%26volume%3D26%26spage%3D728%26epage%3D739%26doi%3D10.1016%2Fj.jmgm.2007.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grosskopf, S.</span></span> <span> </span><span class="NLM_article-title">Entwicklung und Synthese von Protein-Tyrosin-Phosphatase Inhibitoren sowie Synthese und Validierung von SHP-2-Inhibitoren in vitro und in vivo</span>. Ph.D. Thesis, <span class="NLM_publisher-name">Freien Universität</span>, <span class="NLM_publisher-loc">Berlin</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Grosskopf&title=Entwicklung+und+Synthese+von+Protein-Tyrosin-Phosphatase+Inhibitoren+sowie+Synthese+und+Validierung+von+SHP-2-Inhibitoren+in+vitro+und+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrosskopf%26aufirst%3DS.%26atitle%3DEntwicklung%2520und%2520Synthese%2520von%2520Protein-Tyrosin-Phosphatase%2520Inhibitoren%2520sowie%2520Synthese%2520und%2520Validierung%2520von%2520SHP-2-Inhibitoren%2520in%2520vitro%2520und%2520in%2520vivo%26pub%3DFreien%2520Universit%25C3%25A4t%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballatore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huryn, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  3rd</span></span> <span> </span><span class="NLM_article-title">Carboxylic Acid (Bio)Isosteres in Drug Design</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2Fcmdc.201200585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=23361977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=385-395&author=C.+Ballatoreauthor=D.+M.+Hurynauthor=A.+B.+Smith&title=Carboxylic+Acid+%28Bio%29Isosteres+in+Drug+Design&doi=10.1002%2Fcmdc.201200585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxylic Acid (Bio)Isosteres in Drug Design</span></div><div class="casAuthors">Ballatore, Carlo; Huryn, Donna M.; Smith, Amos B.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">385-395</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The carboxylic acid functional group can be an important constituent of a pharmacophore, however, the presence of this moiety can also be responsible for significant drawbacks, including metabolic instability, toxicity, as well as limited passive diffusion across biol. membranes.  To avoid some of these shortcomings while retaining the desired attributes of the carboxylic acid moiety, medicinal chemists often investigate the use of carboxylic acid (bio)isosteres.  The same type of strategy can also be effective for a variety other purposes, for example, to increase the selectivity of a biol. active compd. or to create new intellectual property.  Several carboxylic acid isosteres have been reported, however, the outcome of any isosteric replacement cannot be readily predicted as this strategy is generally found to be dependent upon the particular context (i.e., the characteristic properties of the drug and the drug-target).  As a result, screening of a panel of isosteres is typically required.  In this context, the discovery and development of novel carboxylic acid surrogates that could complement the existing palette of isosteres remains an important area of research.  The goal of this Minireview is to provide an overview of the most commonly employed carboxylic acid (bio)isosteres and to present representative examples demonstrating the use and utility of each isostere in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVEcl3NtfHu7Vg90H21EOLACvtfcHk0lj7TS32RDKm7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCms7g%253D&md5=cff8233af1c386439789a0e4ebcb4331</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200585%26sid%3Dliteratum%253Aachs%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26atitle%3DCarboxylic%2520Acid%2520%2528Bio%2529Isosteres%2520in%2520Drug%2520Design%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D385%26epage%3D395%26doi%3D10.1002%2Fcmdc.201200585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J.-P.</span></span> <span> </span><span class="NLM_article-title">Nitro-Group-Containing Drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2851</span>– <span class="NLM_lpage">2893</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00147</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00147" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2851-2893&author=K.+Nepaliauthor=H.-Y.+Leeauthor=J.-P.+Liou&title=Nitro-Group-Containing+Drugs&doi=10.1021%2Facs.jmedchem.8b00147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Nitro-Group-Containing Drugs</span></div><div class="casAuthors">Nepali, Kunal; Lee, Hsueh-Yun; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2851-2893</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The nitro group is considered to be a versatile and unique functional group in medicinal chem.  Despite a long history of use in therapeutics, the nitro group has toxicity issues and is often categorized as a structural alert or a toxicophore, and evidence related to drugs contg. nitro groups is rather contradictory.  In general, drugs contg. nitro groups have been extensively assocd. with mutagenicity and genotoxicity.  In this context, efforts toward the structure-mutagenicity or structure-genotoxicity relationships have been undertaken.  The current Perspective covers various aspects of agents that contain nitro groups, their bioreductive activation mechanisms, their toxicities, and approaches to combat their toxicity issues.  In addn., recent advances in the field of anticancer, antitubercular and antiparasitic agents contg. nitro groups, along with a patent survey on hypoxia-activated prodrugs contg. nitro groups, are also covered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqif1Bbj-Ci4bVg90H21EOLACvtfcHk0ljy3AkgwAE9ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7jO&md5=33969d1c33e2b451a05b3dbdb8574497</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00147%26sid%3Dliteratum%253Aachs%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DLiou%26aufirst%3DJ.-P.%26atitle%3DNitro-Group-Containing%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2851%26epage%3D2893%26doi%3D10.1021%2Facs.jmedchem.8b00147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donvito, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juola, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarenti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dall’Angelo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, W. T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, I. R.</span></span> <span> </span><span class="NLM_article-title">The Trifluoromethyl Group as a Bioisosteric Replacement of the Aliphatic Nitro Group in CB1 Receptor Positive Allosteric Modulators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5049</span>– <span class="NLM_lpage">5062</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00252</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00252" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVKgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5049-5062&author=C.-C.+Tsengauthor=G.+Baillieauthor=G.+Donvitoauthor=M.+A.+Mustafaauthor=S.+E.+Juolaauthor=C.+Zanatoauthor=C.+Massarentiauthor=S.+Dall%E2%80%99Angeloauthor=W.+T.+A.+Harrisonauthor=A.+H.+Lichtmanauthor=R.+A.+Rossauthor=M.+Zandaauthor=I.+R.+Greig&title=The+Trifluoromethyl+Group+as+a+Bioisosteric+Replacement+of+the+Aliphatic+Nitro+Group+in+CB1+Receptor+Positive+Allosteric+Modulators&doi=10.1021%2Facs.jmedchem.9b00252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The Trifluoromethyl Group as a Bioisosteric Replacement of the Aliphatic Nitro Group in CB1 Receptor Positive Allosteric Modulators</span></div><div class="casAuthors">Tseng, Chih-Chung; Baillie, Gemma; Donvito, Giulia; Mustafa, Mohammed A.; Juola, Sophie E.; Zanato, Chiara; Massarenti, Chiara; Dall'Angelo, Sergio; Harrison, William T. A.; Lichtman, Aron H.; Ross, Ruth A.; Zanda, Matteo; Greig, Iain R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5049-5062</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Nitroalkyl-2-phenylindoles were prepd. as analogs of known CB1 receptor pos. allosteric modulators; related 3-(trifluoroalkyl)-2-phenylindoles such as I were prepd. to test if the trifluoromethyl group could act as a bioisostere of the nitro group.  The trifluoromethyl-bearing compds. were generally more potent than their nitro equiv. and also showed improved in vitro metabolic stability.  The racemate of I has similar activity to the known CB1 receptor pos. allosteric modulator (±)-ZCZ011, with both showing promising efficacy in a mouse model of neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWL_RH0bt0ErVg90H21EOLACvtfcHk0ljy3AkgwAE9ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVKgs74%253D&md5=bac1532f77c45b5a5474e3ec782f48c3</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00252%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DC.-C.%26aulast%3DBaillie%26aufirst%3DG.%26aulast%3DDonvito%26aufirst%3DG.%26aulast%3DMustafa%26aufirst%3DM.%2BA.%26aulast%3DJuola%26aufirst%3DS.%2BE.%26aulast%3DZanato%26aufirst%3DC.%26aulast%3DMassarenti%26aufirst%3DC.%26aulast%3DDall%25E2%2580%2599Angelo%26aufirst%3DS.%26aulast%3DHarrison%26aufirst%3DW.%2BT.%2BA.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26aulast%3DZanda%26aufirst%3DM.%26aulast%3DGreig%26aufirst%3DI.%2BR.%26atitle%3DThe%2520Trifluoromethyl%2520Group%2520as%2520a%2520Bioisosteric%2520Replacement%2520of%2520the%2520Aliphatic%2520Nitro%2520Group%2520in%2520CB1%2520Receptor%2520Positive%2520Allosteric%2520Modulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5049%26epage%3D5062%26doi%3D10.1021%2Facs.jmedchem.9b00252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelmalak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tender, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent Indenoisoquinoline Topoisomerase I Poisons Lacking the 3-Nitro Toxicophore</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3997</span>– <span class="NLM_lpage">4015</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3997-4015&author=D.+E.+Beckauthor=M.+Abdelmalakauthor=W.+Lvauthor=P.+V.+N.+Reddyauthor=G.+S.+Tenderauthor=E.+O%E2%80%99Neillauthor=K.+Agamaauthor=C.+Marchandauthor=Y.+Pommierauthor=M.+Cushman&title=Discovery+of+Potent+Indenoisoquinoline+Topoisomerase+I+Poisons+Lacking+the+3-Nitro+Toxicophore&doi=10.1021%2Facs.jmedchem.5b00303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Indenoisoquinoline Topoisomerase I Poisons Lacking the 3-Nitro Toxicophore</span></div><div class="casAuthors">Beck, Daniel E.; Abdelmalak, Monica; Lv, Wei; Reddy, P. V. Narasimha; Tender, Gabrielle S.; O'Neill, Elizaveta; Agama, Keli; Marchand, Christophe; Pommier, Yves; Cushman, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3997-4015</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Nitroindenoisoquinoline human topoisomerase IB (Top1) poisons have potent antiproliferative effects on cancer cells.  The undesirable nitro toxicophore could hypothetically be replaced by other functional groups that would retain the desired biol. activities and minimize potential safety risks.  Eleven series of indenoisoquinolines bearing 3-nitro bioisosteres were synthesized.  The mols. were evaluated in the Top1-mediated DNA cleavage assay and in the National Cancer Institute's 60 cell line cytotoxicity assay.  The data reveal that fluorine and chlorine may substitute for the 3-nitro group with minimal loss of Top1 poisoning activity.  The new information gained from these efforts can be used to design novel indenoisoquinolines with improved safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdbNHV3jO7rrVg90H21EOLACvtfcHk0ljT5j60rMxpGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGitro%253D&md5=7c7a9dac160593af7809b04d2aa7f88a</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00303%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DD.%2BE.%26aulast%3DAbdelmalak%26aufirst%3DM.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DReddy%26aufirst%3DP.%2BV.%2BN.%26aulast%3DTender%26aufirst%3DG.%2BS.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DE.%26aulast%3DAgama%26aufirst%3DK.%26aulast%3DMarchand%26aufirst%3DC.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DCushman%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520Potent%2520Indenoisoquinoline%2520Topoisomerase%2520I%2520Poisons%2520Lacking%2520the%25203-Nitro%2520Toxicophore%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3997%26epage%3D4015%26doi%3D10.1021%2Facs.jmedchem.5b00303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali Dhar, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzabadi, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, R. S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broten, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ransom, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schorn, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendesky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrell, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gluchowski, C.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel Alpha(1)(A) Adrenoceptor-Selective Antagonists. 1. Structure-Activity Relationship in Dihydropyrimidinones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">4764</span>– <span class="NLM_lpage">4777</span>, <span class="refDoi"> DOI: 10.1021/jm990200p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990200p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK1MXmvVSqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=4764-4777&author=D.+Nagarathnamauthor=S.+W.+Miaoauthor=B.+Laguauthor=G.+Chiuauthor=J.+Fangauthor=T.+G.+Murali+Dharauthor=J.+Zhangauthor=S.+Tyagarajanauthor=M.+R.+Marzabadiauthor=F.+Zhangauthor=W.+C.+Wongauthor=W.+Sunauthor=D.+Tianauthor=J.+M.+Wetzelauthor=C.+Forrayauthor=R.+S.+L.+Changauthor=T.+P.+Brotenauthor=R.+W.+Ransomauthor=T.+W.+Schornauthor=T.+B.+Chenauthor=S.+O%E2%80%99Malleyauthor=P.+Klingauthor=K.+Schneckauthor=R.+Bendeskyauthor=C.+M.+Harrellauthor=K.+P.+Vyasauthor=C.+Gluchowski&title=Design+and+Synthesis+of+Novel+Alpha%281%29%28A%29+Adrenoceptor-Selective+Antagonists.+1.+Structure-Activity+Relationship+in+Dihydropyrimidinones&doi=10.1021%2Fjm990200p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel α1a Adrenoceptor-Selective Antagonists. 1. Structure-Activity Relationship in Dihydropyrimidinones</span></div><div class="casAuthors">Nagarathnam, Dhanapalan; Miao, Shou Wu; Lagu, Bharat; Chiu, George; Fang, James; Dhar, T. G. Murali; Zhang, Jack; Tyagarajan, Sriram; Marzabadi, Mohammad R.; Zhang, Fengqi; Wong, Wai C.; Sun, Wanying; Tian, Dake; Wetzel, John M.; Forray, Carlos; Chang, Raymond S. L.; Broten, Theodore P.; Ransom, Richard W.; Schorn, Terry W.; Chen, Tsing B.; O'Malley, Stacey; Kling, Paul; Schneck, Kathryn; Bendesky, Robert; Harrell, Charles M.; Vyas, Kamlesh P.; Gluchowski, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4764-4777</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dihydropyrimidinones such as compd. I exhibited high binding affinity and subtype selectivity for the cloned human α1a receptor.  Systematic modifications of I led to identification of highly potent and subtype-selective compds. with high binding affinity (Ki = 0.2 nM) for α1a receptor and greater than 1500-fold selectivity over α1b and α1d adrenoceptors.  The compds. were found to be functional antagonists in human, rat, and dog prostate tissues.  One of the compds. [(+)SNAP 6201] exhibited excellent selectively to inhibit intraurethral pressure (IUP) as compared to lowering diastolic blood pressure (DBP) in mongrel dogs (Kb(DBP)/Kb(IUP) = 40) suggesting uroselectivity for α1a-selective compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfso0m6xXmxbVg90H21EOLACvtfcHk0ljT5j60rMxpGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmvVSqtLk%253D&md5=af256a5faa2aa3c16b0c137b06ae49cb</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm990200p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990200p%26sid%3Dliteratum%253Aachs%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DMiao%26aufirst%3DS.%2BW.%26aulast%3DLagu%26aufirst%3DB.%26aulast%3DChiu%26aufirst%3DG.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DMurali%2BDhar%26aufirst%3DT.%2BG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTyagarajan%26aufirst%3DS.%26aulast%3DMarzabadi%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DWong%26aufirst%3DW.%2BC.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DD.%26aulast%3DWetzel%26aufirst%3DJ.%2BM.%26aulast%3DForray%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DR.%2BS.%2BL.%26aulast%3DBroten%26aufirst%3DT.%2BP.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DSchorn%26aufirst%3DT.%2BW.%26aulast%3DChen%26aufirst%3DT.%2BB.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DS.%26aulast%3DKling%26aufirst%3DP.%26aulast%3DSchneck%26aufirst%3DK.%26aulast%3DBendesky%26aufirst%3DR.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DVyas%26aufirst%3DK.%2BP.%26aulast%3DGluchowski%26aufirst%3DC.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%2520Alpha%25281%2529%2528A%2529%2520Adrenoceptor-Selective%2520Antagonists.%25201.%2520Structure-Activity%2520Relationship%2520in%2520Dihydropyrimidinones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D4764%26epage%3D4777%26doi%3D10.1021%2Fjm990200p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Troxler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoeffter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenegger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span> <span> </span><span class="NLM_article-title">Decahydroisoquinoline Derivatives as Novel Non-Peptidic, Potent and Subtype-Selective Somatostatin SST(3) Receptor Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1728</span>– <span class="NLM_lpage">1734</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmcl.2010.01.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=20137944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitleht7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1728-1734&author=T.+Troxlerauthor=K.+Hurthauthor=K.-H.+Schuhauthor=P.+Schoeffterauthor=D.+Langeneggerauthor=A.+Enzauthor=D.+Hoyer&title=Decahydroisoquinoline+Derivatives+as+Novel+Non-Peptidic%2C+Potent+and+Subtype-Selective+Somatostatin+SST%283%29+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2010.01.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Decahydroisoquinoline derivatives as novel non-peptidic, potent and subtype-selective somatostatin sst3 receptor antagonists</span></div><div class="casAuthors">Troxler, Thomas; Hurth, Konstanze; Schuh, Karl-Heinrich; Schoeffter, Philippe; Langenegger, Daniel; Enz, Albert; Hoyer, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1728-1734</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from non-peptidic sst1-selective somatostatin receptor antagonists, first compds. with mixed sst1/sst3 affinity were identified by directed structural modifications.  Systematic optimization of these initial leads afforded novel, enantiomerically pure, highly potent and sst3-subtype selective somatostatin antagonists, e.g. I (R = piperonyl, 6-methoxypyridin-3-yl, 6-quinoxalinyl, etc.), based on a (4S,4aS,8aR)-decahydroisoquinoline-4-carboxylic acid core moiety.  These compds. can efficiently be synthesized and show promising PK properties in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Sg4iyYj_hbVg90H21EOLACvtfcHk0lh8M0hC5DWl5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitleht7w%253D&md5=ac00980a8ca3bd081402d74e24469ebe</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.063%26sid%3Dliteratum%253Aachs%26aulast%3DTroxler%26aufirst%3DT.%26aulast%3DHurth%26aufirst%3DK.%26aulast%3DSchuh%26aufirst%3DK.-H.%26aulast%3DSchoeffter%26aufirst%3DP.%26aulast%3DLangenegger%26aufirst%3DD.%26aulast%3DEnz%26aufirst%3DA.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DDecahydroisoquinoline%2520Derivatives%2520as%2520Novel%2520Non-Peptidic%252C%2520Potent%2520and%2520Subtype-Selective%2520Somatostatin%2520SST%25283%2529%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1728%26epage%3D1734%26doi%3D10.1016%2Fj.bmcl.2010.01.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Troxler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenegger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfäffli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoeffter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurth, K.</span></span> <span> </span><span class="NLM_article-title">Ergoline Derivatives as Highly Potent and Selective Antagonists at the Somatostatin SST 1 Receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">982</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.12.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmcl.2007.12.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=18162395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=979-982&author=T.+Troxlerauthor=A.+Enzauthor=D.+Hoyerauthor=D.+Langeneggerauthor=P.+Neumannauthor=P.+Pf%C3%A4ffliauthor=P.+Schoeffterauthor=K.+Hurth&title=Ergoline+Derivatives+as+Highly+Potent+and+Selective+Antagonists+at+the+Somatostatin+SST+1+Receptor&doi=10.1016%2Fj.bmcl.2007.12.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Ergoline derivatives as highly potent and selective antagonists at the somatostatin sst1 receptor</span></div><div class="casAuthors">Troxler, Thomas; Enz, Albert; Hoyer, Daniel; Langenegger, Daniel; Neumann, Peter; Pfaeffli, Paul; Schoeffter, Philippe; Hurth, Konstanze</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">979-982</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Nonpeptidic compds. contg. the octahydro-indolo[4,3-fg]quinoline (ergoline) structural element have been optimized into derivs. with high affinity (pKd r sst1 > 9) and selectivity (>1000-fold for h sst1 over h sst2-h sst5) for the somatostatin sst1 receptor.  In functional assays, these ergolines act as antagonists at human recombinant sst1 receptors.  Pharmacokinetic studies in rodents reveal good oral bioavailability and brain penetration for some of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHSEfQkuZzprVg90H21EOLACvtfcHk0lh8M0hC5DWl5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWktbg%253D&md5=82f935aae404ae0cc85fe0e986636dc3</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.12.030%26sid%3Dliteratum%253Aachs%26aulast%3DTroxler%26aufirst%3DT.%26aulast%3DEnz%26aufirst%3DA.%26aulast%3DHoyer%26aufirst%3DD.%26aulast%3DLangenegger%26aufirst%3DD.%26aulast%3DNeumann%26aufirst%3DP.%26aulast%3DPf%25C3%25A4ffli%26aufirst%3DP.%26aulast%3DSchoeffter%26aufirst%3DP.%26aulast%3DHurth%26aufirst%3DK.%26atitle%3DErgoline%2520Derivatives%2520as%2520Highly%2520Potent%2520and%2520Selective%2520Antagonists%2520at%2520the%2520Somatostatin%2520SST%25201%2520Receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D979%26epage%3D982%26doi%3D10.1016%2Fj.bmcl.2007.12.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anana, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, E. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Smooth Muscle Calcium Channel Antagonist Effects of Alkyl 1,4-dihydro-2,6-dimethyl-4-(pyridinyl)-5-[2-(4,5-dihydro- 4,4-dimethyloxazolin-2-yl)]-3-pyridinecarboxylates</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1002/ardp.19963290807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2Fardp.19963290807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=8915102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK28XmtlWku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=1996&pages=408-412&author=R.+D.+Ananaauthor=E.+E.+Knaus&title=Synthesis+and+Smooth+Muscle+Calcium+Channel+Antagonist+Effects+of+Alkyl+1%2C4-dihydro-2%2C6-dimethyl-4-%28pyridinyl%29-5-%5B2-%284%2C5-dihydro-+4%2C4-dimethyloxazolin-2-yl%29%5D-3-pyridinecarboxylates&doi=10.1002%2Fardp.19963290807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and smooth muscle calcium channel antagonist effects of alkyl 1,4-dihydro-2,6-dimethyl-4-pyridyl-5-[2-(4,5-dihydro-4,4-dimethyloxazolin-2-yl)]-3-pyridinecarboxylates</span></div><div class="casAuthors">Anana, Raymond D.; Knaus, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">8-9</span>),
    <span class="NLM_cas:pages">408-412</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">VCH</span>)
        </div><div class="casAbstract">The racemic title compds. I (R = 3-, 4-pyridyl; R1 = Me, CH2CHMe2, CHMe2) were prepd. by the Hantzsch reaction involving condensation of the corresponding Knoevenagel adducts RCH:C(CO2R1)COMe with 2-(2-amino-1-propenyl)-4,5-dihydro-4,4-dimethyloxazoline.  Compd. I (R = 2-pyridyl; R1 = CHMe2) was prepd. by SOCl2-mediated cyclization of the (hydroxyethyl)aminocarbonyl moiety of hydropyridine II.  In vitro Ca channel antagonist activity was detd. by the guinea pig ileum longitudinal smooth muscle (GPILSM) assay.  Compared to the ref. drug nifedipine, the title compds. exhibited weak Ca channel antagonist activity (IC50 = 10-5-10-6 M).  A comparison of compds. I having a C(4) 3-pyridinyl substituent showed that with respect to the alkyl ester substituent, the relative potency order was CH2CHMe2 ≥ CHMe2 > Me.  The point of attachment of the C(4) pyridinyl substituent in the iso-Pr ester isomeric series of compds. was a determinant of activity where the potency profile was 4-pyridyl ≥ 3-pyridyl > 2-pyridyl.  Although less effective, the 4,5-dihydro-4,4-dimethyloxazolin-2-yl moiety acts as a bioisostere of the alkyl ester substituent present in classical 1,4-dihydropyridine Ca channel antagonists.  The dihydrodimethyloxaxolinyl ring system is not an effective bioisostere of the 3-NO2 group present in 1,4-dihydropyridine Ca channel antagonists since I (R = 2-pyridyl; R1 = CHMe2) produced a modest 10% increase in the in vitro contractile force of guinea pig left atrium at a concn. of 1.64·10-7 M, relative to the ref. 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-pyridyl)-5-pyridinecarboxylate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMcCnA9262zrVg90H21EOLACvtfcHk0lh8M0hC5DWl5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtlWku7w%253D&md5=817caf3d997869e3e4d228063a6477a2</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fardp.19963290807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.19963290807%26sid%3Dliteratum%253Aachs%26aulast%3DAnana%26aufirst%3DR.%2BD.%26aulast%3DKnaus%26aufirst%3DE.%2BE.%26atitle%3DSynthesis%2520and%2520Smooth%2520Muscle%2520Calcium%2520Channel%2520Antagonist%2520Effects%2520of%2520Alkyl%25201%252C4-dihydro-2%252C6-dimethyl-4-%2528pyridinyl%2529-5-%255B2-%25284%252C5-dihydro-%25204%252C4-dimethyloxazolin-2-yl%2529%255D-3-pyridinecarboxylates%26jtitle%3DArch.%2520Pharm.%26date%3D1996%26volume%3D329%26spage%3D408%26epage%3D412%26doi%3D10.1002%2Fardp.19963290807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mittapalli, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamboni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKelvy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong-Staal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, J. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of ITX 4520: a Highly Potent Orally Bioavailable Hepatitis C Virus Entry Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4955</span>– <span class="NLM_lpage">4961</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.06.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmcl.2012.06.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=22784640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVamtL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4955-4961&author=G.+K.+Mittapalliauthor=F.+Zhaoauthor=A.+Jacksonauthor=H.+Gaoauthor=H.+Leeauthor=S.+Chowauthor=M.+P.+Kaurauthor=N.+Nguyenauthor=R.+Zamboniauthor=J.+McKelvyauthor=F.+Wong-Staalauthor=J.+E.+Macdonald&title=Discovery+of+ITX+4520%3A+a+Highly+Potent+Orally+Bioavailable+Hepatitis+C+Virus+Entry+Inhibitor&doi=10.1016%2Fj.bmcl.2012.06.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ITX 4520: A highly potent orally bioavailable hepatitis C virus entry inhibitor</span></div><div class="casAuthors">Mittapalli, Gopi Kumar; Zhao, Fang; Jackson, Andrew; Gao, Hongfeng; Lee, Haekyung; Chow, Stephine; Kaur, Maninder Pal; Nguyen, Natalie; Zamboni, Robert; McKelvy, Jeffrey; Wong-Staal, Flossie; MacDonald, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4955-4961</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The manuscript reports an identification of a highly potent, orally bioavailable hepatitis C virus entry inhibitor through optimization of a previously reported class of mols. (1) that were not stable in the rat plasma.  Compd. 39 (ITX 4520) exhibited an excellent PK profile in both rats and dogs with good oral exposure, half-life and oral bioavailability.  The compd. is also well-tolerated in the preliminary in vivo toxicity studies and has been selected as a pre-clin. candidate for our HCV clin. pipeline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTV8x6msjRVLVg90H21EOLACvtfcHk0lh8M0hC5DWl5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVamtL3K&md5=ecc2ba7532682fcd7d088a4bd5947c09</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.06.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.06.038%26sid%3Dliteratum%253Aachs%26aulast%3DMittapalli%26aufirst%3DG.%2BK.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DJackson%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DChow%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DM.%2BP.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DMcKelvy%26aufirst%3DJ.%26aulast%3DWong-Staal%26aufirst%3DF.%26aulast%3DMacdonald%26aufirst%3DJ.%2BE.%26atitle%3DDiscovery%2520of%2520ITX%25204520%253A%2520a%2520Highly%2520Potent%2520Orally%2520Bioavailable%2520Hepatitis%2520C%2520Virus%2520Entry%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4955%26epage%3D4961%26doi%3D10.1016%2Fj.bmcl.2012.06.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakanyan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Bechec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecocq, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benaiteau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyulkhandanyan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyulkhandanyan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussakis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleury, F.</span></span> <span> </span><span class="NLM_article-title">Screening and Discovery of Nitro-Benzoxadiazole Compounds Activating Epidermal Growth Factor Receptor (EGFR) in Cancer Cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">3977</span>, <span class="refDoi"> DOI: 10.1038/srep03977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fsrep03977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=24496106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVWrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=3977&author=V.+Sakanyanauthor=M.+Angeliniauthor=M.+Le+Bechecauthor=M.+F.+Lecocqauthor=F.+Benaiteauauthor=B.+Rousseauauthor=A.+Gyulkhandanyanauthor=L.+Gyulkhandanyanauthor=C.+Logeauthor=E.+Reiterauthor=C.+Roussakisauthor=F.+Fleury&title=Screening+and+Discovery+of+Nitro-Benzoxadiazole+Compounds+Activating+Epidermal+Growth+Factor+Receptor+%28EGFR%29+in+Cancer+Cells&doi=10.1038%2Fsrep03977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells</span></div><div class="casAuthors">Sakanyan, Vehary; Angelini, Marie; Le Bechec, Mickael; Lecocq, Michele Francoise; Benaiteau, Florence; Rousseau, Benedicte; Gyulkhandanyan, Aram; Gyulkhandanyan, Lusine; Loge, Cedric; Reiter, Eric; Roussakis, Christos; Fleury, Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3977/1-3977/11</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Peptide ligand-induced dimerization of the extracellular region of the epidermal growth factor receptor (sEGFR) is central to the signal transduction of many cellular processes.  A small mol. microarray screen has been developed to search for non-peptide compds. able to bind to sEGFR.  We describe the discovery of nitro-benzoxadiazole (NBD) compds. that enhance tyrosine phosphorylation of EGFR and thereby trigger downstream signaling pathways and other receptor tyrosine kinases in cancer cells.  The protein phosphorylation profile in cells exposed to NBD compds. is to some extent reminiscent of the profile induced by the cognate ligand.  Exptl. studies indicate that the small compds. bind to the dimerization domain of sEGFR, and generate stable dimers providing allosteric activation of the receptor.  Moreover, receptor phosphorylation is assocd. with inhibition of PTP-1B phosphatase.  Our data offer a promising paradigm for investigating new aspects of signal transduction mediated by EGFR in cancer cells exposed to electrophilic NBD compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbek576nbHo7Vg90H21EOLACvtfcHk0ljpbutMeEdUSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVWrsbg%253D&md5=370d1cec1015cac002389d44fe1c5fd6</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fsrep03977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep03977%26sid%3Dliteratum%253Aachs%26aulast%3DSakanyan%26aufirst%3DV.%26aulast%3DAngelini%26aufirst%3DM.%26aulast%3DLe%2BBechec%26aufirst%3DM.%26aulast%3DLecocq%26aufirst%3DM.%2BF.%26aulast%3DBenaiteau%26aufirst%3DF.%26aulast%3DRousseau%26aufirst%3DB.%26aulast%3DGyulkhandanyan%26aufirst%3DA.%26aulast%3DGyulkhandanyan%26aufirst%3DL.%26aulast%3DLoge%26aufirst%3DC.%26aulast%3DReiter%26aufirst%3DE.%26aulast%3DRoussakis%26aufirst%3DC.%26aulast%3DFleury%26aufirst%3DF.%26atitle%3DScreening%2520and%2520Discovery%2520of%2520Nitro-Benzoxadiazole%2520Compounds%2520Activating%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%2520in%2520Cancer%2520Cells%26jtitle%3DSci.%2520Rep.%26date%3D2014%26volume%3D4%26spage%3D3977%26doi%3D10.1038%2Fsrep03977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patani, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaVoie, E. J.</span></span> <span> </span><span class="NLM_article-title">Bioisosterism: A Rational Approach in Drug Design</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">3147</span>– <span class="NLM_lpage">3176</span>, <span class="refDoi"> DOI: 10.1021/cr950066q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr950066q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK28XntFSitLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1996&pages=3147-3176&author=G.+A.+Pataniauthor=E.+J.+LaVoie&title=Bioisosterism%3A+A+Rational+Approach+in+Drug+Design&doi=10.1021%2Fcr950066q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosterism: A rational approach in drug design</span></div><div class="casAuthors">Patani, George A.; LaVoie, Edmond J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3147-3176</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review, with 191 refs., on bioisosteres that incorporates sufficient detail to enable the reader to understand the concepts being delineated.  Classical bioisosteres, such as monovalent atoms and groups, divalent isosteres, trivalent atoms and groups, tetra substituted atoms, and ring equiv., and non-classical bioisosteres, such as cyclic vs. non-cyclic non-classical bioisosteric replacements and non-classical bioisosteric replacements of functional groups, are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADeNoRGbU9LVg90H21EOLACvtfcHk0ljpbutMeEdUSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntFSitLg%253D&md5=4b3ec55087feabc53e0490ebd5a3ddcd</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fcr950066q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr950066q%26sid%3Dliteratum%253Aachs%26aulast%3DPatani%26aufirst%3DG.%2BA.%26aulast%3DLaVoie%26aufirst%3DE.%2BJ.%26atitle%3DBioisosterism%253A%2520A%2520Rational%2520Approach%2520in%2520Drug%2520Design%26jtitle%3DChem.%2520Rev.%26date%3D1996%26volume%3D96%26spage%3D3147%26epage%3D3176%26doi%3D10.1021%2Fcr950066q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span> <i>OpenEye Toolkits 2019.Oct.2</i>; <span class="NLM_publisher-name">OpenEye
Scientific Software</span>: <span class="NLM_publisher-loc">Santa Fe, NM</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+OpenEye+Toolkits+2019.Oct.2%3B+OpenEye%0AScientific+Software%3A+Santa+Fe%2C+NM%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DOpenEye%2520Toolkits%25202019.Oct.2%26pub%3DOpenEye%250AScientific%2520Software%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGann, M.</span></span> <span> </span><span class="NLM_article-title">FRED and HYBRID Docking Performance on Standardized Datasets</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">906</span>, <span class="refDoi"> DOI: 10.1007/s10822-012-9584-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1007%2Fs10822-012-9584-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=22669221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ens7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=897-906&author=M.+McGann&title=FRED+and+HYBRID+Docking+Performance+on+Standardized+Datasets&doi=10.1007%2Fs10822-012-9584-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">FRED and HYBRID docking performance on standardized datasets</span></div><div class="casAuthors">McGann, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">897-906</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The docking performance of the FRED and HYBRID programs are evaluated on two standardized datasets from the Docking and Scoring Symposium of the ACS Spring 2011 national meeting.  The evaluation includes cognate docking and virtual screening performance.  FRED docks 70 % of the structures to within 2 Å in the cognate docking test.  In the virtual screening test, FRED is found to have a mean AUC of 0.75.  The HYBRID program uses a modified version of FRED's algorithm that uses both ligand- and structure-based information to dock mols., which increases its mean AUC to 0.78.  HYBRID can also implicitly account for protein flexibility by making use of multiple crystal structures.  Using multiple crystal structures improves HYBRID's performance (mean AUC 0.80) with a negligible increase in docking time (∼15 %).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDNF1kmgp-WLVg90H21EOLACvtfcHk0lghe_UXw5V2ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ens7bO&md5=299f2e795ca922412f57df9434b52661</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1007%2Fs10822-012-9584-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-012-9584-8%26sid%3Dliteratum%253Aachs%26aulast%3DMcGann%26aufirst%3DM.%26atitle%3DFRED%2520and%2520HYBRID%2520Docking%2520Performance%2520on%2520Standardized%2520Datasets%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2012%26volume%3D26%26spage%3D897%26epage%3D906%26doi%3D10.1007%2Fs10822-012-9584-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span> <span> </span><span class="NLM_article-title">LigandScout: 3-D Pharmacophores Derived From Protein-Bound Ligands and their use as Virtual Screening Filters</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1021/ci049885e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci049885e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FktVKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=160-169&author=G.+Wolberauthor=T.+Langer&title=LigandScout%3A+3-D+Pharmacophores+Derived+From+Protein-Bound+Ligands+and+their+use+as+Virtual+Screening+Filters&doi=10.1021%2Fci049885e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters</span></div><div class="casAuthors">Wolber Gerhard; Langer Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical information and modeling</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">160-9</span>
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    </div><div class="casAbstract">From the historically grown archive of protein-ligand complexes in the Protein Data Bank small organic ligands are extracted and interpreted in terms of their chemical characteristics and features.  Subsequently, pharmacophores representing ligand-receptor interaction are derived from each of these small molecules and its surrounding amino acids.  Based on a defined set of only six types of chemical features and volume constraints, three-dimensional pharmacophore models are constructed, which are sufficiently selective to identify the described binding mode and are thus a useful tool for in-silico screening of large compound databases.  The algorithms for ligand extraction and interpretation as well as the pharmacophore creation technique from the automatically interpreted data are presented and applied to a rhinovirus capsid complex as application example.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVi_-excgTX2BAiYWy6n3SfW6udTcc2ealurH260oYL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FktVKrtg%253D%253D&md5=31f8ff7a2fa4c9411d54b001b7e1da50</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fci049885e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci049885e%26sid%3Dliteratum%253Aachs%26aulast%3DWolber%26aufirst%3DG.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DLigandScout%253A%25203-D%2520Pharmacophores%2520Derived%2520From%2520Protein-Bound%2520Ligands%2520and%2520their%2520use%2520as%2520Virtual%2520Screening%2520Filters%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2005%26volume%3D45%26spage%3D160%26epage%3D169%26doi%3D10.1021%2Fci049885e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span> <i>Desmond 6.1, Schrödinger
Release 2020-1</i>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York,
NY</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Desmond+6.1%2C+Schr%C3%B6dinger%0ARelease+2020-1%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C%0ANY%2C+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DDesmond%25206.1%252C%2520Schr%25C3%25B6dinger%250ARelease%25202020-1%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulten, K.</span></span> <span> </span><span class="NLM_article-title">VMD: Visual Molecular Dynamics</span>. <i>J. Mol. Graphics</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/0263-7855(96)00018-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2F0263-7855%2896%2900018-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=8744570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK28Xis12nsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1996&pages=33-38&author=W.+Humphreyauthor=A.+Dalkeauthor=K.+Schulten&title=VMD%3A+Visual+Molecular+Dynamics&doi=10.1016%2F0263-7855%2896%2900018-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">VDM: visual molecular dynamics</span></div><div class="casAuthors">Humphrey, William; Dalke, Andrew; Schulten, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-8, plates, 27-28</span>CODEN:
                <span class="NLM_cas:coden">JMGRDV</span>;
        ISSN:<span class="NLM_cas:issn">0263-7855</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">VMD is a mol. graphics program designed for the display and anal. of mol. assemblies, in particular, biopolymers such as proteins and nucleic acids.  VMD can simultaneously display any no. of structures using a wide variety of rendering styles and coloring methods.  Mols. are displayed as one or more "representations," in which each representation embodies a particular rendering method and coloring scheme for a selected subset of atoms.  The atoms displayed in each representation are chosen using an extensive atom selection syntax, which includes Boolean operators and regular expressions.  VMD provides a complete graphical user interface for program control, as well as a text interface using the Tcl embeddable parser to allow for complex scripts with variable substitution, control loops, and function calls.  Full session logging is supported, which produces a VMD command script for later playback.  High-resoln. raster images of displayed mols. may be produced by generating input scripts for use by a no. of photorealistic image-rendering applications.  VMD has also been expressly designed with the ability to animate mol. dynamics (MD) simulation trajectories, imported either from files or from a direct connection to a running MD simulation.  VMD is the visualization component of MDScope, a set of tools for interactive problem solving in structural biol., which also includes the parallel MD program NAMD, and the MDCOMM software used to connect the visualization and simulation programs, VMD is written in C++, using an object-oriented design; the program, including source code and extensive documentation, is freely available via anonymous ftp and through the World Wide Web.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0dd54QvBO97Vg90H21EOLACvtfcHk0lh56oKwsFyNFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xis12nsrg%253D&md5=1e3094ec3151fb85c5ff05f8505c78d5</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2F0263-7855%2896%2900018-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0263-7855%252896%252900018-5%26sid%3Dliteratum%253Aachs%26aulast%3DHumphrey%26aufirst%3DW.%26aulast%3DDalke%26aufirst%3DA.%26aulast%3DSchulten%26aufirst%3DK.%26atitle%3DVMD%253A%2520Visual%2520Molecular%2520Dynamics%26jtitle%3DJ.%2520Mol.%2520Graphics%26date%3D1996%26volume%3D14%26spage%3D33%26epage%3D38%26doi%3D10.1016%2F0263-7855%2896%2900018-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span> <i>PyMol 2.5</i>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PyMol+2.5%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPyMol%25202.5%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-J.</span></span> <span> </span><span class="NLM_article-title">Heterocycles and medicine: a survey of the heterocyclic drugs approved by the U.S. FDA from 2000 to Present</span>. In  <i>Progress in Heterocyclic Chemistry</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, G. W.</span>, <span class="NLM_string-name">Joule, J. A.</span></span>, Ed.; <span class="NLM_publisher-name">Elsevier</span>, <span class="NLM_year">2012</span>; Chapter 1, Vol.  <span class="NLM_volume">24</span>, pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">53</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2FB978-0-08-096807-0.00001-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=1-53&author=Y.-J.+Wuauthor=G.+W.+Gribble&author=J.+A.+Joule&title=Progress+in+Heterocyclic+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FB978-0-08-096807-0.00001-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-08-096807-0.00001-4%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-J.%26atitle%3DHeterocycles%2520and%2520medicine%253A%2520a%2520survey%2520of%2520the%2520heterocyclic%2520drugs%2520approved%2520by%2520the%2520U.S.%2520FDA%2520from%25202000%2520to%2520Present%26btitle%3DProgress%2520in%2520Heterocyclic%2520Chemistry%26aulast%3DGribble%26aufirst%3DG.%2BW.%26pub%3DElsevier%26date%3D2012%26volume%3D24%26spage%3D1%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascon-Simorte, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calmiano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riche, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallemand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyaerts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecomte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuberson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batchelor, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-Azaindoles as Novel Inhibitors of c-Met Kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2780</span>– <span class="NLM_lpage">2784</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmcl.2009.03.110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=19369077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltl2rsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2780-2784&author=J.+Porterauthor=S.+Lumbauthor=R.+J.+Franklinauthor=J.+M.+Gascon-Simorteauthor=M.+Calmianoauthor=K.+L.+Richeauthor=B.+Lallemandauthor=J.+Keyaertsauthor=H.+Edwardsauthor=A.+Maloneyauthor=J.+Delgadoauthor=L.+Kingauthor=A.+Foleyauthor=F.+Lecomteauthor=J.+Reubersonauthor=C.+Meierauthor=M.+Batchelor&title=Discovery+of+4-Azaindoles+as+Novel+Inhibitors+of+c-Met+Kinase&doi=10.1016%2Fj.bmcl.2009.03.110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-azaindoles as novel inhibitors of c-Met kinase</span></div><div class="casAuthors">Porter, John; Lumb, Simon; Franklin, Richard J.; Gascon-Simorte, Jose M.; Calmiano, Mark; Le Riche, Kelly; Lallemand, Benedicte; Keyaerts, Jean; Edwards, Helen; Maloney, Alison; Delgado, Jean; King, Lloyd; Foley, Anne; Lecomte, Fabien; Reuberson, James; Meier, Christoph; Batchelor, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2780-2784</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 4-azaindole inhibitors of c-Met kinase, e.g. I (R1 = H, NH2, CO2H, 1-piperazinyl, etc.; R2 = PhSO2, 2-O2NC6H4SO2, benzofurazan-4-ylsulfonyl, etc.), is described.  The postulated binding mode was confirmed by an X-ray crystal structure of complex of I (R1 = CONH2; R2 = 2-O2NC6H4SO2) with c-Met kinase and series optimization was performed on the basis of this structure.  Future directions for series development are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9V4U2KtkairVg90H21EOLACvtfcHk0lh56oKwsFyNFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltl2rsLY%253D&md5=41dac12c5511c2ca5bb33a72704dfb78</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.110%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DJ.%26aulast%3DLumb%26aufirst%3DS.%26aulast%3DFranklin%26aufirst%3DR.%2BJ.%26aulast%3DGascon-Simorte%26aufirst%3DJ.%2BM.%26aulast%3DCalmiano%26aufirst%3DM.%26aulast%3DRiche%26aufirst%3DK.%2BL.%26aulast%3DLallemand%26aufirst%3DB.%26aulast%3DKeyaerts%26aufirst%3DJ.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DMaloney%26aufirst%3DA.%26aulast%3DDelgado%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DL.%26aulast%3DFoley%26aufirst%3DA.%26aulast%3DLecomte%26aufirst%3DF.%26aulast%3DReuberson%26aufirst%3DJ.%26aulast%3DMeier%26aufirst%3DC.%26aulast%3DBatchelor%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25204-Azaindoles%2520as%2520Novel%2520Inhibitors%2520of%2520c-Met%2520Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2780%26epage%3D2784%26doi%3D10.1016%2Fj.bmcl.2009.03.110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinsdale, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, G. M.</span></span> <span> </span><span class="NLM_article-title">Bcl-2 inhibitors: Small Molecules with a Big Impact on Cancer Therapy</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">360</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1038/cdd.2008.137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fcdd.2008.137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=18806758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1WkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=360-367&author=M.+Voglerauthor=D.+Dinsdaleauthor=M.+J.+S.+Dyerauthor=G.+M.+Cohen&title=Bcl-2+inhibitors%3A+Small+Molecules+with+a+Big+Impact+on+Cancer+Therapy&doi=10.1038%2Fcdd.2008.137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Bcl-2 inhibitors: small molecules with a big impact on cancer therapy</span></div><div class="casAuthors">Vogler, M.; Dinsdale, D.; Dyer, M. J. S.; Cohen, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">360-367</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite tremendous advances over the last 15 years in understanding fundamental mechanisms of apoptosis, this has failed to translate into improved cancer therapy for patients.  However, there may now be light at the end of this long tunnel.  Antiapoptotic Bcl-2 family members may be divided into two subclasses, one comprising Bcl-2, Bcl-XL and Bcl-w and the other Mcl-1 and Bcl2A1.  Neutralization of both subclasses is required for apoptosis induction.  Soln. of the structure of antiapoptotic Bcl-2 family proteins has led to the design of novel small mol. inhibitors.  Although many such mols. have been synthesized, rigorous verification of their specificity has often been lacking.  Further studies have revealed that many putative Bcl-2 inhibitors are not specific and have other cellular targets, resulting in non-mechanism based toxicity.  Two notable exceptions are ABT-737 and a related orally active deriv., ABT-263, which bind with high affinity to Bcl-2, Bcl-XL and Bcl-w and may prove to be useful tools for mechanistic studies.  ABT-263 is in early clin. trials in lymphoid malignancies, small-cell lung cancer and chronic lymphocytic leukemia, and some patients have shown promising results.  In in vitro studies, primary cells from patients with various B-cell malignancies are exquisitely sensitive to ABT-737, exhibiting novel morphol. features of apoptosis including marked outer mitochondrial membrane rupture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNZJtEbkYHoLVg90H21EOLACvtfcHk0liNOPV2bOoLeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1WkurY%253D&md5=6a1cf68bf11ba534258ecd34eb407aa0</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2008.137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2008.137%26sid%3Dliteratum%253Aachs%26aulast%3DVogler%26aufirst%3DM.%26aulast%3DDinsdale%26aufirst%3DD.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%2BS.%26aulast%3DCohen%26aufirst%3DG.%2BM.%26atitle%3DBcl-2%2520inhibitors%253A%2520Small%2520Molecules%2520with%2520a%2520Big%2520Impact%2520on%2520Cancer%2520Therapy%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2009%26volume%3D16%26spage%3D360%26epage%3D367%26doi%3D10.1038%2Fcdd.2008.137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wormald, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrow, J. C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Characterization of Novel Isoform-Selective IP6K1 Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">126628</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmcl.2019.126628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=31445853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Cisr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=126628&author=M.+M.+Wormaldauthor=G.+Ernstauthor=H.+Weiauthor=J.+C.+Barrow&title=Synthesis+and+Characterization+of+Novel+Isoform-Selective+IP6K1+Inhibitors&doi=10.1016%2Fj.bmcl.2019.126628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of novel isoform-selective IP6K1 inhibitors</span></div><div class="casAuthors">Wormald, Michael M.; Ernst, Glen; Wei, Huijun; Barrow, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">126628</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Diaminopurines and diaminopurine analogs such as (methoxyindolylethylamino)purine I were prepd. as selective inositol hexakisphosphate kinases (IP6K) inhibitors.  Selected diaminopurines such as I were selective inhibitors of IP6K1 over IP6K2 and IP6K3; I was a more potent inhibitor of IP6K1 and was more water-sol. than the previously known pan-IP6K inhibitor TNP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgBKLyu2nm07Vg90H21EOLACvtfcHk0liNOPV2bOoLeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Cisr7J&md5=466f9d3b8b4b194a183c1660efcead8d</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126628%26sid%3Dliteratum%253Aachs%26aulast%3DWormald%26aufirst%3DM.%2BM.%26aulast%3DErnst%26aufirst%3DG.%26aulast%3DWei%26aufirst%3DH.%26aulast%3DBarrow%26aufirst%3DJ.%2BC.%26atitle%3DSynthesis%2520and%2520Characterization%2520of%2520Novel%2520Isoform-Selective%2520IP6K1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D126628%26doi%3D10.1016%2Fj.bmcl.2019.126628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matozaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuhara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikyo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takai, Y.</span></span> <span> </span><span class="NLM_article-title">Involvement of an SHP-2-Rho Small G protein Pathway in Hepatocyte Growth Factor/Scatter Factor-Induced Cell Scattering</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2565</span>– <span class="NLM_lpage">2575</span>, <span class="refDoi"> DOI: 10.1091/mbc.11.8.2565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1091%2Fmbc.11.8.2565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10930454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtV2rtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2000&pages=2565-2575&author=A.+Kodamaauthor=T.+Matozakiauthor=A.+Fukuharaauthor=M.+Kikyoauthor=M.+Ichihashiauthor=Y.+Takai&title=Involvement+of+an+SHP-2-Rho+Small+G+protein+Pathway+in+Hepatocyte+Growth+Factor%2FScatter+Factor-Induced+Cell+Scattering&doi=10.1091%2Fmbc.11.8.2565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of an SHP-2-Rho small G protein pathway in hepatocyte growth factor/scatter factor-induced cell scattering</span></div><div class="casAuthors">Kodama, Atsuko; Matozaki, Takashi; Fukuhara, Atsunori; Kikyo, Mitsuhiro; Ichihashi, Masamitsu; Takai, Yoshimi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2565-2575</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">Hepatocyte growth factor/scatter factor (HGF/SF) induces cell scattering through the tyrosine kinase-type HGF/SF receptor c-Met.  We have previously shown that Rho small G protein (Rho) is involved in the HGF/SF-induced scattering of Madin-Darby canine kidney (MDCK) cells by regulating at least the assembly and disassembly of stress fibers and focal adhesions, but it remains unknown how c-Met regulates Rho activity.  We have found here a novel signaling pathway of c-Met consisting of SHP-2-Rho that regulates the assembly and disassembly of stress fibers and focal adhesions in MDCK cells.  SHP-2 is a protein-tyrosine phosphatase that contains src homol.-2 domains.  Expression of a dominant neg. mutant of SHP-2 (SHP-2-C/S) markedly increased the formation of stress fibers and focal adhesions in MDCK cells and inhibited their scattering.  C3, a Clostridium botulinum ADP-ribosyltransferase, and Y-27632, a specific inhibitor for ROCK, reversed the stimulatory effect of SHP-2-C/S on stress fiber formation and the inhibitory effect on cell scattering.  Vav2 is a GDP/GTP exchange protein for Rho.  Expression of a dominant neg. mutant of Vav2 blocked the stimulatory effect of SHP-2-C/S on stress fiber formation.  Conversely, expression of mutants of Vav2 that increased stress fiber formation inhibited HGF/SF-induced cell scattering.  These results indicate that SHP-2 physiol. modulates the activity of Rho to form stress fibers and focal adhesions and thereby regulates HGF/SF-induced cell scattering.  In addn., Vav2 may be involved in the SHP-2-Rho pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKBu3BASJ3X7Vg90H21EOLACvtfcHk0liNOPV2bOoLeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtV2rtLg%253D&md5=61791e1cd1ad0d248f8280a30b6681af</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1091%2Fmbc.11.8.2565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.11.8.2565%26sid%3Dliteratum%253Aachs%26aulast%3DKodama%26aufirst%3DA.%26aulast%3DMatozaki%26aufirst%3DT.%26aulast%3DFukuhara%26aufirst%3DA.%26aulast%3DKikyo%26aufirst%3DM.%26aulast%3DIchihashi%26aufirst%3DM.%26aulast%3DTakai%26aufirst%3DY.%26atitle%3DInvolvement%2520of%2520an%2520SHP-2-Rho%2520Small%2520G%2520protein%2520Pathway%2520in%2520Hepatocyte%2520Growth%2520Factor%252FScatter%2520Factor-Induced%2520Cell%2520Scattering%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2000%26volume%3D11%26spage%3D2565%26epage%3D2575%26doi%3D10.1091%2Fmbc.11.8.2565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutterbach, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, B.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kariv, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczak, A. A.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Analysis of HGF-Stimulated Cell Scattering</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">854</span>, <span class="refDoi"> DOI: 10.1177/1087057108324497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1177%2F1087057108324497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=18812567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVymsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=847-854&author=G.+K.+Y.+Chanauthor=B.+A.+Lutterbachauthor=B.-S.+Panauthor=I.+Karivauthor=A.+A.+Szewczak&title=High-Throughput+Analysis+of+HGF-Stimulated+Cell+Scattering&doi=10.1177%2F1087057108324497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput analysis of HGF-stimulated cell scattering</span></div><div class="casAuthors">Chan, Grace K. Y.; Lutterbach, Bart A.; Pan, Bo-Sheng; Kariv, Ilona; Szewczak, Alexander A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">847-854</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Historically, only relatively low-throughput or expensive methods have been available to measure cell migration.  Hepatocyte growth factor (HGF) is a ligand for the tyrosine kinase receptor Met that, in addn. to mediating proliferation and survival, increases cell motility and metastasis.  The authors have developed a high-throughput imaging assay for measuring inhibition of HGF-induced scattering in human HPAF-II pancreatic adenocarcinoma cells.  Following treatment with test compds. and HGF for 24 h, cells are labeled with a nuclear stain and imaged at 10× magnification.  The proximity of neighboring nuclei is measured, and the distribution of internuclear distances across each field of view is used to calc. the fraction of scattered cells.  This method of anal. can be extended to other cell types and signaling pathways and, compared with other membrane-based migration assays currently available, the assay is significantly lower in cost, is less labor intensive, and provides higher throughput.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-BmkkD9T_8rVg90H21EOLACvtfcHk0lgfydfwSSbhcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVymsbY%253D&md5=27acc479efd66eab2de2be792a139d3e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1177%2F1087057108324497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057108324497%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%2BK.%2BY.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DKariv%26aufirst%3DI.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26atitle%3DHigh-Throughput%2520Analysis%2520of%2520HGF-Stimulated%2520Cell%2520Scattering%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2008%26volume%3D13%26spage%3D847%26epage%3D854%26doi%3D10.1177%2F1087057108324497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldino, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S. J.</span></span> <span> </span><span class="NLM_article-title">Selective Oxidation of Phosphorus Ylides by Dimethyldioxirane. Application to the Formation of Vicinal Tricarbonyls</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8231</span>– <span class="NLM_lpage">8235</span>, <span class="refDoi"> DOI: 10.1021/jo00130a023</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00130a023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK2MXpsVOmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1995&pages=8231-8235&author=H.+H.+Wassermanauthor=C.+M.+Baldinoauthor=S.+J.+Coats&title=Selective+Oxidation+of+Phosphorus+Ylides+by+Dimethyldioxirane.+Application+to+the+Formation+of+Vicinal+Tricarbonyls&doi=10.1021%2Fjo00130a023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Oxidation of Phosphorus Ylides by Dimethyldioxirane. Application to the Formation of Vicinal Tricarbonyls</span></div><div class="casAuthors">Wasserman, Harry H.; Baldino, Carmen M.; Coats, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">8231-5</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dimethyldioxirane (DMD) proved to be an effective reagent for the selective conversion of phosphoranylidene intermediates, e.g., I (X = PPh3) to the corresponding vicinal tricarbonyls, e.g., I (X = O).  Unlike existing oxidn. protocols which employ relatively vigorous conditions, this transformation is conducted rapidly at low temp. under neutral conditions, without the necessity of an aq. workup.  Selective oxidn. of the P ylides in the presence of a variety of sensitive functionality was achieved by lowering the reaction temp. and controlling the concn. of oxidant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVSfIV94T4vbVg90H21EOLACvtfcHk0lgfydfwSSbhcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpsVOmurY%253D&md5=47f05b7a369fab8ebe9df663be37c54f</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fjo00130a023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00130a023%26sid%3Dliteratum%253Aachs%26aulast%3DWasserman%26aufirst%3DH.%2BH.%26aulast%3DBaldino%26aufirst%3DC.%2BM.%26aulast%3DCoats%26aufirst%3DS.%2BJ.%26atitle%3DSelective%2520Oxidation%2520of%2520Phosphorus%2520Ylides%2520by%2520Dimethyldioxirane.%2520Application%2520to%2520the%2520Formation%2520of%2520Vicinal%2520Tricarbonyls%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1995%26volume%3D60%26spage%3D8231%26epage%3D8235%26doi%3D10.1021%2Fjo00130a023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Previously reported SHP2 inhibitors and their IC<sub>50</sub> values. Compounds <b>1–4</b> represent active-site inhibitors and <b>5–6</b> are allosteric binders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Azaindoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions (a) NIS, acetone, rt; 2–4 h, 92% (b) Cu(OAc)<sub>2</sub>, DIPEA, rt, 48 h; 18–21% (c) NaHCO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 3:1 ACN/water, 100 °C, 12 h, 42–69% for the first coupling, 2–98% for the second coupling (d) K<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, dioxane/water, 80 °C, 3–6 h, 22–71% for the first coupling, 2.5–38% for the second coupling.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding mode of cocrystalized ligand (II-B08) of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X">3O5X</a><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> (A) and of compounds <b>41</b> (B) and <b>45</b> (C) observed in docking studies targeting the catalytic domain of SHP2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X">3O5X</a><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>). Yellow sphere—hydrophobic interaction, red arrow—hydrogen bond acceptor, red asterisk—negative ionizable, blue ring—aromatic interaction. Figure produced using LigandScout 4.4.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Results from a 20 ns MD simulation of SHP2 in complex with the most active compound <b>45</b>. (A) Depiction of 10 snapshots taken every 2 ns. (B) rmsd plot for ligand and protein atoms. Figures produced using PyMOL 1.8.6<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> and Microsoft Excel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Azaindoles inhibit HGF-induced cell separation in scatter and impedance assays in HPAF-II pancreatic cancer cells. (A) The HPAF-II cell colonies were dissociated because of stimulation with HGF in the control cells (−HGF/+HGF). Treatment with compound <b>45</b> causes inhibition of cell scattering. (B) Quantification of changes in cell scattering was done by analysis of minimum neighbor distances. The mean ± SD values are shown, representing the relative activity compared to control conditions (+HGF/1, −HGF/0). (C) HPAF-II and HepG2 cells were exposed with different concentrations of compounds for 72 h. Cytotoxicity was determined by fluorescence microscopy using TO-PRO-3 staining for dead cell quantification. Mean values ± SD of damaged cells are indicated. (D) Impedance assay displays the changes in cell attachment and spreading because of HGF stimulation during the first 4 h, where the maximum cell index value was reached for the positive control (+HGF). The normalized cell index curves show a clear dose-dependent inhibition by the compound <b>45</b>. (E) Impedance assay dose–response curve. The graph shows the result of the end-point analysis after 4 h HGF exposure and treatment with compound <b>45</b>, demonstrating the inhibitory effect. The relative activity of normalized cell index values compared to control conditions (+HGF/1, −HGF/0) are displayed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/medium/jm0c01265_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Synergistic combination of <b>45</b> with BYL719 and PLX4032 in VACO432 and HCC1806 cell lines. (A) <i>In vitro</i> coinhibition by PLX4032 (vemurafenib) and SHP2 (<b>45</b>) in colony formation experiments with the VACO432 human colorectal cancer cell line. (B) <i>In vitro</i> coinhibition by BYL719 (alpelisib) and SHP2 (<b>45</b>) in colony formation experiments with the HCC1806 human breast cancer cell line. Three independently repeated experiments were performed with similar results. (C) Blocking of ERK phosphorylation by PLX4032 and <b>45</b> cotreatment. Inhibition of ERK feedback reactivation is sustained after 48 h compared to PLX4032 monotreatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01265/20201203/images/large/jm0c01265_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01265&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i117">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00803" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00803" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 82 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaitzidis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">The Tyrosine Phosphatase Shp2 (PTPN11) in Cancer</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1007/s10555-008-9126-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1007%2Fs10555-008-9126-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=18286234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=179-192&author=G.+Chanauthor=D.+Kalaitzidisauthor=B.+G.+Neel&title=The+Tyrosine+Phosphatase+Shp2+%28PTPN11%29+in+Cancer&doi=10.1007%2Fs10555-008-9126-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase Shp2 (PTPN11) in cancer</span></div><div class="casAuthors">Chan, Gordon; Kalaitzidis, Demetrios; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-192</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Diverse cellular processes are regulated by tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs).  De-regulated tyrosyl phosphorylation, evoked by gain-of-function mutations and/or over-expression of PTKs, contributes to the pathogenesis of many cancers and other human diseases.  PTPs, because they oppose the action of PTKs, had been considered to be prime suspects for potential tumor suppressor genes.  Surprisingly, few, if any, tumor suppressor PTPs have been identified.  However, the Src homol.-2 domain-contg. phosphatase Shp2 (encoded by PTPN11) is a bona fide proto-oncogene.  Germline mutations in PTPN11 cause Noonan and LEOPARD syndromes, whereas somatic PTPN11 mutations occur in several types of hematol. malignancies, most notably juvenile myelomonocytic leukemia and, more rarely, in solid tumors.  Shp2 also is an essential component in several other oncogene signaling pathways.  Elucidation of the events underlying Shp2-evoked transformation may provide new insights into oncogenic mechanisms and novel targets for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbJ8OYsBzvg7Vg90H21EOLACvtfcHk0lh-scZUZexNQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D&md5=fb514f60b97f8ff0dcc0dbd57cab2c9a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs10555-008-9126-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-008-9126-y%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%26aulast%3DKalaitzidis%26aufirst%3DD.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DThe%2520Tyrosine%2520Phosphatase%2520Shp2%2520%2528PTPN11%2529%2520in%2520Cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2008%26volume%3D27%26spage%3D179%26epage%3D192%26doi%3D10.1007%2Fs10555-008-9126-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosário, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span> <span> </span><span class="NLM_article-title">The Tyrosine Phosphatase Shp2 In Development And Cancer</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/s0065-230x(10)06002-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2FS0065-230X%2810%2906002-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=20399956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovVGjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2010&pages=53-89&author=K.+S.+Grossmannauthor=M.+Ros%C3%A1rioauthor=C.+Birchmeierauthor=W.+Birchmeier&title=The+Tyrosine+Phosphatase+Shp2+In+Development+And+Cancer&doi=10.1016%2Fs0065-230x%2810%2906002-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase Shp2 in development and cancer</span></div><div class="casAuthors">Grossmann, Katja S.; Rosario, Marta; Birchmeier, Carmen; Birchmeier, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-89</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Deregulation of signaling pathways, through mutation or other mol. changes, can ultimately result in disease.  The tyrosine phosphatase Shp2 has emerged as a major regulator of receptor tyrosine kinase (RTK) and cytokine receptor signaling.  In the last decade, germline mutations in the human PTPN11 gene, encoding Shp2, were linked to Noonan (NS) and LEOPARD syndromes, two multisymptomatic developmental disorders that are characterized by short stature, craniofacial defects, cardiac defects, and mental retardation.  Somatic Shp2 mutations are also assocd. with several types of human malignancies, such as the most common juvenile leukemia, juvenile myelomonocytic leukemia (JMML).  Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be assocd. with LEOPARD syndrome.  Animal models that carry conditional LOF and GOF mutations have allowed a better understanding of the mechanism of Shp2 function in disease, and shed light on the role of Shp2 in signaling pathways that control decisive events during embryonic development or during cellular transformation/tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgraxAD7u8HbVg90H21EOLACvtfcHk0lh-scZUZexNQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovVGjtr4%253D&md5=45bc842913f2ac8e0fec7c6e1ed8576a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0065-230X%2810%2906002-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-230X%252810%252906002-1%26sid%3Dliteratum%253Aachs%26aulast%3DGrossmann%26aufirst%3DK.%2BS.%26aulast%3DRos%25C3%25A1rio%26aufirst%3DM.%26aulast%3DBirchmeier%26aufirst%3DC.%26aulast%3DBirchmeier%26aufirst%3DW.%26atitle%3DThe%2520Tyrosine%2520Phosphatase%2520Shp2%2520In%2520Development%2520And%2520Cancer%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2010%26volume%3D106%26spage%3D53%26epage%3D89%26doi%3D10.1016%2Fs0065-230x%2810%2906002-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11368</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00249</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00249" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVaqsrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11368&author=X.+Yuanauthor=H.+Buauthor=J.+Zhouauthor=C.-Y.+Yangauthor=H.+Zhang&title=Recent+Advances+of+SHP2+Inhibitors+in+Cancer+Therapy%3A+Current+Development+and+Clinical+Application&doi=10.1021%2Facs.jmedchem.0c00249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application</span></div><div class="casAuthors">Yuan, Xinrui; Bu, Hong; Zhou, Jinpei; Yang, Chao-Yie; Zhang, Huibin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11368-11396</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  SHP2 (Src homol.-2 domain-contg. protein tyrosine phosphatase-2) is a non-receptor protein tyrosine phosphatase that removes tyrosine phosphorylation.  Functionally, SHP2 serves as an important hub to connect several intracellular oncogenic signaling pathways, such as Jak/STAT, PI3K/AKT, RAS/Raf/MAPK, and PD-1/PD-L1 pathways.  Mutations and/or overexpression of SHP2 has been assocd. with genetic developmental diseases and cancers.  Because of the role of SHP2 plays in many diseases, the development of inhibitors targeting the catalytic site in SHP2 has been pursued for more than a decade, but none has advanced to clin. development.  Recent discovery of allosteric inhibitors has inspired a novel approach to selectively target SHP2 via the noncatalytic site.  To date, four SHP2 allosteric inhibitors have entered clin. trials for the treatment of solid tumors.  This review will provide a summary of the physiol. and biol. functions of SHP2 and discuss the development of nonallosteric/allosteric SHP2 inhibitors in recent years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBJjQ8BLJRdLVg90H21EOLACvtfcHk0liaokeb8V10MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVaqsrbK&md5=d7c4a8a93ab73aa4f0e9df0577c38444</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00249%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DBu%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DRecent%2520Advances%2520of%2520SHP2%2520Inhibitors%2520in%2520Cancer%2520Therapy%253A%2520Current%2520Development%2520and%2520Clinical%2520Application%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11368%26doi%3D10.1021%2Facs.jmedchem.0c00249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaeper, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehring, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempkes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span> <span> </span><span class="NLM_article-title">Coupling of Gab1 to c-Met, Grb2, and Shp2 Mediates Biological Responses</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">1419</span>– <span class="NLM_lpage">1432</span>, <span class="refDoi"> DOI: 10.1083/jcb.149.7.1419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1083%2Fjcb.149.7.1419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10871282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVKnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2000&pages=1419-1432&author=U.+Schaeperauthor=N.+H.+Gehringauthor=K.+P.+Fuchsauthor=M.+Sachsauthor=B.+Kempkesauthor=W.+Birchmeier&title=Coupling+of+Gab1+to+c-Met%2C+Grb2%2C+and+Shp2+Mediates+Biological+Responses&doi=10.1083%2Fjcb.149.7.1419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses</span></div><div class="casAuthors">Schaeper, Ute; Gehring, Niels H.; Fuchs, Klaus P.; Sachs, Martin; Kempkes, Bettina; Birchmeier, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1419-1432</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Gab1 is a substrate of the receptor tyrosine kinase c-Met and involved in c-Met-specific branching morphogenesis.  It assocs. directly with c-Met via the c-Met-binding domain, which is not related to known phosphotyrosine-binding domains.  In addn., Gab1 is engaged in a constitutive complex with the adaptor protein Grb2.  We have now mapped the c-Met and Grb2 interaction sites using reverse yeast two-hybrid technol.  The c-Met-binding site is localized to a 13-amino acid region unique to Gab1.  Insertion of this site into the Gab1-related protein p97/Gab2 was sufficient to confer c-Met-binding activity.  Assocn. with Grb2 was mapped to two sites: a classical SH3-binding site (PXXP) and a novel Grb2 SH3 consensus-binding motif (PX(V/I)(D/N)RXXKP).  To detect phosphorylation-dependent interactions of Gab1 with downstream substrates, we developed a modified yeast two-hybrid assay and identified PI(3)K, Shc, Shp2, and CRKL as interaction partners of Gab1.  In a trk-met-Gab1-specific branching morphogenesis assay, assocn. of Gab1 with Shp2, but not PI(3)K, CRKL, or Shc was essential to induce a biol. response in MDCK cells.  Overexpression of a Gab1 mutant deficient in Shp2 interaction could also block HGF/SF-induced activation of the MAPK pathway, suggesting that Shp2 is crit. for c-Met/Gab1-specific signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprKVabpaeh0bVg90H21EOLACvtfcHk0liaokeb8V10MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVKnsr0%253D&md5=34fc6f8db814c2e60eaebf2af07dec26</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1083%2Fjcb.149.7.1419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.149.7.1419%26sid%3Dliteratum%253Aachs%26aulast%3DSchaeper%26aufirst%3DU.%26aulast%3DGehring%26aufirst%3DN.%2BH.%26aulast%3DFuchs%26aufirst%3DK.%2BP.%26aulast%3DSachs%26aufirst%3DM.%26aulast%3DKempkes%26aufirst%3DB.%26aulast%3DBirchmeier%26aufirst%3DW.%26atitle%3DCoupling%2520of%2520Gab1%2520to%2520c-Met%252C%2520Grb2%252C%2520and%2520Shp2%2520Mediates%2520Biological%2520Responses%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2000%26volume%3D149%26spage%3D1419%26epage%3D1432%26doi%3D10.1083%2Fjcb.149.7.1419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">The Role of Shp2 (PTPN11) in Cancer</span>. <i>Curr. Opin. Genet. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.gde.2006.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.gde.2006.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=17227708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslOgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=23-30&author=M.+G.+Mohiauthor=B.+G.+Neel&title=The+Role+of+Shp2+%28PTPN11%29+in+Cancer&doi=10.1016%2Fj.gde.2006.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Shp2 (PTPN11) in cancer</span></div><div class="casAuthors">Mohi, M. Golam; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-30</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs), regulates numerous cellular processes.  Altered expression and/or mutations in PTKs are linked to many forms of cancer, yet until recently little was known about the roles of PTPs in normal cells or in cancer.  Earlier work established that a member of the PTP superfamily, PTEN, is an important tumor suppressor gene.  We now know that at least one other PTP, the SH2 domain-contg. phosphatase Shp2, is a bona fide oncogene that is mutated in several types of leukemia and hyperactivated by other mechanisms in some solid tumors.  Understanding how Shp2 and other PTPs contribute to oncogenesis should provide new insights into pathogenesis and might suggest new targets for anti-neoplastic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ0V_cNPfFwLVg90H21EOLACvtfcHk0liaokeb8V10MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslOgtQ%253D%253D&md5=a571192d3fffdff69ddfc264bb9108ce</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2006.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2006.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DMohi%26aufirst%3DM.%2BG.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DThe%2520Role%2520of%2520Shp2%2520%2528PTPN11%2529%2520in%2520Cancer%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2007%26volume%3D17%26spage%3D23%26epage%3D30%26doi%3D10.1016%2Fj.gde.2006.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jopling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Geemen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Hertog, J.</span></span> <span> </span><span class="NLM_article-title">Shp2 Knockdown and Noonan/LEOPARD Mutant Shp2-Induced Gastrulation Defects</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e225</span> <span class="refDoi"> DOI: 10.1371/journal.pgen.0030225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1371%2Fjournal.pgen.0030225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=18159945" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&author=C.+Joplingauthor=D.+van+Geemenauthor=J.+den+Hertog&title=Shp2+Knockdown+and+Noonan%2FLEOPARD+Mutant+Shp2-Induced+Gastrulation+Defects&doi=10.1371%2Fjournal.pgen.0030225"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.0030225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.0030225%26sid%3Dliteratum%253Aachs%26aulast%3DJopling%26aufirst%3DC.%26aulast%3Dvan%2BGeemen%26aufirst%3DD.%26aulast%3Dden%2BHertog%26aufirst%3DJ.%26atitle%3DShp2%2520Knockdown%2520and%2520Noonan%252FLEOPARD%2520Mutant%2520Shp2-Induced%2520Gastrulation%2520Defects%26jtitle%3DPLoS%2520Genet.%26date%3D2007%26volume%3D3%26doi%3D10.1371%2Fjournal.pgen.0030225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G. J. J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vecchione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1985</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2015.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.celrep.2015.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=26365186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1978-1985&author=A.+Prahalladauthor=G.+J.+J.+E.+Heynenauthor=G.+Germanoauthor=S.+M.+Willemsauthor=B.+Eversauthor=L.+Vecchioneauthor=V.+Gambinoauthor=C.+Lieftinkauthor=R.+L.+Beijersbergenauthor=F.+Di+Nicolantonioauthor=A.+Bardelliauthor=R.+Bernards&title=PTPN11+Is+a+Central+Node+in+Intrinsic+and+Acquired+Resistance+to+Targeted+Cancer+Drugs&doi=10.1016%2Fj.celrep.2015.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs</span></div><div class="casAuthors">Prahallad, Anirudh; Heynen, Guus J. J. E.; Germano, Giovanni; Willems, Stefan M.; Evers, Bastiaan; Vecchione, Loredana; Gambino, Valentina; Lieftink, Cor; Beijersbergen, Roderick L.; Di Nicolantonio, Federica; Bardelli, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1978-1985</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon cancers are intrinsically resistant to these drugs because of feedback activation of EGFR.  We performed an RNA-interference-based genetic screen in BRAF mutant colon cancer cells to search for phosphatases whose knockdown induces sensitivity to BRAF inhibition.  We found that suppression of protein tyrosine phosphatase non-receptor type 11 (PTPN11) confers sensitivity to BRAF inhibitors in colon cancer.  Mechanistically, we found that inhibition of PTPN11 blocks signaling from receptor tyrosine kinases (RTKs) to the RAS-MEK-ERK pathway.  PTPN11 suppression is lethal to cells that are driven by activated RTKs and prevents acquired resistance to targeted cancer drugs that results from RTK activation.  Our findings identify PTPN11 as a drug target to combat both intrinsic and acquired resistance to several targeted cancer drugs.  Moreover, activated PTPN11 can serve as a biomarker of drug resistance resulting from RTK activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr2cE8g_Ejr7Vg90H21EOLACvtfcHk0ljtLftoa6nzbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7fN&md5=521d9847bba4c7c6529ad355da097787</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DHeynen%26aufirst%3DG.%2BJ.%2BJ.%2BE.%26aulast%3DGermano%26aufirst%3DG.%26aulast%3DWillems%26aufirst%3DS.%2BM.%26aulast%3DEvers%26aufirst%3DB.%26aulast%3DVecchione%26aufirst%3DL.%26aulast%3DGambino%26aufirst%3DV.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DPTPN11%2520Is%2520a%2520Central%2520Node%2520in%2520Intrinsic%2520and%2520Acquired%2520Resistance%2520to%2520Targeted%2520Cancer%2520Drugs%26jtitle%3DCell%2520Rep.%26date%3D2015%26volume%3D12%26spage%3D1978%26epage%3D1985%26doi%3D10.1016%2Fj.celrep.2015.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mainardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulero-Sánchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krimpenfort, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves-Ribeiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">SHP2 is Required for Growth of KRAS-Mutant Non-Small-Cell Lung Cancer In Vivo</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0023-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fs41591-018-0023-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=29808006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=961-967&author=S.+Mainardiauthor=A.+Mulero-S%C3%A1nchezauthor=A.+Prahalladauthor=G.+Germanoauthor=A.+Bosmaauthor=P.+Krimpenfortauthor=C.+Lieftinkauthor=J.+D.+Steinbergauthor=N.+de+Witauthor=S.+Gon%C3%A7alves-Ribeiroauthor=E.+Nadalauthor=A.+Bardelliauthor=A.+Villanuevaauthor=R.+Bernards&title=SHP2+is+Required+for+Growth+of+KRAS-Mutant+Non-Small-Cell+Lung+Cancer+In+Vivo&doi=10.1038%2Fs41591-018-0023-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo</span></div><div class="casAuthors">Mainardi, Sara; Mulero-Sanchez, Antonio; Prahallad, Anirudh; Germano, Giovanni; Bosma, Astrid; Krimpenfort, Paul; Lieftink, Cor; Steinberg, Jeffrey D.; de Wit, Niels; Goncalves-Ribeiro, Samuel; Nadal, Ernest; Bardelli, Alberto; Villanueva, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">961-967</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">RAS mutations are frequent in human cancer, esp. in pancreatic, colorectal and non-small-cell lung cancers (NSCLCs).  Inhibition of the RAS oncoproteins has proven difficult, and attempts to target downstream effectors have been hampered by the activation of compensatory resistance mechanisms.  It is also well established that KRAS-mutant tumors are insensitive to inhibition of upstream growth factor receptor signaling.  Thus, epidermal growth factor receptor antibody therapy is only effective in KRAS wild-type colon cancers.  Consistently, inhibition of SHP2 (also known as PTPN11), which links receptor tyrosine kinase signaling to the RAS-RAF-MEK-ERK pathway11,12, was shown to be ineffective in KRAS-mutant or BRAF-mutant cancer cell lines.  Tha data also indicate that SHP2 inhibition in KRAS-mutant NSCLC cells under normal cell culture conditions has little effect.  By contrast, SHP2 inhibition under growth factor-limiting conditions in vitro results in a senescence response.  In vivo, inhibition of SHP2 in KRAS-mutant NSCLC also provokes a senescence response, which is exacerbated by MEK inhibition.  Tha data identify SHP2 inhibition as an unexpected vulnerability of KRAS-mutant NSCLC cells that remains undetected in cell culture and can be exploited therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLHUMCtBqtZrVg90H21EOLACvtfcHk0lh8w8eh-oTqrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvL&md5=8e1ce1eb5d30d3985aafdec9d07f205d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0023-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0023-9%26sid%3Dliteratum%253Aachs%26aulast%3DMainardi%26aufirst%3DS.%26aulast%3DMulero-S%25C3%25A1nchez%26aufirst%3DA.%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DGermano%26aufirst%3DG.%26aulast%3DBosma%26aufirst%3DA.%26aulast%3DKrimpenfort%26aufirst%3DP.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DSteinberg%26aufirst%3DJ.%2BD.%26aulast%3Dde%2BWit%26aufirst%3DN.%26aulast%3DGon%25C3%25A7alves-Ribeiro%26aufirst%3DS.%26aulast%3DNadal%26aufirst%3DE.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DSHP2%2520is%2520Required%2520for%2520Growth%2520of%2520KRAS-Mutant%2520Non-Small-Cell%2520Lung%2520Cancer%2520In%2520Vivo%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D961%26epage%3D967%26doi%3D10.1038%2Fs41591-018-0023-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruess, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciecielski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berninger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabacaoglu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Görgülü, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wörmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diakopoulos, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpathaki, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya-Aksoy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Laan, E. A. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Alberca, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazaré, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erkan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopt, U. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainz, B.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algül, H.</span></span> <span> </span><span class="NLM_article-title">Mutant KRAS-driven Cancers Depend on PTPN11/SHP2 Phosphatase</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0024-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fs41591-018-0024-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=29808009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=954-960&author=D.+A.+Ruessauthor=G.+J.+Heynenauthor=K.+J.+Ciecielskiauthor=J.+Aiauthor=A.+Berningerauthor=D.+Kabacaogluauthor=K.+G%C3%B6rg%C3%BCl%C3%BCauthor=Z.+Dantesauthor=S.+M.+W%C3%B6rmannauthor=K.+N.+Diakopoulosauthor=A.+F.+Karpathakiauthor=M.+Kowalskaauthor=E.+Kaya-Aksoyauthor=L.+Songauthor=E.+A.+Z.+van+der+Laanauthor=M.+P.+L%C3%B3pez-Albercaauthor=M.+Nazar%C3%A9author=M.+Reichertauthor=D.+Saurauthor=M.+M.+Erkanauthor=U.+T.+Hoptauthor=B.+Sainzauthor=W.+Birchmeierauthor=R.+M.+Schmidauthor=M.+Lesinaauthor=H.+Alg%C3%BCl&title=Mutant+KRAS-driven+Cancers+Depend+on+PTPN11%2FSHP2+Phosphatase&doi=10.1038%2Fs41591-018-0024-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase</span></div><div class="casAuthors">Ruess, Dietrich A.; Heynen, Guus J.; Ciecielski, Katrin J.; Ai, Jiaoyu; Berninger, Alexandra; Kabacaoglu, Derya; Goerguelue, Kivanc; Dantes, Zahra; Woermann, Sonja M.; Diakopoulos, Kalliope N.; Karpathaki, Angeliki F.; Kowalska, Marlena; Kaya-Aksoy, Ezgi; Song, Liang; van der Laan, Eveline A. Zeeuw; Lopez-Alberca, Maria P.; Nazare, Marc; Reichert, Maximilian; Saur, Dieter; Erkan, Mert M.; Hopt, Ulrich T.; Sainz, Jr, Bruno; Birchmeier, Walter; Schmid, Roland M.; Lesina, Marina; Alguel, Hana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">954-960</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine and integrin receptors1.  Its requirement for complete RAS-MAPK activation and its role as a neg. regulator of JAK-STAT signaling have established SHP2 as an essential player in oncogenic signaling pathways1-7.  Recently, a novel potent allosteric SHP2 inhibitor was presented as a viable therapeutic option for receptor tyrosine kinase-driven cancers, but was shown to be ineffective in KRAS-mutant tumor cell lines in vitro8.  Here, we report a central and indispensable role for SHP2 in oncogenic KRAS-driven tumors.  Genetic deletion of Ptpn11 profoundly inhibited tumor development in mutant KRAS-driven murine models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer.  We provide evidence for a crit. dependence of mutant KRAS on SHP2 during carcinogenesis.  Deletion or inhibition of SHP2 in established tumors delayed tumor progression but was not sufficient to achieve tumor regression.  However, SHP2 was necessary for resistance mechanisms upon blockade of MEK.  Synergy was obsd. when both SHP2 and MEK were targeted, resulting in sustained tumor growth control in murine and human patient-derived organoids and xenograft models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer.  Our data indicate the clin. utility of dual SHP2/MEK inhibition as a targeted therapy approach for KRAS-mutant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoepq09hU77abVg90H21EOLACvtfcHk0lh8w8eh-oTqrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvF&md5=cc09897c2c4b8e32b035b991e5032f32</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0024-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0024-8%26sid%3Dliteratum%253Aachs%26aulast%3DRuess%26aufirst%3DD.%2BA.%26aulast%3DHeynen%26aufirst%3DG.%2BJ.%26aulast%3DCiecielski%26aufirst%3DK.%2BJ.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DBerninger%26aufirst%3DA.%26aulast%3DKabacaoglu%26aufirst%3DD.%26aulast%3DG%25C3%25B6rg%25C3%25BCl%25C3%25BC%26aufirst%3DK.%26aulast%3DDantes%26aufirst%3DZ.%26aulast%3DW%25C3%25B6rmann%26aufirst%3DS.%2BM.%26aulast%3DDiakopoulos%26aufirst%3DK.%2BN.%26aulast%3DKarpathaki%26aufirst%3DA.%2BF.%26aulast%3DKowalska%26aufirst%3DM.%26aulast%3DKaya-Aksoy%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DL.%26aulast%3Dvan%2Bder%2BLaan%26aufirst%3DE.%2BA.%2BZ.%26aulast%3DL%25C3%25B3pez-Alberca%26aufirst%3DM.%2BP.%26aulast%3DNazar%25C3%25A9%26aufirst%3DM.%26aulast%3DReichert%26aufirst%3DM.%26aulast%3DSaur%26aufirst%3DD.%26aulast%3DErkan%26aufirst%3DM.%2BM.%26aulast%3DHopt%26aufirst%3DU.%2BT.%26aulast%3DSainz%26aufirst%3DB.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DSchmid%26aufirst%3DR.%2BM.%26aulast%3DLesina%26aufirst%3DM.%26aulast%3DAlg%25C3%25BCl%26aufirst%3DH.%26atitle%3DMutant%2520KRAS-driven%2520Cancers%2520Depend%2520on%2520PTPN11%252FSHP2%2520Phosphatase%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D954%26epage%3D960%26doi%3D10.1038%2Fs41591-018-0024-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chitranshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dheer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salekdeh, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbasi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Wall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span> <span> </span><span class="NLM_article-title">Loss of Shp2 Rescues BDNF/TrkB Signaling and Contributes to Improved Retinal Ganglion Cell Neuroprotection</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2018.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.ymthe.2018.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=30341011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXis1WqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=424-441&author=N.+Chitranshiauthor=Y.+Dheerauthor=M.+Mirzaeiauthor=Y.+Wuauthor=G.+H.+Salekdehauthor=M.+Abbasiauthor=V.+Guptaauthor=R.+Vander+Wallauthor=Y.+Youauthor=S.+L.+Grahamauthor=V.+Gupta&title=Loss+of+Shp2+Rescues+BDNF%2FTrkB+Signaling+and+Contributes+to+Improved+Retinal+Ganglion+Cell+Neuroprotection&doi=10.1016%2Fj.ymthe.2018.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of Shp2 Rescues BDNF/TrkB Signaling and Contributes to Improved Retinal Ganglion Cell Neuroprotection</span></div><div class="casAuthors">Chitranshi, Nitin; Dheer, Yogita; Mirzaei, Mehdi; Wu, Yunqi; Salekdeh, Ghasem H.; Abbasi, Mojdeh; Gupta, Veer; Vander Wall, Roshana; You, Yuyi; Graham, Stuart L.; Gupta, Vivek</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">424-441</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Glaucoma is characterized by the loss of retinal ganglion cells (RGC), and accordingly the preservation of RGCs and their axons has recently attracted significant attention to improve therapeutic outcomes in the disease.  Here, we report that Src homol. region 2-contg. protein tyrosine phosphatase 2 (Shp2) undergoes activation in the RGCs, in animal model of glaucoma as well as in the human glaucoma tissues and that Shp2 dephosphorylates tropomyosin receptor kinase B (TrkB) receptor, leading to reduced BDNF/TrkB neuroprotective survival signaling.  This was elucidated by specifically modulating Shp2 expression in the RGCs in vivo, using adeno-assocd. virus serotype 2 (AAV2) constructs.  Shp2 upregulation promoted endoplasmic reticulum (ER) stress and apoptosis, along with functional and structural deficits in the inner retina.  In contrast, loss of Shp2 decelerated the loss of RGCs, preserved their function, and suppressed ER stress and apoptosis in glaucoma.  This report constitutes the first identification of Shp2-mediated TrkB regulatory mechanisms in the RGCs that can become a potential therapeutic target in both glaucoma and other neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPxvPqp9eo-LVg90H21EOLACvtfcHk0liztCg1fAAttg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXis1WqurY%253D&md5=3416eacabb611e5ad0540a8b6ec3c13a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2018.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2018.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DChitranshi%26aufirst%3DN.%26aulast%3DDheer%26aufirst%3DY.%26aulast%3DMirzaei%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DSalekdeh%26aufirst%3DG.%2BH.%26aulast%3DAbbasi%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DVander%2BWall%26aufirst%3DR.%26aulast%3DYou%26aufirst%3DY.%26aulast%3DGraham%26aufirst%3DS.%2BL.%26aulast%3DGupta%26aufirst%3DV.%26atitle%3DLoss%2520of%2520Shp2%2520Rescues%2520BDNF%252FTrkB%2520Signaling%2520and%2520Contributes%2520to%2520Improved%2520Retinal%2520Ganglion%2520Cell%2520Neuroprotection%26jtitle%3DMol.%2520Ther.%26date%3D2019%26volume%3D27%26spage%3D424%26epage%3D441%26doi%3D10.1016%2Fj.ymthe.2018.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrlich, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span> <span> </span><span class="NLM_article-title">SHP2 Regulates Intramembranous Ossification by Modifying the TGFbeta and BMP2 Signaling Pathway</span>. <i>Bone</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1016/j.bone.2018.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bone.2018.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=30471432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGgu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=327-335&author=L.+Wangauthor=J.+Huangauthor=D.+C.+Mooreauthor=Y.+Songauthor=M.+G.+Ehrlichauthor=W.+Yang&title=SHP2+Regulates+Intramembranous+Ossification+by+Modifying+the+TGFbeta+and+BMP2+Signaling+Pathway&doi=10.1016%2Fj.bone.2018.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 regulates intramembranous ossification by modifying the TGFβ and BMP2 signaling pathway</span></div><div class="casAuthors">Wang, Lijun; Huang, Jiahui; Moore, Douglas C.; Song, Yueming; Ehrlich, Michael G.; Yang, Wentian</div><div class="citationInfo"><span class="NLM_cas:title">Bone (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">327-335</span>CODEN:
                <span class="NLM_cas:coden">BONEDL</span>;
        ISSN:<span class="NLM_cas:issn">1873-2763</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">SHP2 is a ubiquitously expressed protein tyrosine phosphatase, which is involved in many signaling pathways to regulate the skeletal development.  In endochondral ossification, SHP2 is known to modify the osteogenic fate of osteochondroprogenitors and to impair the osteoblastic transdifferentiation of hypertrophic chondrocytes.  However, how SHP2 regulates osteoblast differentiation in intramembranous ossification remains incompletely understood.  To address this question, we generated a mouse model to ablate SHP2 in the Prrx1-expressing mesenchymal progenitors by using "Cre-loxP"-mediated gene excision and examd. the development of calvarial bone, in which the main process of bone formation is intramembranous ossification.  Phenotypic characterization showed that SHP2 mutants have severe defects in calvarial bone formation.  Cell lineage tracing and in situ hybridization data showed less osteoblast differentiation of mesenchymal cells and reduced osteogenic genes expression, resp.  Further mechanistic studies revealed enhanced TGFβ and suppressed BMP2 signaling in SHP2 ablated mesenchymal progenitors and their derivs.  Our study uncovered the crit. role of SHP2 in osteoblast differentiation through intramembranous ossification and might provide a potential target to treat craniofacial skeleton disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj6PRZSjPQ87Vg90H21EOLACvtfcHk0liztCg1fAAttg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGgu73M&md5=4aa0958c7548a2f9819e05f97d64620e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bone.2018.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bone.2018.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DD.%2BC.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DEhrlich%26aufirst%3DM.%2BG.%26aulast%3DYang%26aufirst%3DW.%26atitle%3DSHP2%2520Regulates%2520Intramembranous%2520Ossification%2520by%2520Modifying%2520the%2520TGFbeta%2520and%2520BMP2%2520Signaling%2520Pathway%26jtitle%3DBone%26date%3D2019%26volume%3D120%26spage%3D327%26epage%3D335%26doi%3D10.1016%2Fj.bone.2018.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leugers, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hefti, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span> <span> </span><span class="NLM_article-title">Tau Interacts With SHP2 in Neuronal Systems And in Alzheimer’s Disease Brains</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">jcs229054</span>, <span class="refDoi"> DOI: 10.1242/jcs.229054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1242%2Fjcs.229054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=31201283" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2019&pages=jcs229054&author=Y.+Kimauthor=G.+Liuauthor=C.+J.+Leugersauthor=J.+D.+Muellerauthor=M.+B.+Francisauthor=M.+M.+Heftiauthor=J.+A.+Schneiderauthor=G.+Lee&title=Tau+Interacts+With+SHP2+in+Neuronal+Systems+And+in+Alzheimer%E2%80%99s+Disease+Brains&doi=10.1242%2Fjcs.229054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1242%2Fjcs.229054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.229054%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLeugers%26aufirst%3DC.%2BJ.%26aulast%3DMueller%26aufirst%3DJ.%2BD.%26aulast%3DFrancis%26aufirst%3DM.%2BB.%26aulast%3DHefti%26aufirst%3DM.%2BM.%26aulast%3DSchneider%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DG.%26atitle%3DTau%2520Interacts%2520With%2520SHP2%2520in%2520Neuronal%2520Systems%2520And%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Brains%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2019%26volume%3D132%26spage%3Djcs229054%26doi%3D10.1242%2Fjcs.229054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of Targeting SHP2 in Human Developmental Disorders and Cancers</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">112117</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.ejmech.2020.112117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=32061959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFWgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=112117&author=D.+Shenauthor=W.+Chenauthor=J.+Zhuauthor=G.+Wuauthor=R.+Shenauthor=M.+Xiauthor=H.+Sun&title=Therapeutic+Potential+of+Targeting+SHP2+in+Human+Developmental+Disorders+and+Cancers&doi=10.1016%2Fj.ejmech.2020.112117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of targeting SHP2 in human developmental disorders and cancers</span></div><div class="casAuthors">Shen, Dadong; Chen, Wenxia; Zhu, Jinlin; Wu, Guofeng; Shen, Runpu; Xi, Meiyang; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112117</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Src homol. 2 (SH2)-contg. protein tyrosine phosphatase 2 (SHP2), encoded by PTPN11, regulates cell proliferation, differentiation, apoptosis and survival via releasing intramol. autoinhibition and modulating various signaling pathways, such as mitogen-activated protein kinase (MAPK) pathway.  Mutations and aberrant expression of SHP2 are implicated in human developmental disorders, leukemias and several solid tumors.  As an oncoprotein in some cancers, SHP2 represents a rational target for inhibitors to interfere.  Nevertheless, its tumor suppressive effect has also been uncovered, indicating the context-specificity.  Even so, two types of SHP2 inhibitors including targeting catalytic pocket and allosteric sites have been developed assocd. with resolved cocrystal complexes.  Herein, we describe its structure, biol. function, deregulation in human diseases and summarize recent advance in development of SHP2 inhibitors, trying to give an insight into the therapeutic potential in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkb-7jOXJ8DLVg90H21EOLACvtfcHk0liEBjClY4Q69Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFWgsrk%253D&md5=9f40f6d2a560deac59c2b24616ac9f94</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112117%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DXi%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DTherapeutic%2520Potential%2520of%2520Targeting%2520SHP2%2520in%2520Human%2520Developmental%2520Disorders%2520and%2520Cancers%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D190%26spage%3D112117%26doi%3D10.1016%2Fj.ejmech.2020.112117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting SHP2 as a Promising Strategy for Cancer Immunotherapy</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">104595</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2019.104595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.phrs.2019.104595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=31838080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGgsrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&pages=104595&author=Q.+Liuauthor=J.+Quauthor=M.+Zhaoauthor=Q.+Xuauthor=Y.+Sun&title=Targeting+SHP2+as+a+Promising+Strategy+for+Cancer+Immunotherapy&doi=10.1016%2Fj.phrs.2019.104595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting SHP2 as a promising strategy for cancer immunotherapy</span></div><div class="casAuthors">Liu, Qianqian; Qu, Jiao; Zhao, Mingxia; Xu, Qiang; Sun, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104595</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Src homol.-2-contg. protein tyrosine phosphatase 2 (SHP2) is a major phosphatase involved in several cellular processes.  In recent years, SHP2 has been the focus of significant attention in human diseases, particular in cancer.  Several studies have shown that SHP2 plays an important role in regulating immune cell functions in tumor microenvironment.  A few clin. trials conducted using SHP2 allosteric inhibitors have shown remarkable anti-tumor benefits and good safety profiles.  This review focuses on the current understanding of the regulation of SHP2 and highlights the vital roles of SHP2 in T lymphocytes, macrophages and cancer cells.  It also summarizes the current development of SHP2 inhibitors as a promising strategy for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZzWn2YQmawLVg90H21EOLACvtfcHk0liEBjClY4Q69Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGgsrnN&md5=5335503a2397f7c09f87e589a8f037ec</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2019.104595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2019.104595%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DTargeting%2520SHP2%2520as%2520a%2520Promising%2520Strategy%2520for%2520Cancer%2520Immunotherapy%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D152%26spage%3D104595%26doi%3D10.1016%2Fj.phrs.2019.104595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1793-1802&author=P.+Sarverauthor=M.+Ackerauthor=J.+T.+Bagdanoffauthor=Z.+Chenauthor=Y.-N.+Chenauthor=H.+Chanauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=H.+Haoauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=G.+Liuauthor=S.+Liuauthor=C.+Liuauthor=E.+McNeillauthor=M.+Mohseniauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=V.+Tamezauthor=R.+Tichkuleauthor=C.+Towlerauthor=H.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=B.+Yuauthor=M.+J.+LaMarche&title=6-Amino-3-methylpyrimidinones+as+Potent%2C+Selective%2C+and+Orally+Efficacious+SHP2+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span></div><div class="casAuthors">Sarver, Patrick; Acker, Michael; Bagdanoff, Jeffrey T.; Chen, Zhouliang; Chen, Ying-Nan; Chan, Homan; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hao, Huaixiang; Hentemann, Murphy; Koenig, Robert; Kato, Mitsunori; LaBonte, Laura R.; Liu, Gang; Liu, Shumei; Liu, Chen; McNeill, Eric; Mohseni, Morvarid; Sendzik, Martin; Stams, Travis; Spence, Stan; Tamez, Victoriano; Tichkule, Ritesh; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; Yu, Bing; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1793-1802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase SHP2 is an oncoprotein assocd. with cancer as well as a potential immune modulator because of its role in the programmed cell death PD-L1/PD-1 pathway.  In the preceding manuscript, we described the optimization of a fused, bicyclic screening hit for potency, selectivity, and physicochem. properties in order to further expand the chem. diversity of allosteric SHP2 inhibitors.  In this manuscript, we describe the further expansion of our approach, morphing the fused, bicyclic system into a novel monocyclic pyrimidinone scaffold through our understanding of SAR and use of structure-based design.  These studies led to the identification of SHP394 (1), an orally efficacious inhibitor of SHP2, with high lipophilic efficiency, improved potency, and enhanced pharmacokinetic properties.  We also report other pyrimidinone analogs with favorable pharmacokinetic and potency profiles.  Overall, this work improves upon our previously described allosteric inhibitors and exemplifies and extends the range of permissible chem. templates that inhibit SHP2 via the allosteric mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaRey6_uE0ULVg90H21EOLACvtfcHk0li9YMMJqr2hLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D&md5=29c357236b7ff51596385e3e256320a5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01726%26sid%3Dliteratum%253Aachs%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.-N.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DH.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMcNeill%26aufirst%3DE.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DTichkule%26aufirst%3DR.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3D6-Amino-3-methylpyrimidinones%2520as%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Efficacious%2520SHP2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1793%26epage%3D1802%26doi%3D10.1021%2Facs.jmedchem.8b01726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarafianos, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C.-K.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1125</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00513</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00513" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A280%3ADC%252BB3crivFClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1125-1137&author=X.+Wuauthor=G.+Xuauthor=X.+Liauthor=W.+Xuauthor=Q.+Liauthor=W.+Liuauthor=K.+A.+Kirbyauthor=M.+L.+Lohauthor=J.+Liauthor=S.+G.+Sarafianosauthor=C.-K.+Qu&title=Small+Molecule+Inhibitor+that+Stabilizes+the+Autoinhibited+Conformation+of+the+Oncogenic+Tyrosine+Phosphatase+SHP2&doi=10.1021%2Facs.jmedchem.8b00513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2</span></div><div class="casAuthors">Wu Xiaoqin; Li Xiaobo; Li Qianjin; Qu Cheng-Kui; Xu Gang; Li Xiaobo; Xu Weiren; Liu Wei; Qu Cheng-Kui; Kirby Karen A; Sarafianos Stefan G; Loh Mignon L; Li Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1125-1137</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Genetic mutations in the phosphatase PTPN11 (SHP2) are associated with childhood leukemias.  These mutations cause hyperactivation of SHP2 due to the disruption of the autoinhibitory conformation.  By targeting the activation-associated protein conformational change, we have identified an SHP2 inhibitor ( E)-1-(1-(5-(3-(2,4-dichlorophenyl)acryloyl)-2-ethoxy-4-hydroxybenzyl)-1,2,5,6-tetrahydropyridin-3-yl)-1 H-benzo[ d]imidazol-2(3 H)-one (LY6, 1) using computer-aided drug design database screening combined with cell-based assays.  This compound inhibited SHP2 with an IC50 value of 9.8 μM, 7-fold more selective for SHP2 than the highly related SHP1.  Fluorescence titration, thermal shift, and microscale thermophoresis quantitative binding assays confirmed its direct binding to SHP2.  This compound was further verified to effectively inhibit SHP2-mediated cell signaling and proliferation.  Furthermore, mouse and patient leukemia cells with PTPN11 activating mutations were more sensitive to this inhibitor than wild-type cells.  This small molecule SHP2 inhibitor has a potential to serve as a lead compound for further optimization studies to develop novel anti-SHP2 therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0hz4mjYe4HMSzjBFCN0BJfW6udTcc2eYtQuCixUYfFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crivFClsQ%253D%253D&md5=e05fd7589519ad6928eb769225b9a607</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00513%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DKirby%26aufirst%3DK.%2BA.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26aulast%3DQu%26aufirst%3DC.-K.%26atitle%3DSmall%2520Molecule%2520Inhibitor%2520that%2520Stabilizes%2520the%2520Autoinhibited%2520Conformation%2520of%2520the%2520Oncogenic%2520Tyrosine%2520Phosphatase%2520SHP2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1125%26epage%3D1137%26doi%3D10.1021%2Facs.jmedchem.8b00513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonakos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunenfelder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slisz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span> <span> </span><span class="NLM_article-title">Allosteric Inhibition of SHP2 Phosphatase Inhibits Cancers Driven by Receptor Tyrosine Kinases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1038/nature18621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fnature18621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=27362227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVOns7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=148-152&author=Y.-N.+P.+Chenauthor=M.+J.+LaMarcheauthor=H.+M.+Chanauthor=P.+Fekkesauthor=J.+Garcia-Fortanetauthor=M.+G.+Ackerauthor=B.+Antonakosauthor=C.+H.-T.+Chenauthor=Z.+Chenauthor=V.+G.+Cookeauthor=J.+R.+Dobsonauthor=Z.+Dengauthor=F.+Feiauthor=B.+Firestoneauthor=M.+Fodorauthor=C.+Fridrichauthor=H.+Gaoauthor=D.+Grunenfelderauthor=H.-X.+Haoauthor=J.+Jacobauthor=S.+Hoauthor=K.+Hsiaoauthor=Z.+B.+Kangauthor=R.+Karkiauthor=M.+Katoauthor=J.+Larrowauthor=L.+R.+La+Bonteauthor=F.+Lenoirauthor=G.+Liuauthor=S.+Liuauthor=D.+Majumdarauthor=M.+J.+Meyerauthor=M.+Palermoauthor=L.+Perezauthor=M.+Puauthor=E.+Priceauthor=C.+Quinnauthor=S.+Shakyaauthor=M.+D.+Shultzauthor=J.+Sliszauthor=K.+Venkatesanauthor=P.+Wangauthor=M.+Warmuthauthor=S.+Williamsauthor=G.+Yangauthor=J.+Yuanauthor=J.-H.+Zhangauthor=P.+Zhuauthor=T.+Ramseyauthor=N.+J.+Keenauthor=W.+R.+Sellersauthor=T.+Stamsauthor=P.+D.+Fortin&title=Allosteric+Inhibition+of+SHP2+Phosphatase+Inhibits+Cancers+Driven+by+Receptor+Tyrosine+Kinases&doi=10.1038%2Fnature18621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases</span></div><div class="casAuthors">Chen, Ying-Nan P.; LaMarche, Matthew J.; Chan, Ho Man; Fekkes, Peter; Garcia-Fortanet, Jorge; Acker, Michael G.; Antonakos, Brandon; Chen, Christine Hiu-Tung; Chen, Zhouliang; Cooke, Vesselina G.; Dobson, Jason R.; Deng, Zhan; Fei, Feng; Firestone, Brant; Fodor, Michelle; Fridrich, Cary; Gao, Hui; Grunenfelder, Denise; Hao, Huai-Xiang; Jacob, Jaison; Ho, Samuel; Hsiao, Kathy; Kang, Zhao B.; Karki, Rajesh; Kato, Mitsunori; Larrow, Jay; La Bonte, Laura R.; Lenoir, Francois; Liu, Gang; Liu, Shumei; Majumdar, Dyuti; Meyer, Matthew J.; Palermo, Mark; Perez, Lawrence; Pu, Minying; Price, Edmund; Quinn, Christopher; Shakya, Subarna; Shultz, Michael D.; Slisz, Joanna; Venkatesan, Kavitha; Wang, Ping; Warmuth, Markus; Williams, Sarah; Yang, Guizhi; Yuan, Jing; Zhang, Ji-Hu; Zhu, Ping; Ramsey, Timothy; Keen, Nicholas J.; Sellers, William R.; Stams, Travis; Fortin, Pascal D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7610</span>),
    <span class="NLM_cas:pages">148-152</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an important role in signal transduction downstream of growth factor receptor signalling and was the first reported oncogenic tyrosine phosphatase.  Activating mutations of SHP2 have been assocd. with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukemia, lung and breast cancer and neuroblastoma.  SHP2 is ubiquitously expressed and regulates cell survival and proliferation primarily through activation of the RAS-ERK signalling pathway2,3.  It is also a key mediator of the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) immune checkpoint pathways.  Redn. of SHP2 activity suppresses tumor cell growth and is a potential target of cancer therapy.  Here we report the discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-mol. SHP2 inhibitor, SHP099, that stabilizes SHP2 in an auto-inhibited conformation.  SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism.  SHP099 suppresses RAS-ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumor xenograft models.  Together, these data demonstrate that pharmacol. inhibition of SHP2 is a valid therapeutic approach for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBs_e02S0Sp7Vg90H21EOLACvtfcHk0lgeq3lcmv2RTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVOns7bI&md5=ec8a4b612d5008a2519bd846d45ce019</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature18621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18621%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.-N.%2BP.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DFekkes%26aufirst%3DP.%26aulast%3DGarcia-Fortanet%26aufirst%3DJ.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DAntonakos%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%2BH.-T.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DDobson%26aufirst%3DJ.%2BR.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DFei%26aufirst%3DF.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGrunenfelder%26aufirst%3DD.%26aulast%3DHao%26aufirst%3DH.-X.%26aulast%3DJacob%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DHsiao%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DLarrow%26aufirst%3DJ.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPalermo%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DC.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DSlisz%26aufirst%3DJ.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DZhu%26aufirst%3DP.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DKeen%26aufirst%3DN.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26atitle%3DAllosteric%2520Inhibition%2520of%2520SHP2%2520Phosphatase%2520Inhibits%2520Cancers%2520Driven%2520by%2520Receptor%2520Tyrosine%2520Kinases%26jtitle%3DNature%26date%3D2016%26volume%3D535%26spage%3D148%26epage%3D152%26doi%3D10.1038%2Fnature18621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia
Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunenfelder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7773</span>– <span class="NLM_lpage">7782</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00680</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00680" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKju7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7773-7782&author=J.+Garcia%0AFortanetauthor=C.+H.-T.+Chenauthor=Y.-N.+P.+Chenauthor=Z.+Chenauthor=Z.+Dengauthor=B.+Firestoneauthor=P.+Fekkesauthor=M.+Fodorauthor=P.+D.+Fortinauthor=C.+Fridrichauthor=D.+Grunenfelderauthor=S.+Hoauthor=Z.+B.+Kangauthor=R.+Karkiauthor=M.+Katoauthor=N.+Keenauthor=L.+R.+LaBonteauthor=J.+Larrowauthor=F.+Lenoirauthor=G.+Liuauthor=S.+Liuauthor=F.+Lombardoauthor=D.+Majumdarauthor=M.+J.+Meyerauthor=M.+Palermoauthor=L.+Perezauthor=M.+Puauthor=T.+Ramseyauthor=W.+R.+Sellersauthor=M.+D.+Shultzauthor=T.+Stamsauthor=C.+Towlerauthor=P.+Wangauthor=S.+L.+Williamsauthor=J.-H.+Zhangauthor=M.+J.+LaMarche&title=Allosteric+Inhibition+of+SHP2%3A+Identification+of+a+Potent%2C+Selective%2C+and+Orally+Efficacious+Phosphatase+Inhibitor&doi=10.1021%2Facs.jmedchem.6b00680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor</span></div><div class="casAuthors">Garcia Fortanet, Jorge; Chen, Christine Hiu-Tung; Chen, Ying-Nan P.; Chen, Zhouliang; Deng, Zhan; Firestone, Brant; Fekkes, Peter; Fodor, Michelle; Fortin, Pascal D.; Fridrich, Cary; Grunenfelder, Denise; Ho, Samuel; Kang, Zhao B.; Karki, Rajesh; Kato, Mitsunori; Keen, Nick; LaBonte, Laura R.; Larrow, Jay; Lenoir, Francois; Liu, Gang; Liu, Shumei; Lombardo, Franco; Majumdar, Dyuti; Meyer, Matthew J.; Palermo, Mark; Perez, Lawrence; Pu, Minying; Ramsey, Timothy; Sellers, William R.; Shultz, Michael D.; Stams, Travis; Towler, Christopher; Wang, Ping; Williams, Sarah L.; Zhang, Ji-Hu; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7773-7782</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell growth and differentiation via the MAPK signaling pathway.  SHP2 also purportedly plays an important role in the programmed cell death pathway (PD-1/PD-L1).  Because it is an oncoprotein assocd. with multiple cancer-related diseases, as well as a potential immunomodulator, controlling SHP2 activity is of significant therapeutic interest.  Recently in our labs., a small mol. inhibitor of SHP2 was identified as an allosteric modulator that stabilizes the autoinhibited conformation of SHP2.  A high throughput screen was performed to identify progressable chem. matter, and X-ray crystallog. revealed the location of binding in a previously undisclosed allosteric binding pocket.  Structure-based drug design was employed to optimize for SHP2 inhibition, and several new protein-ligand interactions were characterized.  These studies culminated in the discovery of 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine (SHP099, 1), a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6RT7zfZnvfLVg90H21EOLACvtfcHk0lhRjFz-bRY6_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKju7fP&md5=dfe43b5253e172576386f86797087f7b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00680%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%2BFortanet%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%2BH.-T.%26aulast%3DChen%26aufirst%3DY.-N.%2BP.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFekkes%26aufirst%3DP.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DGrunenfelder%26aufirst%3DD.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLarrow%26aufirst%3DJ.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPalermo%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DAllosteric%2520Inhibition%2520of%2520SHP2%253A%2520Identification%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Efficacious%2520Phosphatase%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7773%26epage%3D7782%26doi%3D10.1021%2Facs.jmedchem.6b00680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">17626</span>, <span class="refDoi"> DOI: 10.1038/srep17626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fsrep17626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=26626996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGms7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=17626&author=C.+Chenauthor=M.+Caoauthor=S.+Zhuauthor=C.+Wangauthor=F.+Liangauthor=L.+Yanauthor=D.+Luo&title=Discovery+of+a+Novel+Inhibitor+of+the+Protein+Tyrosine+Phosphatase+Shp2&doi=10.1038%2Fsrep17626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2</span></div><div class="casAuthors">Chen, Chuan; Cao, Mengmeng; Zhu, Siyu; Wang, Cuicui; Liang, Fan; Yan, Leilei; Luo, Duqiang</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17626</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Shp2 is a ubiquitously expressed protein tyrosine phosphatase (PTP) related to adult acute myelogenous leukemia and human solid tumors.  In this report, we describe identification of a potent Shp2 inhibitor, Fumosorinone (Fumos) from entomogenous fungi, which shows selective inhibition of Shp2 over other tested PTPs.  Using a surface plasmon resonance anal., we further confirmed the phys. interaction between Shp2 and Fumos.  Fumos inhibits Shp2-dependent activation of the Ras/ERK signal pathway downstream of EGFR, and interrupts EGF-induced Gab1-Shp2 assocn.  As expected, Fumos shows little effects on the Shp2-independent ERK1/2 activation induced by PMA or oncogenic Ras.  Furthermore, Fumos down-regulates Src activation, inhibits phosphorylation of Paxillin and prevents tumor cell invasion.  These results suggest that Fumos can inhibit Shp2-dependent cell signaling in human cells and has a potential for treatment of Shp2-assocd. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoswqt5Y98UCrVg90H21EOLACvtfcHk0liLDFFC6rgAfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGms7bN&md5=ae7d1a3adf914820e57a2862ade65cf7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fsrep17626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep17626%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Inhibitor%2520of%2520the%2520Protein%2520Tyrosine%2520Phosphatase%2520Shp2%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D17626%26doi%3D10.1038%2Fsrep17626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, W.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.-m.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.-r.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Open-Chain Analogs of Cyclic Peptides as Inhibitors of Cellular Shp2 Activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2562</span>– <span class="NLM_lpage">2567</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmc.2015.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=25865131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1ajsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2562-2567&author=X.-l.+Zhenauthor=W.-h.+Yinauthor=X.+Tianauthor=Z.-j.+Maauthor=S.-m.+Fanauthor=J.-r.+Hanauthor=S.+Liu&title=Synthesis+and+Biological+Evaluation+of+Open-Chain+Analogs+of+Cyclic+Peptides+as+Inhibitors+of+Cellular+Shp2+Activity&doi=10.1016%2Fj.bmc.2015.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of open-chain analogs of cyclic peptides as inhibitors of cellular Shp2 activity</span></div><div class="casAuthors">Zhen, Xiao-li; Yin, Wen-hui; Tian, Xia; Ma, Zhen-jie; Fan, Shi-ming; Han, Jian-rong; Liu, Shouxin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2562-2567</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of open-chain analogs of cyclic peptides was designed and synthesized using sansalvamide A as a model compd.  All compds. exhibited low antitumor activity.  Furthermore, the evaluation of their inhibitory potency toward IMPDH, SHP2, ACHE, proteasome, MAGL, and cathepsin B showed that all of the compds. were potent against protein tyrosine phosphatase Shp2.  Specifically, compds. (I) (Ar = Ph, 4-F-C6H4) and (II) (Ar1 = 4-Br-C6H4, 2-naphthol) were found to inhibit SHP2 with IC50 values in the low micromolar range and good selectivity.  Based on the mol. docking results, the binding modes of the chain cyclic peptides in the active center of SHP2 were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFj9G0DtykVbVg90H21EOLACvtfcHk0liLDFFC6rgAfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1ajsbw%253D&md5=7d975b012b3e9afd6f2d670c47081709</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhen%26aufirst%3DX.-l.%26aulast%3DYin%26aufirst%3DW.-h.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DZ.-j.%26aulast%3DFan%26aufirst%3DS.-m.%26aulast%3DHan%26aufirst%3DJ.-r.%26aulast%3DLiu%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Open-Chain%2520Analogs%2520of%2520Cyclic%2520Peptides%2520as%2520Inhibitors%2520of%2520Cellular%2520Shp2%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D2562%26epage%3D2567%26doi%3D10.1016%2Fj.bmc.2015.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mali, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6594</span>– <span class="NLM_lpage">6609</span>, <span class="refDoi"> DOI: 10.1021/jm5006176</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006176" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFajtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6594-6609&author=L.-F.+Zengauthor=R.-Y.+Zhangauthor=Z.-H.+Yuauthor=S.+Liauthor=L.+Wuauthor=A.+M.+Gunawanauthor=B.+S.+Laneauthor=R.+S.+Maliauthor=X.+Liauthor=R.+J.+Chanauthor=R.+Kapurauthor=C.+D.+Wellsauthor=Z.-Y.+Zhang&title=Therapeutic+Potential+of+Targeting+the+Oncogenic+SHP2+Phosphatase&doi=10.1021%2Fjm5006176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase</span></div><div class="casAuthors">Zeng, Li-Fan; Zhang, Ruo-Yu; Yu, Zhi-Hong; Li, Sijiu; Wu, Li; Gunawan, Andrea M.; Lane, Brandon S.; Mali, Raghuveer S.; Li, Xingjun; Chan, Rebecca J.; Kapur, Reuben; Wells, Clark D.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6594-6609</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Src homol. 2 domain contg. protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase assocd. with various kinds of leukemia and solid tumors.  Thus, there is substantial interest in developing SHP2 inhibitors as potential anticancer and antileukemia agents.  Using a structure-guided and fragment-based library approach, we identified a novel hydroxyindole carboxylic acid-based SHP2 inhibitor (I), with an IC50 value of 200 nM and greater than 5-fold selectivity against 20 mammalian PTPs.  Structural and modeling studies reveal that the hydroxyindole carboxylic acid anchors the inhibitor to the SHP2 active site, while interactions of the oxalamide linker and the phenylthiophene tail with residues in the β5-β6 loop contribute to I's binding potency and selectivity.  Evidence suggests that I specifically attenuates the SHP2-dependent signaling inside the cell.  Moreover, I blocks growth factor mediated Erk1/2 and Akt activation and exhibits excellent antiproliferative activity in lung cancer and breast cancer as well as leukemia cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ko-q4-PSXbVg90H21EOLACvtfcHk0liLDFFC6rgAfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFajtrvO&md5=ac8e5359387e614782c95c02f32fd97d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm5006176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006176%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DL.-F.%26aulast%3DZhang%26aufirst%3DR.-Y.%26aulast%3DYu%26aufirst%3DZ.-H.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DLane%26aufirst%3DB.%2BS.%26aulast%3DMali%26aufirst%3DR.%2BS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26atitle%3DTherapeutic%2520Potential%2520of%2520Targeting%2520the%2520Oncogenic%2520SHP2%2520Phosphatase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6594%26epage%3D6609%26doi%3D10.1021%2Fjm5006176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of SHP2 Tyrosine Phosphatase Discovered by Virtual Screening</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4238</span>– <span class="NLM_lpage">4242</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.05.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmcl.2011.05.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=21669525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFWku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4238-4242&author=Z.-H.+Yuauthor=L.+Chenauthor=L.+Wuauthor=S.+Liuauthor=L.+Wangauthor=Z.-Y.+Zhang&title=Small+Molecule+Inhibitors+of+SHP2+Tyrosine+Phosphatase+Discovered+by+Virtual+Screening&doi=10.1016%2Fj.bmcl.2011.05.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening</span></div><div class="casAuthors">Yu, Zhi-Hong; Chen, Lan; Wu, Li; Liu, Sijiu; Wang, Lina; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4238-4242</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SHP2, encoded by PTPN11, is a non-receptor protein tyrosine phosphatase (PTP) contg. two tandem Src homol.-2 (SH2) domains.  It is expressed ubiquitously and plays crit. roles in growth factor mediated processes, primarily by promoting the activation of the RAS/ERK signaling pathway.  Genetic and biochem. studies have identified SHP2 as the first bona fide oncoprotein in the PTP superfamily, and a promising target for anti-cancer and anti-leukemia therapy.  Here, we report a structure-based approach to identify SHP2 inhibitors with a novel scaffold.  Through sequential virtual screenings and in vitro inhibition assays, a reversible competitive SHP2 inhibitor (C21, I) was identified.  C21 is structurally distinct from all known SHP2 inhibitors.  Combining mol. dynamics simulation and binding free energy calcn., a most likely binding mode of C21 with SHP2 is proposed, and further validated by site-directed mutagenesis and structure-activity relationship studies.  This binding mode is consistent with the obsd. potency and specificity of C21, and reveals the mol. determinants for further optimization based on the new scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7ByUkOMeL57Vg90H21EOLACvtfcHk0li1038H48pzTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFWku7o%253D&md5=9ff6409bd28a309bbdc8258da774fe66</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.05.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.05.078%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DZ.-H.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520SHP2%2520Tyrosine%2520Phosphatase%2520Discovered%2520by%2520Virtual%2520Screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4238%26epage%3D4242%26doi%3D10.1016%2Fj.bmcl.2011.05.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, M. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1124/mol.106.025536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1124%2Fmol.106.025536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=16717135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnslyjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=562-570&author=L.+Chenauthor=S.-S.+Sungauthor=M.+L.+R.+Yipauthor=H.+R.+Lawrenceauthor=Y.+Renauthor=W.+C.+Guidaauthor=S.+M.+Sebtiauthor=N.+J.+Lawrenceauthor=J.+Wu&title=Discovery+of+a+Novel+Shp2+Protein+Tyrosine+Phosphatase+Inhibitor&doi=10.1124%2Fmol.106.025536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel Shp2 protein tyrosine phosphatase inhibitor</span></div><div class="casAuthors">Chen, Liwei; Sung, Shen-Shu; Yip, M. L. Richard; Lawrence, Harshani R.; Ren, Yuan; Guida, Wayne C.; Sebti, Said M.; Lawrence, Nicholas J.; Wu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">562-570</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Shp2 is a non-receptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene.  It is involved in growth factor-induced activation of mitogen-activated protein (MAP) kinases Erk1 and Erk2 (Erk1/2) and has been implicated in the pathogenicity of the oncogenic bacterium Helicobacter pylori.  Moreover, gain-of-function Shp2 mutations have been found in childhood leukemias and Noonan syndrome.  Thus, small mol. Shp2 PTP inhibitors are much needed reagents for evaluation of Shp2 as a therapeutic target and for chem. biol. studies of Shp2 function.  By screening the National Cancer Institute (NCI) Diversity Set chem. library, we identified 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877) as a potent Shp2 PTP inhibitor.  Mol. modeling and site-directed mutagenesis studies suggested that NSC-87877 binds to the catalytic cleft of Shp2 PTP.  NSC-87877 cross-inhibited Shp1 in vitro, but it was selective for Shp2 over other PTPs (PTP1B, HePTP, DEP1, CD45, and LAR).  It is noteworthy that NSC-87877 inhibited epidermal growth factor (EGF)-induced activation of Shp2 PTP, Ras, and Erk1/2 in cell cultures but did not block EGF-induced Gab1 tyrosine phosphorylation or Gab1-Shp2 assocn.  Furthermore, NSC-87877 inhibited Erk1/2 activation by a Gab1-Shp2 chimera but did not affect the Shp2-independent Erk1/2 activation by phorbol 12-myristate 13-acetate.  These results identified NSC-87877 as the first PTP inhibitor capable of inhibiting Shp2 PTP in cell cultures without a detectable off-target effect.  Our study also provides the first pharmacol. evidence that Shp2 mediates EGF-induced Erk1/2 MAP kinase activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA4XVGUjw3W7Vg90H21EOLACvtfcHk0li1038H48pzTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnslyjsrk%253D&md5=a2ce03150ecbe6937876bb292ced30dc</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.025536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.025536%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSung%26aufirst%3DS.-S.%26aulast%3DYip%26aufirst%3DM.%2BL.%2BR.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Shp2%2520Protein%2520Tyrosine%2520Phosphatase%2520Inhibitor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D70%26spage%3D562%26epage%3D570%26doi%3D10.1124%2Fmol.106.025536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabinger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span> <span> </span><span class="NLM_article-title">Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2482</span>– <span class="NLM_lpage">2493</span>, <span class="refDoi"> DOI: 10.1021/jm901645u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901645u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFyhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2482-2493&author=X.+Zhangauthor=Y.+Heauthor=S.+Liuauthor=Z.+Yuauthor=Z.-X.+Jiangauthor=Z.+Yangauthor=Y.+Dongauthor=S.+C.+Nabingerauthor=L.+Wuauthor=A.+M.+Gunawanauthor=L.+Wangauthor=R.+J.+Chanauthor=Z.-Y.+Zhang&title=Salicylic+Acid+Based+Small+Molecule+Inhibitor+for+the+Oncogenic+Src+homology-2+Domain+Containing+Protein+Tyrosine+Phosphatase-2+%28SHP2%29&doi=10.1021%2Fjm901645u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)</span></div><div class="casAuthors">Zhang, Xian; He, Yantao; Liu, Sijiu; Yu, Zhihong; Jiang, Zhong-Xing; Yang, Zhenyun; Dong, Yuanshu; Nabinger, Sarah C.; Wu, Li; Gunawan, Andrea M.; Wang, Lina; Chan, Rebecca J.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2482-2493</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Src homol.-2 domain contg. protein tyrosine phosphatase-2 (SHP2) plays a pivotal role in growth factor and cytokine signaling.  Gain-of-function SHP2 mutations are assocd. with Noonan syndrome, various kinds of leukemias, and solid tumors.  Thus, there is considerable interest in SHP2 as a potential target for anticancer and antileukemia therapy.  We report a salicylic acid based combinatorial library approach aimed at binding both active site and unique nearby subpockets for enhanced affinity and selectivity.  Screening of the library led to the identification of a SHP2 inhibitor II-B08 (compd. 9) with highly efficacious cellular activity.  Compd. 9 blocks growth factor stimulated ERK1/2 activation and hematopoietic progenitor proliferation, providing supporting evidence that chem. inhibition of SHP2 may be therapeutically useful for anticancer and antileukemia treatment.  X-ray crystallog. anal. of the structure of SHP2 in complex with 9 reveals mol. determinants that can be exploited for the acquisition of more potent and selective SHP2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC82T5JpCRArVg90H21EOLACvtfcHk0li1038H48pzTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFyhs7k%253D&md5=6f87897eda38ea485dc08e189f1b5ca8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm901645u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901645u%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DZ.-X.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DNabinger%26aufirst%3DS.%2BC.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26atitle%3DSalicylic%2520Acid%2520Based%2520Small%2520Molecule%2520Inhibitor%2520for%2520the%2520Oncogenic%2520Src%2520homology-2%2520Domain%2520Containing%2520Protein%2520Tyrosine%2520Phosphatase-2%2520%2528SHP2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2482%26epage%3D2493%26doi%3D10.1021%2Fjm901645u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pireddu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanski, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, M. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Src homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (Shp2) Based on Oxindole Scaffolds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4956</span>, <span class="refDoi"> DOI: 10.1021/jm8002526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8002526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptl2hu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4948-4956&author=H.+R.+Lawrenceauthor=R.+Piredduauthor=L.+Chenauthor=Y.+Luoauthor=S.-S.+Sungauthor=A.+M.+Szymanskiauthor=M.+L.+R.+Yipauthor=W.+C.+Guidaauthor=S.+M.+Sebtiauthor=J.+Wuauthor=N.+J.+Lawrence&title=Inhibitors+of+Src+homology-2+Domain+Containing+Protein+Tyrosine+Phosphatase-2+%28Shp2%29+Based+on+Oxindole+Scaffolds&doi=10.1021%2Fjm8002526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (Shp2) Based on Oxindole Scaffolds</span></div><div class="casAuthors">Lawrence, Harshani R.; Pireddu, Roberta; Chen, Liwei; Luo, Yunting; Sung, Shen-Shu; Szymanski, Ann Marie; Yip, M. L. Richard; Guida, Wayne C.; Sebti, Said M.; Wu, Jie; Lawrence, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4948-4956</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Screening of the NCI diversity set of compds. has led to the identification of NSC-117199, which inhibits the protein tyrosine phosphatase (PTP) Shp2 with an IC50 of 47 μM.  A focused library incorporating an isatin scaffold was designed and evaluated for inhibition of Shp2 and Shp1 PTP activities.  Several compds. were identified that selectively inhibit Shp2 over Shp1 and PTP1B with low to submicromolar activity.  A model for the binding of the active compds. is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRqLAauyGNBbVg90H21EOLACvtfcHk0li1038H48pzTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptl2hu7o%253D&md5=572227c5a8cfffb108388616bd36fdfe</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm8002526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8002526%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DPireddu%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSung%26aufirst%3DS.-S.%26aulast%3DSzymanski%26aufirst%3DA.%2BM.%26aulast%3DYip%26aufirst%3DM.%2BL.%2BR.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26atitle%3DInhibitors%2520of%2520Src%2520homology-2%2520Domain%2520Containing%2520Protein%2520Tyrosine%2520Phosphatase-2%2520%2528Shp2%2529%2520Based%2520on%2520Oxindole%2520Scaffolds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4948%26epage%3D4956%26doi%3D10.1021%2Fjm8002526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marasco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berteotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyershaeuser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorausch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikorska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krausze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamel, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, T.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanism of SHP2 Activation by PD-1 Stimulation</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">eaay4458</span> <span class="refDoi"> DOI: 10.1126/sciadv.aay4458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1126%2Fsciadv.aay4458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=32064351" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&author=M.+Marascoauthor=A.+Berteottiauthor=J.+Weyershaeuserauthor=N.+Thorauschauthor=J.+Sikorskaauthor=J.+Krauszeauthor=H.+J.+Brandtauthor=J.+Kirkpatrickauthor=P.+Riosauthor=W.+W.+Schamelauthor=M.+Kohnauthor=T.+Carlomagno&title=Molecular+Mechanism+of+SHP2+Activation+by+PD-1+Stimulation&doi=10.1126%2Fsciadv.aay4458"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aay4458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aay4458%26sid%3Dliteratum%253Aachs%26aulast%3DMarasco%26aufirst%3DM.%26aulast%3DBerteotti%26aufirst%3DA.%26aulast%3DWeyershaeuser%26aufirst%3DJ.%26aulast%3DThorausch%26aufirst%3DN.%26aulast%3DSikorska%26aufirst%3DJ.%26aulast%3DKrausze%26aufirst%3DJ.%26aulast%3DBrandt%26aufirst%3DH.%2BJ.%26aulast%3DKirkpatrick%26aufirst%3DJ.%26aulast%3DRios%26aufirst%3DP.%26aulast%3DSchamel%26aufirst%3DW.%2BW.%26aulast%3DKohn%26aufirst%3DM.%26aulast%3DCarlomagno%26aufirst%3DT.%26atitle%3DMolecular%2520Mechanism%2520of%2520SHP2%2520Activation%2520by%2520PD-1%2520Stimulation%26jtitle%3DSci.%2520Adv.%26date%3D2020%26volume%3D6%26doi%3D10.1126%2Fsciadv.aay4458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span> <span> </span><span class="NLM_article-title">Protein Tyrosine Phosphatases: Prospects for Therapeutics</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1016/s1367-5931(00)00223-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2FS1367-5931%2800%2900223-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=11470605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltlyqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2001&pages=416-423&author=Z.-Y.+Zhang&title=Protein+Tyrosine+Phosphatases%3A+Prospects+for+Therapeutics&doi=10.1016%2Fs1367-5931%2800%2900223-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine phosphatases: prospects for therapeutics</span></div><div class="casAuthors">Zhang, Z.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">416-423</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with refs.  Protein tyrosine phosphatases (PTPs) form a large family of enzymes that serve as key regulatory components in signal transduction pathways.  Recent gene knockout studies in mice identify PTP1B as a promising target for anti-diabetes/obesity drug discovery.  PTPs are also implicated in a wide variety of other disorders, including cancer.  Significant progress has been made in identifying small mols. that simultaneously bind both the active site and a unique adjacent site that enables specific inhibition of individual PTP isoenzymes.  As a consequence, there are compelling reasons to believe that PTP inhibitors may ultimately serve as powerful therapeutic weapons in the authors' arsenal for battling human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgujWWYVWfjbVg90H21EOLACvtfcHk0liWAVYHAyUqIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltlyqsLs%253D&md5=eee42d18a57b314321cffca4e3892ac1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS1367-5931%2800%2900223-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1367-5931%252800%252900223-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.-Y.%26atitle%3DProtein%2520Tyrosine%2520Phosphatases%253A%2520Prospects%2520for%2520Therapeutics%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2001%26volume%3D5%26spage%3D416%26epage%3D423%26doi%3D10.1016%2Fs1367-5931%2800%2900223-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of PTP1B Complexed With a Potent and Selective Bidentate Inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">12406</span>– <span class="NLM_lpage">12414</span>, <span class="refDoi"> DOI: 10.1074/jbc.m212491200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1074%2Fjbc.M212491200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=12547827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVOntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=12406-12414&author=J.-P.+Sunauthor=A.+A.+Fedorovauthor=S.-Y.+Leeauthor=X.-L.+Guoauthor=K.+Shenauthor=D.+S.+Lawrenceauthor=S.+C.+Almoauthor=Z.-Y.+Zhang&title=Crystal+Structure+of+PTP1B+Complexed+With+a+Potent+and+Selective+Bidentate+Inhibitor&doi=10.1074%2Fjbc.m212491200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of PTP1B Complexed with a Potent and Selective Bidentate Inhibitor</span></div><div class="casAuthors">Sun, Jin-Peng; Fedorov, Alexander A.; Lee, Seung-Yub; Guo, Xiao-Ling; Shen, Kui; Lawrence, David S.; Almo, Steven C.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">12406-12414</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase 1B (PTP1B) has been implicated as an important regulator in several signaling pathways including those initiated by insulin and leptin.  Potent and specific PTP1B inhibitors could serve as useful tools in elucidating the physiol. functions of PTP1B and may constitute valuable therapeutics in the treatment of several human diseases.  We have detd. the crystal structure of PTP1B in complex with compd. 2, the most potent and selective PTP1B inhibitor reported to date.  The structure at 2.15-Å resoln. reveals that compd. 2 simultaneously binds to the active site and a unique proximal noncatalytic site formed by Lys-41, Arg-47, and Asp-48.  The structural data are further corroborated by results from kinetic analyses of the interactions of PTP1B and its site-directed mutants with compd. 2 and several of its variants.  Although many of the residues important for interactions between PTP1B and compd. 2 are not unique to PTP1B, the combinations of all contact residues differ between PTP isoenzymes, which provide a structural basis for potent and selective PTP1B inhibition.  Our data further suggest that potent, yet highly selective, PTP1B inhibitory agents can be acquired by targeting the area defined by residues Lys-41, Arg-47, and Asp-48, in addn. to the previously identified second aryl phosphate-binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfSAHANv6sqbVg90H21EOLACvtfcHk0liWAVYHAyUqIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVOntLs%253D&md5=bf71f97839eb174ae4f644f72fb5289a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M212491200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M212491200%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.-P.%26aulast%3DFedorov%26aufirst%3DA.%2BA.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DGuo%26aufirst%3DX.-L.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DLawrence%26aufirst%3DD.%2BS.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26atitle%3DCrystal%2520Structure%2520of%2520PTP1B%2520Complexed%2520With%2520a%2520Potent%2520and%2520Selective%2520Bidentate%2520Inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D12406%26epage%3D12414%26doi%3D10.1074%2Fjbc.m212491200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntaganda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1781</span>– <span class="NLM_lpage">1792</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01725</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01725" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1781-1792&author=J.+T.+Bagdanoffauthor=Z.+Chenauthor=M.+Ackerauthor=Y.-N.+Chenauthor=H.+Chanauthor=M.+Doreauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=S.+Liuauthor=M.+Mohseniauthor=R.+Ntagandaauthor=P.+Sarverauthor=T.+Smithauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=C.+Towlerauthor=H.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=M.+J.+LaMarche&title=Optimization+of+Fused+Bicyclic+Allosteric+SHP2+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span></div><div class="casAuthors">Bagdanoff, Jeffrey T.; Chen, Zhouliang; Acker, Michael; Chen, Ying-Nan; Chan, Homan; Dore, Michael; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hentemann, Murphy; Kato, Mitsunori; Koenig, Robert; La Bonte, Laura R.; Liu, Shumei; Mohseni, Movarid; Ntaganda, Rukundo; Sarver, Patrick; Smith, Troy; Sendzik, Martin; Stams, Travis; Spence, Stan; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; La Marche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1781-1792</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a nonreceptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controlling cell growth, differentiation, and oncogenic transformation.  SHP2 also participates in the programed cell death pathway (PD-1/PD-L1) governing immune surveillance.  Small-mol. inhibition of SHP2 has been widely investigated, including in our previous reports describing SHP099 (2), which binds to a tunnel-like allosteric binding site.  To broaden our approach to allosteric inhibition of SHP2, we conducted addnl. hit finding, evaluation, and structure-based scaffold morphing.  These studies, reported here in the first of two papers, led to the identification of multiple 5,6-fused bicyclic scaffolds that bind to the same allosteric tunnel as 2.  We demonstrate the structural diversity permitted by the tunnel pharmacophore and culminated in the identification of pyrazolopyrimidinones (e.g., SHP389, 1) that modulate MAPK signaling in vivo.  These studies also served as the basis for further scaffold morphing and optimization, detailed in the following manuscript.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra2OF_vrNnP7Vg90H21EOLACvtfcHk0lgPExcEhkZGAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D&md5=e810a8a6bd1d1fb7bfadc5bc1448ff22</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01725%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.-N.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DDore%26aufirst%3DM.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DNtaganda%26aufirst%3DR.%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DOptimization%2520of%2520Fused%2520Bicyclic%2520Allosteric%2520SHP2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1781%26epage%3D1792%26doi%3D10.1021%2Facs.jmedchem.8b01725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.-L.</span></span> <span> </span><span class="NLM_article-title">Scaffold-based Novel SHP2 Allosteric Inhibitors Design Using Receptor-Ligand Pharmacophore Model, Virtual Screening and Molecular Dynamics</span>. <i>Comput. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1016/j.compbiolchem.2018.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.compbiolchem.2018.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=29494926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsF2kurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=179-188&author=W.-Y.+Jinauthor=Y.+Maauthor=W.-Y.+Liauthor=H.-L.+Liauthor=R.-L.+Wang&title=Scaffold-based+Novel+SHP2+Allosteric+Inhibitors+Design+Using+Receptor-Ligand+Pharmacophore+Model%2C+Virtual+Screening+and+Molecular+Dynamics&doi=10.1016%2Fj.compbiolchem.2018.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics</span></div><div class="casAuthors">Jin, Wen-Yan; Ma, Ying; Li, Wei-Ya; Li, Hong-Lian; Wang, Run-Ling</div><div class="citationInfo"><span class="NLM_cas:title">Computational Biology and Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">179-188</span>CODEN:
                <span class="NLM_cas:coden">CBCOCH</span>;
        ISSN:<span class="NLM_cas:issn">1476-9271</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SHP2 is a potential target for the development of novel therapies for SHP2-dependent cancers.  In our research, with the aid of the 'Receptor-Ligand Pharmacophore' technique, a 3D-QSAR method was carried out to explore structure activity relationship of SHP2 allosteric inhibitors.  Structure-based drug design was employed to optimize SHP099, an efficacious, potent, and selective SHP2 allosteric inhibitor.  A novel class of selective SHP2 allosteric inhibitors was discovered by using the powerful 'SBP', 'ADMET' and 'CDOCKER' techniques.  By means of mol. dynamics simulations, it was obsd. that these novel inhibitors not only had the same function as SHP099 did in inhibiting SHP2, but also had more favorable conformation for binding to the receptor.  Thus, this report may provide a new method in discovering novel and selective SHP2 allosteric inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzg1OlgVdJ5bVg90H21EOLACvtfcHk0lgPExcEhkZGAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsF2kurc%253D&md5=327433bbc88dbce0bdbda3369648e797</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.compbiolchem.2018.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.compbiolchem.2018.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DW.-Y.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.-Y.%26aulast%3DLi%26aufirst%3DH.-L.%26aulast%3DWang%26aufirst%3DR.-L.%26atitle%3DScaffold-based%2520Novel%2520SHP2%2520Allosteric%2520Inhibitors%2520Design%2520Using%2520Receptor-Ligand%2520Pharmacophore%2520Model%252C%2520Virtual%2520Screening%2520and%2520Molecular%2520Dynamics%26jtitle%3DComput.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D73%26spage%3D179%26epage%3D188%26doi%3D10.1016%2Fj.compbiolchem.2018.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellegast, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemulapalli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span> <span> </span><span class="NLM_article-title">Identification of an Allosteric Benzothiazolopyrimidone Inhibitor of the Oncogenic Protein Tyrosine Phosphatase SHP2</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6479</span>– <span class="NLM_lpage">6485</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmc.2017.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=29089257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A280%3ADC%252BC1M7mtlOksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=6479-6485&author=J.+R.+LaRochelleauthor=M.+Fodorauthor=J.+M.+Ellegastauthor=X.+Liuauthor=V.+Vemulapalliauthor=M.+Mohseniauthor=T.+Stamsauthor=S.+J.+Buhrlageauthor=K.+Stegmaierauthor=M.+J.+LaMarcheauthor=M.+G.+Ackerauthor=S.+C.+Blacklow&title=Identification+of+an+Allosteric+Benzothiazolopyrimidone+Inhibitor+of+the+Oncogenic+Protein+Tyrosine+Phosphatase+SHP2&doi=10.1016%2Fj.bmc.2017.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2</span></div><div class="casAuthors">LaRochelle Jonathan R; Liu Xiaoxi; Vemulapalli Vidyasiri; Buhrlage Sara J; Fodor Michelle; Stams Travis; Ellegast Jana M; Mohseni Morvarid; Acker Michael G; Stegmaier Kimberly; LaMarche Matthew J; Blacklow Stephen C</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6479-6485</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The PTPN11 oncogene encodes the cytoplasmic protein tyrosine phosphatase SHP2, which, through its role in multiple signaling pathways, promotes the progression of hematological malignancies and other cancers.  Here, we employ high-throughput screening to discover a lead chemical scaffold, the benzothiazolopyrimidones, that allosterically inhibits this oncogenic phosphatase by simultaneously engaging the C-SH2 and PTP domains.  We improved our lead to generate an analogue that better suppresses SHP2 activity in vitro.  Suppression of Erk phopsphorylation by the lead compound is also consistent with SHP2 inhibition in AML cells.  Our findings provide an alternative starting point for therapeutic intervention and will catalyze investigations into the relationship between SHP2 conformational regulation, activity, and disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQovWlxLHSQ4MRAV4D_Ins_fW6udTcc2ebUzinGIgMNF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7mtlOksA%253D%253D&md5=4425bb1a20f079aa02986fb0b8a082e7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DLaRochelle%26aufirst%3DJ.%2BR.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DEllegast%26aufirst%3DJ.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DVemulapalli%26aufirst%3DV.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26atitle%3DIdentification%2520of%2520an%2520Allosteric%2520Benzothiazolopyrimidone%2520Inhibitor%2520of%2520the%2520Oncogenic%2520Protein%2520Tyrosine%2520Phosphatase%2520SHP2%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D6479%26epage%3D6485%26doi%3D10.1016%2Fj.bmc.2017.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemulapalli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span> <span> </span><span class="NLM_article-title">Structural Reorganization of SHP2 by Oncogenic Mutations and Implications for Oncoprotein Resistance to Allosteric Inhibition</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4508</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-06823-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fs41467-018-06823-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=30375388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A280%3ADC%252BB3cvkslelsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4508&author=J.+R.+LaRochelleauthor=M.+Fodorauthor=V.+Vemulapalliauthor=M.+Mohseniauthor=P.+Wangauthor=T.+Stamsauthor=M.+J.+LaMarcheauthor=R.+Chopraauthor=M.+G.+Ackerauthor=S.+C.+Blacklow&title=Structural+Reorganization+of+SHP2+by+Oncogenic+Mutations+and+Implications+for+Oncoprotein+Resistance+to+Allosteric+Inhibition&doi=10.1038%2Fs41467-018-06823-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition</span></div><div class="casAuthors">LaRochelle Jonathan R; Vemulapalli Vidyasiri; Blacklow Stephen C; LaRochelle Jonathan R; Vemulapalli Vidyasiri; Blacklow Stephen C; Fodor Michelle; Mohseni Morvarid; Wang Ping; Stams Travis; LaMarche Matthew J; Chopra Rajiv; Acker Michael G</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4508</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Activating mutations in PTPN11, encoding the cytosolic protein tyrosine phosphatase SHP2, result in developmental disorders and act as oncogenic drivers in patients with hematologic cancers.  The allosteric inhibitor SHP099 stabilizes the wild-type SHP2 enzyme in an autoinhibited conformation that is itself destabilized by oncogenic mutations.  Here, we report the impact of the highly activated and most frequently observed mutation, E76K, on the structure of SHP2, and investigate the effect of E76K and other oncogenic mutations on allosteric inhibition by SHP099.  SHP2(E76K) adopts an open conformation but can be restored to the closed, autoinhibited conformation, near-identical to the unoccupied wild-type enzyme, when complexed with SHP099.  SHP099 inhibitory activity against oncogenic SHP2 variants in vitro and in cells scales inversely with the activating strength of the mutation, indicating that either oncoselective or vastly more potent inhibitors will be necessary to suppress oncogenic signaling by the most strongly activating SHP2 mutations in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRglXfZMl481dts4TFFB11gfW6udTcc2ebUzinGIgMNF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvkslelsA%253D%253D&md5=ceac9384173a0439b945b51f7bc65ea1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-06823-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-06823-9%26sid%3Dliteratum%253Aachs%26aulast%3DLaRochelle%26aufirst%3DJ.%2BR.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DVemulapalli%26aufirst%3DV.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26atitle%3DStructural%2520Reorganization%2520of%2520SHP2%2520by%2520Oncogenic%2520Mutations%2520and%2520Implications%2520for%2520Oncoprotein%2520Resistance%2520to%2520Allosteric%2520Inhibition%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D4508%26doi%3D10.1038%2Fs41467-018-06823-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, T. B. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.-X.</span></span> <span> </span><span class="NLM_article-title">Resistance to Allosteric SHP2 Inhibition in FGFR-Driven Cancers Through Rapid Feedback Activation of FGFR</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.27435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.18632%2Foncotarget.27435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=32076487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A280%3ADC%252BB387jvFCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=265-281&author=H.+Luauthor=C.+Liuauthor=H.+Huynhauthor=T.+B.+U.+Leauthor=M.+J.+LaMarcheauthor=M.+Mohseniauthor=J.+A.+Engelmanauthor=P.+S.+Hammermanauthor=G.+Caponigroauthor=H.-X.+Hao&title=Resistance+to+Allosteric+SHP2+Inhibition+in+FGFR-Driven+Cancers+Through+Rapid+Feedback+Activation+of+FGFR&doi=10.18632%2Foncotarget.27435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR</span></div><div class="casAuthors">Lu Hengyu; Liu Chen; Mohseni Morvarid; Engelman Jeffrey A; Hammerman Peter S; Caponigro Giordano; Hao Huai-Xiang; Huynh Hung; Le Thi Bich Uyen; LaMarche Matthew J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">265-281</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">SHP2 mediates RAS activation downstream of multiple receptor tyrosine kinases (RTKs) and cancer cell lines dependent on RTKs are in general dependent on SHP2.  Profiling of the allosteric SHP2 inhibitor SHP099 across cancer cell lines harboring various RTK dependencies reveals that FGFR-dependent cells are often insensitive to SHP099 when compared to EGFR-dependent cells.  We find that FGFR-driven cells depend on SHP2 but exhibit resistance to SHP2 inhibitors in vitro and in vivo.  Treatment of such models with SHP2 inhibitors results in an initial decrease in phosphorylated ERK1/2 (p-ERK) levels, however p-ERK levels rapidly rebound within two hours.  This p-ERK rebound is blocked by FGFR inhibitors or high doses of SHP2 inhibitors.  Mechanistically, compared with EGFR-driven cells, FGFR-driven cells tend to express high levels of RTK negative regulators such as the SPRY family proteins, which are rapidly downregulated upon ERK inhibition.  Moreover, over-expression of SPRY4 in FGFR-driven cells prevents MAPK pathway reactivation and sensitizes them to SHP2 inhibitors.  We also identified two novel combination approaches to enhance the efficacy of SHP2 inhibitors, either with a distinct site 2 allosteric SHP2 inhibitor or with a RAS-SOS1 interaction inhibitor.  Our findings suggest the rapid FGFR feedback activation following initial pathway inhibition by SHP2 inhibitors may promote the open conformation of SHP2 and lead to resistance to SHP2 inhibitors.  These findings may assist to refine patient selection and predict resistance mechanisms in the clinical development of SHP2 inhibitors and to suggest strategies for discovering SHP2 inhibitors that are more effective against upstream feedback activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4IpjIyuuylN-cVm4E2RlLfW6udTcc2ebUzinGIgMNF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387jvFCrug%253D%253D&md5=13f0863f77d980842bd0ba3981a65456</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.27435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.27435%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DHuynh%26aufirst%3DH.%26aulast%3DLe%26aufirst%3DT.%2BB.%2BU.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DHao%26aufirst%3DH.-X.%26atitle%3DResistance%2520to%2520Allosteric%2520SHP2%2520Inhibition%2520in%2520FGFR-Driven%2520Cancers%2520Through%2520Rapid%2520Feedback%2520Activation%2520of%2520FGFR%26jtitle%3DOncotarget%26date%3D2020%26volume%3D11%26spage%3D265%26epage%3D281%26doi%3D10.18632%2Foncotarget.27435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Emergence of Allosteric Drug-Resistance Mutations: New Challenges for Allosteric Drug Discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2019.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.drudis.2019.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=31634592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVaqtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=177-184&author=S.+Luauthor=Y.+Qiuauthor=D.+Niauthor=X.+Heauthor=J.+Puauthor=J.+Zhang&title=Emergence+of+Allosteric+Drug-Resistance+Mutations%3A+New+Challenges+for+Allosteric+Drug+Discovery&doi=10.1016%2Fj.drudis.2019.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of allosteric drug-resistance mutations: new challenges for allosteric drug discovery</span></div><div class="casAuthors">Lu, Shaoyong; Qiu, Yuran; Ni, Duan; He, Xinheng; Pu, Jun; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">177-184</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Allosteric drugs have several significant advantages over traditional orthosteric drugs, encompassing higher selectivity and lower toxicity.  Although allosteric drugs have potential advantages as therapeutic agents to treat human diseases, allosteric drug-resistance mutations still occur, rendering these drugs ineffective.  Here, we review the emergence of allosteric drug-resistance mutations with an emphasis on examples covering clin. important therapeutic targets, including Breakpoint cluster region-Abelson tyrosine kinase (Bcr-Abl), Akt kinase [also called Protein Kinase B (PKB)], isocitrate dehydrogenase (IDH), MAPK/ERK kinase (MEK), and SRC homol. 2 domain-contg. phosphatase 2 (SHP2).  We also discuss challenges assocd. with tackling allosteric drug resistance and the possible strategies to overcome this issue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4a4rK610lLLVg90H21EOLACvtfcHk0lgwawhBdvyTrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVaqtr3I&md5=052d6b87051bd173ab692aa963bdd3ea</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2019.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2019.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DPu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DEmergence%2520of%2520Allosteric%2520Drug-Resistance%2520Mutations%253A%2520New%2520Challenges%2520for%2520Allosteric%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D177%26epage%3D184%26doi%3D10.1016%2Fj.drudis.2019.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Leukemia-Associated SHP2(E69K) Mutant by the Allosteric SHP2 Inhibitor SHP099</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1246</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0020-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fs41375-018-0020-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=29568093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOmsrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1246-1249&author=X.+Sunauthor=Y.+Renauthor=S.+Gunawanauthor=P.+Tengauthor=Z.+Chenauthor=H.+Lawrenceauthor=J.+Caiauthor=N.+Lawrenceauthor=J.+Wu&title=Selective+Inhibition+of+Leukemia-Associated+SHP2%28E69K%29+Mutant+by+the+Allosteric+SHP2+Inhibitor+SHP099&doi=10.1038%2Fs41375-018-0020-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099</span></div><div class="casAuthors">Sun, X.; Ren, Y.; Gunawan, S.; Teng, P.; Chen, Z.; Lawrence, H. R.; Cai, J.; Lawrence, N. J.; Wu, J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1246-1249</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The article studies selective inhibition of leukemia-assocd. SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099.  Our findings here identify SHP2E69K as a SHP099-sensitive mutation, wherein three of four most common oncogenic SHP2 mutants studied here are resistant to SHP099.  Moreover, whether Noonan syndrome-assocd. SHP2 mutants are sensitive to SHP099 remained to be tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBQzBW1E1YhLVg90H21EOLACvtfcHk0lgwawhBdvyTrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOmsrrK&md5=2cb9342a2e06eac4b9d9043163e4095c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0020-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0020-5%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DGunawan%26aufirst%3DS.%26aulast%3DTeng%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLawrence%26aufirst%3DH.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DSelective%2520Inhibition%2520of%2520Leukemia-Associated%2520SHP2%2528E69K%2529%2520Mutant%2520by%2520the%2520Allosteric%2520SHP2%2520Inhibitor%2520SHP099%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D1246%26epage%3D1249%26doi%3D10.1038%2Fs41375-018-0020-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Backer, L. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raveendra-Panickar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celeridad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotegut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodiles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holleran, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergienko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosford, N. D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tautz, L.</span></span> <span> </span><span class="NLM_article-title">A Cellular Target Engagement Assay for the Characterization of SHP2 (PTPN11) Phosphatase Inhibitors</span>. <i>J. Bio. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>295</i></span>,  <span class="NLM_fpage">2601</span>– <span class="NLM_lpage">2613</span>, <span class="refDoi"> DOI: 10.1074/jbc.ra119.010838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1074%2Fjbc.RA119.010838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=31953320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFOiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2020&pages=2601-2613&author=C.+Romeroauthor=L.+J.+Lambertauthor=D.+J.+Shefflerauthor=L.+J.+S.+De+Backerauthor=D.+Raveendra-Panickarauthor=M.+Celeridadauthor=S.+Grotegutauthor=S.+Rodilesauthor=J.+Holleranauthor=E.+Sergienkoauthor=E.+B.+Pasqualeauthor=N.+D.+P.+Cosfordauthor=L.+Tautz&title=A+Cellular+Target+Engagement+Assay+for+the+Characterization+of+SHP2+%28PTPN11%29+Phosphatase+Inhibitors&doi=10.1074%2Fjbc.ra119.010838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors</span></div><div class="casAuthors">Romero, Celeste; Lambert, Lester J.; Sheffler, Douglas J.; De Backer, Laurent J. S.; Raveendra-Panickar, Dhanya; Celeridad, Maria; Grotegut, Stefan; Rodiles, Socorro; Holleran, John; Sergienko, Eduard; Pasquale, Elena B.; Cosford, Nicholas D. P.; Tautz, Lutz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2601-2613</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">1083-351X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The nonreceptor protein-tyrosine phosphatase (PTP) SHP2 is encoded by the proto-oncogene PTPN11 and is a ubiquitously expressed key regulator of cell signaling, acting on a no. of cellular processes and components, including the Ras/Raf/Erk, PI3K/Akt, and JAK/STAT pathways and immune checkpoint receptors.  Aberrant SHP2 activity has been implicated in all phases of tumor initiation, progression, and metastasis.  Gain-of-function PTPN11 mutations drive oncogenesis in several leukemias and cause developmental disorders with increased risk of malignancy such as Noonan syndrome.  Until recently, small mol.-based targeting of SHP2 was hampered by the failure of orthosteric active-site inhibitors to achieve selectivity and potency within a useful therapeutic window.  However, new SHP2 allosteric inhibitors with excellent potency and selectivity have sparked renewed interest in the selective targeting of SHP2 and other PTP family members.  Crucially, drug discovery campaigns focusing on SHP2 would greatly benefit from the ability to validate the cellular target engagement of candidate inhibitors.  Here, we report a cellular thermal shift assay that reliably detects target engagement of SHP2 inhibitors.  Using this assay, based on the DiscoverX InCell Pulse enzyme complementation technol., we characterized the binding of several SHP2 allosteric inhibitors in intact cells.  Moreover, we demonstrate the robustness and reliability of a 384-well miniaturized version of the assay for the screening of SHP2 inhibitors targeting either WT SHP2 or its oncogenic E76K variant.  Finally, we provide an example of the assay's ability to identify and characterize novel compds. with specific cellular potency for either WT or mutant SHP2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp919MGtTF9nrVg90H21EOLACvtfcHk0lgwawhBdvyTrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFOiu7k%253D&md5=e744bad7159435d110927ffad19cba00</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.010838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.010838%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DC.%26aulast%3DLambert%26aufirst%3DL.%2BJ.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DDe%2BBacker%26aufirst%3DL.%2BJ.%2BS.%26aulast%3DRaveendra-Panickar%26aufirst%3DD.%26aulast%3DCeleridad%26aufirst%3DM.%26aulast%3DGrotegut%26aufirst%3DS.%26aulast%3DRodiles%26aufirst%3DS.%26aulast%3DHolleran%26aufirst%3DJ.%26aulast%3DSergienko%26aufirst%3DE.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DCosford%26aufirst%3DN.%2BD.%2BP.%26aulast%3DTautz%26aufirst%3DL.%26atitle%3DA%2520Cellular%2520Target%2520Engagement%2520Assay%2520for%2520the%2520Characterization%2520of%2520SHP2%2520%2528PTPN11%2529%2520Phosphatase%2520Inhibitors%26jtitle%3DJ.%2520Bio.%2520Chem.%26date%3D2020%26volume%3D295%26spage%3D2601%26epage%3D2613%26doi%3D10.1074%2Fjbc.ra119.010838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hellmuth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosskopf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurtele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roder, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kries, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span> <span> </span><span class="NLM_article-title">Specific Inhibitors of the Protein Tyrosine Phosphatase Shp2 Identified by High-Throughput Docking</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">7275</span>– <span class="NLM_lpage">7280</span>, <span class="refDoi"> DOI: 10.1073/pnas.0710468105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1073%2Fpnas.0710468105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=18480264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFCqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=7275-7280&author=K.+Hellmuthauthor=S.+Grosskopfauthor=C.+T.+Lumauthor=M.+Wurteleauthor=N.+Roderauthor=J.+P.+von+Kriesauthor=M.+Rosarioauthor=J.+Rademannauthor=W.+Birchmeier&title=Specific+Inhibitors+of+the+Protein+Tyrosine+Phosphatase+Shp2+Identified+by+High-Throughput+Docking&doi=10.1073%2Fpnas.0710468105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking</span></div><div class="casAuthors">Hellmuth, Klaus; Grosskopf, Stefanie; Lum, Ching Tung; Wuertele, Martin; Roeder, Nadine; von Kries, Jens Peter; Rosario, Marta; Rademann, Jorg; Birchmeier, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7275-7280</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The protein tyrosine phosphatase Shp2 is a pos. regulator of growth factor signaling.  Gain-of-function mutations in several types of leukemia define Shp2 as a bona fide oncogene.  We performed a high-throughput in silico screen for small-mol.-wt. compds. that bind the catalytic site of Shp2.  We have identified the phenylhydrazonopyrazolone sulfonate PHPS1 as a potent and cell-permeable inhibitor, which is specific for Shp2 over the closely related tyrosine phosphatases Shp1 and PTP1 B.  PHPS1 inhibits Shp2-dependent cellular events such as hepatocyte growth factor/scatter factor (HGF/SF)-induced epithelial cell scattering and branching morphogenesis.  PHPS1 also blocks Shp2-dependent downstream signaling, namely HGF/SF-induced sustained phosphorylation of the Erk1/2 MAP kinases and dephosphorylation of paxillin.  Furthermore, PHPS1 efficiently inhibits activation of Erk1/2 by the leukemia-assocd. Shp2 mutant, Shp2-E76K, and blocks the anchorage-independent growth of a variety of human tumor cell lines.  The PHPS compd. class is therefore suitable for further development of therapeutics for the treatment of Shp2-dependent diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGponh1kw_h7jrVg90H21EOLACvtfcHk0ljY3klkrAQnKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFCqsLs%253D&md5=39c7dda94e32134c305e135e4c48b9d1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0710468105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0710468105%26sid%3Dliteratum%253Aachs%26aulast%3DHellmuth%26aufirst%3DK.%26aulast%3DGrosskopf%26aufirst%3DS.%26aulast%3DLum%26aufirst%3DC.%2BT.%26aulast%3DWurtele%26aufirst%3DM.%26aulast%3DRoder%26aufirst%3DN.%26aulast%3Dvon%2BKries%26aufirst%3DJ.%2BP.%26aulast%3DRosario%26aufirst%3DM.%26aulast%3DRademann%26aufirst%3DJ.%26aulast%3DBirchmeier%26aufirst%3DW.%26atitle%3DSpecific%2520Inhibitors%2520of%2520the%2520Protein%2520Tyrosine%2520Phosphatase%2520Shp2%2520Identified%2520by%2520High-Throughput%2520Docking%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D7275%26epage%3D7280%26doi%3D10.1073%2Fpnas.0710468105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grosskopf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radetzki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kries, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibitors of the Protein Tyrosine Phosphatase SHP2 Block Cellular Motility and Growth of Cancer Cells In Vitro and In Vivo</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2Fcmdc.201500015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=25877780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFers7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=815-826&author=S.+Grosskopfauthor=C.+Eckertauthor=C.+Arkonaauthor=S.+Radetzkiauthor=K.+B%C3%B6hmauthor=U.+Heinemannauthor=G.+Wolberauthor=J.-P.+von+Kriesauthor=W.+Birchmeierauthor=J.+Rademann&title=Selective+Inhibitors+of+the+Protein+Tyrosine+Phosphatase+SHP2+Block+Cellular+Motility+and+Growth+of+Cancer+Cells+In+Vitro+and+In+Vivo&doi=10.1002%2Fcmdc.201500015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibitors of the Protein Tyrosine Phosphatase SHP2 Block Cellular Motility and Growth of Cancer Cells in vitro and in vivo</span></div><div class="casAuthors">Grosskopf, Stefanie; Eckert, Chris; Arkona, Christoph; Radetzki, Silke; Boehm, Kerstin; Heinemann, Udo; Wolber, Gerhard; von Kries, Jens-Peter; Birchmeier, Walter; Rademann, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">815-826</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective inhibitors of the protein tyrosine phosphatase SHP2 (src homol. region 2 domain phosphatase; PTPN11), an enzyme that is deregulated in numerous human tumors, were generated through a combination of chem. synthesis and structure-based rational design.  Seventy pyridazolon-4-ylidenehydrazinyl benzenesulfonates were prepd. and evaluated in enzyme assays.  The binding modes of active inhibitors were simulated in silico using a newly generated crystal structure of SHP2.  The most powerful compd. I inhibited SHP2 with an IC50 value of 71±15 nM in the enzyme assay and was 29- and 45-fold more active toward SHP2 than against related SHP1 and PTP1B.  In cell culture expts. compd. I was found to block hepatocyte growth factor (HGF)-stimulated epithelial-mesenchymal transition of human pancreatic adenocarcinoma (HPAF) cells, as indicated by a decrease in the min. neighbor distances of cells.  Moreover, I inhibited cell colony formation in the nonsmall-cell lung cancer cell line LXFA 526 L in soft agar.  Finally, I was obsd. to inhibit tumor growth in a murine xenograft model.  Therefore, the novel specific compd. I strengthens the hypothesis that SHP2 is a relevant protein target for the inhibition of mobility and invasiveness of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovDT-98edFurVg90H21EOLACvtfcHk0ljY3klkrAQnKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFers7g%253D&md5=72fa2915b67c514076144b3005441b17</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500015%26sid%3Dliteratum%253Aachs%26aulast%3DGrosskopf%26aufirst%3DS.%26aulast%3DEckert%26aufirst%3DC.%26aulast%3DArkona%26aufirst%3DC.%26aulast%3DRadetzki%26aufirst%3DS.%26aulast%3DB%25C3%25B6hm%26aufirst%3DK.%26aulast%3DHeinemann%26aufirst%3DU.%26aulast%3DWolber%26aufirst%3DG.%26aulast%3Dvon%2BKries%26aufirst%3DJ.-P.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DRademann%26aufirst%3DJ.%26atitle%3DSelective%2520Inhibitors%2520of%2520the%2520Protein%2520Tyrosine%2520Phosphatase%2520SHP2%2520Block%2520Cellular%2520Motility%2520and%2520Growth%2520of%2520Cancer%2520Cells%2520In%2520Vitro%2520and%2520In%2520Vivo%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D815%26epage%3D826%26doi%3D10.1002%2Fcmdc.201500015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gannett, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, B.</span></span> <span> </span><span class="NLM_article-title">Aryl Radical Formation During the Metabolism of Arylhydrazines by Microsomes</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1372</span>– <span class="NLM_lpage">1377</span>, <span class="refDoi"> DOI: 10.1021/tx970084y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx970084y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK2sXnsFOls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1997&pages=1372-1377&author=P.+M.+Gannettauthor=X.+Shiauthor=T.+Lawsonauthor=C.+Kolarauthor=B.+Toth&title=Aryl+Radical+Formation+During+the+Metabolism+of+Arylhydrazines+by+Microsomes&doi=10.1021%2Ftx970084y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Aryl Radical Formation during the Metabolism of Arylhydrazines by Microsomes</span></div><div class="casAuthors">Gannett, Peter M.; Shi, Xiangling; Lawson, Terence; Kolar, Carol; Toth, Bela</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1372-1377</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here we have looked for the formation of aryl radicals from arylhydrazines and microsomes by ESR spin trapping.  Only hydroxyl radicals are trapped upon incubation of p-methylphenylhydrazine with rat liver microsomes and 5,5-dimethyl-1-pyrroline N-oxide (DMPO).  However, hydroxyl and aryl radicals were trapped upon incubation of p-(methoxymethyl)phenylhydrazine with rat liver microsomes.  Evidence for hydroperoxyl radical formation was also obtained.  In contrast, when either of these substrates was incubated with microsomes from C5O cells, aryl and hydroxyl radicals were trapped.  The ESR signal intensity of the spin-trapped aryl radicals parallels the extent of C8-arylguanine formation in DNA, and therefore, the aryl radical is likely the intermediate responsible for C8-arylguanine adduct formation.  Aryl radicals and C8-arylguanine adducts may be related to the genotoxicity of arylhydrazines and related compds. that are oxidatively metabolized to arenediazonium ions, the precursor to aryl radicals, including arylalkyl nitrosamines, arylazo compds., and triazenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP1mMMJeouprVg90H21EOLACvtfcHk0ljY3klkrAQnKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsFOls7o%253D&md5=b5aea2acb5f1d4ed20721b35244fdf53</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Ftx970084y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx970084y%26sid%3Dliteratum%253Aachs%26aulast%3DGannett%26aufirst%3DP.%2BM.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DLawson%26aufirst%3DT.%26aulast%3DKolar%26aufirst%3DC.%26aulast%3DToth%26aufirst%3DB.%26atitle%3DAryl%2520Radical%2520Formation%2520During%2520the%2520Metabolism%2520of%2520Arylhydrazines%2520by%2520Microsomes%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1997%26volume%3D10%26spage%3D1372%26epage%3D1377%26doi%3D10.1021%2Ftx970084y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span> <span> </span><span class="NLM_article-title">Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00903</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00903" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=36-44&author=J.+B.+Baellauthor=J.+W.+M.+Nissink&title=Seven+Year+Itch%3A+Pan-Assay+Interference+Compounds+%28PAINS%29+in+2017-Utility+and+Limitations&doi=10.1021%2Facschembio.7b00903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations</span></div><div class="casAuthors">Baell, Jonathan B.; Nissink, J. Willem M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on all necessary considerations for the appropriate use of PAINs filters formulated to process hundreds and thousands of compds. in seconds, and identify PAINS in order to exclude them from further anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocZ7E_j7zxfbVg90H21EOLACvtfcHk0lgQ4WMM-oNW5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bK&md5=051115704137d6a91b8271702c619682</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00903%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26atitle%3DSeven%2520Year%2520Itch%253A%2520Pan-Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520in%25202017-Utility%2520and%2520Limitations%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D36%26epage%3D44%26doi%3D10.1021%2Facschembio.7b00903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murdock, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, S. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, M.-W.</span></span> <span> </span><span class="NLM_article-title">Effects of the Nitro-Group on the Mutagenicity and Toxicity of Some Benzamines</span>. <i>Environ. Mol. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1002/(sici)1098-2280(1996)27:1<67::aid-em9>3.0.co;2-b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2F%28SICI%291098-2280%281996%2927%3A1%3C67%3A%3AAID-EM9%3E3.0.CO%3B2-B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=8625950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK28XhsVOnt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1996&pages=67-74&author=K.-T.+Chungauthor=C.+A.+Murdockauthor=Y.+Zhouauthor=S.+E.+Stevensauthor=Y.-S.+Liauthor=C.-I.+Weiauthor=S.+Y.+Fernandoauthor=M.-W.+Chou&title=Effects+of+the+Nitro-Group+on+the+Mutagenicity+and+Toxicity+of+Some+Benzamines&doi=10.1002%2F%28sici%291098-2280%281996%2927%3A1%3C67%3A%3Aaid-em9%3E3.0.co%3B2-b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the nitro-group on the mutagenicity and toxicity of some benzamines</span></div><div class="casAuthors">Chung, King-Thom; Murdock, Chris A.; Zhou, Yonggui; Stevens, S. Edward, Jr.; Li, Ying-Sing; Wei, Cheng-I.; Fernando, S. Y.; Chou, Ming-W.</div><div class="citationInfo"><span class="NLM_cas:title">Environmental and Molecular Mutagenesis</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-74</span>CODEN:
                <span class="NLM_cas:coden">EMMUEG</span>;
        ISSN:<span class="NLM_cas:issn">0893-6692</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss</span>)
        </div><div class="casAbstract">The Ames Salmonella/microsomal assay was employed to test the mutagenicity of some benzamines (aniline, and o- and p-phenylenediamine) and their nitro-derivs. (p-nitroaniline, 2-nitro-p-phenylenediamine, 3- and 4-nitro-o-phenylenediamine), using strains TA98 and TA100 and their nitroreductase-deficient mutants, TA98NR and TA100NR, in the presence and absence of rat S9 mix.  The addn. of the nitro-group to benzamine mols. converted them into direct mutagens.  Furthermore, the position of the nitro-group affected their mutagenic activities.  Cytotoxicity testing with Chinese hamster ovary cells (CHO-K1) showed that the presence of the nitro-group in these compds. had no specific effect on toxicity.  The test compds. all showed a dose-related increase in inducing chromosomal aberration in CHO cells.  However, the presence of the nitro-group did not affect potency in inducing chromosomal aberrations.  Compds. contg. the nitro-group had higher initial oxidn. potentials and dipole moments (μ) than their nonnitro-contg. counterparts.  The mutagenicity and toxicity of these compds. were not related to physico-chem. properties, including oxidn. potential, energy difference (ΔE) between the LUMO and the HOMO, ionization potential (I.P.), and μ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFWlQRb-YEIrVg90H21EOLACvtfcHk0lgQ4WMM-oNW5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsVOnt78%253D&md5=baa95de9846ca0b18287f02e5dbff02f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291098-2280%281996%2927%3A1%3C67%3A%3AAID-EM9%3E3.0.CO%3B2-B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291098-2280%25281996%252927%253A1%253C67%253A%253AAID-EM9%253E3.0.CO%253B2-B%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DK.-T.%26aulast%3DMurdock%26aufirst%3DC.%2BA.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DStevens%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DY.-S.%26aulast%3DWei%26aufirst%3DC.-I.%26aulast%3DFernando%26aufirst%3DS.%2BY.%26aulast%3DChou%26aufirst%3DM.-W.%26atitle%3DEffects%2520of%2520the%2520Nitro-Group%2520on%2520the%2520Mutagenicity%2520and%2520Toxicity%2520of%2520Some%2520Benzamines%26jtitle%3DEnviron.%2520Mol.%2520Mutagen.%26date%3D1996%26volume%3D27%26spage%3D67%26epage%3D74%26doi%3D10.1002%2F%28sici%291098-2280%281996%2927%3A1%3C67%3A%3Aaid-em9%3E3.0.co%3B2-b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macherey, A. C.</span>; <span class="NLM_string-name">Dansette, P. M.</span></span> <span> </span><span class="NLM_article-title">Biotransformations Leading to Toxic Metabolites</span>. In  <i>The Practice of Medicinal Chemistry</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wermuth, C.</span>, <span class="NLM_string-name">Aldous, D.</span>, <span class="NLM_string-name">Raboisson, P.</span>, <span class="NLM_string-name">Rognan, D.</span></span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2015</span>; pp  <span class="NLM_fpage">675</span>– <span class="NLM_lpage">696</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2FB978-0-12-417205-0.00025-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=675-696&author=A.+C.+Macherey&author=P.+M.+Dansetteauthor=C.+Wermuth&author=D.+Aldous&author=P.+Raboisson&author=D.+Rognan&title=The+Practice+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-417205-0.00025-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-417205-0.00025-0%26sid%3Dliteratum%253Aachs%26aulast%3DMacherey%26aufirst%3DA.%2BC.%26atitle%3DBiotransformations%2520Leading%2520to%2520Toxic%2520Metabolites%26btitle%3DThe%2520Practice%2520of%2520Medicinal%2520Chemistry%26aulast%3DWermuth%26aufirst%3DC.%26pub%3DAcademic%2520Press%26date%3D2015%26spage%3D675%26epage%3D696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslait73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1701-1714&author=M.+D.+Shultz&title=Two+Decades+under+the+Influence+of+the+Rule+of+Five+and+the+Changing+Properties+of+Approved+Oral+Drugs&doi=10.1021%2Facs.jmedchem.8b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1701-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two decades have passed since the rule of five ushered in the concept of "drug-like" properties.  Attempts to quantify, correlate, and categorize mols. based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines.  Examn. of oral drug parameters approved before and after the original Ro5 anal. demonstrates that some parameters such as clogP and HBD remained const. while the cutoffs for parameters such as mol. wt. and HBA have increased substantially over the past 20 years.  The time dependent increase in the mol. wt. of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that mol. wt. is a "drug-like" property.  This anal. does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAnoxpQsv2kbVg90H21EOLACvtfcHk0lgQ4WMM-oNW5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslait73K&md5=d3c8b1107133dc0b7b277d22fa029597</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00686%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DTwo%2520Decades%2520under%2520the%2520Influence%2520of%2520the%2520Rule%2520of%2520Five%2520and%2520the%2520Changing%2520Properties%2520of%2520Approved%2520Oral%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1701%26epage%3D1714%26doi%3D10.1021%2Facs.jmedchem.8b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldblum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span> <span> </span><span class="NLM_article-title">Understanding Drug-Likeness</span>. <i>Wiley Interdiscip. Rev.: Comput. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1002/wcms.52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2Fwcms.52" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWrtrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=760-781&author=O.+Ursuauthor=A.+Rayanauthor=A.+Goldblumauthor=T.+I.+Oprea&title=Understanding+Drug-Likeness&doi=10.1002%2Fwcms.52"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding drug-likeness</span></div><div class="casAuthors">Ursu, Oleg; Rayan, Anwar; Goldblum, Amiram; Oprea, Tudor I.</div><div class="citationInfo"><span class="NLM_cas:title">Wiley Interdisciplinary Reviews: Computational Molecular Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">760-781</span>CODEN:
                <span class="NLM_cas:coden">WIRCAH</span>;
        ISSN:<span class="NLM_cas:issn">1759-0884</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  "Drug-likeness", a qual. property of chems. assigned by experts committee vote, is wedely integrated into the early stages of lead and drug discovery.  Its conceptual evolution paralleled work related to Pfizer's "rule of five" and lead-likeness, and is placed within this framework.  The discrimination between "drugs" (represented by a collection of pharmaceutically relevant small mols., some of which are marketed drugs) and "nondrugs" (typically, chem. reagents) is possible using a wide variety of statistical tools and chem. descriptor systems.  Here we summarize 18 papers focused on drug-likeness, and provide a comprehensive overview of progress in the field.  Tools that est. drug-likeness are valuable in the early stages of lead discovery, and can be used to filter out compds. with undersirable properties from screening libraries and to prioritize hits from primary screens.  As the goal is, most often, to develop orally available drugs, it is also useful to optimize drug-like pharmacokinetic properties.  We examine tools that evaluate drug-likeness and some of their shortcomings, challenges facing these tools, and address the following issues: What is the definition of drug-likeness and how can it be utilized to reduce attrition rate in drug discovery.  How difficult is it to distinguish drugs from nondrugs.  Are nondrug datasets reliable.  Can we est. oral drug-likeness.  We discuss a drug-like filter and recent advances in the prediction of oral drug-likeness.  The heuristic aspect of drug-likeness is also addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeTi02F5W647Vg90H21EOLACvtfcHk0lgDRu32DE29TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWrtrbO&md5=3cd46a7a7a082d6d3730e6bbf16712d2</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fwcms.52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwcms.52%26sid%3Dliteratum%253Aachs%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DRayan%26aufirst%3DA.%26aulast%3DGoldblum%26aufirst%3DA.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26atitle%3DUnderstanding%2520Drug-Likeness%26jtitle%3DWiley%2520Interdiscip.%2520Rev.%253A%2520Comput.%2520Mol.%2520Sci.%26date%3D2011%26volume%3D1%26spage%3D760%26epage%3D781%26doi%3D10.1002%2Fwcms.52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosey, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span> <span> </span><span class="NLM_article-title">BDDCS, the Rule of 5 and Drugability</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2016.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.addr.2016.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=27182629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFOisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2016&pages=89-98&author=L.+Z.+Benetauthor=C.+M.+Hoseyauthor=O.+Ursuauthor=T.+I.+Oprea&title=BDDCS%2C+the+Rule+of+5+and+Drugability&doi=10.1016%2Fj.addr.2016.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">BDDCS, the Rule of 5 and drugability</span></div><div class="casAuthors">Benet, Leslie Z.; Hosey, Chelsea M.; Ursu, Oleg; Oprea, Tudor I.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The Rule of 5 methodol. appears to be as useful today in defining drugability as when it was proposed, but recognizing that the database that we used includes only drugs that successfully reached the market.  We do not view addnl. criteria necessary nor did we find significant deficiencies in the four Rule of 5 criteria originally proposed by Lipinski and coworkers.  BDDCS builds upon the Rule of 5 and can quite successfully predict drug disposition characteristics for drugs both meeting and not meeting Rule of 5 criteria.  More recent expansions of classification systems have been proposed and do provide useful qual. and quant. predictions for clearance relationships.  However, the broad range of applicability of BDDCS beyond just clearance predictions gives a great deal of further usefulness for the combined Rule of 5/BDDCS system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF2rl3biM_77Vg90H21EOLACvtfcHk0lgDRu32DE29TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFOisLk%253D&md5=4512bd3c8f7eb921f91fbb9487f9cbb3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DHosey%26aufirst%3DC.%2BM.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26atitle%3DBDDCS%252C%2520the%2520Rule%2520of%25205%2520and%2520Drugability%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D101%26spage%3D89%26epage%3D98%26doi%3D10.1016%2Fj.addr.2016.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span> <span> </span><span class="NLM_article-title">Bioisosteres and Scaffold Hopping in Medicinal Chemistry</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1002/minf.201400037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2Fminf.201400037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=27485983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovFCmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=458-462&author=N.+Brown&title=Bioisosteres+and+Scaffold+Hopping+in+Medicinal+Chemistry&doi=10.1002%2Fminf.201400037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteres and Scaffold Hopping in Medicinal Chemistry</span></div><div class="casAuthors">Brown, Nathan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">458-462</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The twin concepts of bioisosteric replacement and scaffold hopping are increasingly becoming important in modern drug design.  The concepts of isosterism stretch back over a century, but only recently have systematic and data-intensive methods been used to explore appropriate replacements.  Here, a summary of the history of bioisosterism is presented to provide context to the methods applied.  Mol. similarity and data mining methods are introduced as approaches to introduce these replacements to rationalise the space of synthetic targets to consider in a medicinal chem. project.  Lastly, an outlook of the field is given of potential future improvements and areas of focus that should be considered to anyone interested in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjI1uBH0tL3rVg90H21EOLACvtfcHk0lgDRu32DE29TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovFCmtbc%253D&md5=01b5cfa1427ae7e038cf4478bf07be5a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fminf.201400037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201400037%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%26atitle%3DBioisosteres%2520and%2520Scaffold%2520Hopping%2520in%2520Medicinal%2520Chemistry%26jtitle%3DMol.%2520Inf.%26date%3D2014%26volume%3D33%26spage%3D458%26epage%3D462%26doi%3D10.1002%2Fminf.201400037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langdon, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span> <span> </span><span class="NLM_article-title">Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1002/minf.201000019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2Fminf.201000019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=27463193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsVSgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=366-385&author=S.+R.+Langdonauthor=P.+Ertlauthor=N.+Brown&title=Bioisosteric+Replacement+and+Scaffold+Hopping+in+Lead+Generation+and+Optimization&doi=10.1002%2Fminf.201000019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization</span></div><div class="casAuthors">Langdon, Sarah R.; Ertl, Peter; Brown, Nathan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">366-385</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Bioisosteric replacement and scaffold hopping are twin methods used in drug design to improve the synthetic accessibility, potency and drug like properties of a compd. and to move into novel chem. space.  Bioisosteric replacement involves swapping functional groups of a mol. with other functional groups that have similar biol. properties.  Scaffold hopping is the replacement of the core framework of a mol. with another scaffold that will improve the properties of the mol. or to find similar potent compds. that exist in novel chem. space.  This review outlines the key concepts, importance and challenges of both methods using examples and comparisons of techniques available for finding bioisosteric replacements and scaffold hops.  There are many methods available for bioisosteric replacement and scaffold hopping, all with their own advantages and disadvantages.  Drug design projects would benefit from a combination of these methods to retrieve diverse and complimentary results.  Continuing progress in these fields will allow further validation of both methods as well as the accumulation of knowledge on bioisosteres and possible scaffold replacements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJsbL69-PF-7Vg90H21EOLACvtfcHk0lgDRu32DE29TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsVSgur4%253D&md5=372b9094a34108fb978f5d9fa95831cd</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fminf.201000019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201000019%26sid%3Dliteratum%253Aachs%26aulast%3DLangdon%26aufirst%3DS.%2BR.%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DN.%26atitle%3DBioisosteric%2520Replacement%2520and%2520Scaffold%2520Hopping%2520in%2520Lead%2520Generation%2520and%2520Optimization%26jtitle%3DMol.%2520Inf.%26date%3D2010%26volume%3D29%26spage%3D366%26epage%3D385%26doi%3D10.1002%2Fminf.201000019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span> <span> </span><span class="NLM_article-title">Intramolecular Hydrogen Bonding in Medicinal Chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2601</span>– <span class="NLM_lpage">2611</span>, <span class="refDoi"> DOI: 10.1021/jm100087s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100087s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Clur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2601-2611&author=B.+Kuhnauthor=P.+Mohrauthor=M.+Stahl&title=Intramolecular+Hydrogen+Bonding+in+Medicinal+Chemistry&doi=10.1021%2Fjm100087s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Intramolecular Hydrogen Bonding in Medicinal Chemistry</span></div><div class="casAuthors">Kuhn, Bernd; Mohr, Peter; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2601-2611</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The formation of intramol. hydrogen bonds has a very pronounced effect on mol. structure and properties.  We study both aspects in detail with the aim of enabling a more rational use of this class of interactions in medicinal chem.  On the basis of exhaustive searches in crystal structure databases, we derive propensities for intramol. hydrogen bond formation of five- to eight-membered ring systems of relevance in drug discovery.  A no. of motifs, several of which are clearly underutilized in drug discovery, are analyzed in more detail by comparing small mol. and protein-ligand X-ray structures.  To investigate effects on physicochem. properties, sets of closely related structures with and without the ability to form intramol. hydrogen bonds were designed, synthesized, and characterized with respect to membrane permeability, water soly., and lipophilicity.  We find that changes in these properties depend on a subtle balance between the strength of the hydrogen bond interaction, geometry of the newly formed ring system, and the relative energies of the open and closed conformations in polar and unpolar environments.  A no. of general guidelines for medicinal chemists emerge from this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdaV7tFRU4k7Vg90H21EOLACvtfcHk0ljbLQvVPs5SPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Clur8%253D&md5=b9b6865dfcc9bdf7796d15218f6e8ff2</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm100087s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100087s%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DIntramolecular%2520Hydrogen%2520Bonding%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2601%26epage%3D2611%26doi%3D10.1021%2Fjm100087s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uang, B.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H.-P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Inhibitors of Aurora Kinases with Indazole Scaffold: In Silico Fragment-Based and Knowledge-Based Drug Design</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.08.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.ejmech.2016.08.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=27573544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVaktbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=186-199&author=C.-F.+Changauthor=W.-H.+Linauthor=Y.-Y.+Keauthor=Y.-S.+Linauthor=W.-C.+Wangauthor=C.-H.+Chenauthor=P.-C.+Kuoauthor=J.+T.+A.+Hsuauthor=B.-J.+Uangauthor=H.-P.+Hsieh&title=Discovery+of+Novel+Inhibitors+of+Aurora+Kinases+with+Indazole+Scaffold%3A+In+Silico+Fragment-Based+and+Knowledge-Based+Drug+Design&doi=10.1016%2Fj.ejmech.2016.08.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design</span></div><div class="casAuthors">Chang, Chun-Feng; Lin, Wen-Hsing; Ke, Yi-Yu; Lin, Yih-Shyan; Wang, Wen-Chieh; Chen, Chun-Hwa; Kuo, Po-Chu; Hsu, John T. A.; Uang, Biing-Jiun; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">186-199</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Aurora kinases have emerged as important anticancer targets so that there are several inhibitors have advanced into clin. study.  Herein, the authors identified novel indazole derivs. as potent Aurora kinases inhibitors by utilizing in silico fragment-based approach and knowledge-based drug design.  After intensive hit-to-lead optimization, compds. I (dual Aurora A and B), II (Aurora B selective) and III (Aurora A selective) possessed indazole privileged scaffold with different substituents, which provide sub-type kinase selectivity.  Computational modeling helps in understanding that the isoform selectivity could be targeted specific residue in the Aurora kinase binding pocket in particular targeting residues Arg220, Thr217 or Glu177.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6E3wCvY_TIrVg90H21EOLACvtfcHk0ljbLQvVPs5SPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVaktbfL&md5=0d049378be04d320ab2212fdc2aa1e6f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.08.026%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DC.-F.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DKe%26aufirst%3DY.-Y.%26aulast%3DLin%26aufirst%3DY.-S.%26aulast%3DWang%26aufirst%3DW.-C.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DKuo%26aufirst%3DP.-C.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%2BA.%26aulast%3DUang%26aufirst%3DB.-J.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DDiscovery%2520of%2520Novel%2520Inhibitors%2520of%2520Aurora%2520Kinases%2520with%2520Indazole%2520Scaffold%253A%2520In%2520Silico%2520Fragment-Based%2520and%2520Knowledge-Based%2520Drug%2520Design%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D186%26epage%3D199%26doi%3D10.1016%2Fj.ejmech.2016.08.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, A. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sale, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.-Q.</span></span> <span> </span><span class="NLM_article-title">A Robust Protocol for Pd(II)-catalyzed C-3 Arylation of (1H) Indazoles and Pyrazoles: Total Synthesis of Nigellidine Hydrobromide</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2374</span>– <span class="NLM_lpage">2379</span>, <span class="refDoi"> DOI: 10.1039/c3sc50184a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1039%2Fc3sc50184a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=23691269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntV2jsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=2374-2379&author=M.+Yeauthor=A.+J.+F.+Edmundsauthor=J.+A.+Morrisauthor=D.+Saleauthor=Y.+Zhangauthor=J.-Q.+Yu&title=A+Robust+Protocol+for+Pd%28II%29-catalyzed+C-3+Arylation+of+%281H%29+Indazoles+and+Pyrazoles%3A+Total+Synthesis+of+Nigellidine+Hydrobromide&doi=10.1039%2Fc3sc50184a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A robust protocol for Pd(ii)-catalyzed C-3 arylation of (1H) indazoles and pyrazoles: total synthesis of nigellidine hydrobromide</span></div><div class="casAuthors">Ye, Mengchun; Edmunds, Andrew J. F.; Morris, James A.; Sale, David; Zhang, Yejia; Yu, Jin-Quan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2374-2379</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">C3-arylated indazole and pyrazoles are privileged structural motifs in agrochems. and pharmaceuticals.  C-3 C-H arylation of (1H) indazole and pyrazole was a significant challenge due to the poor reactivity of the C-3 position.  Herein, the authors report a practical Pd(ii)/Phen catalyst and conditions for the direct C-3 arylation of indazole and pyrazole with ArI or ArBr without using Ag additives as halide scavengers.  The use of toluene, chlorobenzene, trifluoromethylbenzene and mesitylene as the solvent is crucial for the selectivity and reactivity.  The authors further demonstrate the robustness of this protocol through the first total synthesis of nigellidine hydrobromide as well as the expedient prepn. of heterocycles structurally related to pesticides and drug mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnosPRY5pAt7Vg90H21EOLACvtfcHk0ljbLQvVPs5SPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntV2jsrk%253D&md5=9918215eeff186e3ddae5b7ec89e4dfb</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1039%2Fc3sc50184a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3sc50184a%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DM.%26aulast%3DEdmunds%26aufirst%3DA.%2BJ.%2BF.%26aulast%3DMorris%26aufirst%3DJ.%2BA.%26aulast%3DSale%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DJ.-Q.%26atitle%3DA%2520Robust%2520Protocol%2520for%2520Pd%2528II%2529-catalyzed%2520C-3%2520Arylation%2520of%2520%25281H%2529%2520Indazoles%2520and%2520Pyrazoles%253A%2520Total%2520Synthesis%2520of%2520Nigellidine%2520Hydrobromide%26jtitle%3DChem.%2520Sci.%26date%3D2013%26volume%3D4%26spage%3D2374%26epage%3D2379%26doi%3D10.1039%2Fc3sc50184a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, N. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqui, M.</span></span> <span> </span><span class="NLM_article-title">Chemistry and Biology of Indoles and Indazoles: a Mini-Review</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1792</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.2174/1389557511313120009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.2174%2F1389557511313120009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=22625410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A280%3ADC%252BC38nlvFGjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1792-1800&author=N.+A.+S.+Aliauthor=B.+A.+Darauthor=V.+Pradhanauthor=M.+Farooqui&title=Chemistry+and+Biology+of+Indoles+and+Indazoles%3A+a+Mini-Review&doi=10.2174%2F1389557511313120009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry and biology of indoles and indazoles: a mini-review</span></div><div class="casAuthors">Ali Nasir Ali Shafakat; Dar Bashir Ahmad; Pradhan Vidya; Farooqui Mazahar</div><div class="citationInfo"><span class="NLM_cas:title">Mini reviews in medicinal chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1792-800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The present review article is related with the method of preparation, importance and medicinal application of indole and indazoles.  The studies of heterocycles is an evergreen field in the branch of organic chemistry and always attract the attention of chemists working not only in the area of natural products but also in the synthetic chemistry.  Moreover many useful drugs have emerged from the successful investigation carried out in this branch.  The derivatives of indoles and indazoles exhibits antibacterial, anticancer, antionidants, anti-inflammatory, antidiabetic, antiviral, atniproliferative, antituberculosis, antispermetogenic activity, antipsychotic drugs etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBPMO4d6esv-_Q9URG6Dx8fW6udTcc2eZ2fASLZ9REbLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38nlvFGjsA%253D%253D&md5=1cc47f0a22c5e81f9cfff7e8382b3ffd</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2174%2F1389557511313120009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557511313120009%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DN.%2BA.%2BS.%26aulast%3DDar%26aufirst%3DB.%2BA.%26aulast%3DPradhan%26aufirst%3DV.%26aulast%3DFarooqui%26aufirst%3DM.%26atitle%3DChemistry%2520and%2520Biology%2520of%2520Indoles%2520and%2520Indazoles%253A%2520a%2520Mini-Review%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D1792%26epage%3D1800%26doi%3D10.2174%2F1389557511313120009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Irie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span> <span> </span><span class="NLM_article-title">7-Azaindole: A Versatile Scaffold for Developing Kinase Inhibitors</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1248/cpb.c17-00380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1248%2Fcpb.c17-00380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=29311509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOntr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2018&pages=29-36&author=T.+Irieauthor=M.+Sawa&title=7-Azaindole%3A+A+Versatile+Scaffold+for+Developing+Kinase+Inhibitors&doi=10.1248%2Fcpb.c17-00380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">7-Azaindole: a versatile scaffold for developing kinase inhibitors</span></div><div class="casAuthors">Irie, Takayuki; Sawa, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-36</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A review.  This review summarized recent examples of 7-azaindole-based kinase inhibitors and discusses their binding interactions with the kinase hinge regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9QuvBOqQ8GrVg90H21EOLACvtfcHk0lio98a2U4HJCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOntr%252FK&md5=69a5097cb54f2598d2e02414e74b3e6b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c17-00380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c17-00380%26sid%3Dliteratum%253Aachs%26aulast%3DIrie%26aufirst%3DT.%26aulast%3DSawa%26aufirst%3DM.%26atitle%3D7-Azaindole%253A%2520A%2520Versatile%2520Scaffold%2520for%2520Developing%2520Kinase%2520Inhibitors%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2018%26volume%3D66%26spage%3D29%26epage%3D36%26doi%3D10.1248%2Fcpb.c17-00380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mérour, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plé, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, S.</span></span> <span> </span><span class="NLM_article-title">The Azaindole Framework in the Design of Kinase Inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">19935</span>– <span class="NLM_lpage">19979</span>, <span class="refDoi"> DOI: 10.3390/molecules191219935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.3390%2Fmolecules191219935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=25460315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVymtLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=19935-19979&author=J.-Y.+M%C3%A9rourauthor=F.+Buronauthor=K.+Pl%C3%A9author=P.+Bonnetauthor=S.+Routier&title=The+Azaindole+Framework+in+the+Design+of+Kinase+Inhibitors&doi=10.3390%2Fmolecules191219935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The azaindole framework in the design of kinase inhibitors</span></div><div class="casAuthors">Merour, Jean-Yves; Buron, Frederic; Ple, Karen; Bonnet, Pascal; Routier, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">19935-19979, 45 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">This review article illustrates the growing use of azaindole derivs. as kinase inhibitors and their contribution to drug discovery and innovation.  The different protein kinases which have served as targets and the known mols. which have emerged from medicinal chem. and Fragment-Based Drug Discovery (FBDD) programs are presented.  The various synthetic routes used to access these compds. and the chem. pathways leading to their synthesis are also discussed.  An anal. of their mode of binding based on X-ray crystallog. data gives structural insights for the design of more potent and selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLLtZrGItBQbVg90H21EOLACvtfcHk0lio98a2U4HJCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVymtLbO&md5=7797450a99abb4a4c8e2492eb8a43dd7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.3390%2Fmolecules191219935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules191219935%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9rour%26aufirst%3DJ.-Y.%26aulast%3DBuron%26aufirst%3DF.%26aulast%3DPl%25C3%25A9%26aufirst%3DK.%26aulast%3DBonnet%26aufirst%3DP.%26aulast%3DRoutier%26aufirst%3DS.%26atitle%3DThe%2520Azaindole%2520Framework%2520in%2520the%2520Design%2520of%2520Kinase%2520Inhibitors%26jtitle%3DMolecules%26date%3D2014%26volume%3D19%26spage%3D19935%26epage%3D19979%26doi%3D10.3390%2Fmolecules191219935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loweth, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravula, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polesskaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marker, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewhurst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbard, H. A.</span></span> <span> </span><span class="NLM_article-title">Discovery, Synthesis, and Characterization of an Orally Bioavailable, Brain Penetrant Inhibitor of Mixed Lineage Kinase 3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8032</span>– <span class="NLM_lpage">8048</span>, <span class="refDoi"> DOI: 10.1021/jm401094t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401094t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVGjtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8032-8048&author=V.+S.+Goodfellowauthor=C.+J.+Lowethauthor=S.+B.+Ravulaauthor=T.+Wiemannauthor=T.+Nguyenauthor=Y.+Xuauthor=D.+E.+Toddauthor=D.+Sheppardauthor=S.+Pollackauthor=O.+Polesskayaauthor=D.+F.+Markerauthor=S.+Dewhurstauthor=H.+A.+Gelbard&title=Discovery%2C+Synthesis%2C+and+Characterization+of+an+Orally+Bioavailable%2C+Brain+Penetrant+Inhibitor+of+Mixed+Lineage+Kinase+3&doi=10.1021%2Fjm401094t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, Synthesis, and Characterization of an Orally Bioavailable, Brain Penetrant Inhibitor of Mixed Lineage Kinase 3</span></div><div class="casAuthors">Goodfellow, Val S.; Loweth, Colin J.; Ravula, Satheesh B.; Wiemann, Torsten; Nguyen, Thong; Xu, Yang; Todd, Daniel E.; Sheppard, David; Pollack, Scott; Polesskaya, Oksana; Marker, Daniel F.; Dewhurst, Stephen; Gelbard, Harris A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8032-8048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of mixed lineage kinase 3 (MLK3) is a potential strategy for treatment of Parkinson's disease and HIV-1 assocd. neurocognitive disorders (HAND), requiring an inhibitor that can achieve significant brain concn. levels.  We report here URMC-099 (1) an orally bioavailable (F = 41%), potent (IC50 = 14 nM) MLK3 inhibitor with excellent brain exposure in mouse PK models and minimal interference with key human CYP450 enzymes or hERG channels.  The compd. inhibits LPS-induced TNFα release in microglial cells, HIV-1 Tat-induced release of cytokines in human monocytes and up-regulation of phospho-JNK in Tat-injected brains of mice.  Compd. 1 likely functions in HAND preclin. models by inhibiting multiple kinase pathways, including MLK3 and LRRK2 (IC50 = 11 nM).  We compare the kinase specificity and BBB penetration of 1 with CEP-1347 (2).  Compd. 1 is well tolerated, with excellent in vivo activity in HAND models, and is under investigation for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosmrog4axXu7Vg90H21EOLACvtfcHk0lio98a2U4HJCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVGjtrfK&md5=53cb667f098b4de13a3a96b92cd546bf</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm401094t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401094t%26sid%3Dliteratum%253Aachs%26aulast%3DGoodfellow%26aufirst%3DV.%2BS.%26aulast%3DLoweth%26aufirst%3DC.%2BJ.%26aulast%3DRavula%26aufirst%3DS.%2BB.%26aulast%3DWiemann%26aufirst%3DT.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DTodd%26aufirst%3DD.%2BE.%26aulast%3DSheppard%26aufirst%3DD.%26aulast%3DPollack%26aufirst%3DS.%26aulast%3DPolesskaya%26aufirst%3DO.%26aulast%3DMarker%26aufirst%3DD.%2BF.%26aulast%3DDewhurst%26aufirst%3DS.%26aulast%3DGelbard%26aufirst%3DH.%2BA.%26atitle%3DDiscovery%252C%2520Synthesis%252C%2520and%2520Characterization%2520of%2520an%2520Orally%2520Bioavailable%252C%2520Brain%2520Penetrant%2520Inhibitor%2520of%2520Mixed%2520Lineage%2520Kinase%25203%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8032%26epage%3D8048%26doi%3D10.1021%2Fjm401094t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Billedeau, R. J.</span>; <span class="NLM_string-name">Kondru, R. K.</span>; <span class="NLM_string-name">Lopez-Tapia, F. J.</span>; <span class="NLM_string-name">Lou, Y.</span>; <span class="NLM_string-name">Owens, T. D.</span>; <span class="NLM_string-name">Qian, Y.</span>; <span class="NLM_string-name">So, S.-S.</span>; <span class="NLM_string-name">Thakkar, K. C.</span>; <span class="NLM_string-name">Wanner, J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Bruton’s Tyrosine Kinase</span>. U.S. Patent <span class="NLM_patent">20,120,295,885A1</span>, Nov 22, <span class="NLM_year">2012</span>, CA157:734758.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+J.+Billedeau&author=R.+K.+Kondru&author=F.+J.+Lopez-Tapia&author=Y.+Lou&author=T.+D.+Owens&author=Y.+Qian&author=S.-S.+So&author=K.+C.+Thakkar&author=J.+Wanner&title=Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBilledeau%26aufirst%3DR.%2BJ.%26atitle%3DInhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axford, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kecman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis-Symynkywicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papillon, J. P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dales, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regard, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinkeviciene, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marro, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Indole Pharmacophore for the Irreversible Inhibition of Myeloperoxidase (MPO)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115548</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2020.115548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmc.2020.115548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=32503688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVWis7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115548&author=A.+Patnaikauthor=L.+Axfordauthor=L.+Dengauthor=E.+Cohickauthor=X.+Renauthor=S.+Loiauthor=S.+Kecmanauthor=M.+Hollis-Symynkywiczauthor=T.+J.+Harrisonauthor=J.+P.+N.+Papillonauthor=N.+Dalesauthor=L.+G.+Hamannauthor=L.+Leeauthor=J.+B.+Regardauthor=J.+Marcinkevicieneauthor=M.+L.+Marroauthor=A.+W.+Patterson&title=Discovery+of+a+Novel+Indole+Pharmacophore+for+the+Irreversible+Inhibition+of+Myeloperoxidase+%28MPO%29&doi=10.1016%2Fj.bmc.2020.115548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel indole pharmacophore for the irreversible inhibition of myeloperoxidase (MPO)</span></div><div class="casAuthors">Patnaik, Anup; Axford, Laura; Deng, Lin; Cohick, Evan; Ren, Xianglin; Loi, Sally; Kecman, Sam; Hollis-Symynkywicz, Micah; Harrison, Tyler J.; Papillon, Julien P. N.; Dales, Natalie; Hamann, Lawrence G.; Lee, Lac; Regard, Jean B.; Marcinkeviciene, Jovita; Marro, Martin L.; Patterson, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">115548</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Myeloperoxidase (MPO) activity and subsequent generation of hypochlorous acid has been assocd. with the killing of host-invading microorganisms (e.g. bacteria, viruses, and fungi).  However, during oxidative stress, high MPO activity can damage host tissue and is linked to several chronic inflammatory conditions.  Herein, we describe the development of a novel biaryl, indole-pyrazole series of irreversible mechanism-based inhibitors of MPO.  Derived from an indole-contg. high-throughput screen hit, optimization efforts resulted in potent and selective 6-substituted indoles with good oral bioavailability and in vivo activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo70Gf5KXoebbVg90H21EOLACvtfcHk0lhSPnan3bH3Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVWis7bJ&md5=f4dd960e658fb912bec1f0d9a1256ecb</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2020.115548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2020.115548%26sid%3Dliteratum%253Aachs%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DAxford%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DCohick%26aufirst%3DE.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DKecman%26aufirst%3DS.%26aulast%3DHollis-Symynkywicz%26aufirst%3DM.%26aulast%3DHarrison%26aufirst%3DT.%2BJ.%26aulast%3DPapillon%26aufirst%3DJ.%2BP.%2BN.%26aulast%3DDales%26aufirst%3DN.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DRegard%26aufirst%3DJ.%2BB.%26aulast%3DMarcinkeviciene%26aufirst%3DJ.%26aulast%3DMarro%26aufirst%3DM.%2BL.%26aulast%3DPatterson%26aufirst%3DA.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Indole%2520Pharmacophore%2520for%2520the%2520Irreversible%2520Inhibition%2520of%2520Myeloperoxidase%2520%2528MPO%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115548%26doi%3D10.1016%2Fj.bmc.2020.115548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span> <span> </span><span class="NLM_article-title">Exploring the Other Side of Biologically Relevant Chemical Space: Insights into Carboxylic, Sulfonic and Phosphonic Acid Bioisosteric Relationships</span>. <i>J. Mol. Graphics Modell.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1016/j.jmgm.2007.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.jmgm.2007.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=17544772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ams7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=728-739&author=A.+Macchiaruloauthor=R.+Pellicciari&title=Exploring+the+Other+Side+of+Biologically+Relevant+Chemical+Space%3A+Insights+into+Carboxylic%2C+Sulfonic+and+Phosphonic+Acid+Bioisosteric+Relationships&doi=10.1016%2Fj.jmgm.2007.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the other side of biologically relevant chemical space: Insights into carboxylic, sulfonic and phosphonic acid bioisosteric relationships</span></div><div class="casAuthors">Macchiarulo, Antonio; Pellicciari, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">728-739</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bioisosteric replacements were widely and successfully applied to develop bioisosteric series of biol. active compds. in medicinal chem.  In this work, the concept of bioisosterism is revisited using a novel approach based on charting the "other side" of biol. relevant chem. space.  This space is composed by the ensemble of binding sites of protein structures.  Explorations into the "other side" of biol. relevant chem. space are exploited to gain insight into the principles that rules mol. recognition and bioisosteric relationships of mol. fragments.  We focused, in particular, on the construction of the "other side" of chem. space covered by binding sites of small mols. contg. carboxylic, sulfonic, and phosphonic acidic groups.  The anal. of differences in the occupation of that space by distinct types of binding sites unveils how evolution has worked in assessing principles that rule the selectivity of mol. recognition, and improves our knowledge on the mol. basis of bioisosteric relationships among carboxylic, sulfonic, and phosphonic acidic groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmUvbx3H_KfrVg90H21EOLACvtfcHk0lhSPnan3bH3Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ams7jE&md5=880e56f011b29d3aeef2ad624369e3e4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.jmgm.2007.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmgm.2007.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DPellicciari%26aufirst%3DR.%26atitle%3DExploring%2520the%2520Other%2520Side%2520of%2520Biologically%2520Relevant%2520Chemical%2520Space%253A%2520Insights%2520into%2520Carboxylic%252C%2520Sulfonic%2520and%2520Phosphonic%2520Acid%2520Bioisosteric%2520Relationships%26jtitle%3DJ.%2520Mol.%2520Graphics%2520Modell.%26date%3D2007%26volume%3D26%26spage%3D728%26epage%3D739%26doi%3D10.1016%2Fj.jmgm.2007.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grosskopf, S.</span></span> <span> </span><span class="NLM_article-title">Entwicklung und Synthese von Protein-Tyrosin-Phosphatase Inhibitoren sowie Synthese und Validierung von SHP-2-Inhibitoren in vitro und in vivo</span>. Ph.D. Thesis, <span class="NLM_publisher-name">Freien Universität</span>, <span class="NLM_publisher-loc">Berlin</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Grosskopf&title=Entwicklung+und+Synthese+von+Protein-Tyrosin-Phosphatase+Inhibitoren+sowie+Synthese+und+Validierung+von+SHP-2-Inhibitoren+in+vitro+und+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrosskopf%26aufirst%3DS.%26atitle%3DEntwicklung%2520und%2520Synthese%2520von%2520Protein-Tyrosin-Phosphatase%2520Inhibitoren%2520sowie%2520Synthese%2520und%2520Validierung%2520von%2520SHP-2-Inhibitoren%2520in%2520vitro%2520und%2520in%2520vivo%26pub%3DFreien%2520Universit%25C3%25A4t%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballatore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huryn, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  3rd</span></span> <span> </span><span class="NLM_article-title">Carboxylic Acid (Bio)Isosteres in Drug Design</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2Fcmdc.201200585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=23361977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=385-395&author=C.+Ballatoreauthor=D.+M.+Hurynauthor=A.+B.+Smith&title=Carboxylic+Acid+%28Bio%29Isosteres+in+Drug+Design&doi=10.1002%2Fcmdc.201200585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxylic Acid (Bio)Isosteres in Drug Design</span></div><div class="casAuthors">Ballatore, Carlo; Huryn, Donna M.; Smith, Amos B.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">385-395</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The carboxylic acid functional group can be an important constituent of a pharmacophore, however, the presence of this moiety can also be responsible for significant drawbacks, including metabolic instability, toxicity, as well as limited passive diffusion across biol. membranes.  To avoid some of these shortcomings while retaining the desired attributes of the carboxylic acid moiety, medicinal chemists often investigate the use of carboxylic acid (bio)isosteres.  The same type of strategy can also be effective for a variety other purposes, for example, to increase the selectivity of a biol. active compd. or to create new intellectual property.  Several carboxylic acid isosteres have been reported, however, the outcome of any isosteric replacement cannot be readily predicted as this strategy is generally found to be dependent upon the particular context (i.e., the characteristic properties of the drug and the drug-target).  As a result, screening of a panel of isosteres is typically required.  In this context, the discovery and development of novel carboxylic acid surrogates that could complement the existing palette of isosteres remains an important area of research.  The goal of this Minireview is to provide an overview of the most commonly employed carboxylic acid (bio)isosteres and to present representative examples demonstrating the use and utility of each isostere in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVEcl3NtfHu7Vg90H21EOLACvtfcHk0lgJlpjhRW3iew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCms7g%253D&md5=cff8233af1c386439789a0e4ebcb4331</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200585%26sid%3Dliteratum%253Aachs%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26atitle%3DCarboxylic%2520Acid%2520%2528Bio%2529Isosteres%2520in%2520Drug%2520Design%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D385%26epage%3D395%26doi%3D10.1002%2Fcmdc.201200585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J.-P.</span></span> <span> </span><span class="NLM_article-title">Nitro-Group-Containing Drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2851</span>– <span class="NLM_lpage">2893</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00147</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00147" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2851-2893&author=K.+Nepaliauthor=H.-Y.+Leeauthor=J.-P.+Liou&title=Nitro-Group-Containing+Drugs&doi=10.1021%2Facs.jmedchem.8b00147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Nitro-Group-Containing Drugs</span></div><div class="casAuthors">Nepali, Kunal; Lee, Hsueh-Yun; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2851-2893</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The nitro group is considered to be a versatile and unique functional group in medicinal chem.  Despite a long history of use in therapeutics, the nitro group has toxicity issues and is often categorized as a structural alert or a toxicophore, and evidence related to drugs contg. nitro groups is rather contradictory.  In general, drugs contg. nitro groups have been extensively assocd. with mutagenicity and genotoxicity.  In this context, efforts toward the structure-mutagenicity or structure-genotoxicity relationships have been undertaken.  The current Perspective covers various aspects of agents that contain nitro groups, their bioreductive activation mechanisms, their toxicities, and approaches to combat their toxicity issues.  In addn., recent advances in the field of anticancer, antitubercular and antiparasitic agents contg. nitro groups, along with a patent survey on hypoxia-activated prodrugs contg. nitro groups, are also covered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqif1Bbj-Ci4bVg90H21EOLACvtfcHk0lgJlpjhRW3iew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7jO&md5=33969d1c33e2b451a05b3dbdb8574497</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00147%26sid%3Dliteratum%253Aachs%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DLiou%26aufirst%3DJ.-P.%26atitle%3DNitro-Group-Containing%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2851%26epage%3D2893%26doi%3D10.1021%2Facs.jmedchem.8b00147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donvito, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juola, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarenti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dall’Angelo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, W. T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, I. R.</span></span> <span> </span><span class="NLM_article-title">The Trifluoromethyl Group as a Bioisosteric Replacement of the Aliphatic Nitro Group in CB1 Receptor Positive Allosteric Modulators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5049</span>– <span class="NLM_lpage">5062</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00252</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00252" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVKgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5049-5062&author=C.-C.+Tsengauthor=G.+Baillieauthor=G.+Donvitoauthor=M.+A.+Mustafaauthor=S.+E.+Juolaauthor=C.+Zanatoauthor=C.+Massarentiauthor=S.+Dall%E2%80%99Angeloauthor=W.+T.+A.+Harrisonauthor=A.+H.+Lichtmanauthor=R.+A.+Rossauthor=M.+Zandaauthor=I.+R.+Greig&title=The+Trifluoromethyl+Group+as+a+Bioisosteric+Replacement+of+the+Aliphatic+Nitro+Group+in+CB1+Receptor+Positive+Allosteric+Modulators&doi=10.1021%2Facs.jmedchem.9b00252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The Trifluoromethyl Group as a Bioisosteric Replacement of the Aliphatic Nitro Group in CB1 Receptor Positive Allosteric Modulators</span></div><div class="casAuthors">Tseng, Chih-Chung; Baillie, Gemma; Donvito, Giulia; Mustafa, Mohammed A.; Juola, Sophie E.; Zanato, Chiara; Massarenti, Chiara; Dall'Angelo, Sergio; Harrison, William T. A.; Lichtman, Aron H.; Ross, Ruth A.; Zanda, Matteo; Greig, Iain R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5049-5062</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Nitroalkyl-2-phenylindoles were prepd. as analogs of known CB1 receptor pos. allosteric modulators; related 3-(trifluoroalkyl)-2-phenylindoles such as I were prepd. to test if the trifluoromethyl group could act as a bioisostere of the nitro group.  The trifluoromethyl-bearing compds. were generally more potent than their nitro equiv. and also showed improved in vitro metabolic stability.  The racemate of I has similar activity to the known CB1 receptor pos. allosteric modulator (±)-ZCZ011, with both showing promising efficacy in a mouse model of neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWL_RH0bt0ErVg90H21EOLACvtfcHk0lgJlpjhRW3iew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVKgs74%253D&md5=bac1532f77c45b5a5474e3ec782f48c3</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00252%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DC.-C.%26aulast%3DBaillie%26aufirst%3DG.%26aulast%3DDonvito%26aufirst%3DG.%26aulast%3DMustafa%26aufirst%3DM.%2BA.%26aulast%3DJuola%26aufirst%3DS.%2BE.%26aulast%3DZanato%26aufirst%3DC.%26aulast%3DMassarenti%26aufirst%3DC.%26aulast%3DDall%25E2%2580%2599Angelo%26aufirst%3DS.%26aulast%3DHarrison%26aufirst%3DW.%2BT.%2BA.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26aulast%3DZanda%26aufirst%3DM.%26aulast%3DGreig%26aufirst%3DI.%2BR.%26atitle%3DThe%2520Trifluoromethyl%2520Group%2520as%2520a%2520Bioisosteric%2520Replacement%2520of%2520the%2520Aliphatic%2520Nitro%2520Group%2520in%2520CB1%2520Receptor%2520Positive%2520Allosteric%2520Modulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5049%26epage%3D5062%26doi%3D10.1021%2Facs.jmedchem.9b00252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelmalak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tender, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent Indenoisoquinoline Topoisomerase I Poisons Lacking the 3-Nitro Toxicophore</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3997</span>– <span class="NLM_lpage">4015</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3997-4015&author=D.+E.+Beckauthor=M.+Abdelmalakauthor=W.+Lvauthor=P.+V.+N.+Reddyauthor=G.+S.+Tenderauthor=E.+O%E2%80%99Neillauthor=K.+Agamaauthor=C.+Marchandauthor=Y.+Pommierauthor=M.+Cushman&title=Discovery+of+Potent+Indenoisoquinoline+Topoisomerase+I+Poisons+Lacking+the+3-Nitro+Toxicophore&doi=10.1021%2Facs.jmedchem.5b00303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Indenoisoquinoline Topoisomerase I Poisons Lacking the 3-Nitro Toxicophore</span></div><div class="casAuthors">Beck, Daniel E.; Abdelmalak, Monica; Lv, Wei; Reddy, P. V. Narasimha; Tender, Gabrielle S.; O'Neill, Elizaveta; Agama, Keli; Marchand, Christophe; Pommier, Yves; Cushman, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3997-4015</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Nitroindenoisoquinoline human topoisomerase IB (Top1) poisons have potent antiproliferative effects on cancer cells.  The undesirable nitro toxicophore could hypothetically be replaced by other functional groups that would retain the desired biol. activities and minimize potential safety risks.  Eleven series of indenoisoquinolines bearing 3-nitro bioisosteres were synthesized.  The mols. were evaluated in the Top1-mediated DNA cleavage assay and in the National Cancer Institute's 60 cell line cytotoxicity assay.  The data reveal that fluorine and chlorine may substitute for the 3-nitro group with minimal loss of Top1 poisoning activity.  The new information gained from these efforts can be used to design novel indenoisoquinolines with improved safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdbNHV3jO7rrVg90H21EOLACvtfcHk0lgsdTNMTll1JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGitro%253D&md5=7c7a9dac160593af7809b04d2aa7f88a</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00303%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DD.%2BE.%26aulast%3DAbdelmalak%26aufirst%3DM.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DReddy%26aufirst%3DP.%2BV.%2BN.%26aulast%3DTender%26aufirst%3DG.%2BS.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DE.%26aulast%3DAgama%26aufirst%3DK.%26aulast%3DMarchand%26aufirst%3DC.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DCushman%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520Potent%2520Indenoisoquinoline%2520Topoisomerase%2520I%2520Poisons%2520Lacking%2520the%25203-Nitro%2520Toxicophore%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3997%26epage%3D4015%26doi%3D10.1021%2Facs.jmedchem.5b00303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali Dhar, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzabadi, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, R. S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broten, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ransom, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schorn, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendesky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrell, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gluchowski, C.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel Alpha(1)(A) Adrenoceptor-Selective Antagonists. 1. Structure-Activity Relationship in Dihydropyrimidinones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">4764</span>– <span class="NLM_lpage">4777</span>, <span class="refDoi"> DOI: 10.1021/jm990200p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990200p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK1MXmvVSqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=4764-4777&author=D.+Nagarathnamauthor=S.+W.+Miaoauthor=B.+Laguauthor=G.+Chiuauthor=J.+Fangauthor=T.+G.+Murali+Dharauthor=J.+Zhangauthor=S.+Tyagarajanauthor=M.+R.+Marzabadiauthor=F.+Zhangauthor=W.+C.+Wongauthor=W.+Sunauthor=D.+Tianauthor=J.+M.+Wetzelauthor=C.+Forrayauthor=R.+S.+L.+Changauthor=T.+P.+Brotenauthor=R.+W.+Ransomauthor=T.+W.+Schornauthor=T.+B.+Chenauthor=S.+O%E2%80%99Malleyauthor=P.+Klingauthor=K.+Schneckauthor=R.+Bendeskyauthor=C.+M.+Harrellauthor=K.+P.+Vyasauthor=C.+Gluchowski&title=Design+and+Synthesis+of+Novel+Alpha%281%29%28A%29+Adrenoceptor-Selective+Antagonists.+1.+Structure-Activity+Relationship+in+Dihydropyrimidinones&doi=10.1021%2Fjm990200p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel α1a Adrenoceptor-Selective Antagonists. 1. Structure-Activity Relationship in Dihydropyrimidinones</span></div><div class="casAuthors">Nagarathnam, Dhanapalan; Miao, Shou Wu; Lagu, Bharat; Chiu, George; Fang, James; Dhar, T. G. Murali; Zhang, Jack; Tyagarajan, Sriram; Marzabadi, Mohammad R.; Zhang, Fengqi; Wong, Wai C.; Sun, Wanying; Tian, Dake; Wetzel, John M.; Forray, Carlos; Chang, Raymond S. L.; Broten, Theodore P.; Ransom, Richard W.; Schorn, Terry W.; Chen, Tsing B.; O'Malley, Stacey; Kling, Paul; Schneck, Kathryn; Bendesky, Robert; Harrell, Charles M.; Vyas, Kamlesh P.; Gluchowski, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4764-4777</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dihydropyrimidinones such as compd. I exhibited high binding affinity and subtype selectivity for the cloned human α1a receptor.  Systematic modifications of I led to identification of highly potent and subtype-selective compds. with high binding affinity (Ki = 0.2 nM) for α1a receptor and greater than 1500-fold selectivity over α1b and α1d adrenoceptors.  The compds. were found to be functional antagonists in human, rat, and dog prostate tissues.  One of the compds. [(+)SNAP 6201] exhibited excellent selectively to inhibit intraurethral pressure (IUP) as compared to lowering diastolic blood pressure (DBP) in mongrel dogs (Kb(DBP)/Kb(IUP) = 40) suggesting uroselectivity for α1a-selective compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfso0m6xXmxbVg90H21EOLACvtfcHk0lgsdTNMTll1JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmvVSqtLk%253D&md5=af256a5faa2aa3c16b0c137b06ae49cb</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm990200p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990200p%26sid%3Dliteratum%253Aachs%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DMiao%26aufirst%3DS.%2BW.%26aulast%3DLagu%26aufirst%3DB.%26aulast%3DChiu%26aufirst%3DG.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DMurali%2BDhar%26aufirst%3DT.%2BG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTyagarajan%26aufirst%3DS.%26aulast%3DMarzabadi%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DWong%26aufirst%3DW.%2BC.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DD.%26aulast%3DWetzel%26aufirst%3DJ.%2BM.%26aulast%3DForray%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DR.%2BS.%2BL.%26aulast%3DBroten%26aufirst%3DT.%2BP.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DSchorn%26aufirst%3DT.%2BW.%26aulast%3DChen%26aufirst%3DT.%2BB.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DS.%26aulast%3DKling%26aufirst%3DP.%26aulast%3DSchneck%26aufirst%3DK.%26aulast%3DBendesky%26aufirst%3DR.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DVyas%26aufirst%3DK.%2BP.%26aulast%3DGluchowski%26aufirst%3DC.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%2520Alpha%25281%2529%2528A%2529%2520Adrenoceptor-Selective%2520Antagonists.%25201.%2520Structure-Activity%2520Relationship%2520in%2520Dihydropyrimidinones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D4764%26epage%3D4777%26doi%3D10.1021%2Fjm990200p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Troxler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoeffter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenegger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span> <span> </span><span class="NLM_article-title">Decahydroisoquinoline Derivatives as Novel Non-Peptidic, Potent and Subtype-Selective Somatostatin SST(3) Receptor Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1728</span>– <span class="NLM_lpage">1734</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmcl.2010.01.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=20137944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitleht7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1728-1734&author=T.+Troxlerauthor=K.+Hurthauthor=K.-H.+Schuhauthor=P.+Schoeffterauthor=D.+Langeneggerauthor=A.+Enzauthor=D.+Hoyer&title=Decahydroisoquinoline+Derivatives+as+Novel+Non-Peptidic%2C+Potent+and+Subtype-Selective+Somatostatin+SST%283%29+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2010.01.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Decahydroisoquinoline derivatives as novel non-peptidic, potent and subtype-selective somatostatin sst3 receptor antagonists</span></div><div class="casAuthors">Troxler, Thomas; Hurth, Konstanze; Schuh, Karl-Heinrich; Schoeffter, Philippe; Langenegger, Daniel; Enz, Albert; Hoyer, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1728-1734</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from non-peptidic sst1-selective somatostatin receptor antagonists, first compds. with mixed sst1/sst3 affinity were identified by directed structural modifications.  Systematic optimization of these initial leads afforded novel, enantiomerically pure, highly potent and sst3-subtype selective somatostatin antagonists, e.g. I (R = piperonyl, 6-methoxypyridin-3-yl, 6-quinoxalinyl, etc.), based on a (4S,4aS,8aR)-decahydroisoquinoline-4-carboxylic acid core moiety.  These compds. can efficiently be synthesized and show promising PK properties in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Sg4iyYj_hbVg90H21EOLACvtfcHk0lgsdTNMTll1JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitleht7w%253D&md5=ac00980a8ca3bd081402d74e24469ebe</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.063%26sid%3Dliteratum%253Aachs%26aulast%3DTroxler%26aufirst%3DT.%26aulast%3DHurth%26aufirst%3DK.%26aulast%3DSchuh%26aufirst%3DK.-H.%26aulast%3DSchoeffter%26aufirst%3DP.%26aulast%3DLangenegger%26aufirst%3DD.%26aulast%3DEnz%26aufirst%3DA.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DDecahydroisoquinoline%2520Derivatives%2520as%2520Novel%2520Non-Peptidic%252C%2520Potent%2520and%2520Subtype-Selective%2520Somatostatin%2520SST%25283%2529%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1728%26epage%3D1734%26doi%3D10.1016%2Fj.bmcl.2010.01.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Troxler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenegger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfäffli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoeffter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurth, K.</span></span> <span> </span><span class="NLM_article-title">Ergoline Derivatives as Highly Potent and Selective Antagonists at the Somatostatin SST 1 Receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">982</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.12.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmcl.2007.12.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=18162395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=979-982&author=T.+Troxlerauthor=A.+Enzauthor=D.+Hoyerauthor=D.+Langeneggerauthor=P.+Neumannauthor=P.+Pf%C3%A4ffliauthor=P.+Schoeffterauthor=K.+Hurth&title=Ergoline+Derivatives+as+Highly+Potent+and+Selective+Antagonists+at+the+Somatostatin+SST+1+Receptor&doi=10.1016%2Fj.bmcl.2007.12.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Ergoline derivatives as highly potent and selective antagonists at the somatostatin sst1 receptor</span></div><div class="casAuthors">Troxler, Thomas; Enz, Albert; Hoyer, Daniel; Langenegger, Daniel; Neumann, Peter; Pfaeffli, Paul; Schoeffter, Philippe; Hurth, Konstanze</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">979-982</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Nonpeptidic compds. contg. the octahydro-indolo[4,3-fg]quinoline (ergoline) structural element have been optimized into derivs. with high affinity (pKd r sst1 > 9) and selectivity (>1000-fold for h sst1 over h sst2-h sst5) for the somatostatin sst1 receptor.  In functional assays, these ergolines act as antagonists at human recombinant sst1 receptors.  Pharmacokinetic studies in rodents reveal good oral bioavailability and brain penetration for some of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHSEfQkuZzprVg90H21EOLACvtfcHk0lgbewPO0vQOWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWktbg%253D&md5=82f935aae404ae0cc85fe0e986636dc3</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.12.030%26sid%3Dliteratum%253Aachs%26aulast%3DTroxler%26aufirst%3DT.%26aulast%3DEnz%26aufirst%3DA.%26aulast%3DHoyer%26aufirst%3DD.%26aulast%3DLangenegger%26aufirst%3DD.%26aulast%3DNeumann%26aufirst%3DP.%26aulast%3DPf%25C3%25A4ffli%26aufirst%3DP.%26aulast%3DSchoeffter%26aufirst%3DP.%26aulast%3DHurth%26aufirst%3DK.%26atitle%3DErgoline%2520Derivatives%2520as%2520Highly%2520Potent%2520and%2520Selective%2520Antagonists%2520at%2520the%2520Somatostatin%2520SST%25201%2520Receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D979%26epage%3D982%26doi%3D10.1016%2Fj.bmcl.2007.12.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anana, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, E. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Smooth Muscle Calcium Channel Antagonist Effects of Alkyl 1,4-dihydro-2,6-dimethyl-4-(pyridinyl)-5-[2-(4,5-dihydro- 4,4-dimethyloxazolin-2-yl)]-3-pyridinecarboxylates</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1002/ardp.19963290807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1002%2Fardp.19963290807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=8915102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK28XmtlWku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=1996&pages=408-412&author=R.+D.+Ananaauthor=E.+E.+Knaus&title=Synthesis+and+Smooth+Muscle+Calcium+Channel+Antagonist+Effects+of+Alkyl+1%2C4-dihydro-2%2C6-dimethyl-4-%28pyridinyl%29-5-%5B2-%284%2C5-dihydro-+4%2C4-dimethyloxazolin-2-yl%29%5D-3-pyridinecarboxylates&doi=10.1002%2Fardp.19963290807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and smooth muscle calcium channel antagonist effects of alkyl 1,4-dihydro-2,6-dimethyl-4-pyridyl-5-[2-(4,5-dihydro-4,4-dimethyloxazolin-2-yl)]-3-pyridinecarboxylates</span></div><div class="casAuthors">Anana, Raymond D.; Knaus, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">8-9</span>),
    <span class="NLM_cas:pages">408-412</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">VCH</span>)
        </div><div class="casAbstract">The racemic title compds. I (R = 3-, 4-pyridyl; R1 = Me, CH2CHMe2, CHMe2) were prepd. by the Hantzsch reaction involving condensation of the corresponding Knoevenagel adducts RCH:C(CO2R1)COMe with 2-(2-amino-1-propenyl)-4,5-dihydro-4,4-dimethyloxazoline.  Compd. I (R = 2-pyridyl; R1 = CHMe2) was prepd. by SOCl2-mediated cyclization of the (hydroxyethyl)aminocarbonyl moiety of hydropyridine II.  In vitro Ca channel antagonist activity was detd. by the guinea pig ileum longitudinal smooth muscle (GPILSM) assay.  Compared to the ref. drug nifedipine, the title compds. exhibited weak Ca channel antagonist activity (IC50 = 10-5-10-6 M).  A comparison of compds. I having a C(4) 3-pyridinyl substituent showed that with respect to the alkyl ester substituent, the relative potency order was CH2CHMe2 ≥ CHMe2 > Me.  The point of attachment of the C(4) pyridinyl substituent in the iso-Pr ester isomeric series of compds. was a determinant of activity where the potency profile was 4-pyridyl ≥ 3-pyridyl > 2-pyridyl.  Although less effective, the 4,5-dihydro-4,4-dimethyloxazolin-2-yl moiety acts as a bioisostere of the alkyl ester substituent present in classical 1,4-dihydropyridine Ca channel antagonists.  The dihydrodimethyloxaxolinyl ring system is not an effective bioisostere of the 3-NO2 group present in 1,4-dihydropyridine Ca channel antagonists since I (R = 2-pyridyl; R1 = CHMe2) produced a modest 10% increase in the in vitro contractile force of guinea pig left atrium at a concn. of 1.64·10-7 M, relative to the ref. 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-pyridyl)-5-pyridinecarboxylate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMcCnA9262zrVg90H21EOLACvtfcHk0lgbewPO0vQOWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtlWku7w%253D&md5=817caf3d997869e3e4d228063a6477a2</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fardp.19963290807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.19963290807%26sid%3Dliteratum%253Aachs%26aulast%3DAnana%26aufirst%3DR.%2BD.%26aulast%3DKnaus%26aufirst%3DE.%2BE.%26atitle%3DSynthesis%2520and%2520Smooth%2520Muscle%2520Calcium%2520Channel%2520Antagonist%2520Effects%2520of%2520Alkyl%25201%252C4-dihydro-2%252C6-dimethyl-4-%2528pyridinyl%2529-5-%255B2-%25284%252C5-dihydro-%25204%252C4-dimethyloxazolin-2-yl%2529%255D-3-pyridinecarboxylates%26jtitle%3DArch.%2520Pharm.%26date%3D1996%26volume%3D329%26spage%3D408%26epage%3D412%26doi%3D10.1002%2Fardp.19963290807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mittapalli, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamboni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKelvy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong-Staal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, J. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of ITX 4520: a Highly Potent Orally Bioavailable Hepatitis C Virus Entry Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4955</span>– <span class="NLM_lpage">4961</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.06.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmcl.2012.06.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=22784640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVamtL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4955-4961&author=G.+K.+Mittapalliauthor=F.+Zhaoauthor=A.+Jacksonauthor=H.+Gaoauthor=H.+Leeauthor=S.+Chowauthor=M.+P.+Kaurauthor=N.+Nguyenauthor=R.+Zamboniauthor=J.+McKelvyauthor=F.+Wong-Staalauthor=J.+E.+Macdonald&title=Discovery+of+ITX+4520%3A+a+Highly+Potent+Orally+Bioavailable+Hepatitis+C+Virus+Entry+Inhibitor&doi=10.1016%2Fj.bmcl.2012.06.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ITX 4520: A highly potent orally bioavailable hepatitis C virus entry inhibitor</span></div><div class="casAuthors">Mittapalli, Gopi Kumar; Zhao, Fang; Jackson, Andrew; Gao, Hongfeng; Lee, Haekyung; Chow, Stephine; Kaur, Maninder Pal; Nguyen, Natalie; Zamboni, Robert; McKelvy, Jeffrey; Wong-Staal, Flossie; MacDonald, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4955-4961</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The manuscript reports an identification of a highly potent, orally bioavailable hepatitis C virus entry inhibitor through optimization of a previously reported class of mols. (1) that were not stable in the rat plasma.  Compd. 39 (ITX 4520) exhibited an excellent PK profile in both rats and dogs with good oral exposure, half-life and oral bioavailability.  The compd. is also well-tolerated in the preliminary in vivo toxicity studies and has been selected as a pre-clin. candidate for our HCV clin. pipeline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTV8x6msjRVLVg90H21EOLACvtfcHk0lgbewPO0vQOWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVamtL3K&md5=ecc2ba7532682fcd7d088a4bd5947c09</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.06.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.06.038%26sid%3Dliteratum%253Aachs%26aulast%3DMittapalli%26aufirst%3DG.%2BK.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DJackson%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DChow%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DM.%2BP.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DMcKelvy%26aufirst%3DJ.%26aulast%3DWong-Staal%26aufirst%3DF.%26aulast%3DMacdonald%26aufirst%3DJ.%2BE.%26atitle%3DDiscovery%2520of%2520ITX%25204520%253A%2520a%2520Highly%2520Potent%2520Orally%2520Bioavailable%2520Hepatitis%2520C%2520Virus%2520Entry%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4955%26epage%3D4961%26doi%3D10.1016%2Fj.bmcl.2012.06.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakanyan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Bechec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecocq, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benaiteau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyulkhandanyan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyulkhandanyan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussakis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleury, F.</span></span> <span> </span><span class="NLM_article-title">Screening and Discovery of Nitro-Benzoxadiazole Compounds Activating Epidermal Growth Factor Receptor (EGFR) in Cancer Cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">3977</span>, <span class="refDoi"> DOI: 10.1038/srep03977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fsrep03977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=24496106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVWrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=3977&author=V.+Sakanyanauthor=M.+Angeliniauthor=M.+Le+Bechecauthor=M.+F.+Lecocqauthor=F.+Benaiteauauthor=B.+Rousseauauthor=A.+Gyulkhandanyanauthor=L.+Gyulkhandanyanauthor=C.+Logeauthor=E.+Reiterauthor=C.+Roussakisauthor=F.+Fleury&title=Screening+and+Discovery+of+Nitro-Benzoxadiazole+Compounds+Activating+Epidermal+Growth+Factor+Receptor+%28EGFR%29+in+Cancer+Cells&doi=10.1038%2Fsrep03977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells</span></div><div class="casAuthors">Sakanyan, Vehary; Angelini, Marie; Le Bechec, Mickael; Lecocq, Michele Francoise; Benaiteau, Florence; Rousseau, Benedicte; Gyulkhandanyan, Aram; Gyulkhandanyan, Lusine; Loge, Cedric; Reiter, Eric; Roussakis, Christos; Fleury, Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3977/1-3977/11</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Peptide ligand-induced dimerization of the extracellular region of the epidermal growth factor receptor (sEGFR) is central to the signal transduction of many cellular processes.  A small mol. microarray screen has been developed to search for non-peptide compds. able to bind to sEGFR.  We describe the discovery of nitro-benzoxadiazole (NBD) compds. that enhance tyrosine phosphorylation of EGFR and thereby trigger downstream signaling pathways and other receptor tyrosine kinases in cancer cells.  The protein phosphorylation profile in cells exposed to NBD compds. is to some extent reminiscent of the profile induced by the cognate ligand.  Exptl. studies indicate that the small compds. bind to the dimerization domain of sEGFR, and generate stable dimers providing allosteric activation of the receptor.  Moreover, receptor phosphorylation is assocd. with inhibition of PTP-1B phosphatase.  Our data offer a promising paradigm for investigating new aspects of signal transduction mediated by EGFR in cancer cells exposed to electrophilic NBD compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbek576nbHo7Vg90H21EOLACvtfcHk0lglL1er3D_16w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVWrsbg%253D&md5=370d1cec1015cac002389d44fe1c5fd6</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fsrep03977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep03977%26sid%3Dliteratum%253Aachs%26aulast%3DSakanyan%26aufirst%3DV.%26aulast%3DAngelini%26aufirst%3DM.%26aulast%3DLe%2BBechec%26aufirst%3DM.%26aulast%3DLecocq%26aufirst%3DM.%2BF.%26aulast%3DBenaiteau%26aufirst%3DF.%26aulast%3DRousseau%26aufirst%3DB.%26aulast%3DGyulkhandanyan%26aufirst%3DA.%26aulast%3DGyulkhandanyan%26aufirst%3DL.%26aulast%3DLoge%26aufirst%3DC.%26aulast%3DReiter%26aufirst%3DE.%26aulast%3DRoussakis%26aufirst%3DC.%26aulast%3DFleury%26aufirst%3DF.%26atitle%3DScreening%2520and%2520Discovery%2520of%2520Nitro-Benzoxadiazole%2520Compounds%2520Activating%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%2520in%2520Cancer%2520Cells%26jtitle%3DSci.%2520Rep.%26date%3D2014%26volume%3D4%26spage%3D3977%26doi%3D10.1038%2Fsrep03977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patani, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaVoie, E. J.</span></span> <span> </span><span class="NLM_article-title">Bioisosterism: A Rational Approach in Drug Design</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">3147</span>– <span class="NLM_lpage">3176</span>, <span class="refDoi"> DOI: 10.1021/cr950066q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr950066q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK28XntFSitLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1996&pages=3147-3176&author=G.+A.+Pataniauthor=E.+J.+LaVoie&title=Bioisosterism%3A+A+Rational+Approach+in+Drug+Design&doi=10.1021%2Fcr950066q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosterism: A rational approach in drug design</span></div><div class="casAuthors">Patani, George A.; LaVoie, Edmond J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3147-3176</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review, with 191 refs., on bioisosteres that incorporates sufficient detail to enable the reader to understand the concepts being delineated.  Classical bioisosteres, such as monovalent atoms and groups, divalent isosteres, trivalent atoms and groups, tetra substituted atoms, and ring equiv., and non-classical bioisosteres, such as cyclic vs. non-cyclic non-classical bioisosteric replacements and non-classical bioisosteric replacements of functional groups, are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADeNoRGbU9LVg90H21EOLACvtfcHk0lglL1er3D_16w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntFSitLg%253D&md5=4b3ec55087feabc53e0490ebd5a3ddcd</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fcr950066q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr950066q%26sid%3Dliteratum%253Aachs%26aulast%3DPatani%26aufirst%3DG.%2BA.%26aulast%3DLaVoie%26aufirst%3DE.%2BJ.%26atitle%3DBioisosterism%253A%2520A%2520Rational%2520Approach%2520in%2520Drug%2520Design%26jtitle%3DChem.%2520Rev.%26date%3D1996%26volume%3D96%26spage%3D3147%26epage%3D3176%26doi%3D10.1021%2Fcr950066q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span> <i>OpenEye Toolkits 2019.Oct.2</i>; <span class="NLM_publisher-name">OpenEye
Scientific Software</span>: <span class="NLM_publisher-loc">Santa Fe, NM</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+OpenEye+Toolkits+2019.Oct.2%3B+OpenEye%0AScientific+Software%3A+Santa+Fe%2C+NM%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DOpenEye%2520Toolkits%25202019.Oct.2%26pub%3DOpenEye%250AScientific%2520Software%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGann, M.</span></span> <span> </span><span class="NLM_article-title">FRED and HYBRID Docking Performance on Standardized Datasets</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">906</span>, <span class="refDoi"> DOI: 10.1007/s10822-012-9584-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1007%2Fs10822-012-9584-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=22669221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ens7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=897-906&author=M.+McGann&title=FRED+and+HYBRID+Docking+Performance+on+Standardized+Datasets&doi=10.1007%2Fs10822-012-9584-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">FRED and HYBRID docking performance on standardized datasets</span></div><div class="casAuthors">McGann, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">897-906</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The docking performance of the FRED and HYBRID programs are evaluated on two standardized datasets from the Docking and Scoring Symposium of the ACS Spring 2011 national meeting.  The evaluation includes cognate docking and virtual screening performance.  FRED docks 70 % of the structures to within 2 Å in the cognate docking test.  In the virtual screening test, FRED is found to have a mean AUC of 0.75.  The HYBRID program uses a modified version of FRED's algorithm that uses both ligand- and structure-based information to dock mols., which increases its mean AUC to 0.78.  HYBRID can also implicitly account for protein flexibility by making use of multiple crystal structures.  Using multiple crystal structures improves HYBRID's performance (mean AUC 0.80) with a negligible increase in docking time (∼15 %).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDNF1kmgp-WLVg90H21EOLACvtfcHk0lglL1er3D_16w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ens7bO&md5=299f2e795ca922412f57df9434b52661</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1007%2Fs10822-012-9584-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-012-9584-8%26sid%3Dliteratum%253Aachs%26aulast%3DMcGann%26aufirst%3DM.%26atitle%3DFRED%2520and%2520HYBRID%2520Docking%2520Performance%2520on%2520Standardized%2520Datasets%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2012%26volume%3D26%26spage%3D897%26epage%3D906%26doi%3D10.1007%2Fs10822-012-9584-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span> <span> </span><span class="NLM_article-title">LigandScout: 3-D Pharmacophores Derived From Protein-Bound Ligands and their use as Virtual Screening Filters</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1021/ci049885e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci049885e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FktVKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=160-169&author=G.+Wolberauthor=T.+Langer&title=LigandScout%3A+3-D+Pharmacophores+Derived+From+Protein-Bound+Ligands+and+their+use+as+Virtual+Screening+Filters&doi=10.1021%2Fci049885e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters</span></div><div class="casAuthors">Wolber Gerhard; Langer Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical information and modeling</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">160-9</span>
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    </div><div class="casAbstract">From the historically grown archive of protein-ligand complexes in the Protein Data Bank small organic ligands are extracted and interpreted in terms of their chemical characteristics and features.  Subsequently, pharmacophores representing ligand-receptor interaction are derived from each of these small molecules and its surrounding amino acids.  Based on a defined set of only six types of chemical features and volume constraints, three-dimensional pharmacophore models are constructed, which are sufficiently selective to identify the described binding mode and are thus a useful tool for in-silico screening of large compound databases.  The algorithms for ligand extraction and interpretation as well as the pharmacophore creation technique from the automatically interpreted data are presented and applied to a rhinovirus capsid complex as application example.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVi_-excgTX2BAiYWy6n3SfW6udTcc2eY986cdar6rQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FktVKrtg%253D%253D&md5=31f8ff7a2fa4c9411d54b001b7e1da50</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fci049885e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci049885e%26sid%3Dliteratum%253Aachs%26aulast%3DWolber%26aufirst%3DG.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DLigandScout%253A%25203-D%2520Pharmacophores%2520Derived%2520From%2520Protein-Bound%2520Ligands%2520and%2520their%2520use%2520as%2520Virtual%2520Screening%2520Filters%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2005%26volume%3D45%26spage%3D160%26epage%3D169%26doi%3D10.1021%2Fci049885e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span> <i>Desmond 6.1, Schrödinger
Release 2020-1</i>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York,
NY</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Desmond+6.1%2C+Schr%C3%B6dinger%0ARelease+2020-1%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C%0ANY%2C+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DDesmond%25206.1%252C%2520Schr%25C3%25B6dinger%250ARelease%25202020-1%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulten, K.</span></span> <span> </span><span class="NLM_article-title">VMD: Visual Molecular Dynamics</span>. <i>J. Mol. Graphics</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/0263-7855(96)00018-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2F0263-7855%2896%2900018-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=8744570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK28Xis12nsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1996&pages=33-38&author=W.+Humphreyauthor=A.+Dalkeauthor=K.+Schulten&title=VMD%3A+Visual+Molecular+Dynamics&doi=10.1016%2F0263-7855%2896%2900018-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">VDM: visual molecular dynamics</span></div><div class="casAuthors">Humphrey, William; Dalke, Andrew; Schulten, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-8, plates, 27-28</span>CODEN:
                <span class="NLM_cas:coden">JMGRDV</span>;
        ISSN:<span class="NLM_cas:issn">0263-7855</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">VMD is a mol. graphics program designed for the display and anal. of mol. assemblies, in particular, biopolymers such as proteins and nucleic acids.  VMD can simultaneously display any no. of structures using a wide variety of rendering styles and coloring methods.  Mols. are displayed as one or more "representations," in which each representation embodies a particular rendering method and coloring scheme for a selected subset of atoms.  The atoms displayed in each representation are chosen using an extensive atom selection syntax, which includes Boolean operators and regular expressions.  VMD provides a complete graphical user interface for program control, as well as a text interface using the Tcl embeddable parser to allow for complex scripts with variable substitution, control loops, and function calls.  Full session logging is supported, which produces a VMD command script for later playback.  High-resoln. raster images of displayed mols. may be produced by generating input scripts for use by a no. of photorealistic image-rendering applications.  VMD has also been expressly designed with the ability to animate mol. dynamics (MD) simulation trajectories, imported either from files or from a direct connection to a running MD simulation.  VMD is the visualization component of MDScope, a set of tools for interactive problem solving in structural biol., which also includes the parallel MD program NAMD, and the MDCOMM software used to connect the visualization and simulation programs, VMD is written in C++, using an object-oriented design; the program, including source code and extensive documentation, is freely available via anonymous ftp and through the World Wide Web.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0dd54QvBO97Vg90H21EOLACvtfcHk0lgGS2geMeW2eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xis12nsrg%253D&md5=1e3094ec3151fb85c5ff05f8505c78d5</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2F0263-7855%2896%2900018-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0263-7855%252896%252900018-5%26sid%3Dliteratum%253Aachs%26aulast%3DHumphrey%26aufirst%3DW.%26aulast%3DDalke%26aufirst%3DA.%26aulast%3DSchulten%26aufirst%3DK.%26atitle%3DVMD%253A%2520Visual%2520Molecular%2520Dynamics%26jtitle%3DJ.%2520Mol.%2520Graphics%26date%3D1996%26volume%3D14%26spage%3D33%26epage%3D38%26doi%3D10.1016%2F0263-7855%2896%2900018-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span> <i>PyMol 2.5</i>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PyMol+2.5%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPyMol%25202.5%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-J.</span></span> <span> </span><span class="NLM_article-title">Heterocycles and medicine: a survey of the heterocyclic drugs approved by the U.S. FDA from 2000 to Present</span>. In  <i>Progress in Heterocyclic Chemistry</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, G. W.</span>, <span class="NLM_string-name">Joule, J. A.</span></span>, Ed.; <span class="NLM_publisher-name">Elsevier</span>, <span class="NLM_year">2012</span>; Chapter 1, Vol.  <span class="NLM_volume">24</span>, pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">53</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2FB978-0-08-096807-0.00001-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=1-53&author=Y.-J.+Wuauthor=G.+W.+Gribble&author=J.+A.+Joule&title=Progress+in+Heterocyclic+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FB978-0-08-096807-0.00001-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-08-096807-0.00001-4%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-J.%26atitle%3DHeterocycles%2520and%2520medicine%253A%2520a%2520survey%2520of%2520the%2520heterocyclic%2520drugs%2520approved%2520by%2520the%2520U.S.%2520FDA%2520from%25202000%2520to%2520Present%26btitle%3DProgress%2520in%2520Heterocyclic%2520Chemistry%26aulast%3DGribble%26aufirst%3DG.%2BW.%26pub%3DElsevier%26date%3D2012%26volume%3D24%26spage%3D1%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascon-Simorte, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calmiano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riche, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallemand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyaerts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecomte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuberson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batchelor, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-Azaindoles as Novel Inhibitors of c-Met Kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2780</span>– <span class="NLM_lpage">2784</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmcl.2009.03.110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=19369077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltl2rsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2780-2784&author=J.+Porterauthor=S.+Lumbauthor=R.+J.+Franklinauthor=J.+M.+Gascon-Simorteauthor=M.+Calmianoauthor=K.+L.+Richeauthor=B.+Lallemandauthor=J.+Keyaertsauthor=H.+Edwardsauthor=A.+Maloneyauthor=J.+Delgadoauthor=L.+Kingauthor=A.+Foleyauthor=F.+Lecomteauthor=J.+Reubersonauthor=C.+Meierauthor=M.+Batchelor&title=Discovery+of+4-Azaindoles+as+Novel+Inhibitors+of+c-Met+Kinase&doi=10.1016%2Fj.bmcl.2009.03.110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-azaindoles as novel inhibitors of c-Met kinase</span></div><div class="casAuthors">Porter, John; Lumb, Simon; Franklin, Richard J.; Gascon-Simorte, Jose M.; Calmiano, Mark; Le Riche, Kelly; Lallemand, Benedicte; Keyaerts, Jean; Edwards, Helen; Maloney, Alison; Delgado, Jean; King, Lloyd; Foley, Anne; Lecomte, Fabien; Reuberson, James; Meier, Christoph; Batchelor, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2780-2784</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 4-azaindole inhibitors of c-Met kinase, e.g. I (R1 = H, NH2, CO2H, 1-piperazinyl, etc.; R2 = PhSO2, 2-O2NC6H4SO2, benzofurazan-4-ylsulfonyl, etc.), is described.  The postulated binding mode was confirmed by an X-ray crystal structure of complex of I (R1 = CONH2; R2 = 2-O2NC6H4SO2) with c-Met kinase and series optimization was performed on the basis of this structure.  Future directions for series development are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9V4U2KtkairVg90H21EOLACvtfcHk0lgo0Z1S0PxKLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltl2rsLY%253D&md5=41dac12c5511c2ca5bb33a72704dfb78</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.110%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DJ.%26aulast%3DLumb%26aufirst%3DS.%26aulast%3DFranklin%26aufirst%3DR.%2BJ.%26aulast%3DGascon-Simorte%26aufirst%3DJ.%2BM.%26aulast%3DCalmiano%26aufirst%3DM.%26aulast%3DRiche%26aufirst%3DK.%2BL.%26aulast%3DLallemand%26aufirst%3DB.%26aulast%3DKeyaerts%26aufirst%3DJ.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DMaloney%26aufirst%3DA.%26aulast%3DDelgado%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DL.%26aulast%3DFoley%26aufirst%3DA.%26aulast%3DLecomte%26aufirst%3DF.%26aulast%3DReuberson%26aufirst%3DJ.%26aulast%3DMeier%26aufirst%3DC.%26aulast%3DBatchelor%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25204-Azaindoles%2520as%2520Novel%2520Inhibitors%2520of%2520c-Met%2520Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2780%26epage%3D2784%26doi%3D10.1016%2Fj.bmcl.2009.03.110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinsdale, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, G. M.</span></span> <span> </span><span class="NLM_article-title">Bcl-2 inhibitors: Small Molecules with a Big Impact on Cancer Therapy</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">360</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1038/cdd.2008.137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1038%2Fcdd.2008.137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=18806758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1WkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=360-367&author=M.+Voglerauthor=D.+Dinsdaleauthor=M.+J.+S.+Dyerauthor=G.+M.+Cohen&title=Bcl-2+inhibitors%3A+Small+Molecules+with+a+Big+Impact+on+Cancer+Therapy&doi=10.1038%2Fcdd.2008.137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Bcl-2 inhibitors: small molecules with a big impact on cancer therapy</span></div><div class="casAuthors">Vogler, M.; Dinsdale, D.; Dyer, M. J. S.; Cohen, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">360-367</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite tremendous advances over the last 15 years in understanding fundamental mechanisms of apoptosis, this has failed to translate into improved cancer therapy for patients.  However, there may now be light at the end of this long tunnel.  Antiapoptotic Bcl-2 family members may be divided into two subclasses, one comprising Bcl-2, Bcl-XL and Bcl-w and the other Mcl-1 and Bcl2A1.  Neutralization of both subclasses is required for apoptosis induction.  Soln. of the structure of antiapoptotic Bcl-2 family proteins has led to the design of novel small mol. inhibitors.  Although many such mols. have been synthesized, rigorous verification of their specificity has often been lacking.  Further studies have revealed that many putative Bcl-2 inhibitors are not specific and have other cellular targets, resulting in non-mechanism based toxicity.  Two notable exceptions are ABT-737 and a related orally active deriv., ABT-263, which bind with high affinity to Bcl-2, Bcl-XL and Bcl-w and may prove to be useful tools for mechanistic studies.  ABT-263 is in early clin. trials in lymphoid malignancies, small-cell lung cancer and chronic lymphocytic leukemia, and some patients have shown promising results.  In in vitro studies, primary cells from patients with various B-cell malignancies are exquisitely sensitive to ABT-737, exhibiting novel morphol. features of apoptosis including marked outer mitochondrial membrane rupture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNZJtEbkYHoLVg90H21EOLACvtfcHk0lgo0Z1S0PxKLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1WkurY%253D&md5=6a1cf68bf11ba534258ecd34eb407aa0</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2008.137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2008.137%26sid%3Dliteratum%253Aachs%26aulast%3DVogler%26aufirst%3DM.%26aulast%3DDinsdale%26aufirst%3DD.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%2BS.%26aulast%3DCohen%26aufirst%3DG.%2BM.%26atitle%3DBcl-2%2520inhibitors%253A%2520Small%2520Molecules%2520with%2520a%2520Big%2520Impact%2520on%2520Cancer%2520Therapy%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2009%26volume%3D16%26spage%3D360%26epage%3D367%26doi%3D10.1038%2Fcdd.2008.137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wormald, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrow, J. C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Characterization of Novel Isoform-Selective IP6K1 Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">126628</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1016%2Fj.bmcl.2019.126628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=31445853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Cisr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=126628&author=M.+M.+Wormaldauthor=G.+Ernstauthor=H.+Weiauthor=J.+C.+Barrow&title=Synthesis+and+Characterization+of+Novel+Isoform-Selective+IP6K1+Inhibitors&doi=10.1016%2Fj.bmcl.2019.126628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of novel isoform-selective IP6K1 inhibitors</span></div><div class="casAuthors">Wormald, Michael M.; Ernst, Glen; Wei, Huijun; Barrow, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">126628</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Diaminopurines and diaminopurine analogs such as (methoxyindolylethylamino)purine I were prepd. as selective inositol hexakisphosphate kinases (IP6K) inhibitors.  Selected diaminopurines such as I were selective inhibitors of IP6K1 over IP6K2 and IP6K3; I was a more potent inhibitor of IP6K1 and was more water-sol. than the previously known pan-IP6K inhibitor TNP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgBKLyu2nm07Vg90H21EOLACvtfcHk0lgo0Z1S0PxKLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Cisr7J&md5=466f9d3b8b4b194a183c1660efcead8d</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126628%26sid%3Dliteratum%253Aachs%26aulast%3DWormald%26aufirst%3DM.%2BM.%26aulast%3DErnst%26aufirst%3DG.%26aulast%3DWei%26aufirst%3DH.%26aulast%3DBarrow%26aufirst%3DJ.%2BC.%26atitle%3DSynthesis%2520and%2520Characterization%2520of%2520Novel%2520Isoform-Selective%2520IP6K1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D126628%26doi%3D10.1016%2Fj.bmcl.2019.126628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matozaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuhara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikyo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takai, Y.</span></span> <span> </span><span class="NLM_article-title">Involvement of an SHP-2-Rho Small G protein Pathway in Hepatocyte Growth Factor/Scatter Factor-Induced Cell Scattering</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2565</span>– <span class="NLM_lpage">2575</span>, <span class="refDoi"> DOI: 10.1091/mbc.11.8.2565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1091%2Fmbc.11.8.2565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10930454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtV2rtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2000&pages=2565-2575&author=A.+Kodamaauthor=T.+Matozakiauthor=A.+Fukuharaauthor=M.+Kikyoauthor=M.+Ichihashiauthor=Y.+Takai&title=Involvement+of+an+SHP-2-Rho+Small+G+protein+Pathway+in+Hepatocyte+Growth+Factor%2FScatter+Factor-Induced+Cell+Scattering&doi=10.1091%2Fmbc.11.8.2565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of an SHP-2-Rho small G protein pathway in hepatocyte growth factor/scatter factor-induced cell scattering</span></div><div class="casAuthors">Kodama, Atsuko; Matozaki, Takashi; Fukuhara, Atsunori; Kikyo, Mitsuhiro; Ichihashi, Masamitsu; Takai, Yoshimi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2565-2575</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">Hepatocyte growth factor/scatter factor (HGF/SF) induces cell scattering through the tyrosine kinase-type HGF/SF receptor c-Met.  We have previously shown that Rho small G protein (Rho) is involved in the HGF/SF-induced scattering of Madin-Darby canine kidney (MDCK) cells by regulating at least the assembly and disassembly of stress fibers and focal adhesions, but it remains unknown how c-Met regulates Rho activity.  We have found here a novel signaling pathway of c-Met consisting of SHP-2-Rho that regulates the assembly and disassembly of stress fibers and focal adhesions in MDCK cells.  SHP-2 is a protein-tyrosine phosphatase that contains src homol.-2 domains.  Expression of a dominant neg. mutant of SHP-2 (SHP-2-C/S) markedly increased the formation of stress fibers and focal adhesions in MDCK cells and inhibited their scattering.  C3, a Clostridium botulinum ADP-ribosyltransferase, and Y-27632, a specific inhibitor for ROCK, reversed the stimulatory effect of SHP-2-C/S on stress fiber formation and the inhibitory effect on cell scattering.  Vav2 is a GDP/GTP exchange protein for Rho.  Expression of a dominant neg. mutant of Vav2 blocked the stimulatory effect of SHP-2-C/S on stress fiber formation.  Conversely, expression of mutants of Vav2 that increased stress fiber formation inhibited HGF/SF-induced cell scattering.  These results indicate that SHP-2 physiol. modulates the activity of Rho to form stress fibers and focal adhesions and thereby regulates HGF/SF-induced cell scattering.  In addn., Vav2 may be involved in the SHP-2-Rho pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKBu3BASJ3X7Vg90H21EOLACvtfcHk0lgWauq0c97sDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtV2rtLg%253D&md5=61791e1cd1ad0d248f8280a30b6681af</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1091%2Fmbc.11.8.2565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.11.8.2565%26sid%3Dliteratum%253Aachs%26aulast%3DKodama%26aufirst%3DA.%26aulast%3DMatozaki%26aufirst%3DT.%26aulast%3DFukuhara%26aufirst%3DA.%26aulast%3DKikyo%26aufirst%3DM.%26aulast%3DIchihashi%26aufirst%3DM.%26aulast%3DTakai%26aufirst%3DY.%26atitle%3DInvolvement%2520of%2520an%2520SHP-2-Rho%2520Small%2520G%2520protein%2520Pathway%2520in%2520Hepatocyte%2520Growth%2520Factor%252FScatter%2520Factor-Induced%2520Cell%2520Scattering%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2000%26volume%3D11%26spage%3D2565%26epage%3D2575%26doi%3D10.1091%2Fmbc.11.8.2565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutterbach, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, B.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kariv, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczak, A. A.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Analysis of HGF-Stimulated Cell Scattering</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">854</span>, <span class="refDoi"> DOI: 10.1177/1087057108324497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=10.1177%2F1087057108324497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=18812567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVymsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=847-854&author=G.+K.+Y.+Chanauthor=B.+A.+Lutterbachauthor=B.-S.+Panauthor=I.+Karivauthor=A.+A.+Szewczak&title=High-Throughput+Analysis+of+HGF-Stimulated+Cell+Scattering&doi=10.1177%2F1087057108324497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput analysis of HGF-stimulated cell scattering</span></div><div class="casAuthors">Chan, Grace K. Y.; Lutterbach, Bart A.; Pan, Bo-Sheng; Kariv, Ilona; Szewczak, Alexander A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">847-854</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Historically, only relatively low-throughput or expensive methods have been available to measure cell migration.  Hepatocyte growth factor (HGF) is a ligand for the tyrosine kinase receptor Met that, in addn. to mediating proliferation and survival, increases cell motility and metastasis.  The authors have developed a high-throughput imaging assay for measuring inhibition of HGF-induced scattering in human HPAF-II pancreatic adenocarcinoma cells.  Following treatment with test compds. and HGF for 24 h, cells are labeled with a nuclear stain and imaged at 10× magnification.  The proximity of neighboring nuclei is measured, and the distribution of internuclear distances across each field of view is used to calc. the fraction of scattered cells.  This method of anal. can be extended to other cell types and signaling pathways and, compared with other membrane-based migration assays currently available, the assay is significantly lower in cost, is less labor intensive, and provides higher throughput.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-BmkkD9T_8rVg90H21EOLACvtfcHk0lgWauq0c97sDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVymsbY%253D&md5=27acc479efd66eab2de2be792a139d3e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1177%2F1087057108324497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057108324497%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%2BK.%2BY.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DKariv%26aufirst%3DI.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26atitle%3DHigh-Throughput%2520Analysis%2520of%2520HGF-Stimulated%2520Cell%2520Scattering%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2008%26volume%3D13%26spage%3D847%26epage%3D854%26doi%3D10.1177%2F1087057108324497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldino, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S. J.</span></span> <span> </span><span class="NLM_article-title">Selective Oxidation of Phosphorus Ylides by Dimethyldioxirane. Application to the Formation of Vicinal Tricarbonyls</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8231</span>– <span class="NLM_lpage">8235</span>, <span class="refDoi"> DOI: 10.1021/jo00130a023</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00130a023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;key=1%3ACAS%3A528%3ADyaK2MXpsVOmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1995&pages=8231-8235&author=H.+H.+Wassermanauthor=C.+M.+Baldinoauthor=S.+J.+Coats&title=Selective+Oxidation+of+Phosphorus+Ylides+by+Dimethyldioxirane.+Application+to+the+Formation+of+Vicinal+Tricarbonyls&doi=10.1021%2Fjo00130a023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Oxidation of Phosphorus Ylides by Dimethyldioxirane. Application to the Formation of Vicinal Tricarbonyls</span></div><div class="casAuthors">Wasserman, Harry H.; Baldino, Carmen M.; Coats, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">8231-5</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dimethyldioxirane (DMD) proved to be an effective reagent for the selective conversion of phosphoranylidene intermediates, e.g., I (X = PPh3) to the corresponding vicinal tricarbonyls, e.g., I (X = O).  Unlike existing oxidn. protocols which employ relatively vigorous conditions, this transformation is conducted rapidly at low temp. under neutral conditions, without the necessity of an aq. workup.  Selective oxidn. of the P ylides in the presence of a variety of sensitive functionality was achieved by lowering the reaction temp. and controlling the concn. of oxidant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVSfIV94T4vbVg90H21EOLACvtfcHk0lgWauq0c97sDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpsVOmurY%253D&md5=47f05b7a369fab8ebe9df663be37c54f</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fjo00130a023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00130a023%26sid%3Dliteratum%253Aachs%26aulast%3DWasserman%26aufirst%3DH.%2BH.%26aulast%3DBaldino%26aufirst%3DC.%2BM.%26aulast%3DCoats%26aufirst%3DS.%2BJ.%26atitle%3DSelective%2520Oxidation%2520of%2520Phosphorus%2520Ylides%2520by%2520Dimethyldioxirane.%2520Application%2520to%2520the%2520Formation%2520of%2520Vicinal%2520Tricarbonyls%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1995%26volume%3D60%26spage%3D8231%26epage%3D8235%26doi%3D10.1021%2Fjo00130a023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X','PDB','3O5X'); return false;">PDB: 3O5X</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i112"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01265">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_47028"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01265?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01265</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Docking complexes in PDB format (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_001.zip">ZIP</a>)</p></li><li><p class="inline">Ligand alignment studies, alternative synthetic pathway for the preparation of the azaindoles, docking poses of the representative compounds, full-detailed phosphatase and kinase profiling, cell permeability experiments, and HRMS data of the key compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds <b>8</b>–<b>46</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_001.zip">jm0c01265_si_001.zip (465.35 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_002.pdf">jm0c01265_si_002.pdf (994.9 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01265/suppl_file/jm0c01265_si_003.csv">jm0c01265_si_003.csv (3.27 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01265&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01265%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01265" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b1776a8d23d42","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
